,id,ticker,title,category,content,date,provider,url,article_id
106665,328180,DXCM,Premarket analyst action   healthcare,news,LIvaNova  NASDAQ LIVN  initiated with Buy rating and  115  20  upside  price target at Stifel Eli Lilly  NYSE LLY  initiated with Overweight rating and  100  16  upside  price target at Cantor Fitzgerald  Pfizer   NYSE PFE  initiated with Overweight rating and  45  23  upside  price target at Cantor LeMaitre Vascular  NASDAQ LMAT  resumed with Buy rating and  38  13  upside  price target at Roth Capital Quest Diagnostics  NYSE DGX  upgraded to Outperform with a  115  7  upside  price target at William Blair  DexCom   NASDAQ DXCM  upgraded to Overweight with a  115  29  upside  price target at JPMorgan  NYSE JPM   Shares up 2  premarket Now read ,2018-06-08,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action--healthcare-1485929,1485929
106669,328184,DXCM,Dexcom giving  250M in stock to Verily in amended license deal,news,In a filing  Dexcom  NASDAQ DXCM  notes it s entered an amended licensing agreement with Verily  the life sciences unit of Alphabet  GOOG  GOOGL   with an eye to speeding up Dexcom s work in Type 2 diabetes  The amendment also improves future profitability for Dexcom  the company said  It strengthens product development timelines for the second generation CGM system  increases synergy with Verily s Onduo franchise  which makes Dexcom the preferred CGM device supplier  expanded options to collaborate on additional products and software  and scraps royalty payments that Dexcom would have owed  Dexcom will make an initial payment of  250M in stock  and additional payments of up to  280M may be due and payable with product launch and revenue milestones  up to  275M of the milestone payments may be made in stock as well  After hours  DXCM  1 5   GOOG  0 3   GOOGL  0 1   Now read ,2018-11-20,Seeking Alpha,https://www.investing.com/news/stock-market-news/dexcom-giving-250m-in-stock-to-verily-in-amended-license-deal-1696238,1696238
106670,328185,DXCM,Hologic  HOLX  Q1 Earnings Meet  Revenues Beat Estimates,opinion,"Hologic  Inc    NASDAQ HOLX   reported first quarter fiscal 2020 adjusted earnings per share  EPS  of 61 cents  up 5 2  year over year  The bottom line was in line with the Zacks Consensus Estimate On a GAAP  reported  basis  the company s earnings of  1 43 per share reflect a stupendous surge of 297 2  from the year ago quarter Revenues in DetailRevenues grossed  850 5 million in the reported quarter  up 2 4  year over year  up 2 8  at constant exchange rate or CER   The metric beat the Zacks Consensus Estimate of  844 95 million by 0 7  Hologic  Inc  Price  Consensus and EPS Surprise
    Excluding the divested Blood Screening and Medical Aesthetics businesses  total revenues were  773 2 million  up 5  year over year and 5 4  at CER  Excluding the divestitures and the acquired SuperSonic Imagine  SSI  business  organic revenues of  767 1 million increased 4 1  and 4 6  in constant currency U S  revenues of  632 7 million increased 1 8   Additionally  international revenues of  217 8 million grew 4 3  or 6  in constant currency Organically  revenues in the United States rose 3 2  year over year to  588 6 million in the quarter  Moreover  global revenues were up 7 3   up 9 2  at CER  to  178 5 million Segments in DetailRevenues at the Diagnostics segment rose 5  year over year  up 5 5  at CER  to  311 5 million in the quarter under review  with Molecular Diagnostics being the major driver  Molecular Diagnostics  revenues of  178 5 million climbed 8 6   up 9  at CER   continuing the division s strong performance  However  Blood Screening revenues of  12 million registered a 15 5  dip  down 15 5  at CER  Revenues at the Breast Health segment increased 2   up 2 4  at CER  to  331 1 million  Domestic sales drove Breast Health growth in the quarter  with 1 5  revenue rise year over year  However  outside the United States  Breast Health sales increased 5 5  in total but dipped 1 4   without SSI  against robust growth of 16 1  in the prior year period Although revenues at the GYN Surgical business grew 9 9   up 10 2  at CER  to  119 1 million  which is the segment s highest growth rate in 11 quarters   the Medical Aesthetic business revenues of  65 3 million reflects a 18 2  decline  down 17 7  at CER  in the reported quarter on the divestiture of the Cynosure Medical Aesthetics business Revenues at Skeletal Health rose 10 8   up 11 4  at CER  to  23 5 million Operational UpdateIn the fiscal first quarter  Hologic s adjusted gross margin contracted 60 basis points  bps  to 61 6   The downside was primarily due to the strong U S  dollar  an adverse product and geographic sales mix  and divested Cynosure s weak performance Adjusted operating expenses amounted to  289 3 million  up 5 3  year over year  Also  adjusted operating margin contracted 170 bps to 27 5  Financial UpdateHologic exited the first quarter of fiscal 2020 with cash and cash equivalents of  370 8 million compared with  601 8 million at the end of fourth quarter fiscal 2019  Total long term debt was  2 77 billion in the reported quarter compared with  2 78 billion at the end of the year ago quarter At the end of the fiscal first quarter  net cash provided by operating activities was  113 9 million compared with  104 6 million a year ago GuidanceHologic issued guidance for the second quarter and fiscal 2020  For fiscal 2020  the company expects adjusted revenues of  3 24  3 27 billion  a decline of 3 8 2 9  on a reported basis and 3 5 2 6  at CER   The Zacks Consensus Estimate for revenues stands at  3 36 billion  which is above the company s guidance Hologic envisions adjusted EPS of  2 63  2 67 for fiscal 2020  up by 8 2 9 9  on a reported basis   The consensus mark for the metric is pegged at  2 62  which is below the lower end of the company s guidance range For second quarter fiscal 2020  Hologic anticipates adjusted revenues of  770  780 million  a decline of 5 9 4 7  on a reported basis and 5 4 4 2  at CER   The consensus estimate for revenues stands at  820 2 million  above the company s projection Adjusted EPS is estimated at 61 63 cents for second quarter fiscal 2020  up by 5 2 8 6  on a reported basis   The Zacks Consensus Estimate for the same is pegged at 63 cents  which lies in the upper end of the company s guidance range Our TakeHologic exited the first quarter of fiscal 2020 on a solid note  Strong top line growth was led by a solid year over year rise in core businesses like GYN Surgical and Molecular Diagnostics  We are upbeat about the recent regulatory clearances for the Unifi Workspace reading solution and 3DQuorum artificial intelligence imaging technology in Breast Health  and the Definity cervical dilator in GYN Surgical  Also  the acquisition of a controlling interest in SSI started to contribute to the company s top line On the flip side  both margins contracted in the quarter under review  Also  the company was hit by lower Brevera capital sales Zacks Rank and Key PicksHologic currently carries a Zacks Rank  3  Hold  Some better ranked stocks in the broader medical space are SeaSpine Holdings Corporation   NASDAQ SPNE    STERIS plc   NYSE STE   and DexCom  Inc    NASDAQ DXCM    all three currently carrying a Zacks Rank of 2  You can see The Zacks Consensus Estimate for SeaSpine s fourth quarter 2019 revenues is pegged at  43 6 million  suggesting 14 7  growth from the prior year reported figure  The same for loss per share is anticipated at 44 cents  implying a 16 9  improvement from the year ago reported number The Zacks Consensus Estimate for STERIS s third quarter fiscal 2020 revenues is pegged at  749 7 million  hinting at a 7 7  increase from the year earlier reported figure  The same for adjusted earnings per share stands at  1 43  indicating a 13 5  rise from the year ago reported figure The Zacks Consensus Estimate for DexCom s fourth quarter 2019 revenues is pegged at  457 million  suggesting 35 2  growth from the prior year reported figure  The same for adjusted earnings per share stands at 72 cents  implying a 33 3  improvement from the year earlier reported figure Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  50    83  and  164  in as little as 2 months  The stocks in this report could perform even better ",2020-01-29,Zacks Investment Research,https://www.investing.com/analysis/hologic-holx-q1-earnings-meet-revenues-beat-estimates-200503216,200503216
106676,328191,DXCM,Stocks   U S  Futures Rebound as China  U S  Said to Agree to Cancel Some Tariffs ,news,"Investing com   U S  futures rebounded on Thursday  after the Chinese commerce ministry said Beijing and Washington have agreed to phase out tariffs imposed during their 16 month long trade war  
 The trade war started with tariffs  and should end with the cancellation of tariffs   ministry spokesman Gao Feng said at a news briefing  Cancelling tariffs is vital to the phase one trade agreement  which both sides have agreed to do as negotiation progress is made  he added  
The two sides are working toward signing a deal this month but have yet to decide on a location for U S  President Donald Trump and Chinese President Xi Jinping to meet   
Nasdaq 100 futures were up 41 points or 0 5  by 6 40 AM ET  10 40 GMT   while Dow futures gained 148 points or 0 5  and S P 500 futures rose 12 points or 0 4   
Nielsen Holdings  NYSE NLSN  was in focus  after the media research company announced it plans to split into two independently public traded companies  
Qualcomm  NASDAQ QCOM  gained 6 1  in premarket trade after its earnings came in better than expected during its fiscal fourth quarter  while   DexCom    NASDAQ DXCM  surged 19 2  after the glucose monitoring manufacturer raised its full year outlook  Square  NYSE SQ  inched up 1 4  after giving an upbeat earnings forecast for the current quarter   
Elsewhere    Roku    NASDAQ ROKU  tumbled 13 8  despite beating on the top and bottom lines  reporting an increase in users and raising its full year guidance  TripAdvisor  NASDAQ TRIP  dropped 4 9  in after hours trading after its earnings fell short of estimates  while   Expedia    NASDAQ EXPE  plunged 13 5  after reporting gross bookings came in shy of forecasts 
On the data front  weekly jobless claims numbers are released at 8 30 AM ET  
In commodities  gold futures fell 0 6  to  1 484 10 a troy ounce  while the U S  dollar index  which measures the greenback against a basket of six major currencies  was down 0 1  to 97 703  Crude oil futures surged 1 3  to  57 09 a barrel ",2019-11-07,Investing.com,https://www.investing.com/news/stock-market-news/stocks--us-futures-rebound-as-china-us-said-to-agree-to-cancel-some-tariffs-2014507,2014507
106677,328192,DXCM,Why Diabetes Stocks DexCom and Insulet Soared 83  and 116   Respectively  in 2019,news,"What happened
Shares of DexCom  NASDAQ DXCM  and Insulet  NASDAQ PODD  rocketed 82 6  and 116   respectively  last year  according to data from S P Global Market Intelligence  The S P 500 returned 31 5  over this period 
Both medical device companies are focused on the diabetes space and were among last year s top performing large cap stocks in the healthcare space  DexCom makes a continuous glucose monitoring  CGM  system  the G6  Insulet is a leader in tubeless insulin pump technology with its Omnipod pump 

So what
We can attribute these two diabetes stocks  strong 2019 performances to the companies  robust financial performances and investor optimism about their growth potential  Diabetes is  unfortunately  a growth space  as the global incidence of the disease    both types 1 and 2    has been rising for some time and is expected to continue to increase 
Let s look at these two companies  most recent quarterly reports  In the third quarter  DexCom s revenue soared 49  year over year to  396 3 million  Adjusted earnings per share  EPS  rocketed 261  to  0 65  smashing the  0 20 that Wall Street had expected  In the third quarter  Insulet s revenue jumped 27  year over year to  192 1 million  and adjusted EPS tripled to  0 09  crushing the analyst consensus estimate of  0 03   
Now what
Investors should be getting material news next month from both diabetes companies 
DexCom hasn t yet scheduled a date for the release of its fourth quarter and full year 2019 results  but it should be in mid to late February  For the full year  the company has guided for revenue growth of 38  to 41  year over year  Moreover  it expects a gross profit margin of 63  and an operating profit margin of 7  
Insulet is slated to report its fourth quarter and full year results on Monday  Feb  24  after the market closes  For the full year  it expects revenue to increase about 28  to 29   The company doesn t provide a profitability outlook 
DexCom and Insulet have a business tie  Late this year  Insulet plans to launch its Horizon automated insulin delivery system  which uses a DexCom continuous glucose monitor to dose insulin ",2020-01-09,The Motley Fool,https://invst.ly/pg59g,2056539
106678,328193,DXCM,DexCom and Livongo Health Team up in Glucose Data Deal,news,"Two companies active in the diabetes segment  DexCom  NASDAQ DXCM  and Livongo Health  NASDAQ LVGO  announced on Monday they were collaborating on user data dissemination  In a joint press release  the two companies said that users of Livongo s health information platform would be able to sync their data from DexCom s G6 glucose  blood sugar  monitoring system 
The two companies said this will allow Livongo users to utilize that data with other information tracked by the platform  such as weight and blood pressure  to obtain a deeper understanding of the state of their health 

 Livongo can now aggregate data from the Dexcom G6  cross reference with proprietary blood pressure and weight data from its connected devices  and then use advanced data science to interpret that data and offer Members personalized health insights  or Health Nudges  based on their comprehensive health profile   the companies wrote in their announcement 
At the end of September  the Livongo software platform had over 770 customers  The system allows users to monitor and manage chronic illnesses  particularly type 2 diabetes  It can also track developments in hypertension  among other health issues 
DexCom is a specialist in continuous glucose monitoring  CGM   its G6 is a product that takes readings from a small sensor inserted just under the skin  The readings are transmitted wirelessly and can be monitored on a display device such as a smartphone 
DexCom and Livongo did not provide the terms or the financial details of their new arrangement 
On Monday  the paths of the two healthcare stocks diverged  Livongo s shares closed up by nearly 6   In contrast  DexCom s were down  albeit only marginally ",2020-01-13,The Motley Fool,https://invst.ly/phjsp,2058474
106679,328194,DXCM,Better Buy  DexCom vs  Abbott Laboratories,news,"Healthcare stocks languished during most of 2019 as the markets fretted over political risks associated with the upcoming presidential election  But the sector picked up some steam in the last three months of the year as those worries subsided and investors turned to the sector looking for opportunities that could hold up well if the economy turns down 
DexCom  NASDAQ DXCM  and Abbott Laboratories  NYSE ABT  are two very successful healthcare companies that appeal to different sorts of investors  DexCom is a pure play in one of the hottest areas in healthcare  while Abbott Labs is a diversified  steady performer  Which one wins the nod as the better stock to own for the next few years 
DexCom s business
DexCom specializes in one type of medical device for people with diabetes  continuous glucose monitors  CGMs   and has been wildly successful in that space  The company s current line of monitors uses a small sensor inserted under the skin and a Bluetooth transmitter that connects to a DexCom receiver  a smartphone  or a smartwatch  The system takes blood glucose measurements every five minutes and alerts the wearer when glucose levels fall outside a safe range 

The advantages of frequent measurements and no requirement for pricking fingers have resulted in rapid sales growth for DexCom  Through the first three quarters of 2019  revenue is up a whopping 46  to  1 01 billion  and non GAAP  adjusted  earnings per share are  0 69  up from a loss of  0 19 in the first nine months of 2018 
Abbott s business
Abbott Labs also makes CGMs  but it s a broadly diversified healthcare company that s over 20 times the size of DexCom and sells more than 1 500 products  The company has four business segments  Medical devices  at 38  of revenue  is the company s biggest  along with diagnostics  nutrition  and established pharmaceuticals 
All four segments are contributing to Abbott s steady but relatively unspectacular growth  Overall  the company has grown year to date revenue by 7 4  on an organic basis  that is  excluding currency effects and the effect of a discontinued business  to  23 6 billion  Revenue from medical devices has grown 10 2  organically over the prior year  pharmaceuticals are up 6 5   diagnostics has grown 5 7   and nutrition 5 2   Earnings per share are up 10 6  to  2 29 
Abbott s glucose monitor  FreeStyle Libre  actually outsells DexCom s and is growing faster  The Abbott CGM generated  496 million in revenue in Q3  compared with  396 million for DexCom s  Sales growth for the product line was 63   beating DexCom s 49  growth in the quarter 
DexCom s growth prospects
DexCom s rapid growth will likely continue for at least a few more years  although perhaps at a somewhat slower pace  In a recent update  the company gave muted guidance of revenue growth between 17  and 21  in 2020  down from 42  growth in 2019  but the company regularly underpromises and then beats expectations 

DexCom s core customers are diabetes patients on intensive insulin therapy who need to regulate blood glucose level to within a range  That market is growing with the diabetes epidemic  and DexCom has plenty of runway  Only about 15  of the type 2 diabetes patients in the U S  on intensive therapy are using CGMs  The company is gearing up to launch an improved version of its devices in late 2020  which should boost sales and improve profits due to a lower manufacturing cost 
Longer term  DexCom has plenty of room to grow outside its core market  though  The company is growing its sales team to market to hospitals for glucose monitoring in inpatient settings and is conducting studies with pregnant women for management of gestational diabetes  Ultimately  the larger population of patients with type 2 diabetes who aren t on intensive diabetes therapy and even the 84 million people in the U S  who are pre diabetic could be part of the company s addressable market  Monitoring blood glucose could become an important part of controlling diet and exercise to halt the progression of the disease 
Abbott s growth prospects
Sales of Abbott s CGM may be growing faster than Dexcom s  but they re small compared with the overall total for the company  Fortunately for Abbott s shareholders  the company has other bright spots that are driving growth 

Abbott s MitraClip  an implant to repair leaky heart valves  is growing sales at over 30   Alinity is a family of high throughput systems for core laboratory testing such as blood chemistry analysis  and the recent rollout of the products in Europe is helping to grow that product line in double digits  Abbott s established pharmaceuticals business is focused on selling branded generic medicines into emerging markets  where demographics and improving standards of living are tailwinds for growth 
There really aren t any weak points in Abbott s highly diversified business  which makes the company s bottom line steady and very predictable  It is guiding toward non GAAP EPS growth of about 12  for 2019  and it should be able to maintain growth at about that rate for years 
Dividends and valuation
DexCom doesn t pay dividends  but Abbott is a Dividend Aristocrat  having increased its payout for 48 consecutive years  Last month it raised the quarterly dividend a healthy 12 5   and it now yields 1 6  
Shares are priced to reflect the massive growth that investors expect to see from the business  The stock sells for 122 times the analyst consensus estimate for earnings in 2020  which assumes about 33  growth from 2019 
Abbott s stock sells for about 25 times expected 2020 EPS  which is much cheaper than DexCom  but doesn t exactly put the stock in value territory given a growth rate in the low teens 
For growth  buy DexCom  Value investors will prefer Abbott
Given DexCom s strong business momentum and wide open avenues for long term growth  I think investors will continue to award the stock a high multiple and the shares will likely outperform those of Abbott Labs over the next few years  But DexCom s valuation adds risk to the stock  and there is also a good chance the investors will have a bumpy ride on the way to gains  especially if the market turns down and shuns risk for a time  DexCom would be my pick for risk tolerant growth stock investors 
Abbott Laboratories is more suitable for some investors  though  The well managed blue chip produces steady growth that s diversified across a broad portfolio  And though the yield isn t particularly high  it s a dependable dividend stock that isn t very susceptible to either the economy or the whims of the market  Conservative investors who want a stock they can buy and forget about for decades should consider Abbott Labs over DexCom ",2020-01-25,The Motley Fool,https://invst.ly/pmr9v,2067727
106680,328195,DXCM,Align Technology  ALGN  Earnings Beat In Q4  Margins Rise,opinion,"Align Technology  Inc  s   NASDAQ ALGN   fourth quarter 2019 earnings per share  EPS  were  1 53  reflecting a 27 5  increase from a year ago  The figure beat the Zacks Consensus Estimate by 10 1  For 2019  EPS came in at  5 53  showing a year over year increase of 12 4   The figure surpassed the Zacks Consensus Estimate by 2 6  RevenuesRevenues grew 21 7  year over year to  649 8 million in the quarter  surpassing the Zacks Consensus Estimate by 0 6  The robust top line performance was led by double digit increase in Invisalign case shipments from the year ago quarter  Moreover  increased revenues from iTero scanner contributed substantially For the full year  revenues totaled  2 41 billion  up 22 4  from the year ago number  The figure beat the Zacks Consensus Estimate by a marginal 0 4  Segments in DetailIn the fourth quarter  revenues at the Clear Aligner segment rose 22  year over year to  543 6 million  Within the segment  Invisalign case shipments amounted to 413 7 thousand  up 23 9  year over year  The upside was primarily driven by continued adoption by teenage and younger patients as well as increased utilization among orthodontists and expansion of the company s global customer base Align Technology  Inc  Price  Consensus and EPS Surprise
  
   During the quarter  Invisalign volumes were up 19 3  and 30 1  year over year in the Americas and International regions  respectively  Invisalign volume for teenage patients was 116 000 cases  up 33 1  year over year Revenues from Scanner and Services improved a significant 20 2  to  106 2 million on increased sales of iTero scanner and services MarginsGross margin in the quarter under review expanded 89 basis points  bps  year over year to 72 6  despite a 17 8  rise in cost of net revenues During the quarter  Align Technology witnessed a 23 2  year over year increase in selling  general and administrative expenses to  279 5 million and a 15 4  rise in research and development expenses to  41 3 million  However  operating margin expanded 70 bps to 23 3  in the quarter under review Financial DetailsAt the end of the fiscal year  Align Technology had cash  cash equivalents and short term marketable securities of  868 6 million  compared with  744 5 million at the end of fiscal 2018 At the end of 2019  net cash provided by operating activities was  747 2 million  compared with  554 7 million at the end of the year ago period In the reported quarter  Align Technology repurchased 389 000 stocks under its accelerated stock repurchase agreement  introduced in July 2019   The company currently has approximately  100 million left under its May 2018 repurchase program Q1 GuidanceFor the first quarter of 2020  the company projects EPS of  1 19 to  1 28 on revenues of  615 million to  630 million   indicating 12 15  growth from a year ago   The company estimates Invisalign case shipments in the band of 396 000 406 000  suggesting a 13  to 16  rise from a year ago Meanwhile  the Zacks Consensus Estimate for first quarter EPS is pinned at  1 44 on revenues of  658 9 million  Both earnings and revenue estimates lie above the company s respective projected bands Our TakeWe are upbeat about Align Technology s continued momentum in Invisalign volumes across all geographies  We are also encouraged by the solid adoption of Invisalign treatment across the teenage patient market  The expansion of Invisalign customer base  which totaled 67 000 active doctors worldwide in the fourth quarter  buoys optimism  The company also registered solid uptick in its Scanner and Services revenues  On the flip side  operating costs rose considerably in the fourth quarter Zacks Rank and Key PicksAlign Technology currently has a Zacks Rank 3  Hold   Some better ranked stocks in the broader medical space are SeaSpine Holdings Corporation   NASDAQ SPNE    STERIS plc   NYSE STE   and DexCom  Inc    NASDAQ DXCM    all three carrying a Zacks Rank of 2  Buy   You can see  The Zacks Consensus Estimate for SeaSpine s fourth quarter 2019 revenues is pegged at  43 6 million  suggesting 14 7  growth from the prior year reported figure  The same for loss per share is anticipated at 44 cents  implying a 16 9  improvement from the year ago reported number The Zacks Consensus Estimate for STERIS  third quarter fiscal 2020 revenues is pegged at  749 7 million  hinting at a 7 7  increase from the year earlier reported figure  The same for adjusted earnings per share stands at  1 43  indicating a 13 5  rise from the year ago reported figure The Zacks Consensus Estimate for DexCom s fourth quarter 2019 revenues is pegged at  457 million  suggesting 35 2  growth from the prior year reported figure  The same for adjusted earnings per share stands at 72 cents  implying a 33 3  improvement from the year earlier reported figure Breakout Biotech Stocks with Triple Digit Profit Potential The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  50    83  and  164  in as little as 2 months  The stocks in this report could perform even better ",2020-01-30,Zacks Investment Research,https://www.investing.com/analysis/align-technology-algn-earnings-beat-in-q4-margins-rise-200503023,200503023
106681,328196,DXCM,Varian  VAR  Earnings And Revenues Miss Estimates In Q1,opinion,"Varian Medical Systems  Inc    NYSE VAR   reported first quarter fiscal 2020 adjusted earnings per share  EPS  of  1 16  missing the Zacks Consensus Estimate of  1 21  The figure however improved 9 4  year over year This Zacks Rank  3  Hold  company reported revenues of  828 9 million  which lagged the consensus mark of  830 8 million  On a year over year basis  revenues rose 11 9  and 13  at constant currency  cc   Organically  revenues grew 8  Segment DetailsOncology Systems  Revenues totaled  782 4 million  up 11 4  year over year and 9  at cc  Operating earnings at the segment were  136 million  up 10  year over year Varian s worldwide net installed base had 8 496 units  up by 366 units on a year over year basis  As a whole  gross orders grew 8  from the year ago quarter to  77 4 million Orders in the United States rose 7  year over year on 4  growth in North America  In EMEA  orders rose 8  year over year  In APAC  orders climbed 9  year over year driven by growth in China  South East Asia and Korea but partially offset by softness in Japan Proton Solutions  Revenues at the segment dropped 28 3  to  27 6 million  Per management  operating earnings were impacted by project mix and costs Other  Revenues at this segment grossed  18 9 million  For investors  notice  the segment comprises interventional oncology business  including cryoablation  embolic microspheres  and microwave ablation  as well as the company s cardiac radioablation assets Varian Medical Systems  Inc  Price  Consensus and EPS Surprise
    MarginsTotal gross profit in the reported quarter was  366 8 million  up 16  year over year  Gross margin in the reported quarter was 44 2  of net revenues  up 150 basis points  bps  Research and development expenses rose 10 2  year over year to  67 1 million  Selling  general and administrative expenses increased 25 4  year over year to  177 million Adjusted operating income in the fiscal first quarter totaled  134 6 million  up 12 9  year over year  As a percentage of revenues  operating margin was 16 2   down 30 bps Guidance RetainedFor fiscal 2020  Varian continues to expect revenues within  3 52  3 61 billion  representing year over year growth of 9 12  and organic growth of 7 9   The Zacks Consensus Estimate for the same stands at  3 57 billion Adjusted EPS is projected between  5 30 and  5 45  The Zacks Consensus Estimate is pegged at  5 39 Our TakeVarian exited the fiscal first quarter on a weak note  However  the company continues to gain from its core Oncology Systems segment  which saw solid overseas growth  especially in EMEA and China  In fact  management foresees tremendous opportunities in China owing to the recent tariff exclusions  Gross orders surged in the quarter  Management is optimistic about the recently closed acquisitions of CyberHeart  Cancer Treatment Services International  Endocare and Alicon  Expansion in gross margin is an added positive  Varian retained its outlook for fiscal 2020 On the flip side  the Proton Solutions unit was weak in the quarter  Moreover  Varian saw some softness in orders in Japan Key PicksSome better ranked stocks in the broader medical space are Cerner   NASDAQ CERN    DexCom   NASDAQ DXCM   and HealthEquity   NASDAQ HQY    each carrying a Zacks Rank  2  Buy   You can see  The Zacks Consensus Estimate for Cerner s fourth quarter revenues is pegged at  1 43 billion  suggesting a year over year increase of 5   The same for EPS stands at 74 cents  indicating a year over year upside of 17 5  The Zacks Consensus Estimate for DexCom s fourth quarter revenues is pinned at  457 million  calling for a year over year increase of 35 2   The same for EPS stands at 72 cents  hinting at year over year growth of 33 3  The Zacks Consensus Estimate for HealthEquity s fiscal fourth quarter revenues is pegged at  193 6 million  calling for a year over year increase of 155 5   The same for EPS stands at 19 cents Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  50    83  and  164  in as little as 2 months  The stocks in this report could perform even better ",2020-01-30,Zacks Investment Research,https://www.investing.com/analysis/varian-var-earnings-and-revenues-miss-estimates-in-q1-200503021,200503021
106682,328197,DXCM,CONMED  CNMD  Earnings And Revenues Beat Estimates In Q4,opinion,CONMED Corporation   NASDAQ CNMD   reported fourth quarter 2019 adjusted earnings per share of 90 cents  which beat the Zacks Consensus Estimate of 89 cents by 1 1   Further  the figure improved 23 3  from the year ago quarter The New York based medical products manufacturer reported revenues of  264 9 million  up 9 2  on a year over year basis and 9 3  at constant currency  cc   Notably  the figure surpassed the Zacks Consensus Estimate by 0 01  2019 at a GlanceIn 2019  the company reported revenues worth  955 1 million  which improved 11 1  from the previous year Adjusted EPS for the year was  2 64  which improved 21 1  from 2018 Segment DetailsOrthopedic SurgeryRevenues in the segment totaled  123 8 million  down 0 8  from the year ago quarter Both domestically and on international basis Orthopedics revenue fell 0 8  from their respective prior year quarter s levels General SurgeryRevenues in the segment totaled  141 1 million  up 19 9  year over year Domestically  General Surgery sales improved 23 1  year over year and international sales advanced 14  Sales by GeographyIn the reported quarter  sales in the United States amounted to  142 5 million  up 13 8  year over year  International sales improved 4 4  to  122 4 million CONMED Corporation Price  Consensus and EPS Surprise    MarginsGross profit in the quarter totaled  141 9 million  up 7  year over year  Per management  adjusted gross margin was 54 1   contracting 60 bps Operating income came in at  27 9 million  up 7 9  year over year  Operating margin was 10 5   down 20 bps year over year Financial ConditionCash flow from operations for the year was  95 1 million compared with  74 7 million in 2018  Long term debt at the end of the year was  753 6 million  down 3 5  sequentially 2020 GuidanceCONMED expects 2020 organic constant currency sales growth between 7  and 7 5   On the basis of current exchange rates  the negative impact to 2020 sales from forex is now anticipated between 120 bps and 150 bps CONMED projects adjusted diluted net earnings per share in the range of  3 08 to  3 13  indicating growth of about 17 19  over 2019  Notably  the Zacks Consensus Estimate is pegged at  3 04  lower than the guided range Wrapping UpCONMED exited the fourth quarter on a solid note  wherein earnings and revenues beat the respective estimates  The company s core unit   General Surgery   continues to aid the top line  Solid international sales growth remains a positive  Strong 2020 guidance instills optimism in the stock  The company continues to expect investments in R D to be between 4 5  and 5  of sales in 2020 Apart from this  the company completed the successful integration of the Buffalo Filter buyout and launched a wide array of innovative new products  Notably  CONMED exited the year by raising investment in its sales organization during the fourth quarter as planned  further strengthening its foundation for sustainable near  and long term revenue and profitability growth Meanwhile  the company s high long term debt remains a concern  Further  the company s Orthopedic Surgery unit displayed weak performance in the quarter under review  Additionally  CONMED operates in a highly competitive environment  especially with respect to the General Surgery business Zacks RankCONMED currently carries a Zacks Rank  2  Buy  Other Key PicksSome other top ranked stocks in the broader medical space are SeaSpine Holdings Corporation   NASDAQ SPNE    STERIS plc   NYSE STE   and DexCom  Inc    NASDAQ DXCM    all three carrying a Zacks Rank of 2  You can see  The Zacks Consensus Estimate for SeaSpine s fourth quarter 2019 revenues is pegged at  43 6 million  suggesting growth of 14 7  from the prior year reported figure  The same for loss per share is anticipated at 44 cents  indicating an improvement of 16 9  from the year ago reported figure The Zacks Consensus Estimate for STERIS s fourth quarter fiscal 2020 revenues is pegged at  749 7 million  indicating an improvement of 7 7  from the year earlier reported figure  The same for adjusted earnings per share stands at  1 43  indicating growth of 13 5  from the year ago reported figure The Zacks Consensus Estimate for DexCom s fourth quarter 2019 revenues is pegged at  457 million  suggesting growth of 35 2  from the prior year reported figure  The same for adjusted earnings per share stands at 72 cents  indicating an improvement 33 3  from the prior year reported figure Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2019  while the S P 500 gained and impressive  53 6   five of our strategies returned  65 8    97 1    118 0    175 7  and even  186 7  This outperformance has not just been a recent phenomenon  From 2000   2019  while the S P averaged  6 0  per year  our top strategies averaged up to  54 7  per year ,2020-01-30,Zacks Investment Research,https://www.investing.com/analysis/conmed-cnmd-earnings-and-revenues-beat-estimates-in-q4-200503550,200503550
106683,328198,DXCM,IDEXX  IDXX  Q4 Earnings Top Estimates  Revenues Grow Y Y,opinion,"IDEXX Laboratories  Inc    NASDAQ IDXX   posted fourth quarter 2019 earnings per share  EPS  of  1 04  reflecting a 6 1  year over year rise  The figure surpassed the Zacks Consensus Estimate by 14 3   Comparable constant currency EPS growth was 17   which excludes the impact of CEO transition charges of 14 cents per share For 2019  EPS came in at  4 89  up 14 8   up 21  at comparable constant currency basis  from the year ago tally  The figure surpassed the Zacks Consensus Estimate by 2 7  Revenues in DetailFourth quarter revenues grew 10 2  year over year to  605 4 million  The metric also beat the Zacks Consensus Estimate by 0 9   The year over year upside was primarily driven by strong global gains in Companion Animal Group   CAG   Diagnostics  recurring revenues For 2019  revenues totaled  2 41 billion  up 9  on a reported basis and 10  on an organic basis  The figure surpassed the Zacks Consensus Estimate by 0 4  Segmental AnalysisIDEXX derives revenues from four operating segments   CAG  Water  Livestock  Poultry and Dairy  LPD   and Other  In the fourth quarter  CAG revenues rose 11   up 11  organically  year over year to  529 8 million  The Water segment s revenues were up 9   up 10  organically  year over year to  32 87 million  LPD revenues rose 8   up 10  organically  to  36 7 million  Revenues at the Other segment grew to  6 1 million IDEXX Laboratories  Inc  Price  Consensus and EPS Surprise
  
   Margins
Gross profit in the fourth quarter rose 10 3  to  331 1 million despite a 10 1  rise in cost of revenues to  274 3 million  Accordingly  gross margin expanded 2 basis points  bps  to 54 7  Sales and marketing expenses rose 10 2  to  105 7 million  while general and administrative expenses moved up 26 6  to  74 7 million  Additionally  research and development expenses rose 16 7  to  35 2 million  Operating margin in the quarter contracted 190 bps to 19 1  Financial PositionIDEXX exited fiscal 2019 with cash and cash equivalents of  90 3 million compared with  123 8 million at the end of 2018  Net cash provided by operating activities at the end of fiscal 2019 was  459 2 million compared with  400 1 million at the end of 2018 2020 OutlookIDEXX has raised its revenue guidance for 2020 to a band of  2 62 2 65 billion  indicating organic and reported revenue growth of 9 10 5    The Zacks Consensus Estimate for revenues of  2 64 billion falls within the company s guided range Meanwhile  the EPS projection has been raised by 12 cents to the band of  5 42    5 58  suggesting annualized growth of 13 16  at CER The Zacks Consensus Estimate for EPS stands at  5 42  within the company s projected range Our TakeIDEXX exited the fourth quarter on a strong note  with better than expected numbers  Solid organic revenue growth is encouraging  The top line in the quarter was driven by strong sales at the CAG business  The company witnessed sturdy gains from CAG Diagnostics in the quarter under review  It also saw strong performances in IDEXX VetLab consumables  reference laboratory diagnostic and consulting as well as moderately robust growth in rapid assay product revenues globally  The strong performance of the company can be attributed to impressive growth in the LPD arm  The global adoption of its latest products and services  including the rapid expansion of Catalyst installed base  is another contributing factor  However  operating margin contracted during the quarter Zacks Rank and Key PicksIDEXX currently has a Zacks Rank  3  Hold   Some better ranked stocks in the broader medical space are SeaSpine Holdings Corporation   NASDAQ SPNE    STERIS plc   NYSE STE   and DexCom  Inc    NASDAQ DXCM    all three carrying a Zacks Rank of 2  Buy   You can see  The Zacks Consensus Estimate for SeaSpine s fourth quarter 2019 revenues is pegged at  43 6 million  suggesting 14 7  growth from the prior year reported figure  The same for loss per share is anticipated at 44 cents  implying a 16 9  improvement from the year ago reported number The Zacks Consensus Estimate for STERIS  third quarter fiscal 2020 revenues is pegged at  749 7 million  hinting at a 7 7  increase from the year earlier reported figure  The same for adjusted earnings per share stands at  1 43  indicating a 13 5  rise from the year ago reported figure The Zacks Consensus Estimate for DexCom s fourth quarter 2019 revenues is pegged at  457 million  suggesting 35 2  growth from the prior year reported figure  The same for adjusted earnings per share stands at 72 cents  implying a 33 3  improvement from the year earlier reported figure Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2019  while the S P 500 gained and impressive  53 6   five of our strategies returned  65 8    97 1    118 0    175 7  and even  186 7  This outperformance has not just been a recent phenomenon  From 2000   2019  while the S P averaged  6 0  per year  our top strategies averaged up to  54 7  per year ",2020-01-30,Zacks Investment Research,https://www.investing.com/analysis/idexx-idxx-q4-earnings-top-estimates-revenues-grow-yy-200503723,200503723
106684,328199,DXCM,ResMed  RMD  Q2 Earnings Beat Estimates  Margins Expand,opinion,"ResMed Inc    NYSE RMD   announced second quarter fiscal 2020 results  wherein adjusted earnings per share  EPS  were  1 21  up 21  year over year  The metric also beat the Zacks Consensus Estimate by 19 8  On a GAAP  reported  basis  EPS was  1 10 for the quarter under review  reflecting an increase of 27 9  from the year ago period Second quarter revenues  on a reported basis  increased 13 1  year over year  up 14  at constant exchange rate or CER  to  736 2 million  The figure surpassed the Zacks Consensus Estimate by 1 5  Non GAAP revenues  adding back fair value adjustment of deferred revenues  were  736 8 million  reflecting an improvement of 12 8  from the year ago adjusted figure ResMed Inc  Price  Consensus and EPS Surprise
    A Closer View of the Top LineGeographically  excluding Software as a Service  revenues in the United States  Canada and Latin America improved 14  from the prior year period to  408 million on the robust performance of its mask and device product portfolios Global revenues from Software as a Service in the quarter under review summed  86 7 million  representing a 37  increase year over year Revenues in combined Europe  Asia and other markets were  241 5 million  highlighting an 8  rise at CER from the year earlier number MarginsGross margin for the fiscal second quarter was 59 7   reflecting a 72 basis point  bps  expansion from the year ago number  The expansion was fueled by benefits from changes in the product mix  and manufacturing and procurement efficiencies Selling  general and administrative expenses were up 6 1  year over year to  171 4 million  up by 8  at constant exchange rate or CER   However  excluding the effects of recent acquisitions  the metric rose to 23 3  year over year  or up 2  at CER  Research and development expenses increased 15 8  to  49 9 million  up 18  at CER   This  in turn  increased adjusted operating expenses by 8 1   which amounted to  221 4 million  However  adjusted operating margin in the reported quarter expanded 209 bps to 29 6  Financial UpdatesResMed exited the second quarter of fiscal 2020 with cash and cash equivalents of  204 1 million compared with  172 2 million at the end of the first quarter Cumulative cash flow from operating activities was  232 3 million at the end of the second quarter compared with  177 6 million in the year ago period Along with the earnings release  ResMed announced a regular quarterly dividend payout of 39 cents per share Our TakeThe company exited second quarter fiscal 2020 on a solid note  with earnings and revenues beating the Zacks Consensus Estimate  It is encouraging to note that ResMed registered growth at CER across both its key operating segments   Total Sleep and Respiratory Care  and Software as a Service Mask sales were particularly strong in Europe and Asia  Within Software as a Service  the company recorded continued momentum in the Brightree service portfolio and an additional contribution from the MatrixCare buyout However  in the quarter  device sales in France were impacted as customers completed their connected device upgrade programs Zacks Rank and Key PicksResMed currently carries a Zacks Rank  3  Hold  Some better ranked stocks in the broader medical space are SeaSpine Holdings Corporation   NASDAQ SPNE    STERIS plc   NYSE STE   and DexCom  Inc    NASDAQ DXCM    all these currently carry a Zacks Rank of 2  Buy   You can see The Zacks Consensus Estimate for SeaSpine s fourth quarter 2019 revenues is pegged at  43 6 million  suggesting 14 7  growth from the prior year reported figure  The same for loss per share is anticipated at 44 cents  implying a 16 9  improvement from the year ago reported number The Zacks Consensus Estimate for STERIS s third quarter fiscal 2020 revenues is pegged at  749 7 million  hinting at a 7 7  increase from the year earlier reported figure  The same for adjusted earnings per share stands at  1 43  indicating a 13 5  rise from the year ago reported figure The Zacks Consensus Estimate for DexCom s fourth quarter 2019 revenues is pegged at  457 million  suggesting 35 2  growth from the prior year reported figure  The same for adjusted earnings per share stands at 72 cents  implying a 33 3  improvement from the year earlier reported figure Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2019  while the S P 500 gained and impressive  53 6   five of our strategies returned  65 8    97 1    118 0    175 7  and even  186 7  This outperformance has not just been a recent phenomenon  From 2000   2019  while the S P averaged  6 0  per year  our top strategies averaged up to  54 7  per year ",2020-01-30,Zacks Investment Research,https://www.investing.com/analysis/resmed-rmd-q2-earnings-beat-estimates-margins-expand-200503695,200503695
106686,328201,DXCM,Edwards Lifesciences  EW  Q4 Earnings Lag  Sales Top Estimates,opinion,"Edwards Lifesciences Corporation s   NYSE EW   fourth quarter 2019 adjusted earnings per share  EPS  were  1 46  missing the Zacks Consensus Estimate by 1 4   Moreover  the figure improved 24 8  year over year The company s EPS  on a reported basis  was  1 32 in the quarter  marking a massive surge from the year ago figure of 3 cents For 2019  adjusted EPS was  5 57  up 18 5  from the year ago number  The figure missed the Zacks Consensus Estimate by 0 5  Sales DetailsFourth quarter net sales improved 20  year over year to  1 17 billion and surpassed the Zacks Consensus Estimate by 1 7   Additionally  underlying sales increased 19  Revenues were primarily driven by significant growth in Transcatheter Aortic Valve Replacement  TAVR  sales and strong performance of the Critical Care product line For the year  net sales were  4 35 billion  up 16 9  from the year ago figure  The figure beat the Zacks Consensus Estimate by 0 5  Edwards Lifesciences Corporation Price  Consensus and EPS Surprise
    Segmental DetailsIn the fourth quarter  sales in the TAVR product group amounted to  763 million  up 30  from the prior year figure  both on reported and underlying basis In the United States  total TAVR procedures rose around 40  year over year  Outside the United States  total TAVR procedures grew in the high teens on a year over year basis Surgical Structural Heart s sales in the quarter totaled  205 million  down 1  from the year ago quarter on a reported basis and down 3  on an underlying basis  Per management  the downside resulted from lower surgical aortic valve procedures in the United States as TAVR adoption increased Critical Care sales totaled  199 million in the fourth quarter  up 12  from the year ago quarter on a reported basis and up 8  on an underlying basis The upside was driven by robust demand for the HemoSphere advance monitoring platform and continued adoption of Smart Recovery Transcatheter Mitral and Tricuspid Therapies  TMTT  sales totaled  7 million  adversely impacted by the voluntary PASCAL system field corrective action completed in the fourth quarter MarginsIn the fourth quarter  gross margin contracted 37 bps to 75 6   Favorable impacts from foreign exchange rates and product mix were offset by spending in support of the new European device regulations and manufacturing variances SG A expenses rose 20 5  year over year to  347 million  driven by increased field clinical personnel to support TAVR cases in the United States and TMTT cases in Europe R D expenditures escalated 18 9  year over year to  194 million due to significant investments in transcatheter structural heart programs  Adjusted operating margin in the quarter contracted 31 bps to 29 5   Cash PositionEdwards Lifesciences exited 2019 with cash and cash equivalents  and short term investments of  1 5 billion compared with  0 86 billion at the end of 2018  Long term debt at the end of 2019 was  594 4 million compared with  593 8 million at the end of 2018 At the end of 2019  net cash provided from operating activities was  1 18 billion compared with  0 93 billion a year ago  Capital expenditure rose to  254 4 million from  238 7 million a year ago Guidance ImpressiveFor 2020  Edwards Lifesciences updated its 2020 guidance  The company now projects 2020 adjusted EPS of 6 15  6 40  higher than  6 05  6 30 mentioned earlier  The Zacks Consensus Estimate is pegged at  6 14  indicating a decline from the company s guided range Edwards Lifesciences projects 2020 total revenues of  4 6  5 0 billion compared with  4 5  5 0 billion mentioned earlier  The Zacks Consensus Estimate of  4 80 billion falls within the company s guidance For first quarter 2020  the company forecasts total sales between  1 15 billion and  1 2 billion  The Zacks Consensus Estimate for the same stands at  1 14 billion  which lies below Edwards Lifesciences  envisioned range  Adjusted EPS is anticipated between  1 49 and  1 59  The Zacks Consensus Estimate for the same is pegged at  1 47  below the company s guided range Our TakeEdwards Lifesciences exited the fourth quarter on a mixed note  Globally  TAVR procedures delivered growth  led by strong therapy adoption across all geographies  particularly in the United States  We are also upbeat about robust sales growth within the Critical Care segment  Moreover  lifted 2020 EPS guidance increases investors  optimism on the stock However  dismal performances in Surgical Structural Heart and TMTT segments are worrying   Also  both margins contracted in the fourth quarter  Moreover  tough competition in the cardiac devices market and reimbursement issues raise concerns Zacks Rank and Key PicksEdwards Lifesciences currently has a Zacks Rank 3  Hold   Some better ranked stocks in the broader medical space are SeaSpine Holdings Corporation   NASDAQ SPNE    STERIS plc   NYSE STE   and DexCom  Inc    NASDAQ DXCM    all three currently carry a Zacks Rank of 2  Buy   You can see  The Zacks Consensus Estimate for SeaSpine s fourth quarter 2019 revenues is pegged at  43 6 million  suggesting 14 7  growth from the prior year reported figure  The consensus estimate for loss per share is anticipated at 44 cents  implying a 16 9  improvement from the year ago reported number The Zacks Consensus Estimate for STERIS s third quarter fiscal 2020 revenues is pegged at  749 7 million  hinting at a 7 7  increase from the year earlier reported figure  The consensus estimate for adjusted earnings per share stands at  1 43  indicating a 13 5  rise from the year ago reported figure The Zacks Consensus Estimate for DexCom s fourth quarter 2019 revenues is pegged at  457 million  suggesting 35 2  growth from the prior year reported figure  The consensus estimate for adjusted earnings per share stands at 72 cents  implying a 33 3  improvement from the year earlier reported figure Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2019  while the S P 500 gained and impressive  53 6   five of our strategies returned  65 8    97 1    118 0    175 7  and even  186 7  This outperformance has not just been a recent phenomenon  From 2000   2019  while the S P averaged  6 0  per year  our top strategies averaged up to  54 7  per year ",2020-01-30,Zacks Investment Research,https://www.investing.com/analysis/edwards-lifesciences-ew-q4-earnings-lag-sales-top-estimates-200503691,200503691
106691,328206,DXCM,Best Thematic ETFs For 2020  Cloud  Internet Of Things   More,opinion,"In this episode of ETF Spotlight  I speak with Jay Jacobs  Head of Research   Strategy at Global X  Global X is well known for its suite of 17 ETFs focused on disruptive growth trends 
Cloud is fast emerging as the new model of computing as many companies now prefer to rely on cloud based service providers for highly specialized computing services so that they can focus on their core businesses 
Cloud computing revenues soared 246  in the past decade  and are expected to grow by another 30  before 2023  according to  
The Global X Cloud Computing ETF   which made its debut in April last year  has already gathered about  468 million in assets  While Amazon   NASDAQ AMZN   and Microsoft   NASDAQ MSFT   the leaders in cloud computing are included in the portfolio  the fund s top holdings are pure play cloud companies like Zscaler   NASDAQ ZS    Shopify   NYSE SHOP   and Twilio   NYSE TWLO   
The Internet of Things  IoT  has received a lot of attention over the past few years  thanks mainly to the growing appetite for smart  connected devices  The says in a recent issue   One forecast is that by 2035 the world will have a trillion connected computers  built into everything from food packaging to bridges and clothes  
5G technology will enable handling massive data volumes at very high speeds from billions of connected devices and unlock the full potential of the IoT 
The Global X Internet Of Things ETF   SI SNSR   holds companies that facilitate the IoT industry  Its top holdings include Skyworks   NASDAQ SWKS   and DexCom   NASDAQ DXCM   
The Global X Video Games   Esports ETF   JK HERO   invests in video game developers   publishers  hardware manufacturers  esports and streaming providers  and operators and owners of leagues  Nvidia   NASDAQ NVDA   and Electronic Arts   NASDAQ EA   are among the top holdings 
The Global X U S  Infrastructure Development ETF  could benefit from bipartisan support for investing in America s infrastructure 
The Global X Thematic Growth ETF  is a fund of funds that invests in a basket of individual thematic ETFs 
Please visit to learn more about these ETFs  Make sure to be on the lookout for the next edition of the ETF Spotlight  If you have any comments or questions  please email 
Disclosure  I own CLOU and SNSR in the ETF Investor portfolio that I manage 
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2020-01-30,Zacks Investment Research,https://www.investing.com/analysis/best-thematic-etfs-for-2020-cloud-internet-of-things--more-200503661,200503661
113243,334758,DXCM,FDA OKs Tandem Diabetes Care s new t slim X2 insulin pump  shares up 63 ,news,Nano cap Tandem Diabetes Care  TNDM  62 8   jumps on the news that the FDA has approved its t slim X2 Insulin Pump that is integrated with  DexCom  s  DXCM  0 4   G5 Mobile continuous glucose monitor  The company says it is the first sensor augmented insulin pump approved that allows users to make treatment decisions without a finger prick blood sample Commercial launch is underway Now read ,2017-08-28,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-tandem-diabetes-cares-new-tslim-x2-insulin-pump-shares-up-63-523013,523013
113244,334759,DXCM,Healthcare   Top 5 Gainers   Losers as of 11 00 am,news,Gainers  APOP  54   CCXI  38   AHPI  16   BOLD  14   VNRX  13  Losers  AQB  19   INSY  17   DXCM  9   DRIO  8   ONCE  8  Now read ,2018-01-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/healthcare--top-5-gainers--losers-as-of-1100-am-1063040,1063040
113245,334760,DXCM,DexCom down 10  on Medicare coverage for Abbott s FreeStyle Libre CGM,news,DexCom   DXCM  10 3   is under pressure on 50  higher volume in apparent response to Abbott s  ABT  0 5   announcement that its continuous glucose monitoring  CGM  system  FreeStyle Libre  now has Medicare coverage Abbott says the device is calibrated at the factory so no user calibration is necessary and there is no need for routine fingersticks  DexCom s G5 requires both Now read ,2018-01-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/dexcom-down-10-on-medicare-coverage-for-abbotts-freestyle-libre-cgm-1063027,1063027
113390,334905,DXCM,What s In The Cards For Exact Sciences   EXAS  Q4 Earnings ,opinion,Exact Sciences Corporation   NASDAQ EXAS   is set to report fourth quarter and 2019 results on Feb 11  after market close In the last reported quarter  the company posted a positive earnings surprise of 24 39   It reported better than expected earnings in three of the trailing four quarters  with a surprise of 19 92   on average Let s take a look at how things have shaped up for this announcement Exact Sciences Corporation Price and EPS Surprise   Key CatalystsThe main contributor to Exact Sciences  top line is the laboratory service revenues generated from Cologuard  a non invasive screening test for colorectal cancer  Cologuard volume grew quite impressively in the third quarter on receiving higher number of orders for the Cologuard test from healthcare providers  This growth is likely to have continued in the fourth quarter as well Further  going by the company s outlook  the average Cologuard revenue per test and per completed test is projected to be higher in the fourth quarter than its previous quarter level on the back of full quarter accretion from the opening of a new lab Key DevelopmentThe highlight of the fourth quarter was the completion of the previously announced combination with Genomic Health  thus joining two leading brands in cancer diagnostics   Cologuard and Oncotype DX   and providing a robust platform for continued growth  The company  while announcing its preliminary result  provided an update related to the integration synergy of Genomic Health in the fourth quarter  which we have discussed in the following segment Q4 and 2019 Preliminary ResultsExact Sciences announced preliminary revenue results for fourth quarter and full year 2019 on Jan 12  2020 The company expects total revenues for the fourth quarter between  294 million and  296 million whereas the same metric for 2019 is  874 5  876 5 million  The company expects a boost in the total revenues for the year owing to growth in Cologuard and Oncotype DX  Also  Screening  revenues from Cologuard and Biomatrica products  and Precision Oncology  global Oncotype DX product  proforma revenues are projected to see growth Cologuard and Oncotype DX are expected to have performed impressively in the to be reported quarter with volume increases of 477 000  up 63   and 41 000  up 14   respectively  For the quarter  Screening revenues are likely to be around  229  230 million  indicating an increase of 61  year over year Precision Oncology proforma revenues for the fourth quarter are expected between  118 million and  119 million  suggesting 13  rise   provided the Genomic Health buyout is the only driving factor  However  Precision Oncology revenues for the period between Nov 8 and Dec 31  2019 are likely to be  65  66 million  following the completion of the Genomic Health acquisition Q4   2019 EstimatesThe Zacks Consensus Estimate for total revenues of  294 6 million suggests growth of 106 1  from the prior year quarter s reported figure  Also  the consensus mark for loss per share of 34 cents indicates an improvement of 22 7  from the year ago quarter s reported figure For the year  the Zacks Consensus Estimate for total revenues is pegged at  875 4 million  The same for loss per share is pegged at  1 61  suggesting a decline of 18 4  from the year ago period What Our Quantitative Model PredictsOur proven model predicts an earnings beat for Exact Sciences this time around  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the chances of an earnings beat  You can uncover the best stocks to buy or sell before they re reported with our  Earnings ESP  Exact Sciences has an Earnings ESP of  7 01  Zacks Rank  The company currently carries a Zacks Rank  3 Other Stocks to ConsiderHere are a few other medical stocks worth considering  as these too have the right combination of elements to post an earnings beat this quarter DexCom  Inc    NASDAQ DXCM   currently has an Earnings ESP of  12 27  and a Zacks Rank  2  You can see Tandem Diabetes Care  Inc    NASDAQ TNDM   has an Earnings ESP of  27 59   It currently has a Zacks Rank  2 Xenon Pharmaceuticals Inc    NASDAQ XENE   has an Earnings ESP of  237 50   It currently sports a Zacks Rank  1 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 7  per year  So be sure to give these hand picked 7 your immediate attention ,2020-02-05,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-cards-for-exact-sciences-exas-q4-earnings-200504464,200504464
113391,334906,DXCM,BD Life Sciences To Aid Becton  Dickinson  BDX  Q1 Earnings,opinion,"Becton  Dickinson and Company s   NYSE BDX    popularly known as BD  first quarter fiscal 2020 results are scheduled for release on Feb 6  before market opens  While the results are likely to show steady growth in the core BD Life Sciences segment  foreign exchange and tariff headwinds are expected to leave an impact BD delivered a positive earnings surprise of 0 3  in the last reported quarter and has a positive average earnings surprise of 0 5  for the trailing four quarters How Are Estimates Placed For the quarter to be reported  the Zacks Consensus Estimate for BD s adjusted earnings per share  EPS  is pegged at  2 64  suggesting a year over year decline of 2 2   The same for revenues stands at  4 17 billion  indicating an increase of 0 2  Let s see how things are shaping up prior to the earnings release Becton  Dickinson and Company Price and EPS Surprise
    BD Life Sciences Likely to Hold KeyIn the first quarter  BD Life Sciences is expected to have benefited from strong year over year growth in revenues from assays  which are used to detect a broad range of infectious diseases  healthcare associated infections and cancer It is encouraging to note that for the fiscal first quarter  the Zacks Consensus Estimate for the segment s revenues is pegged at  1 09 billion  suggesting a year over year rise of 2 8   Notably  strong performance by the Diagnostic Systems and Biosciences sub units is expected to have worked in favor  In fact  the Zacks Consensus Estimate for the Biosciences sub unit is pinned at  294 million  calling for a rise of 4 6  year over year  The same for BD Diagnostic systems stands at  391 million  suggesting a 2 4  hike Also  strength in molecular platform   BD MAX and microbiology solutions are likely to be key catalysts  Management expects BD Life Sciences revenues to grow between 6  and 7  Other Factors at PlayStrong performance by the BD Interventional arm might reflect on the company s first quarter results BD expects its Critical Care business and the Arctic Sun Stat launch under its Interventional arm to have driven the segment s first quarter revenues  Resultantly  the Zacks Consensus Estimate for the segment s first quarter revenues is pegged at  994 million  indicating a rise of 2 5  year over year In the quarter to be reported  management expects BD Life Sciences and Interventional to see strong double digit growth in China while BD Medical is likely to witness single digit growth However  a strengthening U S  dollar is expected to have impacted the segment s overseas revenues That s not all  Management at BD expects tariff and foreign currency related headwinds to show on first quarter results  Hence  BD projects lower than expected fiscal first quarter EPS between  2 55 and  2 65 What Does Our Model Say Per our proven model  a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise  However  that is not the case here Earnings ESP  BD has an Earnings ESP of 0 00   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  BD carries a Zacks Rank  4  Sell  Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this time around DexCom   NASDAQ DXCM   has an Earnings ESP of  12 27  and a Zacks Rank  2 Change Healthcare   NASDAQ CHNG   has an Earnings ESP of  1 83  and a Zacks Rank  1 Glaukos   NYSE GKOS   has an Earnings ESP of  17 65  and a Zacks Rank  3 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 7  per year  So be sure to give these hand picked 7 your immediate attention ",2020-02-05,Zacks Investment Research,https://www.investing.com/analysis/bd-life-sciences-to-aid-becton-dickinson-bdx-q1-earnings-200504275,200504275
113412,334927,DXCM,What s In The Cards For Zimmer Biomet  ZBH  In Q4 Earnings ,opinion,"Zimmer Biomet Holdings  Inc    NYSE ZBH   is set to report fourth quarter 2019 results on Feb 4  before market open The company delivered a positive earnings surprise of 0 57  in the last reported quarter  The metric beat the consensus mark in the preceding four quarters  the average beat being 0 41  Let s take a look at how things are shaping up prior to this announcement Zimmer Biomet Holdings  Inc  Price and EPS Surprise
    Key CatalystsThe company s multinational distribution agreement with Align  NASDAQ ALGN  Technology  inked in September 2019  for the latter s iTero Element family of intraoral scanners is expected to have contributed to the top line in the fourth quarter Zimmer Biomet is likely to have registered strong sales growth in the Asia Pacific  the Americas and EMEA  Europe  Middle East and Africa  regions in the fourth quarter on the solid performance of its knee portfolio The S E T  arm  comprising Surgical  Sports Medicine  Foot and Ankle  Extremities and Trauma  is likely to have performed well in the fourth quarter  banking on supply stability  which continues to grow sales force confidence  increased traction in the specialized sales channel and new products across the business  Earlier  the company planned to prioritize innovation and accelerate investments in its specialized sales channel in the second half of 2019 to further intensify focus on high growth S E T  markets  Impacts of this might get reflected in fourth quarter results  Further  the ROSA portfolio has been performing well  which is likely to have continued in the fourth quarter as well Within Dental  the company has been gaining traction over the past few quarters  courtesy of investments in priority areas and operational improvements However  in Spine   CMF  Zimmer Biomet has been witnessing growth deceleration due to difficult comps Over the past several months  Zimmer Biomet has been securing a number of important regulatory clearances for knee  brain and spine applications under its ROSA robotics platform  Strength in its FDA cleared JuggerStitch meniscal repair device  which is the next generation meniscus repair technology  along with robust product array is expected to have contributed to the top line in the quarter Per Zimmer Biomet  impacts of the focus on its restructuring program instead of generating a profit motive in 2019  which is a two year effort to streamline its operations  are likely to get reflected in fourth quarter results  The momentum from the move is also expected to get reflected in the company s operating results Meanwhile  as Zimmer Biomet has been concentrating solely on its restructuring initiative  its operating segments are unlikely to have delivered robust performances in the fourth quarter Further  for 2019  the company expects the impact of foreign exchange to be at the high end of 125 175 basis points Q4   2019 EstimatesThe Zacks Consensus Estimate for total revenues of  2 11 billion suggests growth of 1 7  from the prior year quarter s reported figure  Also  the consensus mark for earnings of  2 26 per share indicates a 3 67   rise from the year ago quarter s reported figure For the year  the Zacks Consensus Estimate for total revenues is pegged at  7 96 billion  The same for earnings is pegged at  7 83 per share  suggesting an improvement of 2 49  from the year ago period What Our Quantitative Model PredictsOur proven model predicts an earnings beat for Zimmer Biomet this time around  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the chances of an earnings beat  You can uncover the best stocks to buy or sell before they re reported with our  Earnings ESP  Zimmer Biomet has an Earnings ESP of  0 38  Zacks Rank  The company currently carries a Zacks Rank  3 Other Stocks Worth a LookHere are a few other medical stocks worth considering  as these too have the right combination of elements to post an earnings beat this quarter DexCom  Inc    NASDAQ DXCM   currently has an Earnings ESP of  17 07  and a Zacks Rank  2  You can see DENTSPLY SIRONA Inc    NASDAQ XRAY   presently has an Earnings ESP of  1 16  and a Zacks Rank  2 Tandem Diabetes Care  Inc    NASDAQ TNDM   has an Earnings ESP of  27 59   It currently sports a Zacks Rank  1 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2020-01-28,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-cards-for-zimmer-biomet-zbh-in-q4-earnings-200502572,200502572
113413,334928,DXCM,Stryker  SYK  Q4 Earnings And Revenues Surpass Estimates,opinion,Stryker Corporation   NYSE SYK   reported fourth quarter 2019 adjusted earnings per share  EPS  of  2 49  which beat the Zacks Consensus Estimate by 1 2   Further  the bottom line improved 14 2  year over year and exceeded the high end of management s guidance range The Michigan based medical device company reported revenues of  4 13 billion  which outpaced the Zacks Consensus Estimate by 0 7   Revenues improved 8 8  on a year over year basis and 9 4  at constant currency  cc  2019 at a GlanceIn 2019  the company reported revenues worth  14 88 billion  which beat the Zacks Consensus Estimate  On a year over year basis  the top line improved 9 4  Adjusted EPS for the year was  8 26  which beat the Zacks Consensus Estimate by 0 4   The bottom line also increased 13  year over year Stryker Corporation Price  Consensus and EPS Surprise    Revenues by GeographyRevenues in United States came in at  3 04 billion  up 9 8  year over year  International sales were up 6 2  to  1 09 billion U S  organic sales improved 8 2  and international organic sales came in at 7 6   While solid performance across Orthopaedics  MedSurg and Neurotechnology segments drove growth in the United States  robust gains in emerging markets  Europe  Japan and Canada led to higher international organic sales Segmental AnalysisOrthopaedic  In the quarter under review  revenues in the segment totaled  1 47 billion  up 6 7  year over year  The segment s revenues improved 7 3  at cc  The performance can be attributed to better results at the Knees  Hips and Other sub segments  The company continues to witness solid demand for Mako TKA  Total Knee Arthoplasty  platform or cementless knee and other 3D printed products MedSurg  This segment reported sales of  1 84 billion  up 6 8  year over year  Sales at the segment increased 7 4  at cc  Per management  the segment improved 6 8  organically in the reported quarter  led by strong Endoscopy  Instruments and Medical performances Neurotechnology   Spine  Sales in the segment amounted to  827 million  up 18  year over year and 18 2  at cc  Organically  the segment witnessed growth of 12 5   Per management  the upside was driven by solid performance by the neurotech product lines MarginsIn the fourth quarter  gross profit totaled  2 70 billion  up 10 1  from the year ago quarter  Adjusted gross margin was 66 3   up 60 bps Operating income totaled  944 million  up 35 2  from the prior year quarter  Adjusted operating margin was 28 3   up 80 bps Financial UpdateCash and cash equivalents came in at  4 34 billion  up 19 9  from the year ago quarter Cash flow from operating activities as of Dec 31  2019  came in at  2 19 billion  down 16 1  from the year ago period 2020 OutlookStryker expects 2020 organic net sales growth to be in the range of 6 5 7 5  On a full year basis  adjusted EPS is expected in the band of  9 00 to  9 20  The Zacks Consensus Estimate is pegged at  9 03  within the company s guided range For first quarter 2020  adjusted EPS is anticipated within  2 05 and  2 10  The Zacks Consensus Estimate stands at  2 05  within the company s projected range Wrapping UpStryker exited fourth quarter 2019 on a strong note  with both earnings and revenues beating their respective consensus marks  The company continues to gain from its core MedSurg unit that put up a strong show in the reported quarter  Additionally  strength in flagship Mako platform continues to favor the company  Moreover  solid performance by the neurotech product lines drove the core Neurotechnology   Spine unit in the quarter under review  Solid international growth also buoys optimism  Expansion in operating margin is a positive while a strong outlook for 2020 is indicative of bright prospects However  pricing pressure continues to plague Stryker  Stiff competition in the MedTech space also remains a concern Zacks RankStryker currently carries a Zacks Rank  3  Hold  Key PicksSome better ranked stocks in the broader medical space are SeaSpine Holdings Corporation   NASDAQ SPNE    STERIS plc   NYSE STE   and DexCom  Inc    NASDAQ DXCM    all three carrying a Zacks Rank of 2  Buy   You can see  The Zacks Consensus Estimate for SeaSpine s fourth quarter 2019 revenues is pegged at  43 6 million  suggesting growth of 14 7  from the prior year reported figure  The same for loss per share is anticipated at 44 cents  indicating an improvement of 16 9  from the year ago reported figure The Zacks Consensus Estimate for STERIS s third quarter fiscal 2020 revenues is pegged at  749 7 million  indicating an improvement of 7 7  from the year earlier reported figure  The same for adjusted earnings per share stands at  1 43  indicating growth of 13 5  from the year ago reported figure The Zacks Consensus Estimate for DexCom s fourth quarter 2019 revenues is pegged at  457 million  suggesting growth of 35 2  from the prior year reported figure  The same for adjusted earnings per share stands at 72 cents  indicating an improvement 33 3  from the prior year reported figure Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2020-01-28,Zacks Investment Research,https://www.investing.com/analysis/stryker-syk-q4-earnings-and-revenues-surpass-estimates-200502677,200502677
113414,334929,DXCM,Can Solid IC Growth Aid Boston Scientific  BSX  Q4 Earnings ,opinion,Boston Scientific Corporation   NYSE BSX   is scheduled to report fourth quarter 2019 results on Feb 5  before the opening bell In the last reported quarter  the company s earnings per share exceeded the Zacks Consensus Estimate by 2 63   Meanwhile  it delivered a positive surprise in three of the trailing four quarters  the average beat being 1 97  Let s see how things are shaping up prior to this announcement Key CatalystsWe are upbeat about solid contributions from Boston Scientific s Cardiovascular business group  which comprises Interventional Cardiology  IC  and Peripheral Interventions  PI  Interventional CardiologyWe are once again optimistic about the IC business  which is likely to have helped the company maintain an impressive global growth momentum in the fourth quarter as well  courtesy of an innovative portfolio and robust commercial teamsacross structural heart and coronary therapies  Complex PCI  percutaneous coronary intervention  products within IC are gaining a strong traction from successful global expansion efforts Within IC  the company is demonstrating consistent strength in structural heart with WATCHMAN  ACURATE  SENTINEL and complex PCI and PCI guidance portfolios  In the last reported quarter  WATCHMAN sales growth rate accelerated from the second quarter level as the platform continued to build global momentum on sturdy customer adoption  With Watchman recently securing a reimbursement approval in Japan and riding on the rising uptake and expanding international footprint of the device  this trendmost likely continued in the fourth quarter too Boston Scientific Corporation Price and EPS Surprise   Within catheter business  the ACURATE neo sales grew faster than the market during the third quarter and the product is now available across 45 countries  On continued solid global uptake  we expect this uptrend to reflect on the company s top line in the upcoming quarterly results as well The SENTINEL Cerebral embolic protection device s rollout has been going on extremely well  leading to robust growth rates as supply scales up  We expect this momentum to boost the impending quarterly results Further  the launch of LOTUS Edge in the United States and Europe is drawing a favorable customer response and is also expected to get reflected in the to be reported quarter s results The Zacks Consensus Estimate for IC revenues is pegged at  682 million  indicating an increase of 10  from the year ago reported figure Peripheral Interventions In recent quarters  the PI business steadily demonstrated a solid uptrend across segments like peripheral arterial disease  venous and interventional oncology  The unveiling of Vici Venous Stent in the United States and Eluvia DES globally is doing well and will most likely positively impact the to be reported quarter s results Further  with the completion of BTG acquisition  in August   the consolidated entity is expected to have been significantly accretive to the fourth quarter top line  In this regard  BTG has three primary businesses  of which Interventional Medicine portfolio including various PI product lines is the largest The Zacks Consensus Estimate for fourth quarter PI revenues stands at  369 million  suggesting a 22 2  rise from the prior year reported figure Other Factors at PlayAmong other segments  MedSurg is expected to report stable numbers for the fourth quarter  led by growth within endoscopy  This is likely to have been fueled by a series of multiple introductions across several franchises  most notably in infection prevention  therapeutic imaging  biliary and luminal hemostasis product lines Urology and Pelvic Health segment is also likely to have registered sturdy growth in the fourth quarter  driven by a likely uptick in Stone franchise via LithoVue  lithotripsy and laser portfolio as well as emerging market growth Within neuromodulation  the company might have register robust sales growth in deep brain stimulation and across the continuum of care for pain patients through complementary platforms in SCS  RF and Vertiflex  The company earlier noted that it expects a steady improvement in SCS for the fourth quarter with WaveWriter software enhancement Preliminary Results at a GlanceFor the to be reported quarter  Boston Scientific projects total revenue growth of 13 4  to  2 90 billion from the year ago reported figure  indicating 14 1  rise on an operational basis and 7 3  improvement on an organic basis  Notably  the company s expectation for the same fell below the Zacks Consensus Estimate of  2 92 billion  The preliminary figures are near the lower end of the company s guidance of 13 15   reported basis   14 16   operational basis  and 8 9   organically  Per Boston Scientific  revenues in the fourth quarter improved in all segments  except for Specialty Pharmaceuticals  Data for the Specialty Pharmaceuticals is unavailable due to its integration since the BTG acquisition in August 2019   Excluding buyouts and divestitures  the company s total revenues are predicted to increase 6 8   read more   Which Way Are Estimates Trending The Zacks Consensus Estimate for fourth quarter total revenues of  2 92 billion suggests growth of 14 1  from the prior year reported number  Also  the consensus mark for earnings of 44 cents per share implies a 12 8  rise from the year ago reported figure What Our Quantitative Model PredictsPer our proven model  a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise  But this is not the case here as you will see below Earnings ESP Boston Scientific has an Earnings ESP of 0 00   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank Boston Scientific carries a Zacks Rank  3  Stocks Worth a LookHere are a few medical stocks worth considering as these have the right combination of elements to beat on earnings this time around DexCom  Inc    NASDAQ DXCM   currently has an Earnings ESP of  17 07  and a Zacks Rank  2  You can see DENTSPLY SIRONA Inc    NASDAQ XRAY   presently has an Earnings ESP of  1 16  and a Zacks Rank of 2 Tandem Diabetes Care  Inc    NASDAQ TNDM   has an Earnings ESP of  27 59   It currently sports a Zacks Rank of 1 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2020-01-28,Zacks Investment Research,https://www.investing.com/analysis/can-solid-ic-growth-aid-boston-scientific-bsx-q4-earnings-200502743,200502743
113415,334930,DXCM,Accuray  ARAY  Q2 Earnings Top Estimates  Gross Orders Fall,opinion,"Accuray Incorporated   NASDAQ ARAY   reported second quarter fiscal 2020 adjusted earnings per share  EPS  of a penny  comparing favorably with the Zacks Consensus Estimate of a loss of 7 cents  The company had reported a loss of 5 cents a year ago  Net revenues of this Zacks Rank  3  Hold  company totaled  98 8 million  edging past the Zacks Consensus Estimate of  98 5 million  On a year over year basis  revenues dropped 3 4   Fiscal Q2 Details Product Revenues  Product revenues fell 8 9  year over year to  43 8 million in the reported quarter  Service Revenues  Service revenues totaled  55 1 million  up 1 5  from the year ago quarter Accuray Incorporated Price  Consensus and EPS Surprise
    Gross Order Update  Gross orders in the fiscal second quarter totaled  98 6 million  down 1 6  year over year  However  per management  gross orders in the quarter were above the projected range of  87  90 million  driven by CyberKnife and Radixact platforms  Margins Gross profit in the fiscal second quarter totaled  37 9 million  down 1 3  on a year over year basis  Gross margin was 38 4   highlighting an expansion of 90 basis points  bps  year over year  Research and development expenses contracted 4 2  year over year to  13 1 million  Selling and marketing expenses declined 25 2  to  11 3 million  General and administrative expenses contracted 5 6  to  9 9 million  Second quarter operating income was  3 6 million against a loss of  868 000 in the year ago quarter  Cash Position The company exited second quarter fiscal 2020 with total cash  cash equivalents  and short term restricted cash of  99 1 million  compared with  86 7 million at the end of Sep 30  2019  Guidance Accuray continues to expect revenues within  410  420 million for fiscal 2020  The Zacks Consensus Estimate for the same is pegged at  414 5 million  Management expects higher revenue growth in the second half of fiscal 2020  compared to the first half  Adjusted EBITDA for fiscal 2020 is expected within  21  26 million  Our Take Accuray exited the fiscal second quarter on a strong note  Solid demand for the Radixact  CyberKnife and TomoTherapy platforms drove the top line  We are also upbeat to note that the company s gross orders were driven by continued strength in China and EMEA  Accuray retained its fiscal 2020 revenue guidance  Expansion of gross margin is encouraging as well  On the flip side  the year over year decline in the top line is concerning  In fact  Accuray s Product revenues were soft in the quarter  Accuray also expects a year over year revenue decline in the first half of fiscal 2020  Key Picks Some better ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    DexCom   NASDAQ DXCM   and HealthEquity   NASDAQ HQY    each carrying a Zacks Rank  2  Buy   You can see   The Zacks Consensus Estimate for Cerner s fourth quarter revenues is pegged at  1 43 billion  suggesting a year over year increase of 5   The same for EPS stands at 74 cents  indicating a year over year upside of 17 5   The Zacks Consensus Estimate for DexCom s fourth quarter revenues is pinned at  457 million  calling for a year over year increase of 35 2   The same for EPS stands at 72 cents  hinting at year over year growth of 33 3   The Zacks Consensus Estimate for HealthEquity s fiscal fourth quarter revenues is pegged at  193 6 million  calling for a year over year increase of 155 5   The same for EPS stands at 19 cents  Looking for Stocks with Skyrocketing Upside  Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2020-01-29,Zacks Investment Research,https://www.investing.com/analysis/accuray-aray-q2-earnings-top-estimates-gross-orders-fall-200502518,200502518
113416,334931,DXCM,Thermo Fisher  TMO  Q4 Earnings Top  Organic Growth Solid,opinion,Thermo Fisher Scientific Inc  s   NYSE TMO   fourth quarter 2019 adjusted earnings per share  EPS  of  3 55 beat the Zacks Consensus Estimate by a penny  The figure also improved from the year ago quarter by 9 2   On a reported basis  EPS was  2 49  increasing 12 2  year over year For the full year  adjusted earnings came in at  12 35 per share  ahead of the Zacks Consensus Estimate by 0 2  and also up 11 1  from the year ago figure  The adjusted figure also surpassed the company s guided range of  12 28  12 34 Revenues in the quarter under review grossed  6 83 billion  up 4 9  year over year  The top line also bettered the Zacks Consensus Estimate by 0 7  Full year revenues of  25 54 billion exceeded the Zacks Consensus Estimate by 0 2  and improved 4 9  from 2018 as well  Further  this exceeded the company s projected revenue range of  25 34  25 50 billion for 2019 Quarter in DetailOrganic revenues in the reported quarter grew 5  year over year while acquisitions  net of a divestiture  increased revenues by 1   However currency translation adversely impacted total revenues by a slight 1  Thermo Fisher operates under four business segments  Life Sciences Solutions  Analytical Instruments  Specialty Diagnostics and Laboratory Products and Services Thermo Fisher Scientific Inc  Price  Consensus and EPS Surprise   Revenues at the Life Sciences Solutions segment  26 9  of total revenues  improved 8  year over year to  1 84 billion while Analytical Instruments Segment sales  22 2   dipped 3 2  to  1 52 billion Revenues at the Laboratory Products and Services segment  41 5   rose 9  to  2 83 billion  The Specialty Diagnostics segment  13 8   recorded marginally flat revenues from compared with the year ago quarter s  0 94 billion Gross margin of 46 3  during the fourth quarter contracted 60 basis points  bps  year over year despite a 3 6  rise in gross profits  Adjusted operating margin for the quarter came in at 24 7   reflecting an expansion of 33 bps The company exited 2019 with cash and cash equivalents of  2 34 billion compared with  2 29 billion at the end of 2018  Full year  net cash provided by operating activities was  4 97 billion compared with  4 54 billion a year ago 2020 GuidanceThe company will provide its 2020 financial guidance during its earnings conference call this morning at 8 30 a m Bottom LineThermo Fisher ended the year on a solid note with both fourth quarter EPS and revenues beating the respective Zacks Consensus Estimate  We are also encouraged that Life Sciences Solutions and Laboratory Products and Services segments witnessed strong year over year revenue growth During the reported quarter  the company launched the Ion Torrent Genexus next generation sequencing instrument In 2019  the company broadened its global market reach by setting up new customer solution centers in Seoul and Shanghai for life sciences applications  new centers in Beijing and Delhi for improving food quality and safety  and a new pharma and biotech customer center in Shanghai to accelerate development of new drug therapies Additionally  in 2019  the company strengthened its pharma services network by acquiring viral vector manufacturer Brammer Bio and the GSK active pharmaceutical ingredient manufacturing site in Ireland  It also expanded production capacity at facilities in North America and Europe to perk up growing demand for biologics and gene therapies Meanwhile  gross margin contraction in the fourth quarter is concerning Zacks Rank and Key PicksThermo Fisher currently has a Zacks Ranks  3  Hold   Some better ranked stocks in the broader medical space are SeaSpine Holdings Corporation   NASDAQ SPNE    STERIS plc   NYSE STE   and DexCom  Inc    NASDAQ DXCM    all three carrying a Zacks Rank  2  Buy   You can see  The Zacks Consensus Estimate for SeaSpine s fourth quarter 2019 revenues is pegged at  43 6 million  suggesting 14 7  growth rate from the prior year reported figure  The same for loss per share is anticipated at 44 cents  implying a 16 9  improvement from the year ago reported number The Zacks Consensus Estimate for STERIS s third quarter fiscal 2020 revenues is pegged at  749 7 million  hinting at a 7 7  increase from the year earlier reported figure  The same for adjusted earnings per share stands at  1 43  indicating a 13 5  rise from the year ago reported figure The Zacks Consensus Estimate for DexCom s fourth quarter 2019 revenues is pegged at  457 million  suggesting 35 2  growth from the prior year reported figure  The same for adjusted earnings per share stands at 72 cents  implying a 33 3  improvement from the year earlier reported figure Breakout Biotech Stocks with Triple Digit Profit Potential The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  50    83  and  164  in as little as 2 months  The stocks in this report could perform even better ,2020-01-29,Zacks Investment Research,https://www.investing.com/analysis/thermo-fisher-tmo-q4-earnings-top-organic-growth-solid-200503228,200503228
113417,334932,DXCM,Illumina  ILMN  Q4 Earnings Beat Estimates  Margins Expand,opinion,"Illumina  Inc  s   NASDAQ ILMN   fourth quarter fiscal 2019 adjusted earnings per share  EPS  of  1 70 surpassed the Zacks Consensus Estimate by 6 9   Moreover  the bottom line improved 28 8  from the year ago quarter Including one time items  the company s GAAP  reported  EPS was  1 61  up 14 2  year over year For 2019  adjusted EPS was  6 57  up 14 9  from the year ago figure  Also  the metric surpassed the consensus mark by 1 7  Illumina  Inc  Price  Consensus and EPS Surprise
    RevenuesIn the quarter under review  Illumina s revenues rose 9 9  year over year to  953 million  The top line also surpassed the Zacks Consensus Estimate by 0 6   The year over year improvement can be attributed to the company s sequencing consumable growth and stronger than expected IVD partnership and non DTC array revenues For fiscal 2019  total revenues were  3 54 billion  up 6 3  from the year ago figure  Moreover  it was in line with the Zacks Consensus Estimate Segment DetailsThe Sequencing consumable subsegment revenues were  572 million in the reported quarter  up 21 7  year over year  The Sequencing systems subsegment revenues were  141 million  down by 12 4  from the year ago quarter figure  Sequencing revenues  a subsegment of the Service   Other segment  were  124 million  up 19 2  from the year ago quarter In the fourth quarter of fiscal 2019  HiSeq consumables declined on customers  transition to NovaSeq  Nevertheless  the overall high throughput consumables portfolio witnessed sequential and year over year growth  NextSeq shipments were lower than expected due to customer timing in the fourth quarter  The same witnessed sequential and year over year growth on the placement of record number of NextSeq Dx Systems in the quarter MarginsGross margin  excluding the amortization of acquired intangible assets  was 70 2  in the reported quarter  up 110 basis points  bps  year over year Research and development expenses declined 8 5  year over year to  161 million  and selling  general   administrative expenses rose 7 4  to  233 million  Adjusted operating margin came in at 31   reflecting a massive surge of 670 bps year over year Financial UpdateIllumina exited the fourth quarter of fiscal 2019 with cash and cash equivalents plus short term investments of  3 41 billion compared with  3 17 million at the end of fiscal 2018 In fiscal 2019  net cash provided by operating activities was  1 05 billion compared with  1 14 billion reported in the year ago quarter Fiscal 2020 GuidanceIllumina issued fiscal 2020 guidance  The company expects adjusted revenues of  3 86 3 93 billion for the year  suggesting 9 11  growth  The Zacks Consensus Estimate for revenues stands at  3 90 billion  which is closer to the upper end of the company s guided range Illumina envisions adjusted EPS of  6 80  7 for fiscal 2020  The consensus mark for the metric is pinned at  6 99  which is close to the high end of the company s guidance For first quarter fiscal 2020  Illumina anticipates adjusted revenues of  850  855 million  The consensus estimate for revenues stands at  907 2 million  above the company s projected range Adjusted EPS is estimated at  1 20 1 25 for first quarter fiscal 2020  The Zacks Consensus Estimate for the same is pegged at  1 55  above the company s expected range Our TakeIllumina exited the fourth quarter of fiscal 2019 on an impressive note  with better than expected earnings and revenue figures  It is encouraging to note that top line growth was witnessed across the company s high and mid throughput categories  Non DTC array revenues were also contributed significantly to the top line Illumina continues to witness robust performance across a broad range of sequencing applications  especially in the sequencing consumables segment  The expansion in the company s capabilities  resulting from partnerships with QIAGEN and Adaptive Biotechnologies regarding IVD test kits  buoys optimism On the flip side  a year over year decline in research and development costs  and lower system revenues in the low throughput category  resulting from a weak performance by MiniSeq  were headwinds Zacks Rank   Stocks to ConsiderIllumina currently carries a Zacks Rank  4  Sell  Some better ranked stocks in the broader medical space are SeaSpine Holdings Corporation   NASDAQ SPNE    STERIS plc   NYSE STE   and DexCom  Inc    NASDAQ DXCM    all currently carrying a Zacks Rank of 2  Buy   You can see The Zacks Consensus Estimate for SeaSpine s fourth quarter 2019 revenues is pegged at  43 6 million  suggesting 14 7  growth from the prior year reported figure  The same for loss per share is anticipated at 44 cents  implying a 16 9  improvement from the year ago reported number The Zacks Consensus Estimate for STERIS s third quarter fiscal 2020 revenues is pegged at  749 7 million  hinting at a 7 7  increase from the year earlier reported figure  The same for adjusted earnings per share stands at  1 43  indicating a 13 5  rise from the year ago reported figure The Zacks Consensus Estimate for DexCom s fourth quarter 2019 revenues is pegged at  457 million  suggesting 35 2  growth from the prior year reported figure  The same for adjusted earnings per share stands at 72 cents  implying a 33 3  improvement from the year earlier reported figure Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  50    83  and  164  in as little as 2 months  The stocks in this report could perform even better ",2020-01-29,Zacks Investment Research,https://www.investing.com/analysis/illumina-ilmn-q4-earnings-beat-estimates-margins-expand-200503219,200503219
113418,334933,DXCM,Quest Diagnostics  DGX  Q4 Earnings Beat  Margins Strong,opinion,Quest Diagnostics Incorporated s   NYSE DGX   fourth quarter 2019 adjusted earnings per share  EPS  of  1 67 surpassed the Zacks Consensus Estimate by 4 4   Adjusted earnings also improved 23 7  from the year ago number  The impact of certain one time items  such as restructuring and integration charges plus amortization expenses  was excluded from both the quarters  adjusted figures GAAP EPS from continuing operations came in at  1 86  skyrocketing 101 2  from the year ago quarter For the full year  adjusted earnings of  6 56 per share came ahead of the Zacks Consensus Estimate by 1 1  and also rose 3 9  from the year ago figure  The figure exceeded the company s projected range of  6 45  6 50 as well Reported revenues in the fourth quarter rose 4 7  year over year to  1 93 billion  The same beat the consensus estimate of  1 92 billion Quest Diagnostics Incorporated Price  Consensus and EPS Surprise   Full year revenues of  7 73 billion topped the Zacks Consensus Estimate of  7 72 billion and improved 2 6  from the 2018 level too  This also edged past the company s expected revenues of  7 72 billion Quarterly DetailsVolumes  measured by the number of requisitions  expanded 4 1  year over year in the fourth quarter  up 3 4  organically   Revenue per requisition also inched up 1 2  year over year Diagnostic information services revenues in the quarter were up 5 1  on a year over year basis to  1 84 billion Cost of services during the reported quarter was  1 26 billion  up 2 3  year over year  Gross margin came in at 34 4   reflecting 153 basis point  bps  growth from the year ago figure Selling  general and administrative expenses dipped 1 9  to  349 million in the quarter under review  Adjusted operating margin of 16 3  represented a 277 bps expansion year over year Quest Diagnostics exited 2019 with cash and cash equivalents of  1 19 billion compared with  135 million at the end of 2018  Full year net cash provided by operating activities was  1 24 billion compared with  1 2 billion a year ago In the fourth quarter the board of directors authorized a 5 7  hike in the company s quarterly dividend to 56 cents per share or  2 24 annually  payable Apr 21  2020  The company also increased its share repurchase authorization by  1 billion  bringing the total buyback available to  1 2 billion as of Dec 31  2019 2020 Guidance Quest Diagnostics provided its 2020 outlook  Adjusted EPS for the full year is predicted to be more than  6 60  The Zacks Consensus Estimate for the metric is pegged at  6 73 Revenues for 2020 are estimated in the band of  7 80  7 96 billion  This indicates anticipated growth of 1 3   The current Zacks Consensus Estimate for revenues of  7 90 billion falls within the company s guided band Operating cash flow for 2020 is envisioned in the range of  1 25  1 30 billion  The capital expenditure is forecast at  375  400 million Our TakeQuest Diagnostics reported a strong fourth quarter with both earnings and revenues beating the respective Zacks Consensus Estimate  We are upbeat about the company s expanded network access  which helped the company accelerate volume growth in the fourth quarter  This solid volume expansion combined with its strategy to attain operational excellence aided it to counter significant reimbursement pressure  The current year outlook seems promising despite the company s having reckoned another year of meaningful reimbursement pressure Zacks Rank   Key PicksQuest Diagnostics currently carries a Zacks Rank  4  Sell  Some better ranked stocks in the broader medical space are SeaSpine Holdings Corporation   NASDAQ SPNE    STERIS plc   NYSE STE   and DexCom  Inc    NASDAQ DXCM    all three carrying a Zacks Rank  2  Buy   You can see  The Zacks Consensus Estimate for SeaSpine s fourth quarter 2019 revenues is pegged at  43 6 million  suggesting 14 7  growth rate from the prior year reported figure  The same for loss per share is anticipated at 44 cents  implying a 16 9  improvement from the year ago reported number The Zacks Consensus Estimate for STERIS s third quarter fiscal 2020 revenues is pegged at  749 7 million  hinting at a 7 7  increase from the year earlier reported figure  The same for adjusted earnings per share stands at  1 43  indicating a 13 5  rise from the year ago reported figure The Zacks Consensus Estimate for DexCom s fourth quarter 2019 revenues is pegged at  457 million  suggesting 35 2  growth from the prior year reported figure  The same for adjusted earnings per share stands at 72 cents  implying 33 3  increase from the year earlier reported figure Breakout Biotech Stocks with Triple Digit Profit Potential The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  50    83  and  164  in as little as 2 months  The stocks in this report could perform even better ,2020-01-29,Zacks Investment Research,https://www.investing.com/analysis/quest-diagnostics-dgx-q4-earnings-beat-margins-strong-200503217,200503217
113449,334964,DXCM,Can Critical Care Aid Edwards Lifesciences  EW  Q4 Earnings ,opinion,Edwards Lifesciences Corporation   NYSE EW   is slated to report fourth quarter 2019 results on Jan 30  after market close  In the last reported quarter  the company s earnings of  1 41 exceeded the Zacks Consensus Estimate by 15 6   The trailing four quarter earnings beat is 6 7   on average Let s see how things are shaping up prior to this announcement Which Way Are Estimates Trending For the fourth quarter  the Zacks Consensus Estimate for earnings per share stands at  1 48  suggesting a rise of 26 5  from the year ago reported figure  The same for revenues is pinned at  1 15 billion  indicating 17 8  growth from the prior year reported number Key CatalystsCritical CareThe fourth quarter results are expected to reflect strength in the core Critical Care product group  The segment has been showing solid growth across all product categories and geographies over the last few quarters Management is optimistic about robust customer adoption of the HemoSphere all in one monitoring platform  particularly in the United States and Europe  As management had stated earlier  demand for the platform is expected to have driven the Critical Care group throughout 2019 Edwards Lifesciences Corporation Price and EPS Surprise   We also look forward to the recently received FDA clearance to use FORE SIGHT  a cerebral oximetry technology  from the CASMED acquisition  on HemoSphere  The integration of the full range of technologies with HemoSphere is supposed to have created a unique offering of enhanced recovery tools and predictive analytics capabilities in the field of smart monitoring  This  in turn  is expected to have contributed to the company s fourth quarter top line strongly For 2019  the company expects underlying sales growth of 8 10  in Critical Care In fact  the Zacks Consensus Estimate for the segment s fourth quarter revenues is pegged at  194 million  calling for growth of 8 9  from the year earlier reported number Surgical Structural HeartWithin the Surgical Structural Heart Group  the company is gaining traction from solid aortic unit volume and continued adoption of its latest premium aortic valves  Strong rollout and steady acceptance of the INSPIRIS RESILIA aortic valve across the globe are likely to reflect on fourth quarter sales Edwards Lifesciences projects 2019 underlying sales growth of 1 3  within this segment However  sales might have suffered due to lower surgical aortic valve procedures in the United States The Zacks Consensus Estimate for the segment s fourth quarter revenues is pegged at  201 million  implying a drop of 5 2  from the year earlier reported figure Other Factors at PlayWithin the Transcatheter Aortic Valve Replacement  TAVR  arm  the company is expected to have reported strong fourth quarter numbers on robust therapy adoption across all geographies with notable strength in the United States  The recent FDA indication expansion for SAPIEN 3 and SAPIEN 3 Ultra systems is also expected to have boosted the company s TAVR revenues in the fourth quarter Outside the United states  in November 2019  the company received a CE Mark to expand use of the Edwards SAPIEN 3 transcatheter heart valve for the treatment of patients with aortic stenosis who are at low risk for open heart surgery  This upside is likely to get reflected in fourth quarter results What Our Model SuggestsOur proven model does not predict an earnings beat for Edwards Lifesciences this time around  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the chances of an earnings beat  You can uncover the best stocks to buy or sell before they re reported with our  Edwards Lifesciences has a Zacks Rank  3 and an Earnings ESP of 0 00   You can see  Other Stocks Worth a LookHere are a few other medical stocks worth considering from the same space with the right mix of elements to also surpass expectations this earnings season DexCom  Inc    NASDAQ DXCM   currently has an Earnings ESP of  17 07  and a Zacks Rank  2 Exact Sciences Corporation   NASDAQ EXAS   presently has an Earnings ESP of  12 08  and a Zacks Rank of 2 Tandem Diabetes Care  Inc    NASDAQ TNDM   currently has an Earnings ESP of  27 59  and a Zacks Rank of 1 Zacks Top 10 Stocks for 2020In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2020 Last year s 2019 Zacks Top 10 Stocks portfolio returned gains as high as  102 7   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys ,2020-01-23,Zacks Investment Research,https://www.investing.com/analysis/can-critical-care-aid-edwards-lifesciences-ew-q4-earnings-200501401,200501401
113450,334965,DXCM,NextGen  NXGN  Earnings And Revenues Beat Estimates In Q3,opinion,"NextGen Healthcare  Inc    NASDAQ NXGN   reported third quarter fiscal 2020 adjusted earnings per share  EPS  of 23 cents  beating the Zacks Consensus Estimate of 20 cents  The metric rose 15  from the year ago quarter s figure  Revenues of this Zacks Rank  4  Sell  company totaled  137 7 million  up 5 3  year over year  However  the figure surpassed the Zacks Consensus Estimate by 1 9   Bookings Update Bookings for the quarter came in at  30 6 million  down 6 7  from the year ago quarter s figure  primarily due to change in sales organization NEXTGEN HEALTHCARE  INC Price  Consensus and EPS Surprise
    Segment Details The company reported third quarter fiscal 2020 revenues under the following segments  Total Recurring revenues grossed  124 8 million  up 6 3  from the year ago quarter  Meanwhile  total Software  hardware and other non recurring revenues came in at  13 million  down 0 3  on a year over year basis  Per management  this reflects headwinds in the managed services and software areas  Margin In the quarter under review  gross profit totaled  69 6 million  up 0 6  from the prior year quarter s tally  Gross margin was 50 5   down 240 basis points  bps   Operating income in the fiscal third quarter was  3 3 million  significantly down from the year ago quarter s  6 2 million  Operating margin  as a percentage of revenues  was 2 4   down 230 bps  Fiscal 2020 View Updated For fiscal 2020  NextGen expects revenues between  541 million and  547 million  narrower than the earlier communicated range of  536  550 million  The mid point of the range   544 million  is above the same for the previous range   543 million  The Zacks Consensus Estimate for revenues is pegged at  542 million  Full year EPS is expected between 80 cents and 84 cents  The mid point of 82 cents lies slightly below the Zacks Consensus Estimate which is pegged at 83 cents  Summing Up NextGen gained from its Recurring segment in the quarter under review  Impressive client addition and an impressive fiscal 2020 outlook instil optimism  Meanwhile  NextGen s Software  hardware and other non recurring revenues were soft in the quarter  Bookings also declined in the quarter  Significant contraction in gross and operating margins raises concern  Additionally  NextGen faces stiff rivalry in the MedTech space  Key Picks Some better ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    DexCom   NASDAQ DXCM   and HealthEquity   NASDAQ HQY    each carrying a Zacks Rank  2  Buy   You can see   The Zacks Consensus Estimate for Cerner s fourth quarter revenues is pegged at  1 43 billion  suggesting a year over year increase of 5   The same for EPS stands at 74 cents  indicating a year over year upside of 17 5   The Zacks Consensus Estimate for DexCom s fourth quarter revenues is pinned at  457 million  calling for a year over year increase of 35 2   The same for EPS stands at 72 cents  hinting at year over year growth of 33 3   The Zacks Consensus Estimate for HealthEquity s fiscal fourth quarter revenues is pegged at  193 6 million  calling for a year over year increase of 155 5   The same for EPS stands at 19 cents  Zacks Top 10 Stocks for 2020 In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2020  Last year s 2019 Zacks Top 10 Stocks portfolio returned gains as high as  102 7   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys ",2020-01-24,Zacks Investment Research,https://www.investing.com/analysis/nextgen-nxgn-earnings-and-revenues-beat-estimates-in-q3-200501321,200501321
113451,334966,DXCM,What s In Store For Thermo Fisher  TMO  In Q4 Earnings ,opinion,Thermo Fisher Scientific Inc    NYSE TMO   is slated to release the fourth quarter and 2019 results on Jan 30  before market open  In the last reported quarter  it posted a positive earnings surprise of 2 08   The company reported better than expected earnings results in all of the trailing four quarters  the average being 1 88  Let s discuss the factors that are likely to get reflected in the upcoming results Key CatalystsFor the past few quarters  Thermo Fisher has been witnessing robust revenue growth and improvement in earnings performance  banking on the continued focus on significant value creation from its R D investments Thermo Fisher Scientific Inc  Price and EPS Surprise   In the last reported quarter  Thermo Fisher benefitted from the launch of analytical instruments for the diagnostic laboratory  The company is expected to have continued gaining from the same in the fourth quarter We are upbeat about continued robust performances of Thermo Fisher s three systems  which are FDA listed Class I medical devices    Vanquish MD High Performance Liquid Chromatography  HPLC   TSQ Altis MD Series mass spectrometer and Quantis MD Series mass spectrometer   in the analytical instruments segment  This  while improving the company s comprehensive platform for developing sensitive and reliable laboratory developed tests  LDTs   is likely to have continued to aid its performance in the fourth quarter The Zacks Consensus Estimate for analytical instruments  revenues is pegged at  15 93 billion for the fourth quarter  suggesting an increase of 1 6  from the year ago quarter s reported figure Product launches through the second half of 2019 are expected to have driven revenue growth for the life science solutions segment in the fourth quarter  A new generation of Krios instrument  Krios G4  in the company s Cryo EM platform for structural biology applications  the real time PCR pathogen detection system and scalable bioreactor workflow called TruBio Discovery Automation System  a scalable bioreactor workflow  are some of the highlighted launches  which are likely to have contribute to Thermo Fisher top line in the fourth quarter Apart from this  the addition of Brammer Bio  a leader in viral vector manufacturing for gene and cell therapies   which expanded the company s offering in the fast growing gene therapy market  is likely to have contributed significantly to its fourth quarter top line  In October 2019  it completed the acquisition of an active pharmaceutical ingredient manufacturing facility from GlaxoSmithKline  GSK   which is expected to have aided to Thermo Fisher s fourth quarter performance The Zacks Consensus Estimate for life science solutions  revenues is pegged at  18 20 billion for the fourth quarter  suggesting an increase of 7 2  from the year ago quarter s reported number Within specialty diagnostics  Thermo Fisher has been witnessing broad based growth  backed by robust performances by transplant diagnostics and immunodiagnostics  Further  the company has been enhancing its capabilities to serve the growing biopharmaceutical industry in China  which is its largest market outside the United States   To this end  it earlier expanded its clinical trial capabilities by setting up a facility in Suzhou  China  The company also announced the official opening of a Customer Solution Center in Shanghai  China  in November 2019  These developments have likely contributed to Thermo Fisher s top line in the fourth quarter The Zacks Consensus Estimate for specialty diagnostics  revenues is pegged at  921 million for the fourth quarter  suggests a decline of 3 2  from the year ago quarter s reported figure Other Factors to NoteTurning to pharma and biotech  the company witnessed strong growth in the third quarter  backed by consistent strength in all end markets  with a wide range of products and services  This is expected to have continued in the fourth quarter However  Thermo Fisher expects foreign exchange fluctuation to have negatively impacted fourth quarter revenues Q4   2019 EstimatesThe Zacks Consensus Estimate for total revenues of  6 78 billion for the fourth quarter suggests growth of 4 25  from the prior year quarter s reported figure  Also  the consensus mark for earnings of  3 54 per share indicates 8 92  rise from the year ago quarter s reported figure For the year  the Zacks Consensus Estimate for total revenues is pegged at  25 50 billion  The same for earnings is pegged at  12 33 per share  suggesting an improvement of 10 88  from the year ago period What Our Quantitative Model PredictsOur proven model predicts an earnings beat for Thermo Fisher this time around  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the chances of an earnings beat  You can uncover the best stocks to buy or sell before they re reported with our  Earnings ESP  Thermo Fisher has an Earnings ESP of   0 25  Zacks Rank  The company currently carries a Zacks Rank  3 Other Stocks Worth a LookHere are a few other medical stocks worth considering  as these too have the right combination of elements to post an earnings beat this quarter DexCom  Inc    NASDAQ DXCM   currently has an Earnings ESP of  17 07  and a Zacks Rank  2  You can see DENTSPLY SIRONA Inc    NASDAQ XRAY   presently has an Earnings ESP of  1 16  and a Zacks Rank  2 Tandem Diabetes Care  Inc    NASDAQ TNDM   has an Earnings ESP of  27 59   It currently sports a Zacks Rank  1 Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2019  while the S P 500 gained an impressive  53 6   five of our strategies returned  65 8    97 1    118 0    175 7  and even  186 7  This outperformance has not just been a recent phenomenon  From 2000   2019  while the S P averaged  6 0  per year  our top strategies averaged up to  54 7  per year ,2020-01-26,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-thermo-fisher-tmo-in-q4-earnings-200501838,200501838
113452,334967,DXCM,Hill Rom s  HRC  Q1 Earnings Top Estimates  Revenues In Line,opinion,Hill Rom Holdings  Inc    NYSE HRC   reported first quarter fiscal 2020 adjusted earnings per share  EPS  of  1 13 excluding certain special items  The figure improved 10 8  from the year ago quarter and also surpassed the Zacks Consensus Estimate by 4 6   This year over year upside came on the back of solid core revenue growth  margin expansion  strategic investments to drive future growth and a lower tax rate On a reported basis  earnings were 59 cents per share  indicating a 4 8  decline from the year ago reported figure Additionally  revenues in the fiscal first quarter came in at  685 million  up 0 2  from the year ago period  up 1  at constant exchange rate or CER   Meanwhile  the top line was on par with the Zacks Consensus Estimate  Dull revenue growth reflects the impact of the divestiture of surgical consumables in 2019 Geographically  in the reported quarter  U S  revenues inched up 2 8  while the metric outside the United States declined 5 5   down 4  at constant exchange rate or CER  Segmental UpdateIn the quarter under review  Patient Support Systems revenues rose 1  year over year  up 1  at CER  to  344 million  This segment s core revenues were up 2   representing strong U S  core revenue growth on robust sales of the company s care communications and mobile offerings as well as its med surg and specialty bed systems including the Centrella Smart Bed  However  the U S  uptick was partially offset by lower international revenues due to the timing of large capital projects in select markets Hill Rom Holdings  Inc  Price  Consensus and EPS Surprise   Revenues at the Front Line Care segment improved 9  to  255 million  up 9  at CER   According to the company  this was driven by broad based global strength across Welch Allyn vital signs monitoring equipment  physical assessment tools  respiratory health products and the vision portfolio The Surgical Solutions segment s revenues declined 21   down 20  at CER  to  86 million  affected by the surgical revenue divestment  However  core revenues rose 9  on strong growth of surgical workflow equipment including Integrated Table Motion for the da Vinci Xi Surgical System Cash PositionThe company exited the fiscal first quarter with cash and cash equivalents of  204 4 million compared with  214 1 million at the end of fiscal 2019  At the end of the fiscal first quarter  net cash provided by operating activities was  77 million compared with  116 million at the end of the year ago period Fiscal 2020 Guidance   For fiscal 2020  Hill Rom has raised the lower end of its adjusted EPS guided range to  5 50 5 56  earlier it was  5 46 5 56  The Zacks Consensus Estimate for fiscal 2020 earnings stands at  5 53  within the company s projected band However  the company s revenue expectation for the full fiscal is reiterated in the 1 2  range  both on reported and constant currency basis  Core revenues are envisioned to grow at 4 5  rate  earlier forecast was 5 6    The Zacks Consensus Estimate for fiscal 2020 revenues is pegged at  2 94 billion For second quarter fiscal 2020  revenues are expected to dip 1 2  from the prior year figure on reported and CER basis  Core revenue growth is predicted at 4   The Zacks Consensus Estimate for quarterly revenues is pegged at  721 9 million Adjusted earnings for the fiscal second quarter are estimated in the bracket of  1 16  1 16 per share  The Zacks Consensus Estimate for the same stands at  1 24  above the company s expected range Our TakeHill Rom exited fiscal 2020 on a mixed note with better than expected earnings and in line revenues  The company saw a solid year over year increase in revenues on robust domestic growth  boosted by sturdy performances in Patient Support Systems  However  internationally  sales suffered due to the unfavorable timing of large capital projects in select markets Sales in Surgical Solutions  dropped significantly  thanks to the divestiture of surgical consumables Zacks Rank and Other Key PicksHill Rom currently has a Zacks Rank  2  Buy   Some other top ranked stocks in the broader medical space are SeaSpine Holdings Corporation   NASDAQ SPNE    STERIS plc   NYSE STE   and DexCom  Inc    NASDAQ DXCM    all three carrying a Zacks Rank of 2  You can see  The Zacks Consensus Estimate for SeaSpine s fourth quarter 2019 revenues is pegged at  43 6 million  suggesting 14 7  growth rate from the prior year reported figure  The same for loss per share is anticipated at 44 cents  implying a 16 9  improvement from the year ago reported number The Zacks Consensus Estimate for STERIS s third quarter fiscal 2020 revenues is pegged at  749 7 million  hinting at a 7 7  increase from the year earlier reported figure  The same for adjusted earnings per share stands at  1 43  indicating a 13 5  rise from the year ago reported figure The Zacks Consensus Estimate for DexCom s fourth quarter 2019 revenues is pegged at  457 million  suggesting 35 2  growth from the prior year reported figure  The same for adjusted earnings per share stands at 72 cents  implying a 33 3  improvement from the year earlier reported figure Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2019  while the S P 500 gained an impressive  53 6   five of our strategies returned  65 8    97 1    118 0    175 7  and even  186 7  This outperformance has not just been a recent phenomenon  From 2000   2019  while the S P averaged  6 0  per year  our top strategies averaged up to  54 7  per year ,2020-01-26,Zacks Investment Research,https://www.investing.com/analysis/hillroms-hrc-q1-earnings-top-estimates-revenues-in-line-200501799,200501799
113453,334968,DXCM,Baxter  BAX  To Report Q4 Earnings  What s In The Cards  ,opinion,Baxter International Inc    NYSE BAX   is expected to release fourth quarter 2019 results on Jan 30  before the opening bell  In the last reported quarter  the company reported preliminary third quarter revenues but did not release any earnings number Q4 EstimatesCurrently  the Zacks Consensus Estimate for fourth quarter revenues is pegged at  2 95 billion  suggesting growth of 3 7  from the year ago reported figure  The consensus mark for earnings is pegged at 87 cents per share  indicating an improvement of 11 5  from the prior year quarter Factors at PlayNew product launches  including PrisMax in the United States  and rising global demand for the company s continuous renal replacement therapies is likely to have contributed to Baxter s Acute Therapies business  This  in turn  is likely to have driven the segment s fourth quarter performance Continued geographic expansion is anticipated to get reflected in the company s fourth quarter revenues  Notably  per the company s preliminary announcement  revenues are anticipated to total  3 billion  up 7  year over year on a reported basis and 9  on an operational basis Baxter International Inc  Price and EPS Surprise    Moreover  the top line is anticipated to have benefited from Baxter s strong product portfolio  and the planned launch of therapies and products Per the preliminary announcement  geographic regions and all of the company s six global business units is likely to have contributed to sales in the fourth quarter Further  growing demand for Baxter s Spectrum IQ and Evo IQ infusion pumps is likely to have positively impacted the fourth quarter performance Rising demand of its hospital pharmacy compounding services  generic injectables and anesthesia products are likely to have driven the company s international sales In fact  as per the company s preliminary announcement  Baxter s revenues in EMEA  Europe  Middle East and Africa  totaled  789 million  up 2 3  from the year ago quarter on a reported basis and 5  on a constant currency  cc  basis  Meanwhile  the company generated revenues of  618 million in APAC  Asia Pacific   improving 7 8  from the prior year quarter on a reported basis and 9  at cc During the third quarter of 2019  the company introduced new data associating Sharesource remote patient management platform with reductions in hospitalizations for home PD patients  Moreover  the company achieved substantial milestones in its innovation pipeline  which includes U S  and Canadian launches of PrisMax  U S  launch of Myxredlin  European launch of Finomel along with U S  launch of Clinolipid Consequently  these launches are likely to get reflected in the company s fourth quarter performance However  the strategic exit made in the U S  Bloodline s business is expected to have negatively impacted Renal Care sales by around  55 million in 2019  This is likely to have weighed on the company s fourth quarter performance Also  Baxter s Pharmaceutical business faces increasing generic competition for cyclophosphamide and Brevibloc What Our Quantitative Model SuggestsPer our proven model  the combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  This is not the case here as you will see below Earnings ESP  Baxter has an Earnings ESP of  0 66   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Baxter carries a Zacks Rank  3 Stocks to ConsiderHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter Stryker Corporation   NYSE SYK   has an Earnings ESP of  0 60  and a Zacks Rank  3  You can see  DexCom  Inc    NASDAQ DXCM   has an Earnings ESP of  17 07  and a Zacks Rank  2 Zimmer Biomet Holdings  Inc    NYSE ZBH   has an Earnings ESP of  0 38  and a Zacks Rank  3 5 Stocks Set to Double Each was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2020-01-27,Zacks Investment Research,https://www.investing.com/analysis/baxter-bax-to-report-q4-earnings-whats-in-the-cards-200502254,200502254
113454,334969,DXCM,PerkinElmer  PKI  Q4 Earnings And Revenues Beat Estimates,opinion,PerkinElmer  Inc    NYSE PKI   reported fourth quarter 2019 adjusted earnings per share  EPS  of  1 35  which beat the Zacks Consensus Estimate of  1 32 per share by 2 3   Further  the bottom line improved 14 4  from the year ago quarter Based in Waltham  MA  this leading MedTech company reported revenues of  805 5 million  up 6 5  from the year ago quarter and improved 5  organically  Adjusted revenues in the reported quarter came in at  805 7 million  up 6 5  year over year  The top line also outpaced the Zacks Consensus Estimate by 0 4  2019 at a GlanceIn 2019  the company reported revenues worth  2 88 billion  which met the Zacks Consensus Estimate  On a year over year basis  the top line improved 3 6  Adjusted EPS for the year was  4 10  which beat the Zacks Consensus Estimate by 0 5   EPS also climbed 13 6  year over year PerkinElmer reports through two major segments   Discovery   Analytical Solutions  DAS  and Diagnostics In 2019  DAS revenues totaled  1 75 billion  61  of net revenues  and Diagnostics  revenues came in at  1 14 billion  39   PerkinElmer  Inc  Price  Consensus and EPS Surprise    Segment DetailsDASAt this segment  revenues totaled  496 5 million  reflecting an improvement of 7 9  from the year ago quarter  Organically  the segment grew 5  in the quarter under review  Per management  continued strength in life sciences and a rebound in the core food business contributed to organic revenues Coming to profits at the DAS segment  the company reported fourth quarter 2019 adjusted operating income of  116 million  up 25 1  from the year ago quarter Diagnostics segmentRevenues at this segment amounted to  309 million  up 4 2  on a year over year basis  Adjusted revenues in the segment totaled  309 2 million  up 4 2  from the prior year quarter  Organically  the segment improved 5  in the fourth quarter  Per management  the upside can be attributed to strength across reproductive health and immunodiagnostics business lines Adjusted operating income in the segment totaled  90 6 million  up 5 6  from the year ago quarter Geographical DetailsPer management  the major geographies witnessed a mixed fourth quarter  with low single digit organic revenue growth in the United States and mid single digit organic revenue growth in Asia Pacific  APAC  and Europe Margin AnalysisGross profit in the quarter came in at  398 2 million  up 5 8  year over year  Adjusted gross margin  as a percentage of revenues was 52 4   up 100 bps year over year Adjusted operating income was  192 3 million  up 17  year over year  Adjusted operating margin  as a percentage of revenues was 23 9   up 220 bps Financial UpdateIn the fourth quarter  cash and cash equivalents came in at  191 9 million  increasing 17 6  from the prior year quarter During the reported quarter  net cash provided by operating activities came in at  215 2 million  up 34 9  from the year ago quarter 2020 GuidancePerkinElmer estimates adjusted earnings per share between  4 50 and  4 60  Moreover  revenues are anticipated to be in the range of  3 05  3 09 billion For the first quarter 2020  the company anticipates adjusted earnings per share of 70 cents  Revenues are expected to total  700 million ConclusionPerkinElmer exited the fourth quarter on a strong note  with both earnings and revenues surpassing their respective consensus marks  The company witnessed strong performances by its core Discover   Analytics Solutions and Diagnostics units in the quarter under review  Continued strength in life sciences  strong performance across reproductive health and immunodiagnostics business lines led to the impressive results  Modest growth in international markets is also encouraging Further  expansion in operating margins buoys optimism  Solid show by Tulip and EUROIMMUN also paints a bright picture However  negative currency movements impacted the company s top line in the quarter under review  Furthermore  PerkinElmer continues to make acquisitions  which increases integration risks Zacks RankCurrently  PerkinElmer carries a Zacks Rank  2  Buy  Other Key PicksSome other top ranked stocks in the broader medical space are SeaSpine Holdings Corporation   NASDAQ SPNE    STERIS plc   NYSE STE   and DexCom  Inc    NASDAQ DXCM    all three carrying a Zacks Rank of 2  You can see  The Zacks Consensus Estimate for SeaSpine s fourth quarter 2019 revenues is pegged at  43 6 million  suggesting growth of 14 7  from the prior year reported figure  The same for loss per share is anticipated at 44 cents  indicating an improvement of 16 9  from the year ago reported figure The Zacks Consensus Estimate for STERIS s third quarter fiscal 2020 revenues is pegged at  749 7 million  indicating an improvement of 7 7  from the year earlier reported figure  The same for adjusted earnings per share stands at  1 43  indicating growth of 13 5  from the year ago reported figure The Zacks Consensus Estimate for DexCom s fourth quarter 2019 revenues is pegged at  457 million  suggesting growth of 35 2  from the prior year reported figure  The same for adjusted earnings per share stands at 72 cents  indicating an improvement 33 3  from the prior year reported figure 5 Stocks Set to Double Each was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2020-01-27,Zacks Investment Research,https://www.investing.com/analysis/perkinelmer-pki-q4-earnings-and-revenues-beat-estimates-200502252,200502252
113485,335000,DXCM,Inogen  INGN  Announces Preliminary Q4 Results  Slashes View,opinion,"Inogen  Inc    NASDAQ INGN   recently announced preliminary results for fourth quarter and full year 2019 Notably  full year revenues are expected within the band of  361 4  362 4 million  suggesting a 0 9 1 2  rise from 2018  The Zacks Consensus Estimate stands at  373 1 million  above the given range For the fourth quarter  revenues are expected at  78 9 million  indicating a decline from  86 5 million in the year ago quarter  The metric also lags the Zacks Consensus Estimate  which is pegged at  90 1 million The company expects to release fourth quarter 2019 results in February Content InvestorsInogen s preliminary results have cheered investors  Post the release  shares of this Zacks Rank  3  Hold  stock have climbed 5 6  to  50 38 at close However  over the past year  shares of Inogen have plunged 65 5  against the  s 16 5  rally  The S P 500 index also grew 24 7  Quarter HighlightsPer management at Inogen  the company experienced some manufacturing challenges in the fourth quarter  which impacted the domestic business to business orders  In the quarter under review  Inogen One G5 is expected to represent more than 40  of total units sold and over 55  of domestic units sold Inogen  Inc Price and Consensus
    Direct to consumer sales are expected at  35 8 million  calling for a decline from the prior year quarter s  36 8 million  However  Inogen is optimistic about its ability to grow direct to consumer sales in 2020 Domestic business to business sales are expected at  20 6 million  suggesting a drop from the year ago  25 4 million  Meanwhile  international business to business sales are expected at  17 1 million versus  18 5 million in the year ago period  Per management  tender uncertainty in various European regions and currency headwinds impacted overseas revenues Rental revenues in the quarter are expected at  5 4 million  indicating a slight decline from the prior year quarter s  5 4 million Inogen also launched the Tidal Assist Ventilator last month in its direct to consumer arm  Additionally  the recent increase in Medicare rates for oxygen therapy is likely to aid Inogen s 2020 rental revenues and improve the ability of domestic home medical equipment providers to restructure their businesses toward portable oxygen concentrators View SlashedFor 2020  Inogen expects revenues within  385  400 million  calling for 6 4 10 5  growth over 2019  This is below the earlier projected range of  410  415 million  suggesting 10 1 11 4  from 2019  The Zacks Consensus Estimate is pinned at  411 5 million  within the guided range Notably  the company expects direct to consumer sales to be its fastest growing channel and expects domestic business to business and international business to business channels to have solid growth rates Rental revenues are expected to grow modestly in 2020  while manufacturing challenges are expected to impact the first quarter Earnings of Other MedTech Majors at a GlanceSome better ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    DexCom   NASDAQ DXCM   and HealthEquity   NASDAQ HQY    While HealthEquity sports a Zacks Rank  1  Strong Buy   Cerner and DexCom carry a Zacks Rank  2  Buy   You can see  Cerner s long term earnings growth rate is estimated at 13 6  DexCom s fourth quarter earnings growth rate is projected at 31 5  HealthEquity s long term earnings growth rate is pegged at 25  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ",2020-01-15,Zacks Investment Research,https://www.investing.com/analysis/inogen-ingn-announces-preliminary-q4-results-slashes-view-200498868,200498868
113486,335001,DXCM,Allscripts Expands Partnership With PIH Health Through 2025,opinion,Allscripts Healthcare Solutions  Inc    NASDAQ MDRX   recently announced the expansion of an agreement with PIH Health through 2025  This is likely to improve comprehensive care for Allscripts  patient communities Following the release  shares of the Zacks Rank  4  Sell  company rose 1 9  to  9 65 at close For investors  notice  California based PIH Health is a fully integrated  nonprofit  regional healthcare delivery network comprised of three hospitals  a host of outpatient medical offices  and a multi specialty medical group  including home health and hospice care How Will Allscripts Gain Since 2004  PIH Health has been using Allscripts  solutions  which include the flagship Sunrise EHR platform  the Allscripts TouchWorks EHR platform and the Allscripts CareInMotion population health suite  This extension signifies the expansion in the use and demand for Allscripts  EHR platforms Notably  Allscripts  solutions will also be extended to its newly acquired PIH Good Samaritan Hospital Other Developments in EHR PlatformAllscripts has seen some developments in its EHR platform of late In January  the company announced the extension of its engagement with Northwell Health  New York State s largest health system  Per terms of the agreement  the use of Allscripts  EHR platforms   Sunrise and TouchWorks   will be implemented by Northwell s physicians That s not all  In 2019  the companies announced plans to jointly develop a next generation EHR platform Last December  Allscripts  client  Wyckoff Heights Medical Center  went live with its use of Sunrise platform  which included Sunrise Acute Care  Sunrise Revenue Cycle  Sunrise Radiology  Sunrise HIM and Sunrise Pharmacy Earlier  the company s Sunrise Community Care suite was selected by San Gorgonio Memorial Hospital   Read More   Strong Preliminary Q4 ResultsReflective of a plethora of developments in its EHR platform  Allscripts announced strong fourth quarter 2019 preliminary results Notably  the company expects bookings within  1 090  1 110 million  suggesting an increase from the prior outlook of  1 050  1 100 million Reported and adjusted revenues for the quarter are expected between  450 million and  455 million  Price PerformanceWe believe that positive developments such as these will provide some cushion to Allscripts which has declined 17 3  against the  s 21 9  rally in a year s time Key PicksSome better ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    DexCom   NASDAQ DXCM   and HealthEquity   NASDAQ HQY    While HealthEquity sports a Zacks Rank  1  Strong Buy   Cerner and DexCom carry a Zacks Rank  2  Buy   You can see  Cerner s long term earnings growth rate is estimated at 13 6  DexCom s fourth quarter earnings growth rate is projected at 31 5  HealthEquity s long term earnings growth rate is pegged at 25  Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2020-01-15,Zacks Investment Research,https://www.investing.com/analysis/allscripts-expands-partnership-with-pih-health-through-2025-200499206,200499206
113487,335002,DXCM,Nevro  NVRO  Gains Ground On Solid Preliminary Q4 Results,opinion,Nevro Corp    NYSE NVRO   announced preliminary results for fourth quarter and full year 2019 on Jan 14 Notably  full year worldwide revenues are expected to total  390 3 million that suggests a rise of 0 8  from 2018 figures  The Zacks Consensus Estimate for the metric is pegged at  385 1 million For the fourth quarter  worldwide revenues are projected at  114 4 million  which calls for a rise of 6  from  107 9 million in the year ago quarter The company expects to release fourth quarter 2019 results in February Content InvestorsNevro s preliminary results have boosted investors  optimism  Post the preliminary release  shares of this Zacks Rank  3  Hold  company have climbed 3 5  to  118 27 at close on Jan 15 Also  in the past three months  the stock has gained 38 5  compared with the  s 11 7  growth  The S P 500 Index is up 9 7  in the same time frame Quarterly ProjectionsU S  revenues are estimated to total  97 9 million  which indicates an increase of 6 9  from the prior year quarter s level  International revenues are projected to be  16 5 million  suggesting a rise of 1 2  from the year ago quarter s figure Revenues from U S  trial procedure grew 17  and the same from permanent implant procedure rose 20  Full Year ProjectionsU S  revenues are expected to amount to  326 million  which calls for a rise of 1 3  from  321 8 million in 2018  International revenues are projected at  64 3 million  indicating a decline of 1 8  from the year ago tally 2020 Worldwide Revenue OutlookNevro currently expects full year worldwide revenues in the range of  435  440 million Summing UpNevro is anticipated to have delivered solid fourth quarter and full year performances  Notably  the company s top line is projected to beat the consensus mark for 2019 An upbeat 2020 worldwide revenue outlook buoys optimism in the stock Key PicksSome better ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    DexCom  Inc    NASDAQ DXCM   and HealthEquity  Inc    NASDAQ HQY    While HealthEquity sports a Zacks Rank  1  Strong Buy   Cerner and DexCom carry a Zacks Rank  2  Buy   You can see  Cerner s long term earnings growth rate is estimated at 13 6  DexCom s fourth quarter earnings growth rate is projected at 31 5  HealthEquity s long term earnings growth rate is pegged at 25  Free  Zacks  Single Best Stock Set to Double Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2020-01-15,Zacks Investment Research,https://www.investing.com/analysis/nevro-nvro-gains-ground-on-solid-preliminary-q4-results-200499304,200499304
113488,335003,DXCM,Diabetes Management Gains FDA Attention  3 Stocks In Focus,opinion,"The FDA has of late been prioritizing approvals for the new generation and advanced line of diabetes management devices  In December 2019  the FDA gave a go ahead to the Control IQ technology of Tandem Diabetes Care   NASDAQ TNDM    The advanced hybrid closed loop system connects with blood glucose sensors and insulin pumps to automatically customize the level of insulin delivery  according to the glucose level in patients of Type 1 diabetes Medtronic   NYSE MDT   is also drawing the attention of regulatory bodies following the filling of PMA for a non adjunctive labeling for its Guardian Sensor 3  a glucose sensor as part of the Continuous Glucose Monitoring  CGM  system  for use with the company s MiniMed 670G insulin management system  In October 2019  Dexcom   NASDAQ DXCM   attained FDA clearance for its G6 Pro CGM System  It is equipped to collect real time data over a span of 10 days While diabetes management companies are coming up with cutting edge innovation to gain traction in this niche market  there are a few stocks that deserve investors  attention now  Let us take a closer look Diabetes Management Space  Plethora of ProspectsPer a report by   the global digital diabetes management market is anticipated to reach a worth of  19 9 billion by 2024 from  6 8 billion in 2019  at a CAGR of 23 8   The key driving factors are growing incidence of diabetes  steadily rising investments in the manufacture and adoption of digital platforms and technological solutions for diabetes management  Favorable reimbursement policies  increasing awareness on self diabetes management and government programs have also fueled growth In emerging nations like India and China  rapid urbanization and fast growing healthcare infrastructure have been lending support to the diabetes care market  The commercial rollout of generic versions of insulin and robust demand for novel insulin for the regulation of blood sugar levels in both Type 1 and Type 2 diabetes patients has also enhanced diabetes care market prospects MedTech companies have been investing in innovation and commercial launches of a growing roster of diabetes management products  These new age treatment options not only give the assurance of a better quality of life for patients A key innovation within the diabetes management field is CGM  These body worn medical devices are known for offering real time readings of glucose levels  Medtronic  Abbott   NYSE ABT   and Dexcom are a few of the leading industry players which have been gaining momentum on their CGM strength  In this regard  Medtronic s Guardian Connect system is the only standalone CGM system that makes use of smart technology to estimate the future glucose level of a patient A few other crucial offerings are smart insulin pens  smart insulin patches and smart glucose meters  The Alternate Controller Enabled  ACE  fusion pump is another path breaking innovation in this field  It is a device designed to infuse drugs into patients by establishing a secure link with external automated drug dosing systems 3 Stocks In FocusHere are three MedTech stocks that have been exhibiting significant potential in the diabetes management space Dexcom  This Zacks Rank  2  Buy  company specializes in the design  development and commercialization of CGM  Lately  DexCom s FDA cleared CGM system   the DexCom G4 Platinum   has been boosting the company s top line  DexCom has announced that the FDA has granted a De Novo request for the newest generation of CGM   DexCom G6 CGM System   for people with diabetes aged two and above  In September 2019  DexCom started selling G6 in Canada and witnessed solid customer response  In early October 2019  the company started the shipping of G6 to Medicare patients In the past three months  the company s shares have outperformed the   The stock has rallied 49 3  compared with the industry s 10 7  rise Tandem Diabetes Care  This Zacks Rank  1  Strong Buy  company is primarily known for the development of the t slim X2 Insulin Delivery System  The company commercially launched the t slim X2 insulin pump with Control IQ technology in January 2020  The company also plans to launch t sport Insulin Delivery System  its next generation hardware platform  in 2020 or 2021 In the past six months  the company s shares have outperformed the   The stock has rallied 8 7   compared with the industry s 6 3  rise Insulet   NASDAQ PODD    This is the leading developer  manufacturer and marketer of the Omnipod Insulin Management System  Insulet has achieved several milestones with respect to broadening Omnipod s market access  In this regard  the company has been consistently gaining from the full commercial launch of the Omnipod DASH system in the United States  In September 2019  the company s Omnipod DASH Insulin Management System attained FDA approval to be designated as an ACE pump  The company has been seeing significant progress with its Omnipod Horizon clinical development work and the technology is ready to be brought to the market by the second half of 2020  With strong estimate revisions  this Zacks Rank  3  Hold  stock promises significant upside in near term 
In the past three months  the company s shares have outperformed the   The stock has rallied 24 5  compared with the industry s 6 5  rise 
7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops   Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ",2020-01-16,Zacks Investment Research,https://www.investing.com/analysis/diabetes-management-gains-fda-attention-3-stocks-in-focus-200499566,200499566
113489,335004,DXCM,Stryker  SYK  To Report Q4 Earnings  What s In The Cards ,opinion,Stryker Corporation   NYSE SYK   is scheduled to release fourth quarter 2019 results on Jan 28 after the closing bell  In the last reported quarter  the company met estimates  Further  it has an average four quarter positive surprise of 1 5  Which Way Are Estimates Trending The Zacks Consensus Estimate for fourth quarter earnings per share is pegged at  2 46  indicating an improvement of 12 8  from the year ago quarter The same for revenues stands at  4 1 billion  suggesting growth of 8  from the prior year quarter Let s take a look at how things are shaping up prior to this announcement MedSurg in FocusThis segment consists of surgical instruments plus endoscopic and emergency medical equipment  Notably  it has been consistently driving Stryker s top line Notably  the Zacks Consensus Estimate for the segment s revenues for the fourth quarter stands at  1 83 billion  suggesting an improvement of 6 6  year ago reported figure MedSurg has three subsegments   Endoscopy  Instruments and Medical Growth across its aforementioned three subsegments is likely to have benefited MedSurg s fourth quarter performance  The segment is anticipated to have witnessed considerable worldwide organic growth in the to be reported quarter driven by instruments Stryker Corporation Price and EPS Surprise    Other Factors at PlayThe company s fourth quarter performance is likely to show broad based strength across its divisions and regions  In fact  robust performance in emerging markets and Europe is expected to get reflected in the upcoming quarterly results Further  the company s Orthopaedics segment is likely to have witnessed strong organic growth on the back of solid performance at the Knee and Hips sub segments  Moreover  sustained strong demand for Mako TKA  Total Knee Arthoplasty  platform or cementless knee and other 3D printed products is anticipated to get reflected in the segment s fourth quarter performance  For the quarter to be reported  the Zacks Consensus Estimate for this segment s sales is pegged at  1 46 billion  indicating an improvement of 5 9  from the prior year quarter With respect to Neurotechnology   Spine segment  a bankable performance within the NeuroTech and Interventional Spine businesses is likely to have contributed to the company s fourth quarter performance  Moreover  sustained solid demand in Europe  China and Japan might have impacted segmental growth  internationally  For the upcoming quarterly announcement  the Zacks Consensus Estimate for the segment s sales stands at  798 million  suggesting year over year growth of 14  The company remains on track to achieve its full year target of 30 to 50 basis points operating margin expansion backed by the top line and continued progress in cost transformation growth initiatives  a trend is likely to have continued in the fourth quarter However  unfavorable pricing is likely to have affected Stryker s fourth quarter top line  Moreover  high debt might have put pressure on the margins What Our Quantitative Model SuggestsPer our proven model  the combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the chances of an earnings beat  This is the case here as you will see Earnings ESP  Stryker has an Earnings ESP of  0 60   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Stryker carries a Zacks Rank  3 Stocks to ConsiderHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter Baxter International   NYSE BAX   has an Earnings ESP of  1 32  and a Zacks Rank  3  You can see  DexCom  Inc    NASDAQ DXCM   has an Earnings ESP of  18 45  and a Zacks Rank  2 Zimmer Biomet Holdings  Inc    NYSE ZBH   has an Earnings ESP of  0 38  and a Zacks Rank  3 Just Released  Zacks  7 Best Stocks for Today Experts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year These 7 were selected because of their superior potential for immediate breakout ,2020-01-21,Zacks Investment Research,https://www.investing.com/analysis/stryker-syk-to-report-q4-earnings-whats-in-the-cards-200500487,200500487
113490,335005,DXCM,Will Segmental Growth Aid Hologic  HOLX  In Q1 Earnings ,opinion,"Hologic  Inc    NASDAQ HOLX   is slated to report first quarter fiscal 2020 results on Jan 29  after the closing bell  In the last reported quarter  the company s earnings of 65 cents were in line with the Zacks Consensus Estimate  However  its earnings surpassed the Zacks Consensus Estimate in three of the last four quarters  with a surprise of 1 7   on average Let s see how things are shaping up prior to the announcement Key Growth DriverHologic s to be reported quarter s results are expected to reflect benefits from the Breast Health segment  Within the business  growth of Breast Imaging and Interventional Breast Solutions sub segments is expected to have aided the to be reported quarter s performance Hologic  Inc  Price and Consensus
    The segment has been expanding  owing to the company s core 3D Mammography business  which has been witnessing robust growth since the past few quarters  Since the second half of 2019  Genius 3D mammography systems  sales have been rising  This is expected to get reflected in the upcoming results For the past few months  Hologic s 3Dimensions and 3D Performance systems have been contributing significantly to the top line  The product portfolio  comprising Intelligent 2D  Clarity HD and SmartCurve  has been witnessing strong market adoption  Also  the Faxitron business  which did not contribute to organic growth in the last reported quarter  is expected to have aided the company s top line in the fiscal first quarter  backed by solid revenue contribution witnessed in the fourth quarter of fiscal 2019  Aptima women s health test kits are expected to have maintained the previous quarter s growth momentum Further  the breast health segment has likely got a boost in the fiscal first quarter from regulatory nods received in November 2019   including the FDA approval for 3DQuorum Imaging Technology powered by Genius AI and the extension of the CE Mark for its LOCalizer radiofrequency identification  RFID  tag for long term placement  The launch of the comprehensive breast diagnostic reading solution  Unifi Workspace  is likely to aid the company s top line Domestic sales of the Breast Health segment have been quite impressive for the past few quarters  backed by product expansion The Zacks Consensus Estimate for the Breast Health segment s revenues is pegged at  331 million  indicating rise of 3 8  from the prior year quarter s reported figure  The consensus estimate for the Interventional Breast Solutions segment s revenues stands at  57 million  suggesting a 6 6  dip from the year earlier quarter s reported number Other Segments in FocusThe company expects its Diagnostics segment to have maintained a stellar performance in the fiscal first quarter as well on strength in the Molecular Diagnostics business  In the United States  it is likely to have gained from expanding market share and increasing utilization of the Panther system   the fully automated molecular diagnostics instrument The company s Panther Fusion platform has likely contributed to the top line  thus continuing its momentum  The Molecular Diagnostics segment is expected to have witnessed global growth in the fiscal first quarter on the Panther system  The Aptima women s health assays are expected to have maintained the strong ongoing momentum in the to be reported quarter as well The Zacks Consensus Estimate for Molecular Diagnostics  revenues is pegged at  177 million  suggesting a 10 6  increase from the year ago quarter s reported level This apart  Hologic is expected to have witnessed an uptick in the GYN Surgical segment  backed by the expansion of the hysteroscopy portfolio with the launch of Omni Lok Cervical Seal in the United States and Canada  The launch of the Definity cervical dilator  which uses the SureAccess balloon technology to seamlessly access uterine cavities without a tenaculum  is expected to have aided the company s performance  It expects the continuation of the strong segmental performance in the fiscal first quarter as well A reformed sales force and a revitalized R D pipeline are also anticipated to have aided Hologic The Zacks Consensus Estimate for Gyn Surgical s revenues is pegged at  113 million  suggesting a 2 7  increase from the year ago quarter s reported level Preliminary AnnouncementThe preliminary results for the to be reported quarter  announced on Jan 12  suggest 2 4  year over year rise in total revenues  up 2 8  at constant exchange rate or CER  to  850 5 million  whereas the Zacks Consensus Estimate is pegged at  844 9 million  This also marginally exceeds the upper limit of the company s earlier provided revenue guidance of  835  850 million Excluding acquisitions and divestitures  total revenues are predicted to increase 4 1   up 4 6  at CER  The Zacks Consensus Estimate for the company s earnings of 61 cents suggests 7  growth from the year ago reported figure What the Model SuggestsOur proven model predicts an earnings beat for Hologic this time around  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the chances of an earnings beat  You can uncover the best stocks to buy or sell before they re reported with our Earnings ESP  Hologic has an Earnings ESP of  2 20  Zacks Rank  The company currently carries a Zacks Rank  3  You can see Other Stocks Worth a LookHere are a few other medical stocks worth considering  as these too have the right combination of elements to post an earnings beat this quarter DexCom  Inc    NASDAQ DXCM   currently has an Earnings ESP of  17 07  and a Zacks Rank  2 Exact Sciences Corporation   NASDAQ EXAS   presently has an Earnings ESP of  12 08  and a Zacks Rank  2 Tandem Diabetes Care  Inc    NASDAQ TNDM   currently has an Earnings ESP of  27 59  and sports a Zacks Rank  1 The Hottest Tech Mega Trend of AllLast year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2020-01-22,Zacks Investment Research,https://www.investing.com/analysis/will-segmental-growth-aid-hologic-holx-in-q1-earnings-200500947,200500947
113491,335006,DXCM,Will New Buyouts Aid Quest Diagnostics  DGX  Q4 Earnings ,opinion,Quest Diagnostics Incorporated   NYSE DGX   is scheduled to report fourth quarter 2019 and full year earnings on Jan 30  before the opening bell In the last reported quarter  the company s earnings of  1 76 exceeded the Zacks Consensus Estimate by 2 33   the average trailing four quarter positive surprise being 1 91  Let s take a look at how things are shaping up prior to this announcement Factors Likely to Impact Q4 ResultsQuest Diagnostics seems well aligned with its two pronged agenda to accelerate growth and drive operational excellence  Per the company  its frequently growing partnerships with other health care leaders and prudent buyouts are creating a pool of opportunities for both the top and the bottom line  At the same time  the patient experience improved and the overall cost of care  reduced As an evidence  despite PAMA reimbursement pressuresweighing heavily on the industry  the company fulfilled all the five elements of its growth acceleration strategy through the last few quarters  We strongly expect this momentum to get reflected in the upcoming quarterly results as well Going by the first element of its growth policy  to further strengthen the top line by 2  via strategically accretive acquisitions   in the fourth quarter  the company acquired Clinical Laboratory Services of Boston Clinical Laboratories in Massachusetts  N J  We hope this transaction will leave a positive impact on the company s earnings and will find reflection in its to be reported results Considering the second element of Quest Diagnostics  key growth plans  which is to expand relationships with hospital health systems  the company is executing this strategy quite successfully  Its top line outcome is expected to reflect the impact of its recent partnerships with Catholic Health Services  CHS   an integrated health care delivery system  and hc1  a bioinformatics player in precision testing  in the impending quarterly release Quest Diagnostics Incorporated Price and EPS Surprise   With respect to the third element of offering its diagnostic innovation a wider access  the company has been witnessing growth in prescription drug monitoring  continued strength in tuberculosis testing in both QuantiFERON and T Spot plus STD testing and CardioIQ  Per the company  its recently inked consolidation deals are predicted to upgrade capabilities in advanced diagnostics  especially in the areas of Women s Health and Infectious Disease  These new developments are expected to have contributed to the company s fourth quarter top line About the fourth element of the company s key catalysts  which is to provide ample choices to consumers  the company s liaison with Walmart  NYSE WMT  already started adding value to this end with higher patient traffic  Moreover  the company s alliance with Safeway currently flaunts more than 200 patient service centers across its retail store locations  This positivity is likely to reflect on Quest Diagnostics  fourth quarter earnings performance The fifth element of Quest Diagnostics  list of major drivers indicates its support to population health within analytics and extended care services  In this regard  the company of late launched Quest Clinical Trial Connect  a patient recruitment service Apart from the above five elements  Quest Diagnostics endeavors to scale up productivity as part of its efforts to ramp up the operating efficiency  This  in turn  enabled the company to successfully manage headcount growth We expect these chief catalysts to replicate the company s success story in its imminent quarterly results  Also  a better than expected third quarter performance is likely to have perked up the same primary metrics in the fourth quarter We strongly believe that all these recent developments might have significantly favored the company s top line in the quarter to be reported On the flip side  Quest Diagnostics has been suffering a significant PAMA driven reimbursement pressure that remains a major headwind to structural changes in the marketplace  In the first half of 2019  Medicare rates were 10  down from the prior year level  This might have affected the company s business through the second half as well  In fact  this should get reflected in the upcoming quarterly results The Zacks Consensus Estimate of  1 60 for fourth quarter earnings implies a 17 7  rise from the year ago reported figure What Our Model SuggestsThe proven Zacks model does not conclusively predict an earnings beat for Quest Diagnostics this season  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of a positive surprise  But that s not the case here  You can uncover the best stocks to buy or sell before they re reported with our  Quest Diagnostics has a Zacks Rank  4  Sell  and an Earnings ESP of 0 00  Stocks Worth a LookHere are a few medical stocks worth considering as these have the right combination of elements to beat on earnings this reporting cycle DexCom  Inc    NASDAQ DXCM   currently has an Earnings ESP of  17 07  and a Zacks Rank  2 Exact Sciences Corporation   NASDAQ EXAS   presently has an Earnings ESP of  12 08  and a Zacks Rank of 2 Tandem Diabetes Care  Inc    NASDAQ TNDM   currently has an Earnings ESP of  27 59  and a Zacks Rank of 1  You can see The Hottest Tech Mega Trend of AllLast year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2020-01-22,Zacks Investment Research,https://www.investing.com/analysis/will-new-buyouts-aid-quest-diagnostics-dgx-q4-earnings-200501070,200501070
113527,335042,DXCM,3 Healthcare Stocks Primed for 2020 Gains,opinion,Not all stocks are equal  Some will generate returns  while others will harvest losses  Some will soar magnificently  while others will crash and find it hard to reignite  The eternal question for the intrepid investor remains unchanged  though  which are the ones bound for fortune and  conversely  which are the ones to avoid While nothing is certain  there are ways to help make the right decision  TipRanks  Best Stocks to Buy tool tracks 8 key metrics and uses the results to score stocks accordingly  The tool displays the most compelling investments and gives them a Smart Score  from 1  down in the doldrums  all the way up to a  Perfect 10  at the peak of the summit In this case  the data crunching tool recognized 3 healthcare stocks  which not only display Strong Buy status but also earned a  Perfect 10  Smart Score  Let s take a closer look at the data at hand Horizon Therapeutics  HZNP In the rollercoaster world of healthcare so much hinges on the FDA s approval or rejection of a new drug  Of course  it s imperative to look at the bigger picture  and realize what these companies are trying to achieve in terms of their respective therapies  There is no doubt  though  that especially in this sector  the market reacts dramatically to both good and bad news One such company looking forward to an FDA decision in the new year is biopharma Horizon Therapeutics  The company s focus is on rare and rheumatic conditions  and a PDUFA date of March 8 will determine the future of Horizon s teprotumumab drug  a treatment for active thyroid eye disease  TED   The disease can potentially lead to loss of vision and the drug could be the first treatment for TED to gain approval from the FDA Clinical trials in both Phases 2 and 3 have displayed positive data  and an approval will add the treatment to a portfolio that the company thinks will generate between  1 28 billion and  1 31 billion in net sales in 2019 Piper Jaffray s David Amsellem believes Horizon is  on the cusp of a seminal milestone   The analyst reveals in a note to clients that a recent physician survey indicated positive feedback for the drug and the approval of teprotumumab will lead to a  relatively high probability of wide adoption   Amsellem sees  ample room for significant further value creation  and thinks Horizon shares are set for multiple expansion Unsurprisingly  then  Amsellem reiterated his Overweight rating and raised his price target from  36 to  49  which represents a potential upside of 36  from current levels   To watch Amsellem s track record  click here The rest of the Street backs the Piper Jaffray analyst unanimously  all the analysts  7 to be precise  tracked over the last 3 months  rate the biopharma a Buy  Therefore  Horizon has a Strong Buy consensus rating  The average price target of  40 57 indicates upside potential of 12    See Horizon stock analysis on TipRanks Aravive Inc  ARAV While the market has provided plentiful returns in 2019  not many have performed better than biotech Aravive  The micro cap  which is focused on treatments for life threatening diseases  has added almost 300  to its share price throughout the year Aravive s lead candidate is AVB 500  a treatment for ovarian cancer and IgA nephropathy  kidney fibrosis   Recent data from a Phase 1b clinical trial of the drug in platinum resistant recurrent ovarian cancer patients displayed positive results  with the study showing that women taking the drug exhibited higher rates of progression free survival  It is still early  though  and the trial was small  with only 31 patients The company recently began a Phase IIa study of AVB 500 in IgA nephropathy patients  and Piper Jaffray s Edward Tenthoff noted the predictive modeling shows that AVB 500  should provide sufficient exposure for therapeutic efficacy and may support a pivotal trial start next year  The 5 star analyst reiterated an Overweight rating  alongside a price target of  31  This implies upside potential of an excellent 125    To watch Tenthoff s track record  click here Further adding to the bull s case is Cantor Fitzgerald s Louise Chen  who believes  positive data readouts from Aravive s pipeline will drive shares higher   Chen rates ARAV an Overweight alongside a  30 price target   To watch Chen s track record  click here Over the last three months  two other analysts have joined the bullish pair with an opinion on Aravive  Both also rate the biotech a Buy  which grants Aravive a Strong Buy consensus rating  The average price target of  28 50 implies upside potential of 109    See Aravive stock analysis on TipRanks DexCom Inc  DXCM The synergy between technology and healthcare is constantly on the rise  The development of new tech enables treatment focused companies to break new ground and solve people s day to day issues in ways not possible only a few years ago This brings us to DexCom  the maker of the CGM  continuous glucose monitoring  system  The system enables diabetics to track and manage sugar levels by inserting a small sensor underneath the skin  The sensor measures glucose levels and through a transmitter which is fastened on top  wirelessly sends the data to a smart device Statistics have shown that over 30 million people had diabetes in 2015  over 9  of the population  and a further 84 million adults have had prediabetes  which if not treated  is a possible gateway to full blown diabetes  Although the numbers are alarming  they present significant market opportunity for Dexcom s sugar monitoring products The company has had an excellent 2019 and its share price skyrocketed over 80   The recent third quarter report helped continue the upward trend  with revenue of  396 million exhibiting growth of 49  from the previous year s same period Merrill Lynch s Travis Steed thinks Dexcom s 2019 performance is set to continue in the new year and rates the stock a  top idea for 2020   The 5 star analyst highlights the company s  competitive moat  and thinks DexCom is undervalued by the Street Therefore  Steed reiterated a Buy rating on DXCM and raised his price target to  250 from  220  This conveys the analyst s confidence in the company s ability to add 14  to its share price over the next 12 months   To watch Steed s track record  click here Steed is not alone in his bullish thesis  as 12 Buys and a single Hold bestow Strong Buy status on the groundbreaking glucose tracker  The average price target of  220 82  though  implies only small upside of 1   This could mean that the analysts haven t updated their models yet to reflect its 2019 gain   See DexCom stock analysis on TipRanks ,2020-01-02,TipRanks,https://invst.ly/pccbr,200495908
113528,335043,DXCM,Walgreens Boots  WBA  Q1 Earnings Lag Estimates  Margins Fall,opinion,"Walgreens Boots Alliance  Inc    NASDAQ WBA   reported adjusted earnings per share  EPS  of  1 37 for first quarter fiscal 2020  down 6 2  year over year  down 5 7  at constant exchange rate or CER   Also  the figure missed the Zacks Consensus Estimate by 2 1  
Reported EPS of 95 cents declined 19 5  on a year over year basis 
Sluggishness in Retail Pharmacy International and margin contraction built pressure on the bottom line 
Total Sales
Walgreens Boots recorded total sales of  34 34 billion in the fiscal first quarter  up 1 6  year over year and 2 3  at constant exchange rate or CER  The top line  however  missed the Zacks Consensus by 0 8   The year over year growth was led by improvement within the Retail Pharmacy USA and Pharmaceutical Wholesale divisions  partially offset by a dull performance by Retail Pharmacy International 
Segments in Detail
Walgreens Boots reports through three segments  Retail Pharmacy USA  Retail Pharmacy International and Pharmaceutical Wholesale Walgreens Boots Alliance  Inc  Price  Consensus and EPS Surprise
 

    
Retail Pharmacy USA
The segment s sales totaled  26 1 billion in the first quarter  highlighting an improvement of 1 6  year over year 
Pharmacy sales increased 2 9  from the year ago quarter on higher brand inflation  prescription volume and growth in central specialty  Pharmacy sales at comparable stores improved 2 5  year over year  while prescriptions filled in comparable stores  adjusted to 30 day equivalents  rose 2 8  in the quarter  Retail sales dipped 2 2  while comparable retail sales slid 0 5  year over year on continued de emphasis of tobacco 
Retail Pharmacy International
Revenues at the Retail Pharmacy International division declined 5 4  on a year over year basis to  2 7 billion in the fiscal first quarter  Sales were down 2 7  at CER due to lower Boots UK sales and lower sales in Chile 
Comparable pharmacy sales increased 0 6  at CER and comparable retail sales declined 3  at CER in the reported quarter 
Pharmaceutical Wholesale
The Pharmaceutical Wholesale division s quarterly sales were  6 billion  up 5 2  year over year  comparable sales were up 8 3  at CER on growth in the emerging markets and the United Kingdom  
Margins
Gross profit in the reported quarter fell 4 9  year over year to  7 26 billion  Gross margin contracted 146 basis points  bps  to 21 1  
Selling  general and administrative  SG A  expenses were down 26 5  year over year to  6 26 billion  Operating income deteriorated 39  to  1 billion  Overall  operating margin contracted 111 bps to 2 9  
Financial Condition
Walgreens Boots exited the first quarter of fiscal 2020 with cash and cash equivalents of  811 million compared with  1 02 billion at the end of fiscal 2019  Long term debt was  10 63 billion at the end of the first quarter of fiscal 2020 compared with  11 09 billion at the end of the fiscal 2019  Net cash provided by operating activities was  1 1 billion  up from  460 million from year ago period 
Fiscal 2020 Guidance 
The company reaffirmed its guidance at roughly flat growth in fiscal 2020 adjusted EPS  on a constant currency basis  with a range of plus or minus 3   The Zacks Consensus Estimate for fiscal 2020 adjusted earnings per share is currently pegged at  5 93 
Our Take
Walgreens Boots exited first quarter fiscal 2020 on a sluggish note as both adjusted earnings as well as revenues missed the Zacks Consensus Estimate  The year over year decline in adjusted earnings is another cause for concern 
Meanwhile  tough market conditions  particularly in retail  have been inducing sluggishness in the Retail Pharmacy International division  Margin pressure is a major overhang on the stock  Overall  the Retail Pharmacy USA division saw an uptick in sales during the quarter on account of comparable prescription growth and a strong retail prescription market 
Also  a rise in Pharmaceutical Wholesale division sales buoys optimism The recently inked agreement with McKesson  NYSE MCK  to create a German joint venture and an exclusive franchise deal in the United Kingdom with Mothercare hold promise 
Zacks Rank and Key Picks
Walgreens Boots currently carries a Zacks Rank  3  Hold  
Some better ranked stocks in the broader medical space are Cerner Corp    NASDAQ CERN    DexCom   NASDAQ DXCM   and HealthEquity   NASDAQ HQY    While HealthEquity sports a Zacks Rank  1  Strong Buy   Cerner and DexCom carry a Zacks Rank  2  Buy   You can see  
The Zacks Consensus Estimate for Cerner s fourth quarter revenues is pegged at  1 43 billion  calling for a year over year increase of 5   The same for EPS stands at 74 cents  suggesting a year over year rise of 17 5  
The Zacks Consensus Estimate for DexCom s fourth quarter revenues is pinned at  427 5 million  indicating a year over year increase of 26 5   The same for EPS stands at 71 cents  suggesting year over year growth of 31 5  
The Zacks Consensus Estimate for HealthEquity s fiscal fourth quarter revenues is pegged at  193 3 million  calling for a year over year increase of 155   The same for EPS stands at 18 cents 
The Hottest Tech Mega Trend of All
Last year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2020-01-08,Zacks Investment Research,https://www.investing.com/analysis/walgreens-boots-wba-q1-earnings-lag-estimates-margins-fall-200497401,200497401
113565,335080,DXCM,Dexcom  DXCM  Hits A 52 Week High  What s Driving The Stock ,opinion,On Nov 22  shares of Dexcom   NASDAQ DXCM   scaled a new 52 week high of  223 52  closing the session marginally lower at  221 85  In fact  the stock has rallied nearly 44 9  since its third quarter earnings announcement on Nov 6 Rising volumes across all channels  strong patient additions  increasing global awareness of the benefits of real time CGM and impressive full year guidance prompted the rally Let us take a closer look at the factors driving growth Robust Q3 EarningsThe company exited the third quarter on a promising note  with better than expected earnings and revenue numbers  International revenues improved 36 1  year over year during the quarter  Per management  international growth was strong  opening up great opportunity on improving global access and awareness Gross profit in the quarter rose a stupendous 46 4  year over year The company reported operating income of  56 million  compared with the year ago quarter s  13 9 million The lifted revenue outlook for 2019 buoys optimism among investors  indicating the continuation of this bullish trend through the rest of the year Other Encouraging FactorsIn September 2019  DexCom started selling G6 in Canada and received great response  In early October  the company commenced the shipping of G6 to Medicare patients  The company recently made submission of its G6 Pro product that is expected to be launched in 2020 Moreover  investors are optimistic about the company s partnership with Walgreens to ensure that all Medicare patients can fill their prescriptions for DexCom CGM through any of Walgreens  nationwide retail locations  The company anticipates more growth for the CGM diagnostic tool market The market is upbeat about the company being poised to achieve its long term target on the expansion of the G6 rollout and improved access to CGM  With this growing demand in mind  the company is on track to meet its goal of doubling G6 capacity by 2019 end  The company has been driving the ongoing transition to G6 in additional international markets  Per management  DexCom is making progress toward finalizing G7 CGM system and projects a late 2020 or early 2021 initial launch Meanwhile  Dexcom has been having a great run on the bourses in the past year  The stock has rallied 76 1   higher than the broader  s growth of 10 2   The company currently has a market cap of  20 31 billion Zacks Rank   Other Stocks Worth a LookDexcom currently carries a Zacks Rank  1  Strong Buy  A few other top rankedstocks from the broader medical space are Haemonetics Corporation   NYSE HAE    NuVasive  Inc   NASDAQ NUVA   and ResMed   NYSE RMD    While Haemonetics carries a Zacks Rank  1  the other two carry a Zacks Rank  2  Buy   You can see Haemonetics has a projected long term earnings growth rate of 13 5  NuVasive has an expected long term earnings growth rate of 10 9  ResMed has a long term earnings growth rate of 12 9  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ,2019-11-24,Zacks Investment Research,https://www.investing.com/analysis/dexcom-dxcm-hits-a-52week-high-whats-driving-the-stock-200487630,200487630
113566,335081,DXCM,MEDNAX  MD  Ties Up With Homestead To Expand In Florida,opinion,Mednax  Inc    NYSE MD   recently announced its affiliation with Arcenio Chac n  M D   P A  and Associated Pediatricians of Homestead  LLC  The all cash deal will be immediately accretive to earnings  However  other terms of the agreement have been kept under wraps Associated Pediatricians of  Homestead  LLC  founded in 1993  is a Miami based private pediatric critical care and hospitalist practice  This established group has served Baptist Health South Florida for more than 25 years  The group consists of four physicians and it caters to the Baptist Children s Hospital and Miami Cancer Institute and Homestead Hospital  It offers pediatric critical care and hospitalist services Mednax is a health care organization which partners with hospitals  health systems and health care facilities   The organization provides clinical services  revenue cycle management  patient engagement and performance improvement consulting solutions  The company strives to make a difference in the lives of patients and their families together with the aid of their growing network of office based specialists Management at Mednax is looking forward to offer the pediatric care not only to the Miami community but also beyond it  This affiliation will aid Mednax to expand presence in Florida with its wide range of network of affiliated physicians across multiple specialties  including maternal fetal medicine  OB hospitalist  neonatology  newborn hearing screen  pediatric cardiology  pediatric critical care  pediatric hospitalist  pediatric surgery plastic surgery  pediatric urology  developmental pediatrics  anesthesiology and radiology Shares of this Zacks Rank  3  Hold  company have gained 17 4  quarter to date  outperforming the  s rally of 11 1   Stocks to ConsiderInvestors interested in the medical sector can take a look at some better ranked stocks like Oxford Immunotec Global PLC   NASDAQ OXFD    DexCon  Incorporation   NASDAQ DXCM   and Tenet Healthcare Corporation   NYSE THC    While Oxford Immunotec Global PLC and DexCon  Incorporation sports a Zacks Rank  1  Strong Buy   Tenet Healthcare Corporation carries a Zacks Rank  2  Buy  You can see Oxford Immunotec focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States  In the trailing four quarters  the company has outperformed the Zcaks Consensus Estimate by 286 97  on average DexCon focuses on the design  development  and commercialization of continuous glucose monitoring  CGM  systems in the United States and internationally   In the last four quarters  the company has outperformed the Zcaks Consensus Estimate by 189 73  on average Tenet Healthcare s general hospitals offer acute care services  operating and recovery rooms  radiology and respiratory therapy services  clinical laboratories  and pharmacies  In the previous four quarters  the company has outperformed the Zcaks Consensus Estimate by 81 73  on average Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ,2019-11-24,Zacks Investment Research,https://www.investing.com/analysis/mednax-md-ties-up-with-homestead-to-expand-in-florida-200487589,200487589
113567,335082,DXCM,Digital Diabetes Management Gains Momentum  3 Stocks In Focus,opinion,The alarming rise in cases of diabetes globally has prompted the National Institute of Health  NIH  to tag it as the biggest epidemic of the 21st century  Going by the figures published by the   around 463 million adults  in the range of 20 79 years  are living with diabetes and this is expected to rise to a staggering 700 million by 2045  In fact  according to the same report  so far in 2019  diabetes has led to at least  760 billion in health expenditure and resulted in 4 2 million deaths Needless to say  detection and prevention of diabetes has been the top most priority for healthcare companies worldwide  This has put major diabetes management companies like Insulet Corporation   NASDAQ PODD    Tandem Diabetes Care  Inc    NASDAQ TNDM   and Roche Holding  SIX ROG  AG   OTC RHHBY   on the radar of the investors Digital Diabetes Management  The Latest BuzzWith technology becoming an integral part of the healthcare sector and rapidly changing the very face of healthcare  interest in digital diabetes management is palpable  The global digital diabetes management market size was valued at  6 3 billion in 2018  According to   this is projected to witness a CAGR of 19 4  till 2026 courtesy of to all technological advancements and innovations Needless to say  investors can take a look at the space as digital diabetes management presents alluring prospects for the MedTech players Prospects of Digital Diabetes Management ToolsContinuous Glucose Monitory System  CGM This method of tracking glucose levels is fast becoming standard of care for diabetes patients  In this regard  Medtronic s FDA approved Guardian Connect System deserves a mention  The system is intended for continuous or periodic monitoring of glucose levels in the tissue fluid under the skin  in persons 14 years of age and older with Type I or Type II diabetes Per a report by   the global CGM market size is estimated to reach  1 33 billion by 2025 at a CAGR of 15 8  Smart Insulin PensPer a report by   the global smart insulin pens market was worth  70 million in 2018 and is projected to reach over  140 million by 2025 at a CAGR of 10 4  during the forecast period of 2019 2025  In fact  bluetooth connected Smart insulin pen segment is anticipated to make up the largest market share during the forecast period  Apart from the growing incidence of diabetes  lower cost of insulin pumps and painless injections will further drive the market Smart Glucose MetersGiven the arrival of non invasive devices  the global blood glucose meters market is projected to expand significantly in the coming years as evident from Fortune Business Insights  report  which states that this market is likely to reach  15 42 billion by 2026 at a CAGR of 9 6   Some of the leading companies in this space are Lifespan  Braun Medical  Ascensia Diabetes Care to name a few Digital Diabetes Management Stocks to Keep an Eye OnHere are three MedTech stocks that have been exhibiting significant potential in the digital diabetes management space DexCom  Inc    NASDAQ DXCM    DexCom was the first company to have a CGM system approved by the FDA  which was the primary reason behind it becoming a major player in the market  The company s FDA cleared CGM system   the DexCom G4 Platinum   has been contributing significantly to the company s top line  In 2018  the FDA approved marketing of the Dexcom G6 integrated continuous glucose monitoring  iCGM  system for determining blood glucose  sugar  levels in children aged two and older and adults with diabetes   For 2019  this Zacks Rank  1  Strong Buy  company s Zacks Consensus Estimate for revenues is pegged at  1 44 billion  indicating an improvement of 40  from the year ago period  You can see  Over the past year  DexCom s shares have gained 75 1   outperforming the  s growth of 8 2  Medtronic plc   NYSE MDT    Medtronic s  which has a dominating presence in the MedTech space  FDA approved Guardian Connect System helps identify trends and track patterns in their glucose levels  In fact  the company s initiatives have been intensifying competition for quite some time now This Zacks Rank  2  Buy  company has a long term earnings growth rate of 7 4   For fiscal 2020  the Zacks Consensus Estimate for revenues is pegged at  31 52 billion  indicating an improvement of 3 2  from the year ago period Over the past year  Medtronic s shares have gained 16 5   outperforming the  s rally of 4 7  Abbott Laboratories   NYSE ABT    Abbott s Freestyle Libre Flash CGM device has been making waves in the digital diabetes management space  The device is utilized for management of diabetes in persons age 18 and older This Zacks Rank  3  Hold  company has a long term earnings growth rate of 10 7   For 2019  the Zacks Consensus Estimate for revenues is pegged at  31 88 billion  indicating an improvement of 4 3  from the year ago period Over the past year  Abbott s shares have gained 16 6   outperforming the  s rally of 4 6   Breakout Biotech Stocks with Triple Digit Profit Potential The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119 and  164 in as little as 1 month  The stocks in this report could perform even better ,2019-11-27,Zacks Investment Research,https://www.investing.com/analysis/digital-diabetes-management-gains-momentum-3-stocks-in-focus-200488658,200488658
113568,335083,DXCM,DexCom  Inc   DXCM  Shares March Higher  Can It Continue  ,opinion,As of late  it has definitely been a great time to be an investor DexCom  Inc    NASDAQ DXCM    The stock has moved higher by 46 1  in the past month  while it is also above its 20 Day SMA too  This combination of strong price performance and favorable technical  could suggest that the stock may be on the right path We certainly think that this might be the case  particularly if you consider DXCM s recent earnings estimate revision activity  From this look  the company s future is quite favorable  as DXCM has earned itself a Zacks Rank  1  Strong Buy   meaning that its recent run may continue for a bit longer  and that this isn t the top for the in focus company  You can see  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ,2019-11-28,Zacks Investment Research,https://www.investing.com/analysis/dexcom-inc-dxcm-shares-march-higher-can-it-continue-200489008,200489008
113604,335119,DXCM,DexCom  DXCM  Earnings And Revenues Beat Estimates In Q3,opinion,DexCom  Inc    NASDAQ DXCM   reported adjusted earnings of 65 cents per share in third quarter 2019  surpassed the Zacks Consensus Estimate of 18 cents by a huge mark  Moreover  the bottom line skyrocketed 261 1  from the prior year quarter Total revenues surged 48 6  to  396 3 million on a year over year basis and also surpassed the Zacks Consensus Estimate by 13 5   Rising volumes across all channels  strong new patient additions and increasing global awareness of the benefits of real time CGM contributed to the upside  Segmental DetailsRevenues at the Sensor segment  80  of total revenues  surged 63 5  on a year over year basis to  317 2 million  Transmitter revenues  16   improved 27 4  year over year to  61 8 million  Receiver revenues  4   declined 28 5  year over year to  17 3 million DexCom  Inc  Price  Consensus and EPS Surprise    Geographical DetailsU S  revenues  78  of total revenues  surged 52 6  on a year over year basis to  308 8 million  International revenues  22   improved 36 1  year over year to  87 5 million Margin Analysis Gross profit in the quarter under review totaled  246 9 million  up 46 4  year over year  However  DexCom generated gross margin  as a percentage of revenues  of 62 3   which contracted 90 bps year over year  Research and development  R D  expenses amounted to  66 7 million in the quarter  up 33 1  year over year  Selling  general and administrative expenses totaled  124 2 million in the reported quarter  up 18 7  year over year  The company reported total operating expenses of  190 9 million  up 23 4  year over year The company reported operating income of  56 million  compared with the year ago quarter s figure of  13 9 million  Financial Position As of Sep 30  2019  DexCom had  1 43 billion in cash and marketable securities  Total cash and cash equivalents came in at  395 6 million  down 44 2  sequentially  2019 Guidance Revised DexCom now expects revenues in the range of  1 43  1 45 billion  up from the previously guided range of  1 33  1 38 billion   The Zacks Consensus Estimate for revenues is currently pegged at  1 36 billion  which is below the lower end of the guided range  Gross profit margin is projected to be around 63  compared with the prior estimated range of 64  to 65  of net revenues  While adjusted operating margin is expected to be about 9  of net revenues  up from the previous projection of 7    adjusted EBITDA margin is anticipated to be 19 5   up from the prior estimate of 18 5    Wrapping Up DexCom exited the third quarter on a strong note  wherein both earnings and revenues beat the Zacks Consensus Estimate  Impressive contributions from the Sensor and Transmitter segments were key catalysts  Strong guidance also instills investor optimism in the stock  Additionally  the glucose monitoring market presents significant commercial opportunity for this company  DexCom s opportunities in alternative markets such as the non intensive diabetes management space  the hospital  gestational  pre diabetes and obesity are likely to provide it a competitive edge in the MedTech space  The company has sustained robust revenue growth momentum in the third quarter  which resulted in another substantial increase in the full year revenue outlook  Meanwhile  cutthroat competition in the market for blood   glucose monitoring devices remains a concern  We believe that the company s margins will continue to remain under pressure in the upcoming quarters owing to high product development costs and rising expenditures on the R D front  Zacks Rank Currently  DexCom carries a Zacks Rank of 2  Buy  Earnings of Other MedTech Majors at a GlanceSome other top ranked stocks that reported solid results this earning season are Edwards Lifesciences   NYSE EW    Thermo Fisher Scientific Inc    NYSE TMO   and ResMed Inc    NYSE RMD    each carrying a Zacks Rank  2  You can see  Edwards Lifesciences delivered fourth quarter 2019 adjusted EPS of  1 41  outpacing the Zacks Consensus Estimate by 15 6   Fourth quarter net sales of  1 09 billion surpassed the Zacks Consensus Estimate by 5 5  Thermo Fisher delivered fourth quarter 2019 adjusted EPS of  2 94  which surpassed the Zacks Consensus Estimate by 2 1   Revenues of  6 27 billion outpaced the Zacks Consensus Estimate by 1 3  ResMed reported fourth quarter 2019 adjusted EPS of 93 cents  which beat the Zacks Consensus Estimate of 87 cents by 6 9   Revenues were  681 1 million  surpassing the Zacks Consensus Estimate by 3 6  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-11-07,Zacks Investment Research,https://www.investing.com/analysis/dexcom-dxcm-earnings-and-revenues-beat-estimates-in-q3-200483942,200483942
113605,335120,DXCM,The Zacks Analyst Blog Highlights  Dexcom  Fortinet And Agnico Eagle,opinion,For Immediate ReleaseChicago  IL  November 12  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Dexcom   NASDAQ DXCM    Fortinet   NASDAQ FTNT   and Agnico Eagle Mines   NYSE AEM   Here are highlights from Monday s Analyst Blog A Struggle to Find Revenue Growth  Global Week AheadIn the Global Week Ahead  a nearly final set of 15 S P 500 members report Q3 results The week s docket has Wal Mart  NYSE WMT   Cisco  NASDAQ CSCO  and Nvidia 447 S P 500 members  about 90   reported results as of Friday  Nov  8  72 5  have beaten EPS estimates  Only 57 9  beat revenue estimates A low Q3 revenue beat number  57 8   is worrisome Over the last 12 quarters  Zacks Research Director Sheraz Mian says quarterly revenue beats have been as high as 75 4  in Q1 18 and as low as 48 3  in Q3 15 Total earnings  aggregate net income  for the 447 companies is down  1 5  y y  This comes with  4 2  higher revenues  The latter amounts to an approximation of trend U S  macro performance  In other words   2 2  real GDP growth and  2 0  consumer inflation Next are Reuters  five world market themes for the Global Week Ahead  1  Do Risk Free Rates Stay at Zero Much Longer Few people will be brave enough to call the end of the 30 year bond bull run  but the idea that sub zero borrowing costs may not be around forever is one people are increasingly willing to entertain Upbeat economic data  signs of a trade war truce and above all  central banks  clear reluctance to cut interest rates further have shrunk the global negative yield bond pool to  12 5 trillion from  17 trillion two months ago In Europe  Germany s long dated government borrowing costs rose above 0  recently  while 10 year yields are up 50 basis points from early September lows  Finnish  Belgian and Austrian 10 year yields are also flirting with the zero mark But are we just seeing another  bond tantrum  that will soon peter out  like for instance the Bund selloff in April 2015  It s true that sub target inflation and deeply negative interest rates in the Eurozone  Japan and elsewhere mean negative yields won t vanish anytime soon  Above all  some governments  such as Germany  still oppose increasing state spending to boost growth So  money managers will be wary of slashing bond exposure  They will be aware  though  that at such low yields  even small moves up will send bond prices crashing  risking big losses on their portfolios  Several countries  from Germany to Japan  will release third quarter growth data in coming days   a robust set of figures could push yields further toward zero  2  Where Is Consumer Price Inflation The Fed lowered interest rates a third time on Oct  30  even with the economy plugging along in OK shape  So what gives  The real concern is inflation   too little  not too much The string of quarter point insurance cuts comes amid concerns about a global slowdown spilling over  and is meant to counter low inflation  which keeps rates down and reduces the Fed s ability to fight the next downturn  Underneath it all lurks the specter of disinflation  or demand crushing Japan style deflation Wednesday brings October s Consumer Price Index  CPI   followed by Fed Chair Jerome Powell s appearance before the congressional joint economic committee  Core year on year CPI is expected at 2 4  and headline at 1 7   But the Fed s favorite measure of core personal consumption expenditures is running around 1 6    hovering mostly below the 2  target since prior to the financial crisis The Fed signaled it may wait into 2020 to cut again  Chicago Fed President Charles Evans said rising inflation expectations are key  It looks like an uphill battle given that consumer inflation expectations are declining even though wages are ticking up On Friday  October retail sales and industrial production data will shed light on whether the consumer can continue to drive growth in the face of a struggling manufacturing sector and months of trade tensions  3  Keep an Eye Out for the Usual Trade HeadlinesA raft of global investors at the Reuters 2020 Investment Outlook Summit declared unwavering keenness to stay invested in a market that has done extremely well in 2019 and is expected to do just as well in the coming year Adding to that enthusiasm among business and investors are news headlines on gradual progress toward some sort of U S  China trade truce  But details remain scarce and  in fact  there isn t much to cheer in China this month Last weekend brought to a close the annual China International Import Expo in Shanghai  where American companies turned out in force October is seasonally weak because of the long Chinese National Day holiday  and recent data showed the trade war continues to take a toll on exports and demand  China s economic growth has slipped to its weakest in three decades  forcing the central bank to make its first rate cut in nearly three years and pump cash into markets Key data on lending  investment and inflation are due in coming days  Even as the hubbub over another regional bank run fades  investors expect to see proof that bank lending and social financing deteriorated further  inflation remained high on rising pork prices and investment in factories was depressed  4  The 11th BRICS Summit on Tuesday in BrazilLeaders of Brazil  Russia  India  China and South Africa meet in Brasilia for their 11th summit on Tuesday Accounting for a third of world GDP  this bloc has evolved into a political organization  which also has its own development bank It s been a long road since Goldman Sachs  analyst Jim O Neill coined the term BRIC in 2001 to describe a grouping of the four biggest emerging markets  The term has evolved from a catchy acronym to an investment concept spawning dozens of funds managing around  25 billion at their peak  Most BRIC funds have since quietly closed  but the countries themselves have adopted the grouping   only it s BRICS now  with the addition of South Africa Times are tough  however  China is mired in a trade war that s damaging its export reliant economy and India s credit rating has been cut by Moody s on worries about growth and the banking sector  Russia s economy is semi stagnant  under U S  sanctions and locking horns with Turkey for domination of the Middle East  Brazil  just emerging from a brutal recession  is struggling to pass vital reforms  South Africa  with anemic growth  risks losing its investment grade credit rating  cutting access to precious investment The upcoming summit is to focus on  economic growth for an innovative future   Given all the problems the quintet face  innovation may be key  5  Erdogan Will Meet Trump on Wednesday in DCTurkey s President Tayyip Erdogan is heading to Washington for a powwow with his U S  counterpart  Donald Trump  on Wednesday  The two have plenty to discuss  Engagement  or disengagement  of Turkish and U S  forces in northern Syria and related bilateral agreements  as well as Ankara s purchase of Russia s S 400 missile defense system  which under U S  law should trigger sanctions Then there is a U S  court case against state owned Halkbank over evading sanctions in Iran  Meanwhile  a U S  House of Representatives  vote to recognize mass killings of Armenians a century ago as genocide has rankled Ankara The two men are said to have a strong bond  according to Turkish sources  The lira   a weathervane for Turkey s economic outlook but also for the state of its geopolitical relations  especially with Washington   is on track for an 8  tumble in 2019  its seventh straight year in the red Those personal ties could prove crucial to Erdogan  who seems adept at managing his relationship with the man at the helm of its largest NATO ally  but may face much more hostility from the U S  legislative branch Zacks  1 Rank Stocks A  Dexcom This is a  198 Medical Instruments stock with an  18B market cap  The stock traded around  150 for months  up to it latest EPS report a few days ago  I see a predictable F for Zacks Value  but an A for Zacks Growth and an A for Zacks Momentum San Diego  CA based DexCom  Inc  is a medical device company focused on the design  development and commercialization of continuous glucose monitoring systems  CGM   These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non diabetic patients  B  Fortinet This is another stock on a roll after a great Q3 EPS report  I see a  96 a share price tag assisting a  16B market cap  The Zacks Value score is F again  with a B for Zacks Growth  This is a major cloud security provider  C  Agnico Eagle Mines This is a  13 8B market mining stock  It trades at around  58 a share right now  Is it time to buy a gold miner  The stock was  40 a share back in late May  I would say you are late to that first and best party  Now  the bull story is about share price consolidating for another leg up Media ContactZacks Investment Research800 767 3771 ext  9339 Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-11-11,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-dexcom-fortinet-and-agnico-eagle-200484574,200484574
113606,335121,DXCM,Healthcare Drives Wall Street  5 Soaring ETFs   Stocks,opinion,"Wall Street has gaining on optimism surrounding the signing of a  phase one  trade deal between the United States and China  The S P 500  in fact  crossed the 3 100 mark this week while the Nasdaq Composite Index breezed past 8 500  read    
Though there is a certain level of lingering uncertainty about how the deal will shape up  causing a safe haven rally occasionally  some sectors have been steady irrespective of the geopolitical scenario  Healthcare is among the few  
Let s dig a little deeper 
What s Driving Healthcare 
Per the  issued on Nov 13  total earnings of 95 1  of the entire healthcare market capitalization in the S P 500 that has reported so far are up 7 1  on revenue growth of 7 4   The earnings and revenue growth rates are the fifth highest among the 16 Zacks classified sectors  Meanwhile  the blended beat ratio of 70 6  is the third highest 
There are about 13 industries in the broader medical sector  out of which 12 sport a favorable Zacks Rank  Below we highlight three key industries 
Medical   Drugs belongs to a favorable Zacks industry  placed at the top 20  of 250  industries   A total of 117 companies reported this season of which 64  beat estimates and 5  met the same  Shares of the Medical   Drugs industry can be availed at 17 43x forward P E ratio against the S P 500 ETF IVV s P E multiple of 18 64x  Though a low P E is not indicative of the stock s future performance  cheaper valuation is always good news  The projected EPS growth rate of the sector is 9 72  versus 5 66  of IVV  The debt to equity ratio of the industry  0 2x  is much lower than 0 72x of IVV 
Large Cap Pharmaceuticals also hails from a favorable Zacks industry  positioned at the top 28    Only 12 companies reported this season  all of which beat estimates  The industry has a forward P E ratio of 14 73x  which reflects its undervalued status  The debt to equity ratio of the industry  0 68x  is in line with that of the S P 500 
Medical   Biomedical And Genetics also comes from a favorable Zacks industry  top 20    About 275 companies reported this season  of which 59  surpassed estimates while 5  met the mark  Though the forward P E ratio of 25 19x is pretty higher in comparison to IVV  the projected EPS growth rate is also higher  10 93   than the S P 500  5 66   
Apart from favorable financials and valuations  the sector is brimming with good news starting from a wave of merger and acquisitions to the release of upbeat drug data  Recently  Biogen   NASDAQ BIIB   spread optimism in the healthcare sector following its Alzheimer s treatment report  The biotech company decided to go ahead with the approval of aducanumab  a treatment for early Alzheimer s diseases  after the drug met the primary endpoint of a Phase 3 Emerge study 
Investors should also note that the healthcare sector offers a slightly defensive approach and thus could be a good bet if there is any uncertainty regarding the trade deal 
ETFs   Stocks in Focus 
Against this backdrop  we highlight a few top performing healthcare ETFs and stocks in the past week  as of Nov 14  2019  
Stocks in Focus  
Clovis Oncology Inc    NASDAQ CLVS     Up 51 4  past week
Forty Seven Inc    NASDAQ FTSV     Up 41 7 
Proteostasis Therapeutics Inc    NASDAQ PTI     Up 40 8 
Aquestive Therapeutics Inc    NASDAQ AQST     Up 35 7 
DexCom Inc    NASDAQ DXCM     Up 34 2 
ETFs in Focus 
ARK Genomic Revolution Multi Sector ETF    Up 3 8 
Invesco DWA Healthcare Momentum ETF   HN PTH     Up 3 4 
Loncar Cancer Immunotherapy ETF    Up 3 2 
SPDR S P Biotech  NYSE XBI  ETF    Up 3 1 
Invesco Dynamic Biotechnology   Genome ETF    Up 3 0 
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2019-11-14,Zacks Investment Research,https://www.investing.com/analysis/healthcare-drives-wall-street-5-soaring-etfs--stocks-200485443,200485443
113607,335122,DXCM,San Gorgonio Hospital Picks Allscripts Sunrise Community Care,opinion,Allscripts Healthcare Solutions   NASDAQ MDRX   recently announced that its electronic health record  EHR  suite Sunrise Community Care has been selected by San Gorgonio Memorial Hospital to serve community hospitals Following the announcement  shares of the Zacks Rank  2  Buy  company climbed 0 5  to  10 77 at close Notably  the San Gorgonio Memorial Hospital offers a variety of high quality  personalized community healthcare services to a diverse population Sunrise at a GlanceAllscripts  Sunrise Community Care is a fully integrated EHR as a service that provides community hospitals with an integrated solution that suits their needs  This Azure hosted platform offers clinical  financial and ambulatory content to help organizations run smoothly and achieve operational and financial success Sunrise Community Care offers both the FollowMyHealth patient portal and analytics solution to enable better patient outcomes In recent times  Allscripts  biggest client Northwell Health has extended the Sunrise partnership EHR and HealthcareThe latest EHR services have been gaining prominence in the U S  MedTech space  Going by   the global EHR market is estimated to reach a worth of  38 29 billion by 2025  at a CAGR of 5 7   Reports suggest that MedTech companies with a strong exposure to big data automated EHRs will excel in terms of operations and margins In this regard  it is imperative to mention key players like Cerner Corporation   NASDAQ CERN   and NextGen Healthcare   NASDAQ NXGN   who have been dominating the headlines  courtesy of their efforts to digitize EHR systems Price PerformanceReflective of these  shares of Allscripts rallied 5 8  compared with the  s 1 6  rise Another Key PickAnother top ranked stock from the broader medical space is DexCom   NASDAQ DXCM    sporting a Zacks Rank  1  Strong Buy   You can see  DexCom s fourth quarter earnings growth is projected at 29 6  Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our just released Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2019-11-14,Zacks Investment Research,https://www.investing.com/analysis/san-gorgonio-hospital-picks-allscripts-sunrise-community-care-200485599,200485599
113608,335123,DXCM,Digital Health Gaining Momentum  3 MedTech Stocks In Focus,opinion,Technology has not only become an integral part of the healthcare sector but is also changing the very face of healthcare  Interest in digital health is palpable from the significant growth in investments in the space over the last five years Geriatric population with prevalence of chronic diseases and current and upcoming changes to regulations and reimbursements will drive adoption of digital health services and technologies in 2019 and beyond  Per a report by   the global digital health market  which was valued at  179 6 billion in 2016  is expected to reach  536 6 billion by the end of 2025 at a CAGR of 13 4   According to Transparency Market Research  technology advancements in the medical and healthcare infrastructure will lend support to this market over the next few years The digital health space includes telemedicine and telehealth  big data and digital transformation  m Health  bioinformatics and digital health  genomics and precision medicine and e health  In fact  investors can take a look at the space as digital health presents alluring prospects for the MedTech players Let us delve deeper Big Data and Digital TransformationThe rise of big data and analytics in the current healthcare environment is not only beneficial for individual patients but also to the industry as a whole  Big data has been playing a crucial role in advancing the industry by preventing cases before their occurrence  reducing prescription errors  more accurate treatment and managed care Tech giants have been making noticeable forays into the healthcare industry since last year   Notably  Ascension s collaboration with Google   NASDAQ GOOGL    which will include exploration of artificial intelligence machine learning applications  has the potential to improve clinical quality and effectiveness  patient safety  and advocacy on behalf of vulnerable populations  This in turn will enhance both consumer and provider satisfaction Telehealth and TelemedicineTelemedicine is an innovative way of offering clinical and medical health care at a distance through the use of telecommunication and information technologies  Per a report by   the U S  Telemedicine market is projected to exceed  64 billion by 2025  Prevalence of chronic diseases is one of the primary factors driving demand in this market Meanwhile  telehealth has been gaining momentum as an increasingly popular alternative to traditional clinical care  With technological advancements enabling a prevention and wellness model  and consumer preferences shifting toward more personalized care  consumers are becoming more open to these virtual solutions Electronic Health RecordElectronic health records  EHRs  have been crucial in improving the quality and safety of health care  The adoption and effective use of health information technology can help reduce medical errors and adverse events  enable better documentation and file organization  help doctors in tracking their treatment protocols and provide patients with information that assists them in following medication regimens and appointments Per a  report  global EHR market is anticipated to exceed  38 billion by 2025  Rising government expenditure and funding for the development of healthcare IT solution for better understanding of diagnosis and treatment pattern is likely to contribute to substantial HER market growth over the projected timeframe Digital Healthcare Stocks to Keep an Eye OnHere are three MedTech stocks that have been exhibiting significant potential in the digital health space Cerner Corporation   NASDAQ CERN    Cerner has been taking significant strides in the digital space with its AI enabled workflow  Chart Assist  and focus on behavioral health technology  In September 2019  Cerner partnered with GetWellNetwork   a global consumer health technology company   to facilitate communication between providers and patients from inpatient to outpatient settings and home This Zacks Rank  3  Hold  company has a long term earnings growth rate of 13 2   For 2019  the Zacks Consensus Estimate for revenues is pegged at  5 69 billion  indicating an improvement of 6 1  from the year ago period  You can see  Over the past year  Cerner s shares have gained 19 6   outperforming the  s growth of 6 7  Masimo Corporation   NASDAQ MASI    Masimo continues to remain committed toward patient monitoring and bolstering the same  In September  the company announced Pathway  which is a feature for the Root Patient Monitoring and Connectivity Platform  Pathway is likely to aid clinicians in simplifying decision making associated with newborn resuscitation This Zacks Rank  3 company has a long term earnings growth rate of 23   For 2019  the Zacks Consensus Estimate for revenues is pegged at  932 9 million  indicating an improvement of 8 7  from the year ago period Over the past year  Masimo s shares have gained 50 5   outperforming the  s rally of 13 2  DexCom  Inc    NASDAQ DXCM    DexCom has stirred up the digital health space  particularly with its G6 Continuous Glucose Monitoring  CGM  system  In October 2019  DexCom G6 Pro CGM received FDA nod  This innovative technology can gather real time glucose data over a period of 10 days and has the ability to be switch between blinded and unblinded mode For 2019  this Zacks Rank  1 company s Zacks Consensus Estimate for revenues is pegged at  1 45 billion  indicating an improvement of 40 1  from the year ago period Over the past year  DexCom s shares have gained 82   outperforming the  s growth of 13 2   Just Released  Zacks  7 Best Stocks for Today Experts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 5  per year These 7 were selected because of their superior potential for immediate breakout ,2019-11-20,Zacks Investment Research,https://www.investing.com/analysis/digital-health-gaining-momentum-3-medtech-stocks-in-focus-200486992,200486992
113639,335154,DXCM,Medical Products  Earnings Roster For Jul 31  MCK  HOLX   More,opinion,The  companies within the broader  sector rely on research and development for growth and are currently reaping benefits as a result with the temporary repeal of 2 3  Medical Device tax in 2018  Consequently  the companies in this space are anticipated to put up a good show this earnings season Over the past few months  the medical device space has witnessed exceptional progress when it comes to innovation   R D to be precise  Some of the path breaking inventions such as wireless brain sensors  Bluetooth enabled smart inhalers  artificial pancreas  human brain pacemaker  precision medicine and many more have helped the medical device space to grow significantly Strong demand in the emerging markets is likely to bolster the performance of the industry participants in this reporting cycle  According to a  report  as stated by Moody s  the medical device makers are likely to exhibit mid single digit revenue growth fueled by product innovation across most of the companies and categories  Additionally  sales in emerging markets are expected to display a double digit percentage rise Backed by the rising medical awareness and economic prosperity  emerging economies are witnessing strong demand for the medical products  In fact  a geriatric population  relaxed regulations  cheap skilled labor  increasing wealth and the government focus on healthcare infrastructure make these markets attractive to the global medical device players However  the U S  Medical Products industry has confronted short term hurdles pertaining to the trade war with China  Per a Medical Imaging   Technology Alliance  MITA  survey  tariffs will cost the companies nearly  138 million every year It is important to note here that the medical product space is facing a significant bottom line pressure  particularly the companies that have production in China  owing to the imposition of U S  tariff and the Chinese retaliation to counter the same  Nonetheless  the latest update on the U S  exemptions of some medical devices from 25  tariff and both the countries  efforts to temporarily resume trade negotiations comes as a relief to investors The U S  medical device excise tax  at 2 3  of U S  sales  is scheduled for reinstatement on Jan 1  2020  According to the aforementioned MedTech Dive report  Moody s stated that the consolidation among payers can increase pricing pressures on medical device makers The latest  anticipates the Medical sector to deliver positive earnings surprises this time around  as of Jul 26   For the quarter under review  earnings growth rate is projected at 3 6  on 5 2  revenue growth What Our Model SaysThe proven Zacks model clearly indicates that a company with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has good chances of beating estimates if it also has a positive   Conversely  a Zacks Rank  4  Sell  or 5  Strong Sell  stocks are best avoided  especially if the companies are witnessing negative estimate revisions  You can uncover the best stocks to buy or sell before they re reported with our  Considering the above factors  we take a look at the following five Medical Products players that are set to release quarterly results on Jul 31 McKesson Corporation   NYSE MCK    The company s U S  Pharmaceutical and Specialty Solutions segment is likely to act as a key catalyst in bolstering the company s fiscal first quarter 2020 results  Notably  the segment is likely to gain momentum on the back of its branded  generic and over the counter pharmaceuticals  This apart  the company is likely to display better than expected performance across the segments   European Pharmaceutical Solutions  Medical Surgical Solutions and Other  which in turn will aid the upcoming quarterly results  read more    McKesson Corporation Price and EPS Surprise    McKesson has a Zacks Rank  2 and an Earnings ESP of  0 77   which makes us reasonably confident of an earnings beat in the to be reported quarter  You can see  Hologic  Inc    NASDAQ HOLX    The company anticipates third quarter fiscal 2019 results to benefit from the Breast Health segment  Within this business  growth of the Breast Imaging and Interventional Breast Solutions sub segments are expected to contribute to the to be reported quarter s results  This apart  the company expects its Diagnostics segment to aid the fiscal third quarter results backed by strength in the Molecular Diagnostics business  However  the company is facing challenges like unfavorable foreign currency movements over the last few quarters  Escalating operating expenses and intense competition  particularly in the tomosynthesis market are likely to weigh on upcoming quarterly results  read more    Hologic  Inc  Price and EPS Surprise    Hologic has a Zacks Rank  2  which when combined with an Earnings ESP of  1 49   makes us reasonably confident of a positive surprise in the to be reported quarter DexCom  Inc    NASDAQ DXCM    The company s second quarter 2019 results are likely to benefit from possible increase in volumes across all channels and rising global awareness of its real time CGM  Moreover  the company has a sizeable international market opportunity on account of the demographic trends and lifestyle in countries outside the United States and Europe  To that end  we expect the company to deliver higher international revenues in the to be reported quarter  However  the company projects restructuring related cost to approximately range between  15 million and  20 million for 2019 with the majority being incurred in the first half  Going by this projection  we expect a similar trend in the to be reported quarter  read more    DexCom  Inc  Price and EPS Surprise    DexCom has an Earnings ESP of 0 00  and a Zacks Rank  1  a combination that makes surprise prediction difficult Masimo Corporation   NASDAQ MASI    The company is expected to gain traction from a slew of developments and product launches  which in turn is likely to aid its second quarter 2019 results  However  Masimo s Royalty and Other unit has been facing softness for a couple of quarters now  In fact  management does not expect any significant contribution from the unit in the quarter to be reported  read more    Masimo Corporation Price and EPS Surprise    Masimo has an Earnings ESP of 0 00  and a Zacks Rank  3  a combination that makes surprise prediction difficult LivaNova PLC   NASDAQ LIVN    LivaNova is a medical device company that designs  develops  manufactures  and sells therapeutic solutions worldwide  Headquartered in London  the U K   the company operates in two segments  Cardiovascular  CV  and Neuromodulation  NM  The Zacks Consensus Estimate for second quarter 2019 revenues is pegged at  274 1 million  indicating a decline of 4 7  from the year ago reported figure  The same for earnings stands at 68 cents  suggesting a decline of 29 2  from the year ago quarter  In the preceding four quarters  the company outpaced the consensus mark  the average being 0 44  LivaNova PLC Price and EPS Surprise    LivaNova has an Earnings ESP of 0 00  and a Zacks Rank  3  a combination that makes surprise prediction difficult Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-07-29,Zacks Investment Research,https://www.investing.com/analysis/medical-products-earnings-roster-for-jul-31-mck-holx--more-200447012,200447012
113640,335155,DXCM,DexCom s Wall Street Darling Status In Danger,opinion,"In previous articles  we ve discussed numerous stocks  which brought their investors great returns in the past decade  Today s material will focus on one that beats them all   DexCom   NASDAQ DXCM    a medical device company  headquartered in San Diego  California 
In November 2008  during the throes of the Financial Crisis  DXCM stock plunged to as low as  1 36 a share  In August 2019  the price reached an all time high of  178 45  The math says this is 55 8  compounded annually for a total return of 13 000  in less than eleven years 





In contrast  the low at  1 36 in 2008 was the result of a selloff from  26 70 in April 2006  It turns out DexCom stock is not immune to price declines after all  The danger is that after many years of huge gains investors tend to forget the fact that no trend lasts forever  So let s examine DexCom s bull market through the prism of the Elliott Wave principle and see what s left of it 

DexCom s weekly logarithmic chart reveals that a complete five wave impulse pattern has been formed  What the bulls probably don t want to hear is that according to the Elliott Wave theory  every impulse is followed by a three wave correction in the other direction 

This is the same pattern which led to an 86  crash in Cigna  NYSE CI  in 2007 2008  A complete impulse pattern was also visible on the chart of EQT Corp  NYSE EQT   right before its own 85  dive  In other words  a fully formed impulse  labeled I II III IV V  must not be taken lightly by DexCom shareholders 

Usually  the corrective phase of the wave cycle erases all of the fifth wave s gains  In DXCM s case  this means a pullback to at least  42 a share where the support of wave IV lies  This would be a massive 70  crash from the current level of  147  Given that the company is barely profitable  we wouldn t be surprised to see an even larger selloff in DexCom ",2019-10-28,EWM Interactive,https://www.investing.com/analysis/dexcoms-wall-street-darling-status-in-danger-200478874,200478874
113641,335156,DXCM,DexCom  DXCM  To Report Q3 Earnings  What s In The Offing ,opinion,DexCom  Inc    NASDAQ DXCM   is expected to release third quarter 2019 results on Nov 6  after the closing bell  In the last reported quarter  the company surpassed the Zacks Consensus Estimate by 8 cents  Further  it has an average four quarter positive surprise of 183 3  Which Way Are Estimates Treading Currently  the Zacks Consensus Estimate for third quarter revenues is pegged at  349 4 million  suggesting growth of 31  from the year ago reported number  The consensus estimate for earnings is pegged at 18 cents per share  indicating an improvement of 5 9  from the year ago reported figure Key CatalystsDexCom s third quarter top line is likely to reflect possible increase in volumes  on the back of new patients across all channels  and rising global awareness about the company s real time CGM Moreover  the company raised 2019 revenue outlook and now anticipates total revenues in the range of  1 33  1 38 billion  up from the previously guided range of  1 25  1 3 billion   Consequently  a similar trend is likely to have continued in the to be reported quarter With respect to DexCom s FDA cleared CGM system   the DexCom G4 Platinum has been boosting the company s top line significantly and a trend that is likely to have continued in the third quarter Per management  the company is well poised to achieve a long term target on the back of the expansion of the rollout of G6 and improve access to CGM  With this growing demand in mind  the company is on track to meet its goal of doubling G6 capacity by the end of 2019  Therefore  rising demand is anticipated to have positively impacted the company s overall performance in the to be reported quarter DexCom has a sizeable international market opportunity on the back of the demographic trends and lifestyle in countries outside the United States and Europe  This trend is likely to have resulted in higher international revenues in the third quarter Given the improved operational discipline  the company is likely to have experienced better operating margins in the third quarter  Moreover  the company s full year gross margin projection ranges between 64 65  and approaching 70  as the company exits 2019 on the back of the broad introduction of lower cost G6 trasmitter in the second half of the year  Going by this projection  a similar trend is likely to have continued in the to be reported quarter However  increase in operating expenses and intense competition are likely to have affected the company s overall performance in the third quarter DexCom  Inc  Price and EPS Surprise    What Our Quantitative Model SuggestsPer our proven model  a combination of   a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    increases the chances of an earnings beat  This is not the case here as you will see Earnings ESP  DexCom has an Earnings ESP of  17 91   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  DexCom carries a Zacks Rank  3 Stocks Worth a LookHere are some medical stocks worth considering as these have the right combination of elements to post an earnings beat this quarter Tandem Diabetes Care  Inc    NASDAQ TNDM   has an Earnings ESP of  33 33  and a Zacks Rank  2  You can see  Neovasc Inc    NASDAQ NVCN   has an Earnings ESP of  16 87  and a Zacks Rank  3 ShockWave Medical  Inc    NASDAQ SWAV   has an Earnings ESP of  3 55  and a Zacks Rank  3 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 5  per year  So be sure to give these hand picked 7 your immediate attention ,2019-10-31,Zacks Investment Research,https://www.investing.com/analysis/dexcom-dxcm-to-report-q3-earnings-whats-in-the-offing-200481451,200481451
113665,335180,DXCM,5 Top Ranked Stocks Crushing The Market In June ,opinion,"Although worsening U S  China trade dispute and global growth worries are shaking the stock market now and then  Wall Street has staged a nice comeback from the May swoon on hopes of monetary easing policies Fed Chair Powell initially suspended the three year monetary policy tightening program this year and has now signaled rate cuts if needed  The Fed is closely monitoring the implications of trade tensions on the economy and would act as appropriate to sustain the expansion  given a strong labor market and inflation near 2  target The latest weak job data and subdued inflation stirred speculation on interest rate cuts  Lower interest rates will keep borrowing cost down  thereby resulting in higher consumer spending and rise in economic activities  Further  the possibility of rate cuts has put pressure on the U S  dollar  making the dollar denominated products cheaper for foreign buyers and thus raising demand for American products 
Additionally  recovery in U S  housing market  Trump s suspension of the planned tariffs against Mexico and wave of mergers and acquisitions added to the strength  Further  the American economy is on a slower growth path buoyed by strong job growth  rising consumer confidence  and higher consumer spending While there are winners from various corners of the space  some stocks have been crushing the brood market and have a solid Zacks ETF Rank  1  Strong Buy  or 2  Buy   Below we have presented a bunch of those that are easily leading the way higher this month and will continue to outperform for the rest of the month given their superior fundamentals  You can see  JinkoSolar Holding Company Limited   NYSE JKS     Up 22 9 The company is a solar product manufacturer with operations based in Jiangxi Province and Zhejiang Province in China  The stock saw positive earnings estimate revision of a penny for this year in a month and has an estimated earnings growth rate of 81 7   higher than the industry s average growth of 79 2   The stock has a market cap of  685 3 million and carries a Zacks Rank  1  It flaunts a solid VGM Score of B 

Salem Media Group Inc    NASDAQ SALM     Up 22 7 It is a radio broadcaster  Internet content provider and magazine and book publisher specializing in Christian and Conservative content  The stock saw no earnings estimate revision for this year over month with an expected earnings growth rate of 216 7   compared with the industry s average earnings decline of 7 3   SALM has a market cap of  61 8 million and carries a Zacks Rank  1  Its VGM Score stands at B 

Ciena Corporation   NYSE CIEN     Up 21 6 This is a network specialist  focused on expanding the possibilities for its customers  networks while reducing their cost of ownership  The stock saw solid earnings estimate revision of 18 cents for the year  ending October 2019  over the past month and has an expected growth rate of 43 2    higher than the industry s average growth of 40 3   It has a Zacks Rank  1 and VGM Score of A  Ciena Corporation has a market cap of  6 7 billion 

DexCom Inc    NASDAQ DXCM     Up 20 6 This company is developing continuous glucose monitoring systems for people with diabetes  With a market cap of  13 2 billion  the stock witnessed no earnings estimate revision for this year in the past month  It has an estimated earnings growth of 166 7   higher than the industry s average growth of 13   The stock has a Zacks Rank  2 and VGM Score of B 

Zumiez Inc    NASDAQ ZUMZ     Up 17 With a market cap of  583 3 million  Zumiez is a leading specialty retailer of apparel  footwear  accessories and hardgoods for young men and women who want to express their individuality through the fashion  music  art and culture of action sports  streetwear  and other unique lifestyles  The stock saw positive earnings estimate revision of 4 cents for the year  ending January 2020  over the past month with an expected earnings growth rate of 5 6  versus 1 3  industry s decline in earnings It has a Zacks Rank  2 and VGM Score of A 

Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-06-14,Zacks Investment Research,https://www.investing.com/analysis/5-topranked-stocks-crushing-the-market-in-june-200431775,200431775
113666,335181,DXCM,The Zacks Analyst Blog Highlights  JinkoSolar  Salem Media  Ciena  DexCom And Zumiez,opinion,"For Immediate Release
Chicago  IL   June 17  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  JinkoSolar Holding Company Ltd    NYSE JKS    Salem Media Group Inc    NASDAQ SALM    Ciena Corp    NYSE CIEN    DexCom Inc    NASDAQ DXCM   and Zumiez Inc    NASDAQ ZUMZ   
Here are highlights from Friday s Analyst Blog  
5 Top Ranked Stocks Crushing the Market in June
Although worsening U S  China trade dispute and global growth worries are shaking the stock market now and then  Wall Street has staged a nice comeback from the May swoon on hopes of monetary easing policies 
Fed Chair Powell initially suspended the three year monetary policy tightening program this year and has now signaled rate cuts if needed  The Fed is closely monitoring the implications of trade tensions on the economy and would act as appropriate to sustain the expansion  given a strong labor market and inflation near 2  target 
The latest weak job data and subdued inflation stirred speculation on interest rate cuts  Lower interest rates will keep borrowing cost down  thereby resulting in higher consumer spending and rise in economic activities  Further  the possibility of rate cuts has put pressure on the U S  dollar  making the dollar denominated products cheaper for foreign buyers and thus raising demand for American products 
Additionally  recovery in U S  housing market  Trump s suspension of the planned tariffs against Mexico and wave of mergers and acquisitions added to the strength  Further  the American economy is on a slower growth path buoyed by strong job growth  rising consumer confidence  and higher consumer spending 
While there are winners from various corners of the space  some stocks have been crushing the brood market and have a solid Zacks ETF Rank  1  Strong Buy  or 2  Buy   Below we have presented a bunch of those that are easily leading the way higher this month and will continue to outperform for the rest of the month given their superior fundamentals  You can see  
JinkoSolar Holding Company Ltd    Up 22 9 
The company is a solar product manufacturer with operations based in Jiangxi Province and Zhejiang Province in China  The stock saw positive earnings estimate revision of a penny for this year in a month and has an estimated earnings growth rate of 81 7   higher than the industry s average growth of 79 2   The stock has a market cap of  685 3 million and carries a Zacks Rank  1  It flaunts a solid VGM Score of B 
Salem Media Group Inc    Up 22 7 
It is a radio broadcaster  Internet content provider and magazine and book publisher specializing in Christian and Conservative content  The stock saw no earnings estimate revision for this year over month with an expected earnings growth rate of 216 7   compared with the industry s average earnings decline of 7 3   SALM has a market cap of  61 8 million and carries a Zacks Rank  1  Its VGM Score stands at B 
Ciena Corp    Up 21 6 
This is a network specialist  focused on expanding the possibilities for its customers  networks while reducing their cost of ownership  The stock saw solid earnings estimate revision of 18 cents for the year  ending October 2019  over the past month and has an expected growth rate of 43 2    higher than the industry s average growth of 40 3   It has a Zacks Rank  1 and VGM Score of A  Ciena Corporation has a market cap of  6 7 billion 
DexCom Inc    Up 20 6 
This company is developing continuous glucose monitoring systems for people with diabetes  With a market cap of  13 2 billion  the stock witnessed no earnings estimate revision for this year in the past month  It has an estimated earnings growth of 166 7   higher than the industry s average growth of 13   The stock has a Zacks Rank  2 and VGM Score of B 
Zumiez Inc    Up 17 
With a market cap of  583 3 million  Zumiez is a leading specialty retailer of apparel  footwear  accessories and hardgoods for young men and women who want to express their individuality through the fashion  music  art and culture of action sports  streetwear  and other unique lifestyles  The stock saw positive earnings estimate revision of 4 cents for the year  ending January 2020  over the past month with an expected earnings growth rate of 5 6  versus 1 3  industry s decline in earnings It has a Zacks Rank  2 and VGM Score of A 
Will you retire a millionaire 
One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  

Media Contact
Zacks Investment Research
800 767 3771 ext  9339
 
 
Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ",2019-06-16,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-jinkosolar-salem-media-ciena-dexcom-and-zumiez-200432139,200432139
113667,335182,DXCM,ETF   Stock Winners Of Longest US Economic Expansion,opinion,"U S  economic expansion stepped into its 11th year on Jul 1  breezing past the  from March 1991 to March 2001  according to the National Bureau of Economic Research 
However  the record breaking expansion  which is now the longest in history   as consumers are cautious about loosening their purse strings after suffering one of the worst recessions in the 2008 2009 period  Starting in June 2009  this record setting run witnessed GDP growing cumulatively by 25    
The Fed s quantitative easing and rock bottom interest rate policy along with the U S  government s Troubled Asset Relief Program  TARP  helped in reviving the domestic economy  Solid job growth  rising consumer confidence  upbeat GDP growth  wealth effect  cheap oil from mid 2014  Trump bump after Nov 2016  Trump tax cuts from the start of 2018  and    collectively fueled the economy and the stock market in the past decade 
Inside the Economic Rise
The unemployment rate at the start of this winning economic cycle was 9 6   while it was 3   a 49 year low  Wage growth in the United States also picked up in recent times  resulting in greater affordability 
As   the final GDP reading in June 2009 came up with a year on year contraction of 0 7   after recording contraction of more than 5  for   In contrast  GDP grew 3 1  year over year in Q1 of 2019 
However  the momentum is cooling down  Job growth has been relatively weaker than in other postwar recoveries    There has lately been a lag in the housing market  The bond market has flashed recessionary signals several times in between  
Not only this  the corporate earnings picture also looks bleak  The S P 500 earnings are expected to decline 3  year over year despite 4 3  gains in revenues  per Zacks  Now 77  of the companies issuing pre announcements hints that  which marks the second worst quarter on record since 2006   
Against this backdrop  below we highlight some ETFs and stocks that weathered all ups and downs last decade and emerged as clear winners 
ETF Winners 
First Trust Dow Jones Internet Index Fund    Up 703 4 
The underlying Dow Jones Internet Composite Index includes only companies whose primary focus is Internet related  The fund has a Zacks Rank  2  Buy  
First Trust NYSE Arca Biotechnology Index Fund    Up 606 9 
The underlying NYSE Arca Biotechnology Index is an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services  The fund has a Zacks Rank  3 
iShares U S  Aerospace   Defense ETF   HM ITA     Up 510 6 
The underlying Dow Jones U S  Select Aerospace   Defense Index measures the performance of the aerospace and defense sector of the U S  equity market  The fund has a Zacks Rank  2  read    
Consumer Discretionary Select Sector SPDR Fund   TSXV XLY     Up 521 5 
The underlying Index seeks to provide an effective representation of the consumer discretionary sector of the S P 500 Index  The fund has a Zacks Rank  2 
Stock Winners 
Domino s Pizza Inc    NYSE DPZ     Up 4040 0 
This Zacks Rank  2 company is the second largest pizza restaurant chain in the world  It belongs to a top ranked Zacks industry  top 37   
Jazz Pharmaceuticals Plc   NASDAQ JAZZ     Up 3817 9 
This Zacks Rank  2 specialty pharmaceutical company is focused on identifying  developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry  It comes from a top ranked Zacks industry  top 28   
lululemon athletica Inc    NASDAQ LULU     Up 2862 1 
This Zacks Rank  2 company designs and retails athletic clothing for women  men and female youth  Its apparel assortment  including items  such as fitness pants  shorts  tops and jackets  is designed for activities such as yoga  running and general fitness 
DexCom Inc    NASDAQ DXCM     Up 2594 5 
This Zacks Rank  1 company is developing continuous glucose monitoring systems for people with diabetes  It hails from a top ranked Zacks industry  top 31   
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2019-07-03,Zacks Investment Research,https://www.investing.com/analysis/etf--stock-winners-of-longest-us-economic-expansion-200436707,200436707
113668,335183,DXCM,Will MedTech Ease Investors  Concern   Outperform  4 Picks ,opinion,Investors putting money into the medical device space are concerned about complex regulatory procedures coming into the way of infrastructural or technology growth  The FDA s significantly long drawn process to review and grant approval to any device is impeding the movement of MedTech stocks on the bourses Despite the industry s  non discretionary  spending nature  solid long term potential and favorable demographic trend  investors  fear of such hindrances has created a gap between the growth potential of this industry and the pace of investment  Lower investment in MedTech might prove to be a concern  more so as gains within this space are staggering A Look Into the Recent MedTech BreakthroughsThe past few months have been remarkable for the medical device space in terms of research and development  R D   Riding on path breaking inventions like wireless brain sensors  Bluetooth enabled smart inhalers  artificial pancreas  human brain pacemaker  electronic skin that displays vital signs of the body  needle free injections  precision medicine and many more  the medical device space has gone from strength to strength MedTech to Rule the Roost A June 2019  claims that the medical device market will outpace the broader economy based on certain favorable demographic trends  like population growth  aging of baby boomers and the rising prevalence of chronic diseases  and the suspension of the 2 3  medical device excise tax  The industry is expected to grow from about  164 billion in 2018 to  208 billion in 2023 at a CAGR of 4 9  While the international trade scenario is a bit tough at present given higher tariffs  uncertainty and tightening credit conditions  per the report  medical device space is in a better position to weather the choppy conditions than the broader economy The sales forecast for the space is quite impressive  Per the latest  consensus forecasts  the worldwide MedTech market will reach sales of  594 5 billion by 2024  witnessing a CAGR of 5 6  between 2017 and 2024 Segments to Dominate shows that in vitro diagnostic is likely to remain the sector leader through 2024  steering ahead of cardiology  with 13 4  of the total medical device market and annual growth of 6 1   Roche Holding  SIX ROG  AG   OTC RHHBY   is expected to lead this space with 18  market share and sales of  12 30 billion by 2024 Diagnostics imaging and orthopedics  which are already on shaky ground  may prove to be the two slowest growing segments in the said time frame with a CAGR of 3 7  during this period MedTech Investing Appears Sensible NowThe above data is just a small indicator of the vast scope of the MedTech market  The most important fact is that the benefit of medical device is not limited to any particular country or geographic territory  With the emergence of complex and transmittable diseases worldwide and with the U S  economy expected to remain strong in the second half of the year as well  this space is undoubtedly going to be in the spotlight Here Are the PicksGiven the diversity in the space  selecting winning stocks is difficult for investors  To make the process easier  we have zeroed in on four stocks  each carrying a Zacks Rank  1  Strong Buy   You can see  The chart below shows the price performance of the four picks in the past six months  Haemonetics Corporation   NYSE HAE   provides blood management solutions to customers encompassing blood and plasma collectors  hospitals and health care providers globally  It has a Zacks Rank  1  The Zacks Consensus Estimate for current year earnings has risen 3 5  over the past 60 days  Moreover  current year earnings are projected to grow at an impressive rate of 22 56  DexCom  Inc    NASDAQ DXCM   is focused on the design  development and commercialization of continuous glucose monitoring systems  The Zacks Rank  1 company is based in San Diego  CA  The Zacks Consensus Estimate for current year earnings has climbed 81 8  over the past three months Orthofix Medical Inc    NASDAQ OFIX   is focused on musculoskeletal products and therapies  The company s long term historical earnings growth rate is 6 7  BIOLASE  Inc    NASDAQ BIOL   is a global player in the field of manufacturing and marketing of proprietary dental laser systems  Earnings are projected to grow at an impressive rate of 15  over the next five years Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-07-04,Zacks Investment Research,https://www.investing.com/analysis/will-medtech-ease-investors-concern--outperform-4-picks-200437310,200437310
113669,335184,DXCM,What s In The Offing For DexCom s  DXCM  Earnings In Q2 ,opinion,DexCom  Inc    NASDAQ DXCM   is expected to release second quarter 2019 results on Jul 31  after the closing bell  In the last reported quarter  the company delivered a positive earnings surprise of 70 6   Further  it has an average four quarter positive surprise of 149 9  Which Way Are Estimates Treading Currently  the Zacks Consensus Estimate for second quarter revenues is pegged at  302 2 million  suggesting growth of 24 6  from the year ago reported number  The same for adjusted earnings is at breakeven level DexCom  Inc  Price and EPS Surprise    Key CatalystsPossible increase in volumes across all channels and rising global awareness of the company s real time CGM is likely to aid DexCom s top line in the upcoming quarterly results Moreover  the company raised 2019 revenue outlook and now anticipates total revenues in the range of  1 25  1 3 billion  up from the previously guided range of  1 18  1 23 billion   Consequently  we expect the company to witness a similar trend in the to be reported quarter With respect to DexCom s FDA cleared CGM system   the DexCom G4 Platinum has been boosting the company s top line significantly and we expect the moment to sustain in the to be reported quarter Per management  the company is well poised to achieve a long term target on the back of the expansion of the rollout of G6 and improve access to CGM  With this growing demand in mind  the company is on track to meet its goal of doubling G6 capacity by the end of 2019  Therefore  this rising demand is anticipated to positively impact the company s overall performance in the to be reported quarter DexCom has a sizeable international market opportunity on the back of the demographic trends and lifestyle in countries outside the United States and Europe  To that end  we expect the company to deliver higher international revenues in the to be reported quarter Given the improved operational discipline  the company might have experienced better operating margins in the second quarter However  the company projects restructuring related cost to approximately range between  15 million and  20 million for 2019 with the majority being incurred in the first half  Going by this projection  we expect a similar trend in the to be reported quarter Earnings WhispersPer our proven model  a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise  This is not the case here as you will see below Earnings ESP  DexCom has an Earnings ESP of 0 00   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  DexCom carries a Zacks Rank  1 Meanwhile  we caution against stocks with a Zacks Rank  4  Sell  or 5  Strong Sell  going into the earnings announcement  especially when the company is seeing negative estimate revision Stocks Worth a LookHere are some medical stocks worth considering as these have the right combination of elements to post an earnings beat this quarter Adamis Pharmaceuticals Corporation   NASDAQ ADMP   has an Earnings ESP of  11 76  and a Zacks Rank  3 You can see   DENTSPLY SIRONA   NASDAQ XRAY   has an Earnings ESP of  6 95  and a Zacks Rank  1 Allena Pharmaceuticals  Inc    NASDAQ ALNA   has an Earnings ESP of  7 55  and a Zacks Rank  2 This Could Be the Fastest Way to Grow Wealth in 2019 Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119 and  164 gains in as little as 1 month ,2019-07-25,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-offing-for-dexcoms-dxcm-earnings-in-q2-200444577,200444577
113687,335202,DXCM,Abbott  ABT  Q1 Earnings Beat Estimates  Organic Sales Solid,opinion,Abbott Laboratories   NYSE ABT   reported first quarter 2019 adjusted earnings from continuing operations of 63 cents per share  beating the Zacks Consensus Estimate by 3 3   The bottom line improved 6 8  year over year and remained above the company s guided range of 60 62 cents  Reported earnings from continuing operation in the quarter came in at 38 cents  a 65 2  surge from the year ago quarter First quarter worldwide sales came in at  7 54 billion  up 1 9  year over year on a reported basis  The top line remained above the Zacks Consensus Estimate of  7 47 billion On an organic basis  adjusting for the impact of foreign exchange as well as certain acquisitions and divestments   sales increased 7 1  year over year in the reported quarter Quarter in DetailAbbott operates through four segments  namely Established Pharmaceuticals Division  EPD   Medical Devices  Nutrition and Diagnostics Abbott Laboratories Price  Consensus and EPS Surprise   In the first quarter  EPD sales dropped 4 9  on a reported basis  improved 5 4  on an organic basis  to  992 million  This included an 10 3  adverse impact from currency fluctuations  Sales in the key emerging markets declined 5 2  year over year on a 12 5  adverse impact of foreign exchange  Organically  sales improved 7 3  in this market The Medical Devices business sales increased 5 5  on a reported basis to  2 89 billion  On an organic basis  sales grew 9 5  Cardiovascular and Neuromodulation sales reportedly  up 3 6  on an organic basis  rose 0 2  on double digit growth in Electrophysiology  Heart Failure  Structural Heart and Diabetes Care  In Electrophysiology  growth was led by strong performance in cardiac mapping and ablation catheters Within Structural Heart  the company registered 15  organic growth on a year over year basis driven by strong performance in several product areas across Abbott s broad portfolio  including MitraClip device Diabetes Care sales improved 34 4   up 42  organically   buoyed consistent consumer uptake of FreeStyle Libre  the revolutionary continuous glucose monitoring system of Abbott Nutrition sales were up 2  year over year on a reported basis  up 6 7  on an organic basis  to  1 79 billion  Pediatric Nutrition sales increased 6 7  on an organic basis  Adult Nutrition sales were up 6 8  organically Diagnostics sales were up a marginal 0 2  year over year on a reported basis  up 4 4  on a comparable operational basis  to  1 84 billion  Core Laboratory Diagnostics sales grew 9 9  while Molecular Diagnostics slipped 5 1   on an organic basis  Point of Care Diagnostics sales were down 4 2   Rapid Diagnostics sales declined 1 4  on an organic basis in the first quarter affected by a difficult comparison versus the first quarter of 2018 when sales were abnormally high due to a strong flu season 2019 GuidanceAdjusting for certain net specified items for the full year  adjusted earnings from continuing operations are reiterated in the band of  3 15  3 25  The Zacks Consensus Estimate of  3 20 remains within this projected range The company has also provided second quarter 2019 adjusted earnings per share outlook  It expects to report adjusted earnings from continuing operations in the range of 79 81 cents  The consensus mark of 81 cents falls at the upper end the predicted range Our TakeAbbott exited the first quarter with better than expected earnings and revenues figures Overall  we are optimistic about Abbott s strong and consistent EPD and Medical Devices performance organically  Particularly  Abbott has been riding high on a healthy growth within its Diabetes Care business  The company has been hogging the limelight for developments in the flagship  sensor based continuous glucose monitoring  CGM  system   FreeStyle Libre System  Also  solid contributions from the company s other two businesses encourage us Meanwhile  the company s emerging market performance has been promising on several strategic developments On the flip side  increasing currency headwinds significantly dented the company s international performance Zacks Rank   Key PicksAbbott currently carries a Zacks Rank  2  Buy  A few other top ranked stocks in the broader medical space are Bio Rad Laboratories  Inc    NYSE BIO    LeMaitre Vascular  Inc    NASDAQ LMAT   and DexCom  Inc    NASDAQ DXCM   Bio Rad is scheduled to release first quarter 2019 results on May 8  The Zacks Consensus Estimate for the quarter s adjusted EPS is pegged at  1 12 and for revenues stands at  548 8 million  The stock sports a Zacks Rank  1  Strong Buy   You can see  LeMaitre Vascular is expected to release first quarter 2019 results on Apr 24  The Zacks Consensus Estimate for the period s adjusted EPS is 19 cents and for revenues   27 99 million  The stock carries a Zacks Rank  2 DexCom is slated to release first quarter 2019 results on May 1  The Zacks Consensus Estimate for adjusted loss per share for the to be reported quarter is 17 cents and for the top line   246 5 million  The stock has a Zacks Rank of 2 Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-04-16,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-q1-earnings-beat-estimates-organic-sales-solid-200407881,200407881
113717,335232,DXCM,Veeva Systems  VEEV  Gains From Solid Results For Fiscal Q4,opinion,On Mar 15  we issued an updated research report on Veeva Systems Inc    NYSE VEEV    A strong fiscal fourth quarter show and product portfolio currently favor this Zacks Rank  2  Buy  company What s Favoring the Stock Veeva Systems ended the fiscal fourth quarter on a strong note  The company s adjusted earnings per share came in at 45 cents per share  outpacing the Zacks Consensus Estimate of 31 cents  The bottom line also increased a whopping 87 5  on a year over year basis Total revenues came in at  232 3 million  beating the Zacks Consensus Estimate of  228 million  On a year over year basis  the top line improved 25  Reflective of these  the company issued a strong guidance for fiscal 2020 For first quarter fiscal 2020  Veeva Systems expects total revenues between  238 million and  239 million  Adjusted earnings per share are expected between 44 cents and 45 cents  Adjusted operating income is projected in the  85  86 million band Revenues are expected between  1 02 billion and  1 03 billion for fiscal 2020  For the fiscal year  adjusted earnings per share are anticipated in the range of  1 91  1 94 Management expects Subscription revenue growth of 21 22  for fiscal 2020  Commercial Cloud subscription revenues are expected to rise 10  Moreover  Veeva Systems  broad solution portfolio includes Veeva Vault  Veeva CRM  Veeva Network and Veeva OpenData  Another new cloud application of the company is Veeva Vault Training  designed to simplify role based training across life sciences organizations and help quality teams remain audit ready and compliant It is encouraging to note that  in fiscal 2020  Veeva Systems aims to release major capabilities within Vault CDMS which are expected to be real game changers for the life sciences industry Price PerformanceOver the past year  shares of Veeva Systems have rallied 60 3  compared with the  s 14  gain  The current level is also higher than the S P 500 index s 4 3  rally Key PicksOther top ranked stocks in the broader medical space are Penumbra  Inc    NYSE PEN    Wright Medical Group N V    NASDAQ WMGI   and DexCom  Inc    NASDAQ DXCM    Notably  each of these stocks currently carries a Zacks Rank  2  You can see  Penumbra s long term earnings growth rate is expected at 20 9  Wright Medical s long term earnings growth rate is estimated at 11 3  DexCom s next quarter earnings per share are projected to grow 120  Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-03-17,Zacks Investment Research,https://www.investing.com/analysis/veeva-systems-veev-gains-from-solid-results-for-fiscal-q4-200398656,200398656
113718,335233,DXCM,Inogen s Prospects In Europe Solid Amid Trade Related Tension,opinion,On Mar 18  we issued an updated research report on Inogen  Inc    NASDAQ INGN    A strong fourth quarter show and solid prospects in Europe currently favor the stock  On the contrary  trade related uncertainties plague this Zacks Rank  3  Hold  company What s Favoring the Stock In the recently reported fourth quarter of 2018  Inogen posted earnings of 44 cents per share  which surpassed the Zacks Consensus Estimate of 25 cents  The bottom line improved from a net loss of 3 cents in the year ago quarter Revenues came in at  86 5 million  which trumped the Zacks Consensus Estimate of  82 million  On a year over year basis  the top line climbed 35 7  Reflective of this  Inogen retained its revenue and EBITDA outlook for 2019 Notably  the company continues to expect revenues between  430 million and  440 million  representing 20 1 22 9  growth over 2018 Full year adjusted EBITDA is projected between  67 million and  71 million  representing 9 3 15 9  growth year over year Moreover  Inogen is optimistic about its prospects in Europe In the fourth quarter of 2018  Inogen s business to business unit saw international revenues of  18 5 million  up 54 5  year over year on continued adoption by the company s European partners  Per management  Europe sales represented 87 8  of fourth quarter international sales DeterrentsDespite a better than expected fourth quarter  Inogen trimmed its 2019 net income guidance range to  40  44 million from the previously issued  48  52 million  Per management  the slashed guidance is due to a fall in estimated provision for income taxes related to excess tax benefits recognized from stock based compensation Additionally  the company s guidance assumes a full impact of the tariffs on applicable Chinese sourced materials since the increase of China import tax has been currently delayed by the United States  giving rise to trade related uncertainties Price PerformanceOver the past year  shares of Inogen have declined 23 5  against the  s 9 8  gain  The current level is also lower than the S P 500 index s 4 3  rally Key PicksA few better ranked stocks in the broader medical space are Penumbra  Inc    NYSE PEN    Wright Medical Group N V    NASDAQ WMGI   and DexCom  Inc    NASDAQ DXCM    Notably  each of these stocks currently carries a Zacks Rank  2  Buy   You can see  Penumbra s long term earnings growth rate is expected at 20 9  Wright Medical s long term earnings growth rate is estimated at 11 3  DexCom s next quarter earnings per share are projected to grow 120  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-03-18,Zacks Investment Research,https://www.investing.com/analysis/inogens-prospects-in-europe-solid-amid-traderelated-tension-200399055,200399055
113719,335234,DXCM,AMN Healthcare Down On Soft Locum Tenens Business  Dull View,opinion,"On Mar 20  we issued an updated research report on AMN Healthcare Services Inc   NYSE AMN    The company s soft Locum Tenens Business and a dull 2019 view are concerning factors at the moment Shares DownOver the past year  the Zacks Rank  4  Sell  stock has declined 16 5  against its  s 15 2  rally  The current level is also lower than the S P 500 index s 6 4  gain Estimates PlummetFor the first quarter  four estimates have moved down over the last 60 days  compared to no movement in the opposite direction  For 2019  five estimates have moved south Reflective of this  AMN Healthcare s current quarter earnings per share projection plunged 18 6  to 70 cents over the past two months  Meanwhile  current year earnings per share estimate moved 33 6  to down  2 98 over the same time frame AMN Healthcare Services Inc Price and Consensus
    What s Deterring the Stock In the recently reported fourth quarter of 2018  Locum Tenens revenues declined 24  to  82 million  far wider than management s expectation of a 14  fall  Per management  there were larger than expected declines in the emergency medicine and hospital specialties due to a drop in demand  Hence  first quarter 2019 Locum Tenens revenues are expected to deteriorate year over year Furthermore  the company expects 2019 organic revenues to decline 6  owing to expectations of lower contributions from the Locum Tenens business  Additionally  Nurse and Allied segment revenues are expected to decline about 1 2  year over year Lastly  AMN Healthcare outsources certain critical applications or business processes to external providers  including cloud based  credentialing and data processing services  Hence  the failure or inability to perform by one or more of these critical suppliers could cause significant disruptions and raise costs for the company However  it is encouraging to note that the company s acquisition of MedPartners has proven accretive in recent times Key PicksA few better ranked stocks in the broader medical space are Penumbra  Inc    NYSE PEN    Veeva Systems   NYSE VEEV   and DexCom  Inc    NASDAQ DXCM    Notably  each of these stocks currently carries a Zacks Rank  2  Buy   You can see  Penumbra s long term earnings growth rate is expected at 20 9  Veeva Systems  long term earnings growth rate is estimated at 14 8  DexCom s next quarter earnings per share are projected to grow 120  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-03-24,Zacks Investment Research,https://www.investing.com/analysis/amn-healthcare-down-on-soft-locum-tenens-business-dull-view-200400765,200400765
113740,335255,DXCM,Chemed Gains Ground On Solid VITAS   Roto Rooter Businesses,opinion,On Feb 27  we issued an updated research report on Chemed Corporation   NYSE CHE    This Zacks Rank  1  Strong Buy  stock currently operates two wholly owned subsidiaries   VITAS Healthcare and Roto Rooter  Over the past few quarters  VITAS has been registering solid admissions and expanded average daily census  Meanwhile  the Roto Rooter business is seeing growth on strong performance by the core plumbing and drain cleaning service segments as well as solid improvement in water restoration In the past six months  Chemed has consistently outperformed the S P 500 market  The stock has gained 3 2  versus the market s 3 5  decline Chemed exited 2018 on a promising note  The company registered strong year over year growth in earnings and revenues  Notably  the company witnessed solid revenue growth across its key subsidiaries  Chemed has seen strong performance in the VITAS business over the past few quarters  During fourth quarter 2018  VITAS admissions generated from hospitals rose 2  and made up 50  of total admissions  Also  home based admissions rose 2 5   For 2019  the company projects VITAS Healthcare revenue growth  prior to Medicare Cap  within 5 5 6  Also  we are upbeat about Roto Rooter which is currently the nation s leading provider of plumbing and drain cleaning services  Through its network of company owned branches  independent contractors and franchises  Roto Rooter offers plumbing and drain cleaning services to more than 90  of the U S  population  During fourth quarter 2018  Roto Rooter reported 10 6  growth year over year  We are currently looking forward to Roto Rooter s recently made acquisitions of certain franchises in California  According to the company  it has acquired five formerly independent Roto Rooter franchises covering several areas of Northern California  This is its largest franchise acquisition to date  with annual sales of  22 million Chemed s capital deployment policy is based on suitable acquisitions and solid return of cash to shareholders through dividends and buybacks  Other Key PicksA few other top ranked stocks in the broader medical space are Penumbra  Inc    NYSE PEN    Wright Medical Group N V    NASDAQ WMGI   and DexCom  Inc    NASDAQ DXCM    Notably  each of these stocks currently carry a Zacks Rank  2  Buy   You can see  Penumbra s long term earnings growth rate is expected at 20  Wright Medical s long term earnings growth rate is expected at 11  DexCom s second quarter earnings per share are projected to grow 160  Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-02-26,Zacks Investment Research,https://www.investing.com/analysis/chemed-gains-ground-on-solid-vitas--rotorooter-businesses-200393033,200393033
113741,335256,DXCM,DexCom  DXCM  Gets Health Canada Approval For G6 CGM System,opinion,DexCom  Inc    NASDAQ DXCM   announced that its next generation G6 CGM system has received an approval from Health Canada  a regulatory authority  The device is designed to cater to diabetes patients in Canada  aged two years and above  The G6 commercial launch in Canada is slated to occur in late 2019  Interestingly  DexCom is already planning for the worldwide launch of the product in the near future About G6 CGMDexCom s G6 CGM system is a diabetes management device  G6 was initially launched in the markets of United States  United Kingdom  Ireland and several other European nations  where it registered robust sales figures in the last reported quarter For investors  notice  G6 is an upgradation of DexCom s flagship G5 mobile system  The G5 mobile system is used to measure glucose levels with a sensor that is fitted just underneath the skin  DexCom is also gearing up for the launch of the G7 system in late 2020 or early 2021  With G7  the company aims to deliver cost effective health benefits to people suffering from non intensive Type 2 diabetes Market ProspectsPer Allied Market Research  the global market of CGM systems is projected to reach  4 921 million by 2024  multiplying at a CAGR of 22 9   from 2018 to 2024   Considering the bountiful prospects  the launch of the G6 CGM system by DexCom is considered to be strategically timed Not to forget  the CGM systems market is an integral part of the broader diabetic devices space  which also includes blood glucose meters and insulin delivery devices Other Recent DevelopmentsIn November 2018  DexCom amended the collaboration and licensing agreement with Verily for the development of a fully disposable real time CGM  The agreement enabled DexCom to more efficiently deal with Type 2 diabetes DexCom has been making solid progress with Insulet for developments on its Horizon platform  DexCom announced a development agreement with Lilly to incorporate CGM into the latter s Connected Diabetes Ecosystem  This will enable Dexcom to introduce both connected pumps and pens to the market  In October 2018  the company announced the collaboration of its smart pen and integration program with Novo Nordisk  CO NOVOb  The company plans to continue investing in several other similar partnerships throughout 2019 and expects DexCom integrated smart pen systems to become commercially accessible to consumers by 2020 Price PerformanceThe stock has outperformed the S P 500 Index over the past three months  The stock has gained 10 8  compared with the index s growth of 4 5  Zacks Rank   Other Key PicksCurrently  DexCom has a Zacks Rank  2  Buy   Other top ranked stocks in the broader medical space include ABIOMED  Inc     NASDAQ ABMD    Penumbra  Inc     NYSE PEN    and Masimo  Inc    NASDAQ MASI    each carrying a Zacks Rank of 2  You can see  ABIOMED s long term earnings growth rate is expected to be 27 67  Penumbra s long term earnings growth rate is projected to be 20  Masimo s long term earnings are projected to grow 15 6  Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-02-26,Zacks Investment Research,https://www.investing.com/analysis/dexcom-dxcm-gets-health-canada-approval-for-g6-cgm-system-200393079,200393079
113744,335259,DXCM,HOLX Vs DXCM  Which MedTech Stock Is A Better Investment Pick ,opinion,"Medical instrument companies Hologic  Inc    NASDAQ HOLX   and DexCom  Inc    NASDAQ DXCM   are solid contenders in the U S  MedTech space  which is expected to reach a worth of  409 5 billion by 2023 at a CAGR of 4 5   Analysts believe that 2019 will prove profitable for U S  medical device companies  courtesy of the 2 3  Medical Device tax abatement along with focus on AI and cybersecurity Meanwhile  it is difficult to make a choice between the above mentioned companies as both carry a Zacks Rank  2  Buy   You can see  However  we make a detailed analysis of the companies  fundamentals to determine which has a slight edge over the other Massachusetts based Hologic develops  manufactures  and supplies diagnostics  medical imaging systems and surgical products which cater to the healthcare needs of women  The company is focused on building mammography systems for breast examination and osteoporosis assessment  Meanwhile  California based DexComis a medical device company focused on the design  development and commercialization of continuous glucose monitoring systems  CGM  Price PerformanceOver the past year  Hologic s shares have gained 19 8  compared with DexCom s 123 5  rally  The Medical Instruments  has rallied 2 7  in the same time frame  Meanwhile  the S P 500 index has declined 1 3   Which Way Are Estimates Headed The Zacks Consensus Estimate for Hologic s current year earnings per share stands at  2 41  suggesting an improvement of 8 1  year over year  The same for DexCom is projected at 46 cents  showing year over year growth of 53 3  
Hologic  Inc  Price and Consensus
    The Zacks Consensus Estimate for Hologic s current year revenues is pegged at  3 32 billion  suggesting growth of 3 2  from the previous year  The same for DexCom is pegged at  1 21 billion  reflecting a rise of 17 5  
DexCom  Inc  Price and Consensus
    What s Favoring the Stocks Hologic currently has a  of C  Meanwhile  DexCom has a Growth Score of A  This reflects possibilities of outperformance over the long haul  Our research shows that stocks with a Growth Score of A or B  when combined with a Zacks Rank  1 or 2  are better picks than most DexCom s FDA cleared CGM system   the DexCom G4 Platinum   is significantly boosting the company s top line  Moreover  the company continues to focus on international markets  Germany in particular  The company is eyeing the sizeable markets of Korea  India  China and Japan as well Over the past four years  Hologic s revenues have seen a CAGR of 19  to  3 22 billion  Meanwhile  DexCom s revenues have seen a CAGR of 156 7  to  1 03 billion Wrapping UpThe above analysis shows that despite being close contenders  DexCom scores higher than Hologic when it comes to growth projections and fundamentals Key PicksA few other top ranked stocks in the broader medical space are Veeva Systems Inc   NYSE VEEV   and Integer Holdings Corporation   NYSE ITGR   Veeva Systems  long term earnings growth rate is projected at 14 8   The stock flaunts a Zacks Rank  2 Integer Holdings projects earnings growth rate of 31 2  for the first quarter  It currently carries a Zacks Rank  2 Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-03-11,Zacks Investment Research,https://www.investing.com/analysis/holx-vs-dxcm-which-medtech-stock-is-a-better-investment-pick-200396583,200396583
113753,335268,DXCM,HealthEquity s  HQY  Preliminary Q4 Results Cheer Investors,opinion,"Prior to the fiscal fourth quarter earnings release  HealthEquity  Inc    NASDAQ HQY   announced preliminary results for fiscal 2019  wherein the total number of HSAs  Health Savings Account  for which it serves as a non bank custodian was 4 million  This reflects an increase of 17  from fiscal 2018 Investors CheerfulHealthEquity s fiscal fourth quarter preliminary results seem to impress investors  Following the announcement  share price of this Zacks Rank  3  Hold  company climbed 2 2  to  66 45 at close If the company manages to outpace the Zacks Consensus Estimate in the fiscal fourth quarter  it will mark the second consecutive quarterly beat Over the past month  shares of HealthEquity have rallied 25 7   higher than the  s 12 5  growth  The current level is also higher than the S P 500 s rally of 6 4  HSA DetailsBy the end of fiscal 2019  total custodial assets held by HSA Members totaled  8 1 billion  up 19  from the earlier year HealthEquity  Inc  Price and Consensus
    In fiscal 2019  the company set a record by opening 674 000 new HSAs which helped HAS members add  1 3 billion worth of custodial assets OutlookFor fiscal 2019  management at HealthEquity anticipates revenues within  284 million and  287 million  The midpoint of the latest guidance of  285 5 million is above the Zacks Consensus Estimate of  284 3 million Adjusted earnings per share are projected between  1 13 and  1 17  higher than the Zacks Consensus Estimate of  1 12 Additionally  the company provided fiscal 2020 revenue guidance  Revenues are expected in the range of  333 million to  339 million  below the Zacks Consensus Estimate of  341 3 million Key PicksA few better ranked stocks in the broader medical space arePenumbra  Inc    NYSE PEN    Wright Medical Group N V    NASDAQ WMGI   and DexCom  Inc    NASDAQ DXCM   Each of these stocks currently carries a Zacks Rank  2  Buy  You can see  Penumbra s long term earnings growth rate is expected at 20  Wright Medical s long term earnings growth rate is expected at 11  DexCom s next quarter earnings per share are projected to grow at 56 3  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ",2019-02-06,Zacks Investment Research,https://www.investing.com/analysis/healthequitys-hqy-preliminary-q4-results-cheer-investors-200385249,200385249
113756,335271,DXCM,BD Gains From Solid Global Base  Headwinds Anticipated,opinion,"On Feb 6  we issued an updated research report on Becton  Dickinson and Company   NYSE BDX    also known as BD  While solid developments and a strong global foothold boost the stock  a few headwinds are anticipated in fiscal 2019 The stock currently carries a Zacks Rank  3  Hold  Price PerformanceIn the past year  BD s shares have rallied 15  against the  s decline of 0 4   The current level also compares favorably with the S P 500 s rally of 6 5  Over the past 60 days  the Zacks Consensus Estimate for the company s fiscal third quarter earnings per share moved up 0 6  to  3 25 Becton  Dickinson and Company Price and Consensus
    What s Favoring BD In recent times  the New Jersey based MedTech giant saw a slew of developments In the recently reported first quarter of fiscal 2019  BD announced the launch of two cloud based applications  BD HealthSight Data Manager and BD HealthSight Diversion Analytics  which enable an enterprise wide connected medication management system  Notably  both form part of the BD HealthSight platform Moreover  in the BD Interventional segment  WavelinQ was made available for sale in the United States in the fiscal first quarter  This product provides a minimally invasive nonsurgical option for creating critical AV fistulas for hemodialysis procedures Last month  BD announced the FDA approval of its second generation BD Nano pen needle for more reliable subcutaneous injection depth  Last December  BD received regulatory approval for the BD MAX enteric viral panel  a molecular diagnostic test BD is focused on geographical expansion into overseas markets Notably  in first quarter fiscal 2019  BD delivered strong sales internationally  which totaled  1 77 billion  up 24 6  from the year ago quarter and 4 1  at constant currency  cc   Per management  overseas revenue growth was backed by strong performance by all three segments in the quarter China saw growth of 13 3  from the year ago quarter  reflecting strength in the Life Science and Interventional segments  The core BD Medical segment excelled in China For fiscal 2019  BD expects growth of about 10  in emerging economies along with low double digit growth in China DeterrentsManagement at BD expects a few headwinds to mar prospects in fiscal 2019 BD expects raw material pricing pressure  which increased in 2018  to accelerate into fiscal 2019  primarily due to resin price increases owing to a supply constrained market  Although pressure from raw materials partially eased in the fiscal first quarter  management expects a 2  headwind from it in fiscal 2019 Additionally  BD expects a 1  headwind from tariffs in 2019  Customer ordering patterns are also expected to negatively impact fiscal second quarter results Key PicksA few better ranked stocks in the broader medical space are Penumbra  Inc    NYSE PEN    Wright Medical Group N V    NASDAQ WMGI   and DexCom  Inc    NASDAQ DXCM    Notably  each of these stocks currently carries a Zacks Rank  2  Buy   You can see  Penumbra s long term earnings growth rate is expected at 20  Wright Medical s long term earnings growth rate is expected at 11  DexCom s next quarter earnings per share is projected to grow at 56 3  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ",2019-02-06,Zacks Investment Research,https://www.investing.com/analysis/bd-gains-from-solid-global-base-headwinds-anticipated-200384974,200384974
113757,335272,DXCM,3 Stocks Setting Up For A Potential Big Time Breakout,opinion,"With the market pulling back in let s take a look at a few charts that may be the next breakouts in play 
Inspire Medical Systems Inc  NYSE INSP  is a recent IPO  from May 2018  that is trading in a tight range on the weekly chart just below its all time high  Note that volume was well above average when  INSP cleared resistance at  48 and closed above the downtrend line  which is a bullish sign 
 INSP lacks earnings but does have four quarters in a row of  80  revenue growth 
A move through the highs of the current three week trading range is the obvious buy point  though the daily chart can be monitored for a lower entry on partial size with the idea of adding on strength  Look for a significant pick up in volume on the move out to confirm the technical pattern 
Reports earnings Feb  26

DexCom Inc  NASDAQ DXCM  gapped above the downtrend line and the 10 week moving average on a pick up in volume a few weeks ago and has since been trading in a tight range  The current tight range is a handle  short term and tight consolidation   which should be monitored closely for a buy point  The obvious entry is over the recent swing high but an earlier entry could develop such as a break of the downtrend line connected from the high of 1 22 to 2 6 
 DXCM also lacks earnings but has impressive revenue growth at  40  the past two quarters and over eight quarters in a row of  20  
Reports earnings Feb  21


Freshpet Inc  NASDAQ FRPT broke out to new all time highs in 2018 after clearing the prior high at  26  The prior high was set in 2015 just a few months after its IPO in November 2014  Like the two setups above   FRPT also cleared the downtrend line on a pick up in volume  The pullback off the recent swing high is deeper in  FRPT than in  INSP or  DXCM  but the pullback did find support above the rising 10 week moving average 
The price action surged above the short term downtrend line this week  which is a positive sign if the price holds above  36 
Reports earnings Feb  26 

The analysis above is part of what we do in our nightly report The Wagner Daily  which is focused on small and mid cap growth stocks that have explosive potential 
Original post",2019-02-10,Deron Wagner,https://www.investing.com/analysis/3-stocks-setting-up-for-a-potential-big-time-breakout-200386065,200386065
113758,335273,DXCM,DexCom  DXCM  To Report Q4 Earnings  What s In The Cards ,opinion,DexCom  Inc    NASDAQ DXCM   fourth quarter 2018 results are scheduled for release on Feb 21  after market close  The large and growing diabetes market  solid sensor volumes and international revenue growth are expected to provide a boost to the quarterly results Q3 Results at a GlanceDexCom reported adjusted earnings of 17 cents per share in the third quarter of 2018  outpacing the Zacks Consensus Estimate of a loss of 12 cents  Also  the figure improved from a loss of 4 cents registered in the year ago quarter  Total revenues rallied 44 5  to  266 7 million on a year over year basis  The top line figure surpassed the Zacks Consensus Estimate of  242 million Furthermore  the company has an average four quarter positive earnings surprise of 37 6  Which Way are Estimates Trending The Zacks Consensus Estimate for fourth quarter earnings is pegged at 14 cents  reflecting 40  growth year over year  The same for revenues is pinned at  330 6 million  mirroring 49 6  improvement year over year Let s delve deeper Sensor Segment to Boost Q4 Results DexCom s unique sensor technology has provided it a competitive edge in the MedTech space  In the third quarter  revenues at the Sensor segment  73  of total revenues  surged 47  on a year over year basis to  194 million The company is expected to gain from strong demand for the G6 sensors  In fact  these sensors are likely to rake in huge profits in the quarter to be reported  By the end of the third quarter of 2018  management at DexCom announced that the G6 system is available in 14 countries and the company will continue to roll it globally in 2019  Meanwhile  DexCom s Insulet and Lilly diabetes management products continue to progress well The Zacks Consensus Estimate for fourth quarter revenues is pegged at  209 million  reflecting 29 8  growth year over year Other Factors at PlayPreliminary ResultsDexCom expects preliminary  unaudited revenues for the fourth quarter to exceed  331 million  mirroring 50  growth year over year  For 2018  total preliminary  unaudited revenues are expected to outpace  1 03 billion  up 42  year over year In the meantime  management remains optimistic about DexCom s strong growth in G6 CGM platform both in the United States and internationally Transmitter Revenues   Receiver RevenuesTransmitter revenues  18  of total revenues  increased 27  year over year to  48 5 million in the third quarter  The Zacks Consensus Estimate for the segment is pegged at  45 9 million for the fourth quarter  up 8 3  year over year In the third quarter  Receiver revenues  9  of total revenues  rallied 68  year over year to  24 2 million  The Zacks Consensus Estimate for the segment stands at  45 9 million for the fourth quarter  up 49 3  year over year What Does Our Model Say Our proven model clearly indicates that a stock needs to have both   a positive Earnings ESP and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    to deliver a positive earnings surprise  This is not the case here Earnings ESP  DexCom has an  of  14 3   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  DexCom carries a Zacks Rank  2  You can see  Please note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions DexCom  Inc  Price and EPS Surprise    Stocks Worth a LookMasimo Corporation   NASDAQ MASI   has an Earnings ESP of  1 04  and a Zacks Rank  3 AxoGen  Inc    NASDAQ AXGN   has an Earnings ESP of  14 29  and a Zacks Rank  3 Wright Medical Group N V    NASDAQ WMGI   has an Earnings ESP of  58 24  and a Zacks Rank  2 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2019-02-12,Zacks Investment Research,https://www.investing.com/analysis/dexcom-dxcm-to-report-q4-earnings-whats-in-the-cards-200387577,200387577
113766,335281,DXCM,Luminex Hurt By Segmental Sluggishness  Stiff Competition,opinion,On Feb 20  we issued an updated research report on Luminex Corporation   NASDAQ LMNX    A weak fourth quarter and stiff competition in the Medtech space currently plague the company The stock currently carries a Zacks Rank  4  Sell  What s Deterring the Stock Luminex saw some sluggishness in the recently reported fourth quarter of 2018 Earnings per share in the fourth quarter dropped on a year over year basis  Per management  the departure of LabCorp impacted results Additionally  Luminex s assay and molecular diagnostic revenues declined year over year in the quarter  impacted by LabCorp  Notably  assay revenues fell 11 7   while molecular diagnostic revenues declined 11  year over year Moreover  Luminex s Other segment saw a revenue decline of 14  year over year in the quarter In addition to this  Luminex operates in the highly competitive life sciences industry  The industry is characterized by rapid and continuous technological innovation  Currently  it is facing significant competitive headwinds in the respiratory market The company s dependence on its partners for revenue generation may add to the woes  Luminex s customers include clinical diagnostic  pharmaceutical  biotechnological  chemical and industrial companies  Reduced spending on research and diagnostics by these companies is likely to dent demand for Luminex s products Price PerformanceDespite the hurdles  shares of Luminex have rallied 28 1  compared with the  s 10 1  gain over the past year  The current level also compares favorably with the S P 500 index s 3  rally Key PicksSome better ranked stocks in the broader medical space are Penumbra  Inc    NYSE PEN    Wright Medical Group N V    NASDAQ WMGI   and DexCom  Inc    NASDAQ DXCM    Notably  each of these stocks currently carries a Zacks Rank  2  Buy   You can see  Penumbra s long term earnings growth rate is expected at 20  Wright Medical s long term earnings growth rate is expected at 11  DexCom s next quarter earnings per share are projected to grow 56 3  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-02-21,Zacks Investment Research,https://www.investing.com/analysis/luminex-hurt-by-segmental-sluggishness-stiff-competition-200390659,200390659
113768,335283,DXCM,Masimo And Saudi Arabia MOH Collaborate For CCHD Screening,opinion,Masimo Corporation   NASDAQ MASI   recently announced a collaboration with the Saudi Arabia Ministry of Health   MOH   to implement a solution designed to streamline the process of critical congenital heart disease   CCHD   screening of newborns  using Masimo SET Notably  Saudi Arabia commenced a mandatory CCHD screening program for all newborns  using the Masimo Eve Newborn Screening Application on the Radical 7 Pulse CO Oximeters in 2016  In 2018  Eve on Rad 97 Pulse CO Oximeters was added to the program It is encouraging to note that in last June  the UAE Ministry of Health   Prevention adopted Masimo s flagship Eve application for CCHD screening in newborns   Read More   In the recent past  Eve received the CE marking   Read More   About EveMasimo s Eve combines the power of Masimo SET Measure through Motion and Low Perfusion pulse oximetry with a pre ductal to post ductal synchronization algorithm designed to reduce calculation errors  This cost effective application is available on the Radical 7 Pulse CO Oximeter Studies have shown that Masimo SET pulse oximetry can improve CCHD screening  helping to save many newborns  lives while reducing the cost of care ProspectsCCHD affects approximately 2 3 newborns per 1000 births and requires intervention soon after birth to prevent significant morbidity or mortality ResearchAndMarkets opines that the global pulse oximetry market is likely to grow at a CAGR of 6 2  between 2019 and 2025 Hence  the latest development has been a well timed one for Masimo Masimo Rides on DevelopmentsIn recent times  MedTech company  based in California  has seen a slew of developments In February  Masimo announced the launch of Doctella  the home based patient engagement and remote care automation platform  to provide end to end home care solution  allowing clinicians to create and manage treatment plans In the last month  Masimo announced FDA clearance of the measurement of respiration rate from the pleth  RRp  on the MightySat Rx spot check fingertip pulse oximeter Moreover  Masimo s Iris Device Management System has been recently launched in the United States  Notably  the system is designed to streamline management of Masimo devices used in a hospital   Shares UpReflective of the above developments  shares of the Zacks Rank  2  Buy  company have rallied 50 8  compared with the  s 10 1  growth and the S P 500 index s 3  return  in a year Other Key PicksSome other top ranked stocks in the broader medical space are Penumbra  Inc    NYSE PEN    Wright Medical Group N V    NASDAQ WMGI   and DexCom  Inc    NASDAQ DXCM    Notably  each of these stocks currently carries a Zacks Rank  2  You can see  Penumbra s long term earnings growth rate is expected to be 20  Wright Medical s long term earnings growth rate is projected to be 11  DexCom s fourth quarter earnings is projected to grow 56 3  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-02-21,Zacks Investment Research,https://www.investing.com/analysis/masimo-and-saudi-arabia-moh-collaborate-for-cchd-screening-200390653,200390653
113791,335306,DXCM,Can CAG Growth Steadily Drive IDEXX  IDXX  In Q4 Earnings ,opinion,IDEXX Laboratories  Inc    NASDAQ IDXX   is scheduled to report fourth quarter 2018 results on Feb 1  before the opening bell  In the last reported quarter  the company delivered a positive earnings surprise of 7 14   Notably  the stock outperformed the Zacks Consensus Estimate in each of the preceding four reported quarters  the average being 6 37  Let s take a look at how things are shaping up prior to this announcement Key CatalystsIDEXX should continue with its momentum in the fourth quarter  courtesy of a strong global rise in Companion Animal Group  CAG  Diagnostics  revenues  In the third quarter  this upside was driven by strong consistent gains from recurring CAG revenues  high premium CAG instrument placements and consistent high growth in digital business  This trend is expected to be retained further In terms of 2018 outlook  IDEXX expects to deliver full year organic growth trend in CAG Diagnostic recurring revenues to be around 13 2   supported by steady strong growth in the United States and expanding international consumable revenues IDEXX Laboratories  Inc  Price and EPS Surprise   The Zacks Consensus Estimate of  474 million for CAG Diagnostics revenues represents an 9 4  improvement over the last reported quarter For the fourth quarter  the company anticipates revenue growth in the range of 7 9   net of an estimated 2  foreign exchange headwind  IDEXX hopes to retain high recurring CAG Diagnostic revenue gains in the quarter under review  aided by sustaining strong trends in the United States The company is projecting moderate overall organic growth in the 9 11  band related to tough prior year comparisons in global instrument placements and expectations for lower revenues in LPD  Livestock and Poultry Diagnostics  business  In this regard  the company forecasts mid to high single digit revenue declines in LPD organic revenues for the fourth quarter Other FactorsWe pin considerable hopes on progress in the Water Business  lying on a growth trajectory of late on the back of encouraging test results in the United States and benefits drawn from the global go direct initiatives  Moreover  the business witnessed 9  organic strength in the last reported quarter The company earlier stated that it is perfectly on track for a continued high single digit organic revenue boost in this business through 2018  The consensus mark for Water revenues stands at  30 98 million for the yet to be reported period  translating into a 7 3  improvement from the year ago number IDEXX constantly expands its global footprint  It has been significantly getting advantages from bountiful opportunities in the emerging companion animal diagnostics markets  Further  management s regular share buybacks underscore the company s robust free cash flow reserve On the flip side  adverse foreign currency movement is a major headwind  Another concern is the company s heavy reliance on third party distributors  The purchasing dynamics of distributors leave a significant impact on the company s sales of instrument consumables and its rapid assay products  Moreover  IDEXX has been witnessing a rise in operating expenses due to increased head count along with higher investments in portfolio development as well as expansion in the United States and internationally Additionally  a competitive landscape in the domestic and overseas markets weighs on IDEXX s performance  Thus  the struggle to gain market traction might be a drag  which in turn  can hurt fourth quarter results Here s what the quantitative model predicts Our proven Zacks model clearly shows that a company with a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has higher chances of beating estimates if it also has a positive  IDEXX has a Zacks Rank  3  which increases the predictive power of ESP  However  it has an Earnings ESP of  0 28   which leaves surprise prediction inconclusive as the company also needs a positive ESP to be confident about a likely surprise  Thus  this combination fails to suggest an earnings beat for the stock this season You can uncover the best stocks to buy or sell before they re reported with our   Stocks Worth a LookHere are a few medical stocks worth considering from the same space as these comprise the right mix of elements to exceed expectations this reporting cycle DexCom  Inc    NASDAQ DXCM   has an Earnings ESP of  8 93  and a Zacks Rank  2  You can see  MacroGenics  Inc    NASDAQ MGNX   has an Earnings ESP of  8 15  and a Zacks Rank of 2 NanoString Technologies  Inc    NASDAQ NSTG   has an Earnings ESP of  4 64  and is a Zacks  2 Ranked stock Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-01-27,Zacks Investment Research,https://www.investing.com/analysis/can-cag-growth-steadily-drive-idexx-idxx-in-q4-earnings-200380145,200380145
113792,335307,DXCM,Can Zimmer Biomet  ZBH  Grow On Hip Business In Q4 Earnings ,opinion,Zimmer Biomet Holdings  Inc    NYSE ZBH   is set to report fourth quarter 2018 results on Feb 1  before the market opens The company delivered an earnings surprise of 1 87  in the last reported quarter  Its earnings topped the consensus mark in three of the preceding four reported quarters  the average beat being 1 54  Let s take a look at how things are shaping up prior to this announcement Key CatalystsZimmer Biomet is again expected to report strong top line numbers for its S E T   Surgical  Sports Medicine  Foot and Ankle  Extremities and Trauma  arm  backed by a firm focus on priority areas like quality remediation  supply recovery and product launches The company is receiving a consistent positive feedback on the already marketed products  Within Sports  Comprehensive Baseplate  Sidus Stem Free Shoulder and jogger stitch are anticipated to see a positive response  Within Extremities and Trauma subcategories  the company is investing a lot as well  We are also optimistic about a strong customer uptake of the company s Comprehensive Augmented Baseplate Zimmer Biomet Holdings  Inc  Price and EPS Surprise   Management keeps envisioning a better show within S E T  during the second half of 2018 as compared to the first half However  the company earlier noted that  it is going to deal with a much more challenging comps in the fourth quarter as compared to the third  This apart  the sequentially last reported quarter reaped notable timing benefits with regard to both tenders and capital sales on the tender front  both in Asia Pacific and EMEA  This benefit is seemingly not visible in the yet to be reported quarter  Meanwhile  the company s S E T business has been of late massively hit by supply issues and a persistent pricing pressure We expect all these factors to impact the company s fourth quarter top line The Zacks Consensus Estimate for S E T  revenues of  455 million remains marginally above  454 million  recorded in fourth quarter 2017 Looking at the focused execution of Zimmer Biomet s sales teams  we expect the global adoption rate of the flagship personalized knee system   Persona   to be impressive The company is seeing a very good uptake of the more recently released Persona Trabecular Metal Tibia The Zacks Consensus Estimate for Knee revenues stands at  730 million as compared to  731 million in the prior year quarter Within Hip business  we anticipate the company to render a sturdy performance in the Asia Pacific region  In the previously reported quarter  the company registered 8 6  sales growth at constant currency exchange rate within Hip in the aforementioned geography  Our consensus estimate for Hip revenues from Asia Pacific is pegged at  136 million  which reflects a 28 3  rise from the year ago quarter The Zacks Consensus Estimate of  500 million for Hip revenues shows a 0 2  rise from the year ago level However  Zimmer Biomet was grappled with pricing pressure of approximately  2 5   during the fourth quarter  In absence of any favorable changes along these lines  the headwinds might affect the company s impending quarterly results Overall  fourth quarter total revenues are projected at  2 06 billion  indicating a 0 67  decline from the year earlier quarter What Our Quantitative Model Suggests Our proven Zacks model clearly shows that a company with a solid Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has good chances of beating estimates if it also has a positive   You can uncover the best stocks to buy or sell before they re reported with our  Zimmer Biomet has a Zacks Rank  3  which increases the predictive power of ESP  It also has an Earnings ESP of  0 05   together which a likely earnings surprise is predicted Other Stocks Worth a LookHere are a few other medical stocks worth considering from the same space as these too comprise the right mix of elements to exceed expectations this reporting cycle DexCom  Inc    NASDAQ DXCM   has an Earnings ESP of  8 93  and a Zacks Rank  2  You can see  MacroGenics  Inc    NASDAQ MGNX   has an Earnings ESP of  8 15  and a Zacks Rank of 2 NanoString Technologies  Inc    NASDAQ NSTG   has an Earnings ESP of  4 64  and is a Zacks  2 Ranked stock Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-01-27,Zacks Investment Research,https://www.investing.com/analysis/can-zimmer-biomet-zbh-grow-on-hip-business-in-q4-earnings-200380132,200380132
113793,335308,DXCM,Cerner  CERN  To Report Q4 Earnings  What s In The Cards ,opinion,"Cerner Corporation s   NASDAQ CERN   fourth quarter 2018 results are scheduled to release on Feb 5  The company is likely to see a soft quarter due to decline in bookings revenues  However  an upbeat guidance for the to be reported quarter instils optimism Q3 ResultsIn the last reported quarter  Cerner s adjusted earnings came in at 63 cents per share in line with the Zacks Consensus Estimate  The metric also improved from the prior year quarter s figure by 2 cents Meanwhile  revenues rose 5  on a year over year basis to  1 34 billion  which missed the Zacks Consensus Estimate of  1 36 billion Which Way Are Q4 Estimates Treading The Zacks Consensus Estimate for fourth quarter earnings is pegged at 63 cents  reflecting growth 8 6  year over year  The same for revenues is pinned at  1 39 billion  mirroring year over year growth of 6 1  Let s delve deeper Cerner Corporation Price and EPS Surprise
    Bookings to Decline in Q4Management at Cerner expects bookings revenues between  1 85 billion and  2 05 billion in the fourth quarter  The midpoint of this range reflects a 16  decrease compared to the company s record high bookings of  2 33 billion in the fourth quarter of 2017  The Zacks Consensus Estimate for fourth quarter bookings is pegged at  2 07 billion  indicating a year over year decline of 11   Notably  softness in bookings might mar the company s revenue growth However  strong contributions from large hospitals  community hospitals  and ambulatory venues are likely to aid bookings  For 2018  bookings are expected to be around  6 71 billion  up 6  year over year  Not to forget  Cerner s bookings totaled  1 59 billion  up 42 9  year over year in the third quarter Other Factors at PlayQ4 GuidanceFor the fourth quarter of 2018  Cerner expects revenues between  1 37 billion and  1 42 billion  The midpoint of this range reflects 6  year over year growth  Adjusted earnings per share are expected in the band of 62 64 cents  The midpoint of this range is 9  higher than the year ago quarter Reimbursed TravelCerner s Reimbursed Travel is likely to be a key catalyst behind the company s top line growth in the quarter to be reported                                                    For the fourth quarter  the Zacks Consensus Estimate for Reimbursed Travel stands at  28 6 million  up 1 5  year over year What Does Our Model Say Our proven model clearly indicates that a stock needs to have both   a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    to deliver a positive earnings surprise  This is not the case here Earnings ESP  Cerner has an Earnings ESP of 0 00   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Cerner carries a Zacks Rank  3 Please note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat in the upcoming releases PerkinElmer  Inc    NYSE PKI   has an Earnings ESP of  0 77  and a Zacks Rank  3 Illumina  Inc    NASDAQ ILMN   has an Earnings ESP of  0 02  and a Zacks Rank  2  You can see  DexCom   NASDAQ DXCM   has an Earnings ESP of  8 93  and a Zacks Rank  2 Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-01-27,Zacks Investment Research,https://www.investing.com/analysis/cerner-cern-to-report-q4-earnings-whats-in-the-cards-200380116,200380116
113794,335309,DXCM,Will Core Business Units Boost McKesson s  MCK  Q3 Earnings ,opinion,McKesson Corporation s   NYSE MCK   third quarter fiscal 2019 results are scheduled to release on Jan 31 The company s core business units   U S  Pharmaceutical and Specialty Solutions  and European Pharmaceutical Solutions   are likely to boost the company s quarterly performance Fiscal Q2 ResultsMcKesson reported second quarter fiscal 2019 earnings of  3 60 per share  beating the Zacks Consensus Estimate of  3 28  Adjusted earnings improved 10  year over year Sales came in at  53 08 billion  which missed the Zacks Consensus Estimate of  53 56 billion  However  the metric rose 1 9  on a year over year basis In the trailing four quarters  McKesson has delivered a positive average earnings surprise of 6 4  McKesson Corporation Price and EPS Surprise    Which Way Are Q3 Estimates Headed The Zacks Consensus Estimate for McKesson s fiscal third quarter earnings is pegged at  3 18  mirroring a 6 7  decline year over year  The same for revenues stands at  55 27 billion  reflecting an increase of 3 1  year over year Let s see how things are shaping up prior to the earnings release Core Business Units to Drive Q3 ResultsMcKesson s Pharmaceutical wing is likely to act as a key catalyst in boosting the company s fiscal third quarter results  Notably  the segment is likely to gain momentum on the back of its branded  generic and over the counter pharmaceuticals  This apart  McKesson s Specialty business is likely to be a major top line contributor  with strong growth in specialty drug distribution Not to forget  the company s U S  Pharmaceutical and Specialty Solutions contributed 70 4  to the company s net revenues in the fiscal second quarter  For the quarter to be reported  the Zacks Consensus Estimate for the U S  Pharmaceutical and Specialty Solutions is pegged at  43 01 billion  showing a sequential rise of 3 4  Other Factors at PlayEuropean Pharmaceutical SolutionsInterestingly  despite stiff competition in France  the European Pharmaceutical revenues contributed 12 5  to McKesson s net revenues in the fiscal second quarter The Zacks Consensus Estimate for European Pharmaceutical s third quarter revenues is pinned at  6 85 billion  indicating a sequential increase of 3 2  Medical Surgical SolutionsThis segment delivers laboratory supplies including reagents  lab equipment  lab glassware  eye wash solution  specimen collection and lab supplies  In the last reported quarter  the unit contributed 3 7  to the company s net revenues For the quarter to be reported  the Zacks Consensus Estimate for the segment s sales stands at  1 98 billion  reflecting a sequential increase of 1 7  What Does Our Model Say Our proven model clearly indicates that a stock needs to have both   a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    to deliver a positive earnings surprise  This is not the case here Earnings ESP  McKesson has an Earnings ESP of  0 08   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  McKesson carries a Zacks Rank  3 Please note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revision Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat in the upcoming releases PerkinElmer  Inc    NYSE PKI   has an Earnings ESP of  0 77  and a Zacks Rank  3 Illumina  Inc    NASDAQ ILMN   has an Earnings ESP of  0 02  and a Zacks Rank  2  You can see  DexCom   NASDAQ DXCM   has an Earnings ESP of  8 93  and a Zacks Rank  2 Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-01-28,Zacks Investment Research,https://www.investing.com/analysis/will-core-business-units-boost-mckessons-mck-q3-earnings-200379916,200379916
113795,335310,DXCM,Can BD Medical Drive Becton  Dickinson s  BDX  Q1 Earnings ,opinion,"Becton  Dickinson and Company s   NYSE BDX    popularly known as BD  first quarter fiscal 2019 results are scheduled to release on Feb 5  before market opens  While the results are likely to show steady growth in the core BD Medical segment  BD Life Sciences may partially mar results Fiscal Q4 Results at a GlanceIn the last reported quarter  BD posted earnings of  2 93 per share which surpassed the Zacks Consensus Estimate by a penny  The bottom line improved 22 1  on a year over year basis and 24 6  at constant currency  cc  Revenues totaled  4 4 billion and outpaced the Zacks Consensus Estimate of  4 36 billion  The reported figure surged 39  from the year ago quarter number  primarily owing to the acquisition of C  R  Bard  At cc  revenues rose 8 4  BD has an average positive earnings surprise of 0 4  for the trailing four quarters Which Way Are Q1 Estimates Treading For the quarter to be reported  the Zacks Consensus Estimate for BD s earnings per share is pegged at  2 59  showing a year over year increase of 4 4   The same for revenues stands at  4 10 billion  reflecting an increase of 33 3  year over year Let s see how things are shaping up prior to the earnings release BD Medical Likely to Drive Q1 EarningsBD Medical  one of the major revenue drivers of the company  is expected to drive the fiscal first quarter results  Strong year over year growth of revenues from needles  syringes and intravenous catheters for medication delivery  prefilled IV flush syringes  syringes and pen needles for diabetes care and others are likely to boost the segment In the last reported quarter  BD Medical accounted for 53 4  of the company s net revenues  The segment posted sales worth  2 35 billion  up 20 7  from the year ago quarter and 10 1  at cc It is encouraging to note that  for the fiscal first quarter  the Zacks Consensus Estimate for the segment s revenues is pegged at  2 11 billion  showing a year over year rise of 3 5   Management expects BD Medical revenues to grow between 5  and 6  in fiscal 2019 Coming to the subsegments  Medication Surgical Systems revenues grew 5 9  in the fourth quarter  The Zacks Consensus Estimate for first quarter revenues is pegged at  957 million  up 3 5  on a year over year basis Diabetes Care revenues grew 1 7  in the fourth quarter  The Zacks Consensus Estimate for fourth quarter revenues is pegged at  27 million  flat when compared to the year ago period At Pharmaceutical Systems  revenues grew 9 4  in the fourth quarter  However  the Zacks Consensus Estimate for the fourth quarter is pinned at  243 million  down 0 4  on a year over year basis Becton  Dickinson and Company Price and EPS Surprise
    Other Factors at PlayPreliminary ResultsPrior to the earnings release  BD posted impressive preliminary first quarter results  which instils optimism in the stock Notably  revenues of  4 16 billion reflect a growth of 35 1  year over year and 5 2  at cc Preliminary adjusted earnings per share of  2 70 reflect a growth of 8 9  on a year over year basis and 14 9  at cc Resultantly  the company continues to expect fiscal 2019 revenue growth of 8 5 9 5   driven by the C  R  Bard acquisition  At cc  revenues are anticipated to increase 5 6   The Zacks Consensus Estimate for the same is pegged at  17 43 billion Fiscal 2019 adjusted earnings per share are expected in the band of  12 05  12 15  mirroring growth of 10  from fiscal 2018  The Zacks Consensus Estimate stands at  12 11 per share DevelopmentsBD has witnessed several developments in recent times which are expected to positively impact the quarter to be reported results Last November  the company received FDA 510 k  clearance for its Phoenix CPO detect test  This will allow hospitals to identify infections caused by carbapenemase producing organisms   Read More   Moreover  management at BD remains optimistic about new products like Alaris Pump and Pyxis ES  BD MAX  BD FACSLyric  BD Horizon Brilliant dyes  Lutonix AV and Covera HeadwindsBD s Life Sciences unit  which accounted for 25 2  of net sales in the last reported quarter  is likely to see a soft fiscal first quarter Notably  the Zacks Consensus Estimate for the segment s first quarter revenues is pinned at  1 04 billion  reflecting a decline of 0 5  year over year Additionally  management foresees some other headwinds which may dent results in fiscal 2019  For instance  raw material pricing pressure  which increased in 2018  is expected to accelerate into fiscal 2019 primarily due to resin price increases  Additionally  the round of tariffs enacted last September is likely to act against the company What Does Our Model Say Per our proven model  a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise in the quarter  However  this is not the case here Earnings ESP  BD has an Earnings ESP of  1 05   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  BD carries a Zacks Rank  2 Meanwhile  we caution against stocks with a Zacks Rank  4  Sell  or 5  Strong Sell  going into the earnings announcement  especially when the company is seeing negative estimate revision Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter PerkinElmer   NYSE PKI   has an Earnings ESP of  0 77  and a Zacks Rank  3 DexCom   NASDAQ DXCM   has an Earnings ESP of  8 93  and a Zacks Rank  2  You can see  Baxter International   NYSE BAX   has an Earnings ESP of  1 83  and a Zacks Rank  3 Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-01-28,Zacks Investment Research,https://www.investing.com/analysis/can-bd-medical-drive-becton-dickinsons-bdx-q1-earnings-200379948,200379948
113796,335311,DXCM,Can Boston Scientific  BSX  Q4 Earnings Fuel Overall Growth ,opinion,Boston Scientific Corporation   NYSE BSX   is scheduled to report fourth quarter 2018 results  before the opening bell on Feb 6 In the last reported quarter  the company s earnings per share beat the Zacks Consensus Estimate by 2 94   Moreover  it delivered positive earnings surprises in three of the trailing four reported quarters  the average beat being 7 5  Let s see  how things are shaping up prior to this announcement Preliminary Results at a Glance Notably  Boston Scientific recently projected an impressive fourth quarter performance and expects to meet the upper end of its own expectations on the revenue front  In the to be reported quarter  Boston Scientific expects total revenue growth of 6 3   up 8 2  on operational basis after excluding the impact of foreign currency fluctuations  on a year over year basis to  2 56 billion  in line with the current Zacks Consensus Estimate However  this meets the upper end of the company s earlier provided revenue guidance of  2 525  2 565 billion  A firm top line is primarily expected on the back of growth across all the company s segments and geographical regions   Read more    Key CatalystsAlike the prior quarter  we are upbeat about strong contributions from Boston Scientific s Cardiovascular business group  which comprises Interventional Cardiology  IC  and Peripheral Interventions  PI   In the last reported quarter  the company generated around 38  of its total revenues from this highest revenue generating segment Boston Scientific Corporation Price and EPS Surprise   We are optimistic about the IC business that will help the company maintain impressive global growth  courtesy of an innovative portfolio and robust commercial teams  Complex PCI  percutaneouscoronary intervention  products within IC are growing strongly on successful global expansion efforts  According to Boston Scientific  the global Complex PCI results are largely offsetting the recent decline in the company s coronary drug eluting stent business Within Structural Heart  we are looking forward to Boston Scientific s WATCHMAN  ACURATE and IRIS product lines that are expected to contribute to the top line in the to be reported quarter  The company expects revenues from WATCHMAN and ACURATE TAVR franchise to total approximately  450 million in 2018 This apart  the recent acquisition of Claret Medical should largely aid Structural Heart s top line  Notably  Claret Medical brought Sentinel  the only cerebral embolic protection system approved in the United States and Europe  to Boston Scientific s Structural Heart portfolio Per the preliminary fourth quarter result  sales from the company s IC were up 5 1  on a reported basis  up 7 6  operationally  on a year over year basis The Zacks Consensus Estimate for IC revenues is pegged at  669 million  indicating an increase of 5 2  on a year over year basis In recent quarters  the PI business consistently demonstrated a solid uptick across segments like peripheral arterial disease  venous and interventional oncology  In the last reported quarter  the company commenced the launch of Eluvia in the United States  According to Boston Scientific  Eluvia has significant market opportunity  given the large addressable patient population  differentiated  sustained release technology and superior clinical outcomes with reduced need for reintervention  We believe  this launch will be accretive to the company s fourth quarter results Meanwhile  the preliminary release highlights the fact that in the fourth quarter  the Peripheral Interventions business was up 9 3   up 11 4    Accordingly  the Zacks Consensus Estimate for fourth quarter PI revenues stands at  295 million  reflecting a 6 5  rise year over year Other Factors at PlayAmong the other segments  MedSurg is estimated to demonstrate a steady performance led by endoscopy  Urology and Pelvic Health are also projected to surpass market levels  driven by investment strategies in the key international geographies Within endoscopy  the company is expected to display sturdy results  riding on a promising EndoChoice performance  particularly in pathology and infection prevention  Urology and Pelvic Health business should also continue to maintain its growth momentum on robust global performance  Boston Scientific s recent acquisitions have added several products  though many are under development  with immense potential to its portfolio  The buyouts of Apama MedicalSecurus Medical in Electrophysiology  Augmenix in Urology along with EmCision in Endoscopy deserve special mention The company is gradually fortifying its presence in the emerging markets of Brazil  Russia  India and China  BRIC   In third quarter 2018  business from the emerging markets registered 20  growth owing to a commendable progress in China and Latin America Boston Scientific is gaining traction in India as well  It is currently targeting about 10 emerging markets for additional emphasis  The company is also pinning hopes on its core cardiology segment  which is gradually stabilizing with growth in the BRIC nations  This trend is expected to sustain in the to be reported quarter as well However  the ongoing tensions between the United States and China regarding the imposition of tariffs on imports have raised concerns for major MedTech players as a single adverse move might affect top line numbers in the coming quarters Overall  the Zacks Consensus Estimate for total revenues of  2 56 billion represents an increase of 6 24  from the prior year quarter  Also  earnings estimates of 37 cents reflect an 8 8  rise on a year over year basis What Our Quantitative Model PredictsOur proven Zacks model clearly shows that a company with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has high chances of beating estimates if it also has a positive   You can uncover the best stocks to buy or sell before they re reported with our  Boston Scientific has a Zacks Rank  2  which increases the predictive power of ESP  However  the company has an Earnings ESP of 0 00   which makes surprise prediction difficult  Thus  this combination fails to suggest any likely earnings beat for the stock this earnings season Stocks Worth a LookHere are a few medical stocks worth considering from the same space as these comprise the right mix of elements to exceed expectations this reporting cycle DexCom  Inc    NASDAQ DXCM   has an Earnings ESP of  8 93  and a Zacks Rank of 2  You can see  MacroGenics  Inc    NASDAQ MGNX   has an Earnings ESP of  8 15  and is a Zacks  2 Ranked player NanoString Technologies  Inc    NASDAQ NSTG   has an Earnings ESP of  4 64  and a Zacks Rank of 1 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-01-30,Zacks Investment Research,https://www.investing.com/analysis/can-boston-scientific-bsx-q4-earnings-fuel-overall-growth-200382063,200382063
113813,335328,DXCM,Can Overall Growth Fuel Align Technology s  ALGN  Q4 Earnings ,opinion,"Align Technology  Inc    NASDAQ ALGN   is set to report fourth quarter 2018 results on Jan 29  after market close In the last reported quarter  the company delivered a positive earnings surprise of 4 2   Also  it has an average four quarter positive surprise of 16 7  Let s take a look at how things are shaping up prior to this announcement Invisalign System   A Key CatalystAlign Technology is expected to gain from continued adoption of Invisalign Technology in the fourth quarter of 2018  The company estimates Invisalign case shipments in the band of 330 000 335 000  up 29 31  from a year ago  Meanwhile  Align Technology reached the milestone of treating over 6 million patients globally  with the Invisalign clear aligner system in December 2018 Also  in October 2018  the company received the FDA approval for commercially marketing Invisalign treatment with mandibular advancement for Class II correction in growing tween and teen patients in the United States  Per management  class II malocclusion represents around 45  of the 9 million teen case starts globally each year This apart  the company had announced the addition of Invisalign First clear aligners for treatment of younger patients with early mixed dentition in May 2018  Also  Align Technology initiated the commercial launch of the offering for Invisalign trained doctors in the United States  Canada  Australia  New Zealand  Japan  and the Europe  Middle East and Africa  EMEA  regions in July 2018 
Align Technology  Inc  Price and EPS Surprise   At the same time  the company expanded its Invisalign clear aligner range by launching Vivera Retainers with Precision Bite Ramps  Notably  the product has been made available to Invisalign trained providers in the Asia Pacific  North America and EMEA regions  Further  the company has been focusing on driving Invisalign utilization among orthodontists These developments should all contribute strongly to the company s top line in the to be reported quarter Strong Scanner and Service Business Align Technology has been raking in solid revenues from the Scanner and Service business over the past few quarters  Moreover  the company has been seeing increased adoption of iTero scanners for Invisalign case submissions instead of PVS impressions  especially in North America  Management expects this trend to reflect in the company s fourth quarter results In this quarter  Align Technology announced several updates to its iTero Element family of Intraoral scanner  iTero Element  Element 2 and Element Flex   expanding its usage in restorative and dental practice workflow Notably  Align Technology had expanded its iTero Element portfolio with the launch of iTero Element 2 and iTero Element Flex scanners in the United States and the majority of European countries including France  Germany  Italy  Spain and the United Kingdom The company is also gaining from the adoption of iTero platform by dental service organizations or DSO partners  Per Align Technology  Heartland Dental plans to install scanners in 90  of supported offices by 2018 end  Moreover  Aspen Dental initiated the rollout of iTero scanners in third quarter 2018 for the next two quarters To commercialize the iTero Element intraoral scanner in China  Align Technology has received approval from the China Food and Drug Administration  which is an added positive Thus  we expect a superb show from the Scanner and Service business in the to be reported quarter Overall  Align Technology projects earnings per share  EPS  of  1 10  1 15 on revenues of  505  515 million for fourth quarter 2018  The Zacks Consensus Estimate for revenues is pegged at  512 03 million  mirroring 21 5  improvement from the year ago figure What Our Quantitative Model SuggestsPer the proven Zacks model  a company with a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has a good chance of beating estimates if it also has a positive   You can uncover the best stocks to buy or sell before they re reported with our  Align Technology has a Zacks Rank  3 and an Earnings ESP of 0 00   a combination that makes surprise prediction difficult The Zacks Consensus Estimate for fourth quarter earnings is pinned at  1 16  reflecting a 2 5  decline on a year over year basis Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter PerkinElmer   NYSE PKI   has an Earnings ESP of  0 77  and a Zacks Rank  3 Illumina  Inc    NASDAQ ILMN   has an Earnings ESP of  0 90  and a Zacks Rank  2  You can see  DexCom   NASDAQ DXCM   has an Earnings ESP of  8 81  and a Zacks Rank  2 Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ",2019-01-22,Zacks Investment Research,https://www.investing.com/analysis/can-overall-growth-fuel-align-technologys-algn-q4-earnings-200378353,200378353
113818,335333,DXCM,What s In Store For Edwards Lifesciences   EW  Q4 Earnings ,opinion,"Edwards Lifesciences Corporation   NYSE EW   is slated to report fourth quarter 2018 results  after market close on Jan 31  Last quarter  the company s earnings beat the Zacks Consensus Estimate by 5 9   Moreover  Edwards Lifesciences delivered positive earnings surprises in the trailing four quarters  the average beat being 7 8   Let s see how things are shaping up prior to this announcement Key CatalystSimilar to the prior quarter  Edwards Lifesciences is expected to gain from strength in Critical Care product group  The segment has been seeing solid growth across all product categories Edwards Lifesciences is also set to keep gaining from Critical Care technologies with the rollout of HemoSphere monitoring platform supported by new group purchasing organization contracts in the United States Last December  the company announced that the HemoSphere advanced hemodynamic monitoring platform received FDA approval for the Acumen suite of intelligent decision support solutions 
Edwards Lifesciences Corporation Price and EPS Surprise
    TheZacks Consensus Estimate for Critical Care product group sales of  171 million shows an increase of 4 3  from the year ago quarter We are also upbeat about the Surgical Structural Heart product group which should continue to see solid uptake of its new premium aortic valves along with solid aortic unit volume  Further  the company has initiated the launch of its INSPIRIS RESILIA aortic valve in Japan which is likely to contribute to the top line in the to be reported quarter Moreover  buoyed by continued adoption of INTUITY Elite valve system  management expects it to continue to drive the top line in the fourth quarter This apart  INSPIRIS RESILIA aortic valve is witnessing encouraging demand in the United States since its rollout initiated last January TheZacks Consensus Estimate for Surgical Structural Heart product sales of  208 million reflects a rise of 1 5  from the year ago quarter Here are a few other factors that might influence Edwards Lifesciences  fourth quarter results Edwards Lifesciences has been seeing consistent performance by the Transcatheter Heart Valve Therapy  THVT  segment  However  during the third quarter earnings announcement  Edwards Lifesciences noted that it is expecting the 2018 underlying sales growth in THVT to remain sluggish  at around 12 5  because of limited contribution from Cardioband Tricuspid Annular Reduction System and a newly revised controlled rollout strategy for SAPIEN 3 Ultra Notably  in transcatheter tricuspid repair  constrained by supply  clinicians are treating a limited number of patients in Europe with Cardioband  With this  in the third quarter  sales were limited to  1 million in both mitral and tricuspid programs  Management expects this trend to continue in the fourth quarter as well Meanwhile  last November  Edwards Lifesciences received CE mark for the SAPIEN 3 Ultra system for transcatheter aortic valve replacement in severe  symptomatic aortic stenosis patients Accordingly  the Zacks Consensus Estimate for total THV sales of  594 million shows an increase of 10  from the year ago quarter Overall  the company projects sales between  950 million and  1 billion in the to be reported quarter  Our consensus estimate for fourth quarter total revenues is pegged at  973 7 million  showing a rise of 9 6  from the prior year quarter What Our Model SuggestsAccording to the Zacks model  a company with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has a good chance of beating estimates if it also has a positive   You can uncover the best stocks to buy or sell before they re reported with our  Edwards Lifesciences has a Zacks Rank  3 and an Earnings ESP of  0 86   a combination that suggests a beat for the company this earnings season The Zacks Consensus Estimate for earnings of  1 17 reflects a 24 5  rise on a year over year basis Other Stocks Worth a LookHere are a few other medical stocks worth considering as these also have the right combination of elements to post an earnings beat in the to be reported quarter PerkinElmer   NYSE PKI   has an Earnings ESP of  0 77  and a Zacks Rank  3 Illumina  Inc    NASDAQ ILMN   has an Earnings ESP of  0 32  and a Zacks Rank  2  You can see  DexCom   NASDAQ DXCM   has an Earnings ESP of  8 93  and a Zacks Rank  2 The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-01-24,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-edwards-lifesciences-ew-q4-earnings-200379432,200379432
113836,335351,DXCM,Are ABMD   DXCM Neck And Neck  Let s Take A Closer Look,opinion,"Medical Instrument companies Abiomed  Inc    NASDAQ ABMD   and DexCom  Inc    NASDAQ DXCM   are two solid contenders in the U S  MedTech space  which is expected to reach a worth of  409 5 billion by 2023 at a CAGR of 4 5   Notably  analysts believe that 2019 is likely to prove profitable for U S  medical device companies  courtesy of the 2 3  Medical Device tax abatement along with focus on Artificial Intelligence and cybersecurity Against this backdrop  it is difficult to choose between the above mentioned companies as they have similar business models  Making things more difficult  the scales apparently look balanced as Abiomed carries a Zacks Rank  2  Buy   while DexCom sports a Zacks Rank  1  Strong Buy   You can see  However  we make a detailed analysis of the companies  fundamentals to determine which has a slight edge over the other Massachusetts based Abiomed is engaged in developing  manufacturing and marketing medical products  designed to assist or replace the pumping function of the failing heart  Meanwhile  California based DexCom is a medical device company focused on the design  development and commercialization of continuous glucose monitoring systems  CGM  Price PerformanceOver the past year  Abiomed s shares have gained 66 4  compared with DexCom s 106 7  rally  The Medical Instruments  has rallied 8 2  in the same time frame  Meanwhile  the S P 500 index has declined 3 5  Which Way Are Estimates Headed EarningsThe Zacks Consensus Estimate for Abiomed s current quarter earnings per share stands at 93 cents  suggesting an improvement of 32 9  year over year  The same for DexCom is projected at 13 cents  showing year over year growth of 30  ABIOMED  Inc  Price and Consensus
    SalesThe Zacks Consensus Estimate for Abiomed s current quarter revenues is pegged at  194 88 million  suggesting growth of 26 5  from the previous year  The same for DexCom is pegged at  283 08 million  reflecting a rise of 28 1  DexCom  Inc  Price and Consensus
    What s Favoring the Stocks Abiomed currently has a  of A  This reflects possibilities of outperformance over the long haul  Our research shows that stocks with a Growth Score of A or B  when combined with a Zacks Rank  1 or 2  are better picks than most Over the past four years  the company s revenues have seen a CAGR of 37 2  to  594 million Abiomed raised its fiscal 2019 guidance  calling for revenues of  765  770 million  showing an increase of 29 30  from the previous fiscal DexCom also has a Growth Score of A  Over the past four years  the company s revenues have seen a CAGR of 40 5  to  719 million DexCom has also raised the 2018 guidance  The company expects revenues of  975 million against the previous projection of  925 million Other Key PicksOther top ranked stocks in the broader medical space are Stryker Corporation   NYSE SYK   and Surmodics  Inc    NASDAQ SRDX   Stryker has a long term expected earnings growth rate of 10  and a Zacks Rank  2 Surmodics  long term earnings growth rate is projected at 10   The stock carries a Zacks Rank  2 The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-12-16,Zacks Investment Research,https://www.investing.com/analysis/are-abmd--dxcm-neck-and-neck-lets-take-a-closer-look-200368662,200368662
113837,335352,DXCM,The Strongest Stocks In The Current Market,opinion,"I ran a stock for the strongest stocks currently in the market that belong to the strongest industries  They all have a relative strength rating of 99  which means they have outperformed 99  of all stocks and ETFs in the past year  An Industry rating of A means they also belong to the strongest 20  of all industries for the past six months  The screen produces 17 results  Attunity Ltd  NASDAQ ATTU   AYX  Caredx Inc  NASDAQ CDNA   CROX  DexCom Inc  NASDAQ DXCM   EHTH  GOL  I  Lifevantage Corporation  NASDAQ LFVN   MongoDB  NASDAQ MDB   Nanostrg Te  NASDAQ NSTG   NVTA  SEND  Tandem Diabetes Care Inc  NASDAQ TNDM   Trade Desk Inc  NASDAQ TTD   TWLO  Veracyte Inc  NASDAQ VCYT  

Out of those 17  the ones that are in a tight range contraction and therefore  most likely to break out and outperform in a near term perspective are  Attunity Ltd  NASDAQ ATTU  and InVitae Corp  NYSE NVTA  ",2019-01-13,Ivaylo Ivanhoff,https://www.investing.com/analysis/the-strongest-stocks-in-the-current-market-200375065,200375065
113838,335353,DXCM,Will Core MedSurg Segment Aid Stryker s  SYK  Q4 Earnings ,opinion,"Stryker Corporation s   NYSE SYK   fourth quarter 2018 results  scheduled for release on Jan 29  after market close  are likely to gain from a strong show by the core MedSurg segment  A strong 2018 view also buoys optimism Q3 Results at a GlanceIn the last reported quarter  Stryker delivered adjusted earnings per share of  1 69  which beat the Zacks Consensus Estimate by a penny  Earnings improved 11 2  year over year and were within the company s guidance The company reported revenues of  3 24 billion  missing the Zacks Consensus Estimate of  3 26 billion by a narrow margin  Revenues increased 7 9  on a year over year basis Stryker has a positive average surprise of 2  for the trailing four quarters Which Way Are Estimates Treading The Zacks Consensus Estimate for fourth quarter earnings per share is pegged at  2 15  reflecting year over year growth of 9 7  The same for revenues is pinned at  3 73 billion  showing growth of 7 6  over the prior year quarter Stryker Corporation Price and EPS Surprise
    Let s see how things are shaping up before the earnings results MedSurg in FocusThis segment consists of surgical instruments  endoscopic and emergency medical equipment and has been consistently driving Stryker s top line In the last reported quarter  the unit contributed a significant 44 4  to Stryker s net sales  Revenues in the segment came in at  1 44 billion  up 10 4  at constant currency  cc  It is encouraging to note that  for the quarter to be reported  the Zacks Consensus Estimate for the segment s revenues stands at  1 69 billion  up 7 2  year over year MedSurg has three subsegments   Endoscopy  Instruments and Medical The Zacks Consensus Estimate for Endoscopy revenues is pegged at  505 million  up 7 7  year over year  The same for Instruments revenues stands at  533 million  showing a year over year rise of 9 2   Moreover  for MedSurg Medical revenues  the consensus estimate is pinned at  590 million  up 6 1  on a year over year basis Other Factors at PlayStrong GuidanceFor the fourth quarter of 2018  earnings are projected within  2 13 to  2 18 In fact  for 2018  Stryker projects earnings in the range of  7 25  7 30  higher than the previous guidance of  7 22  7 27  The Zacks Consensus Estimate for earnings is pegged at  7 28  within the guided range Orthopaedic Implant  Neurotechnology   Spine to Drive GrowthIn the last reported quarter  Stryker s core Orthopaedic segment contributed 36 1  to net sales  For the quarter to be reported  the Zacks Consensus Estimate for the segment s sales is pegged at  1 36 billion  showing a year over year rise of 3 8  Meanwhile  Neurotechnology   Spine accounted for 19 4  of Stryker s revenues in the last reported quarter  For the quarter to be reported  the Zacks Consensus Estimate for the segment s sales stands at  677 million  showing year over year growth of 15 5  Acquisition RisksStryker has lately been on an acquisition spree Last November  the company completed a previously announced acquisition of K2M Group Holdings and in October  it acquired Invuity  While this improves revenue opportunities  it adds to integration risks and also exerts pressure on gross and operating margins What Does Our Model Say Per our proven model  a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise in the quarter  This is not the case here as you will see below Earnings ESP  Stryker has an Earnings ESP of  0 21   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Stryker carries a Zacks Rank  3 Please note that we caution against stocks with a Zacks Rank  4  Sell  or 5  Strong Sell  going into the earnings announcement  especially when the company is seeing negative estimate revision Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter PerkinElmer   NYSE PKI   has an Earnings ESP of  0 77  and a Zacks Rank  3 Baxter International   NYSE BAX   has an Earnings ESP of  1 83  and a Zacks Rank  3 DexCom   NASDAQ DXCM   has an Earnings ESP of  8 81  and a Zacks Rank  2  You can see  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-01-21,Zacks Investment Research,https://www.investing.com/analysis/will-core-medsurg-segment-aid-strykers-syk-q4-earnings-200377587,200377587
113839,335354,DXCM,ResMed Launches Nasal Mask Devise  Extends AirFit Portfolio,opinion,ResMed Inc    NYSE RMD   recently expanded its AirFit mask portfolio with the introduction of its first top of head connected nasal CPAP mask  AirFit N30i  in the United States  The product is already available across Canada  Australia  New Zealand and most of Europe with more launches planned in other geographies  scheduled for late 2019 AirFit N30i in DetailThis device has a top of head connection that keeps tubing out of the wearers  way  letting them comfortably move and sleep in any position  Its nasal cradle cushion reduces facial markings and irritation Per the company  in comparison to other popular nasal top of head masks  three of four users preferred AirFit N30i over the traditional ones Market PotentialGlobally  over 100 million are estimated to be afflicted with sleep apnea  per an article published in The Sleep Zone   This increasing incidence has driven demand for sleep apnea devices  Per a MarketsandMarkets report by  the global sleep apnea devices market is expecting a CAGR of 7 8  to reach  6 49 billion between 2018 and 2023 Going by the same report  North America is projected to be the largest market for sleep apnea devices in 2018 Rising healthcare expenditures  increasing obesity and unhealthy lifestyle practices along with expanded treatment options are anticipated to continue driving demand for sleep apnea devices  In view of this data  we believe  the latest development will help ResMed cash in on opportunities in this niche market Stress on Innovation In order to maintain its leadership position in the sleep disordered breathing  SDB  market and to boost its sales base  ResMed is focusing on product development and innovation  In this regard  the company earlier unveiled its first minimal contact full face CPAP mask   AirFit F30  Further  ResMed consistently sees a strong adoption of AirFit F20 full face mask and AirFit N20 nasal mask products globally  Share Price PerformanceOver the past year  shares of ResMed have outperformed its   The stock has rallied 17 5  against the industry s decline of 3 2  Zacks Rank and Key PicksResMed currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the broader medical space are Veeva Systems   NYSE VEEV    Omnicell  Inc    NASDAQ DXCM   and Illumina  Inc    NASDAQ ILMN   Veeva Systems  long term earnings growth rate is estimated at 19 5   The stock flaunts a Zacks Rank  1  Strong Buy   You can see  Omnicell s long term earnings growth rate is projected at 11 8   The stock carries a Zacks Rank  2  Buy  Illumina s long term earnings growth rate is expected at 23 4   The stock has a Zacks Rank of 2 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-01-21,Zacks Investment Research,https://www.investing.com/analysis/resmed-launches-nasal-mask-devise-extends-airfit-portfolio-200377920,200377920
113867,335382,DXCM,DexCom  DXCM  Catches Eye  Stock Jumps 8 8 ,opinion,DexCom  Inc    NASDAQ DXCM   was a big mover last session  as the company saw its shares rise nearly 9  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This continues the recent uptrend for the company as the stock is now up 17 2  in the past one month time frame The move came after the company reported solid third quarter 2018 results The company has seen a mixed track record when it comes to estimate revision of no increase and one decrease over the past few weeks  while the Zacks Consensus Estimate for the current quarter remained unchanged  The recent price action is encouraging though  so make sure to keep a close watch on this firm in the near future DexCom currently has a Zacks Rank  3  Hold  while its  is negative DexCom  Inc  Price   Investors interested in the Medical   Instruments industry may consider Penumbra  Inc    NYSE PEN    which has a Zacks Rank  1  Strong Buy   You can see the complete list of today s Zacks  1 Rank stocks here Is DXCM going up  Or down  Predict to see what others think Up or DownLooking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-11-07,Zacks Investment Research,https://www.investing.com/analysis/dexcom-dxcm-catches-eye-stock-jumps-88-200356834,200356834
113868,335383,DXCM,Here s Why You Should Buy Integer Holdings  ITGR  Stock Now,opinion,"Integer Holdings Corporation   NYSE ITGR   is currently one of the best performing stocks in the  industry  In fact  its solid focus on portfolio management and operational excellence are commendable  Moving ahead  the company is likely to gain from the Cardio   Vascular  Neuromodulation and Non Medical Electrochem markets Integer Holdings has a Zacks Rank  2  Buy  Impressive Share Price PerformanceA glimpse at the company s price trend reveals that Integer Holdings has outperformed its industry in a year s time  The stock has surged 77 8   significantly higher than the industry s 14 9  rally and the S P 500 index s 6 2  gain Let us take a quick look at three important factors that make Integer Holdings a solid pick for now  Factors at Play Strong Q3 ResultsInteger Holdings wrapped up the third quarter on a solid note  with earnings and revenues beating the respective Zacks Consensus Estimate  Also  the company continues to gain from its Cardio   Vascular product line  Third quarter adjusted earnings came in at  1 06 per share  outpacing the consensus mark by 15 2   The bottom line also improved 16 5  on a year over year basis On a reported basis  revenues improved 6 9  year over year to  305 1 million and surpassed the Zacks Consensus Estimate of  292 million Operational ExcellenceInteger Holdings have been witnessing an increase in profits since the last couple of quarters  courtesy of its consistent efforts to streamline operations  In the third quarter  the company generated gross profit of  91 9 million  up 3 1  year over year  Total operating income amounted to  41 5 million  up 15 7  year over year  Adjusted operating margin was 14 9   up 30 bps year over year Upbeat GuidanceFor 2018  the company expects revenues in the band of  1 195  1 210 million  mirroring 6 7  growth from the previous year s tally  on an adjusted basis  Adjusted earnings are expected in the range of  3 55  3 70 per share  indicating a 15 20  rise from the figure registered a year ago Which Way Are Estimates Treading The Zacks Consensus Estimate for third quarter earnings is pegged at 92 cents  reflecting a year over year decrease of 4 2   The same for revenues stands at  279 9 million  indicating 28 3  decline year over year For the full year  the Zacks Consensus Estimate for earnings is pegged at  3 66  reflecting growth of 30 3  from a year ago  The same for revenues stands at  1 30billion Integer Holdings Corporation Price and Consensus     
Bottom LineInteger Holdings has a stable foothold in the cardiac  orthopedics  vascular and advanced surgical markets  Buoyed by solid prospects  the stock currently has a   The VGM score  V stands for Value  G for Growth and M for Momentum  essentially highlights critical factors in a stock that have the potential to drive its price higher in the near term Our research shows that stocks  with a VGM Score of A or B  when combined with a Zacks Rank  1  Strong Buy  or 2  are better picks than most Key PicksSome other top ranked stocks in the broader medical space are Abiomed  Inc    NASDAQ ABMD    Masimo Corporation   NASDAQ MASI   and DexCom  Inc    NASDAQ DXCM   Abiomed has a long term expected earnings growth rate of 34 3   The stock carries a Zacks Rank of 2  You can see  Masimo s long term earnings growth rate is projected at 14 6   The stock carries a Zacks Rank  2 With a Zacks Rank  1  DexCom has an average four quarter positive earnings surprise of 131 3  3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ",2018-11-13,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-buy-integer-holdings-itgr-stock-now-200359186,200359186
113869,335384,DXCM,Here s Why Investors Should Bet On DexCom  DXCM  Right Now,opinion,DexCom  Inc    NASDAQ DXCM   is currently one of the best performing stocks in the  industry  The large and growing diabetes market  strong product portfolio  collaborative agreements with several companies and focus on international markets are key drivers of the stock at the moment DexCom sports a Zacks Rank  1  Strong Buy  Impressive Share Price PerformanceA glimpse at the company s price trend reveals that DexCom has outperformed its industry in a year s time  The stock has soared 123 8   significantly outperforming the industry s 8  growth and the S P 500 index s 1 1  gain  Let us take a quick look at three important factors that make DexCom a solid pick for now Factors at PlayDeal With VerilyIn a bid to fortify its foothold in the Type 2 diabetes space  DexCom recently announced a new amendment to its license deal with Verily  the life sciences unit of Alphabet   NASDAQ GOOGL    With this deal  DexCom is expected to deliver its next generation CGM  Continuous Glucose Monitoring  platform by the end of 2020 DexCom will make an initial payment of  250 million in stock  Moreover  additional payments of up to  280 million may become due and payable through product launch and revenue milestones  DexCom is likely to pay  275 million of the milestones in stock as well  read more    Solid Q3 Results DexCom reported adjusted earnings of 17 cents per share in the third quarter of 2018  which surpassed the Zacks Consensus Estimate of a loss of 12 cents  Total revenues rallied 44 5  to  266 7 million on a year over year basis and also surpassed the Zacks Consensus Estimate of  242 million Buoyed by solid third quarter results  DexCom raised the 2018 guidance  The company expects revenues of  975 million  up from  925 million anticipated earlier  Reported operating expenses  excluding investments in non intensive programs  are expected to increase 18  from the 2017 level  The projection is significantly higher than the previous forecast of 14  Gross profit margin is projected at 64   in line with the prior guidance Strong International FootholdDexCom continues to focus on international markets  primarily on Germany  It is eyeing the sizeable markets of India  China and Japan as well  In the third quarter of 2018  DexCom s international revenues skyrocketed 93  year over year to  64 3 million  with all major markets nearly doubling from the prior year quarter  Notably  the company received approvals in Japan and Korea Management sees robust growth opportunities in some of the European Union countries as well Which Way Are Estimates Treading The Zacks Consensus Estimate for fourth quarter earnings is pegged at 14 cents  reflecting a year over year increase of 40   The same for revenues stands at  283 1 million  indicating 28 1  decline year over year For the full year  the Zacks Consensus Estimate is pegged at a loss of 12 cents  The same for revenues stands at  977 4 million DexCom  Inc  Price  Consensus and EPS Surprise    Bottom LineDexCom s solid foothold in international markets is commendable  Furthermore  the company exhibits a  of B  Markedly  the VGM Score  V stands for Value  G for Growth and M for Momentum  essentially highlights critical factors in a stock that have the potential to drive its price higher in the near term Our research shows that stocks with a VGM Score of A or B  when combined with a Zacks Rank  1 or 2  Buy  are better picks Other Stocks to ConsiderSome other top ranked stocks in the broader medical space are Abiomed  Inc    NASDAQ ABMD   and Masimo Corporation   NASDAQ MASI   Abiomed has a long term expected earnings growth rate of 34 3   The stock carries a Zacks Rank of 2  You can see  Masimo s long term earnings growth rate is projected at 14 6   The stock has a Zacks Rank  2 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-11-25,Zacks Investment Research,https://www.investing.com/analysis/heres-why-investors-should-bet-on-dexcom-dxcm-right-now-200362353,200362353
113870,335385,DXCM,4 Profitable Stocks Boasting Amazingly High Net Income Ratio,opinion,Profitability analysis is considered one of the best possible ways to assess the prospects of a company  This analysis is used to identify a profitable company from a loss making one  In this context  it can be inferred that a profitable company generally has a high level of sales surplus  which will help it meet all its operating and non operating costs and still offer high returns In this context  it may be wise to invest in shares of a company with a high level of profitability as it normally ensures high returns  As a result  the simplest and most transparent way of checking a company s profitability is by using accounting ratios  There are a variety of profitability ratios  from which we have selected net income ratio here as it is the most useful and simplest profitability metric Net Income RatioThere are a variety of profit ratios like gross income ratio  operating income ratio  pretax profit margin and net income ratio  which can be used to find out a company s profit generating abilities  But net income ratio is widely accepted as the most conservative of the above mentioned ratios Net income in simple words is total earnings a company makes after deducting all the expenses from its sales revenue  Net income ratio or net profit margin is a ratio of a company s net income and sales revenue  A high net income ratio shows that the company is able to effectively manage all its business activities  including production  administration  selling  etc Screening ParametersNet income ratio is one of our key screening parameters  However  to find out the sure winners  we have added a few additional criteria to arrive at an efficient strategy   Zacks Rank equal to  1  Only Strong Buy stocks are allowed  With the Zacks Rank proving itself to be one of the best rating systems out there  this is a great way to start things off   Rating Strong Buy greater than 70   This indicates that 70  of the analysts covering these stocks are optimistic 12 Month Trailing Net Income Ratio Higher than X Industry  High net income ratio indicates a company s solid profitability 12 Month Trailing Sales and Net Income Growth Higher than X Industry  Stocks that possess higher sales and net income growth in the last 12 months showcase better financial performance These few parameters narrowed down the universe of over 7 712 stocks to only 12 Here are four of the 12 stocks that qualified the screen DexCom  Inc    NASDAQ DXCM   is a medical device company  It has an average four quarter positive earnings surprise of more than 100  E TRADE Financial Corporation   NASDAQ ETFC   is a financial services company  It has an average four quarter positive earnings surprise of 10 5  MCBC Holdings  Inc    NASDAQ MCFT   is a designer of sport boats and outboard boats in North America and globally  It has an average four quarter positive earnings surprise of 20 4  Quidel Corporation   NASDAQ QDEL   is a developer of diagnostic testing solutions for applications  It has an average four quarter positive earnings surprise of 34  You can get the rest of the stocks on this list by signing up now for your 2 week free trial to the Research Wizard and start using this screen in your own trading  Further  you can also create your own strategies and test them first before taking the investment plunge The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material Disclosure  Performance information for Zacks  portfolios and strategies are available at   ,2018-11-27,Zacks Investment Research,https://www.investing.com/analysis/4-profitable-stocks-boasting-amazingly-high-net-income-ratio-200362620,200362620
113871,335386,DXCM,What Falling Estimates   Price Mean For Alphatec Holdings  ATEC ,opinion,Similar to wise buying decisions  exiting certain underperformers at the right time helps maximize portfolio returns  Selling off losers can be difficult  but if both the share price and estimates are falling  it could be time to get rid of the security before more losses hit your portfolio One such stock that you may want to consider dropping is Alphatec Holdings  Inc    NASDAQ ATEC    which has witnessed a significant price decline in the past four weeks  and it has seen negative earnings estimate revisions for the current quarter and the current year  A Zacks Rank  5  Strong Sell  further confirms weakness in ATEC A key reason for this move has been the negative trend in earnings estimates revisions  For the full year  we have seen one estimate moving down in the past 30 days  compared with no upward revisions  This trend has caused the consensus estimate to trend lower  going from a loss 61 cents a share a month ago to its current level of loss of 67 cents Also  for the current quarter  Alphatec Holdings has seen one downward estimate revision versus no revisions in the opposite direction  dragging the consensus estimate down to a loss of 12 cents a share from a loss of 7 cents over the past 30 days The stock has also seen some pretty dismal trading lately  as the share price has dropped 17 9  in the past month Alphatec Holdings  Inc  Price and Consensus   So it may not be a good decision to keep this stock in your portfolio anymore  at least if you don t have a long time horizon to wait If you are still interested in the Medical   Instruments industry  you may instead consider a better ranked stock   DexCom  Inc    NASDAQ DXCM    The stock currently holds a Zacks Rank  1  Strong Buy  and may be a better selection at this time  You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-12-09,Zacks Investment Research,https://www.investing.com/analysis/what-falling-estimates--price-mean-for-alphatec-holdings-atec-200366633,200366633
113889,335404,DXCM,The Zacks Analyst Blog Highlights  Bio Rad Laboratories  Mazor Robotics  Tactile Systems  Eli Lilly And DexCom,opinion,For Immediate ReleaseChicago  IL   December 26  2017   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Bio Rad Laboratories  Inc    NYSE BIO    Mazor Robotics Ltd    NASDAQ MZOR    Tactile Systems Technology  Inc    NASDAQ TCMD    Eli Lilly and Company   NYSE LLY   and DexCom  Inc    NASDAQ DXCM   Here are highlights from Friday s Analyst Blog  4 MedTech Stocks to Explode in 2018The medical devices industry  which was once acclaimed for its high paying jobs and research and development opportunities  has been subject to the much controversial 2 3  medical device excise tax  The MedTech fraternity is leaving no stone unturned to permanently do away with the dreadful tax   but has not been able to Interestingly  the year 2017 has been quite an eventful one  courtesy of a series of socio political occurrences that favored the space  The year witnessed the much talked about election wherein Donald Trump took over the nation s charge as President  Not only were the new administration s health schemes thoroughly criticized but the reforms that were brought in taxation schemes became a much talked about subject  Needless to say  these developments kept investors on their toes Standing at the threshold of 2018 it is imperative for the investors thus to find the means which can dilute the macroeconomic woes and help them gain more  But before guiding you to make prudent investments for the year let s take a look at the various developments that have taken place within the space and see what awaits the investors in the coming year Health Policy Qualms to Continue in 2018   It has already been a year since trump became the President   However  his policies continue to be the most debated issue in the space  The new administration s Obamacare  repeal   replacement  effort through Congress and the latest  Executive Order   which apparently has been designed to provide quality healthcare to the nation at affordable rate  has already posed a serious threat to the healthcare community Per critics  this order  forsaking the consideration of pre existing health conditions has been designed to push people into  junk  insurance plans  The American Hospital Association has put forward an extremely bearish view on the executive order related to promote health care choice and competition  The association apprehends that the executive order will solely allow health insurance plans that cover fewer benefits and give lesser consumer protections Tax Reform May Hit Hard in 2018  According a report by Business Insider  the Republican tax plan repeals an itemized deduction that applies to healthcare expenses  If the new bill gets implemented  families with high healthcare expenditure will be impacted as these expenses will no longer be deducted from their taxes  Hence  people will no longer be interested in expensive healthcare or MedTech procedures   A report by The Hill says that the Section 4303 of the Republican tax bill plan imposes a 20  excise tax on goods manufactured overseas by subsidiaries of U S  companies  Under the U S  tax code  Puerto Rico is considered a foreign land which implies that U S  parent companies will have to pay excise taxes if they purchase from their subsidiaries in the island  In this regard  the FDA recently found that around 30  of Puerto Rico s gross domestic product was driven by pharmaceuticals and medical devices in 2016  Undoubtedly  the latest tax plan has created an uproar among MedTech players who might witness a huge reduction in their turnover with the approval of the bill Medical Device Tax Returns in 2018  The medical community was extremely hopeful about Trump s regulatory agenda as it promised to abolish the infamous 2 3  medical device tax that was first was included in the 2010 health care reform law The dreaded tax  imposed on the selling price instead of net profit and amounting to a stupendous sum  wiped out almost a quarter of the profit of medical technology companies  Realizing this  the U S  House and Senate temporarily suspended it for two years at the beginning of 2015 Going by the available data  it is quite evident that this partial two year repeal of the medical device tax has benefited the sector s development  Per data provided by the medical device trade group  in a Ken Blackwell article published by The Daily Caller   within this period  there was roughly an 83  rise in research and development  R D  investments by MedTech players The Republicans however have tightlipped on this tax raising the probability of its return in 2018  Undoubtedly  its comeback will be an additional burden for the MedTech fraternity  largely discouraging R D activities  Per an article by Matt Murphy in wbur  sectors which are going to be hampered most by reimposition of this levy are X ray and MRI machines  surgical instruments and pacemakers Use of  PRO  Concept May Delay Regulatory Process in 2018  The Center for Devices and Radiological Health s  CDRH  strategic priorities have been recently published where it has elaborately discussed the Value and Use of Patient Reported Outcomes  PROs  in Assessing Effects of Medical Devices  According to a Medcitynews article by John Speer  CDRH  the umbrella organization at the FDA  talked about a plan that would entitle patients to have access to high quality  safe and effective medical devices  PRO basically means a patient s assessment of their own health status or quality of life This is especially impactful because the majority of medical devices in the United States are cleared by FDA via the 510 k  premarket submission where patients have no voice as such  With the new PRO concept  this is no longer going to be valid  Per the report   given the expected behavior of the FDA by industry  it might increase the time taken to get through the regulatory process and increase costs to produce Class II devices   This is because  now they will have to conduct some sort of PRO study if this becomes a requirement  Also they will need additional funding to support the study activities FDA User Fee Increase  May Pose a Threat  Per an Emergo Group report  the FDA s 2018 user fees  established by the Medical Device User Fee Amendments of 2017  MDUFA IV   will increase for all registration related categories  including a sizeable fee increase for 510 k  premarket notification submissions by larger companies  In addition  FDA Establishment Registration fees will jump 37  to  4 642 for the 2018 fiscal from  3 382 in 2017  This implementation may pose a huge burden for the digital health industry and small companies in the medical device space 4 Stocks to Brave the ThreatsIn such a tumultuous scenario  to save investors from the time taking process of identifying the powerful MedTech stocks who may brave the industry threats in 2018  we have taken the help of the  Here we have highlighted four MedTech stocks with market cap of  500 million or more with a  Zacks Rank  1  Strong Buy  or 2  Buy  and positive estimate revision trend of more than 5  for fiscal 2018  Based on strong fundamentals and positive vital metrics  these stocks have ample credential to return more to shareholders amid eco political threats  Looking for the Best Stocks for 2018  Be among the first to see our  Bio Rad Laboratories  Inc   Over the years  this  7300 billion market cap stock has successfully demonstrated solid top line growth driven by strong sales of Droplet Digital PCR instruments and consumables  cell biology and food safety products in the life science group  Additionally  the company has a strong cash balance that enables it to carry out share repurchases and provide solid returns to investors  The expansion in gross and operating margin also buoys optimism  The company is also constantly investing in R D for product innovation Based on this bullish sentiment  over the past four weeks the company s EPS estimate for the upcoming fiscal has improved 6 08   The stock sports a Zacks Rank  1  You can see Mazor Robotics Ltd   Market is particularly upbeat about the company s CE Mark approval for its Mazor X Surgical Assurance platform  The approval will allow Mazor Robotics and its partner Medtronic  NYSE MDT  to commercialize  co promote and market the Mazor X platformin countries that recognize CE Mark  This development should get reflected in Mazor s 2018 performance  This  1384 billon stock has a Zacks Rank  2  Over the past month  estimates for the company have moved 9 57  north for the next fiscal Tactile Systems Technology  Inc   This  522 billion company develops and markets at home therapy devices that treat lymphedema and chronic venous insufficiency  The company s offering includes advanced  clinically proven pneumatic compression devices  as well as continuity of care services provided by a national network of product specialists and trainers  reimbursement experts  patient advocates and clinical staff Meanwhile  the figures for Tactile Systems  next year are quite promising  with one estimate moving higher in the past month  compared to none lower  The consensus estimate trend has also seen a 40 4  rise over the said frame  The stock flaunts a Zacks Rank  1 DexCom  Inc   DexCom has collaborative agreements with several companies  which should not only bring in cash in the form of milestone payments and royalties but should also help expand its product portfolio  In this regard  DexCom announced its collaboration in September 2017 with leading wearables brand Fitbit  FIT  to develop and market products for better management of diabetes and get a clearer picture of overall health with easy to use mobile tools In November 2017  the company partnered with Eli Lilly and Company  Per the agreement  DexCom s flagship continuous glucose monitoring system will be added to Lilly s Connected Diabetes Ecosystem This Zacks Rank  2 stock with a market cap of  4 93 billion is a valuable pick for 2018   Over a month  estimates for the company have moved 9 76  north for the next fiscal Where Do Zacks  Investment Ideas Come From You are welcome to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buy  stocks free of charge  There is no better place to start your own stock search  Plus you can access the full list of must avoid Zacks Rank  5  Strong Sells  and other private research  Join us on Facebook  NASDAQ FB   Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ,2017-12-25,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-biorad-laboratories-mazor-robotics-tactile-systems-eli-lilly-and-dexcom-200275768,200275768
113890,335405,DXCM,Why DexCom  DXCM  Might Surprise This Earnings Season,opinion,"Investors are always looking for stocks that are poised to beat at earnings season and DexCom  Inc    NASDAQ DXCM   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because DexCom is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings   with the most up to date information possible   is a pretty good indicator of some favorable trends underneath the surface for DXCM in this report In fact  the Most Accurate Estimate for the current quarter is currently at 9 cents per share for DXCM  compared to a broader Zacks Consensus Estimate of 3 cents per share  This suggests that analysts have very recently bumped up their estimates for DXCM  giving the stock a Zacks Earnings ESP of  175 00  heading into earnings season DexCom  Inc  Price and EPS Surprise
   Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that DXCM has a Zacks Rank  3 and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see  Clearly  recent earnings estimate revisions suggest that good things are ahead for DexCom  and that a beat might be in the cards for the upcoming report Zacks Top 10 Stocks for 2018 In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2018 Last year s 2017 Zacks Top 10 Stocks portfolio produced double digit winners  including FMC Corp  NYSE FMC   and VMware which racked up stellar gains of  67 9  and  61   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys ",2018-02-22,Zacks Investment Research,https://www.investing.com/analysis/why-dexcom-dxcm-might-surprise-this-earnings-season-200293559,200293559
113891,335406,DXCM,Patterson Companies  PDCO  Q3 Earnings  What s In Store  ,opinion,"Patterson Companies  Inc    NASDAQ PDCO   is scheduled to release third quarter fiscal 2018 results on Mar 1  The company anticipates a decline in the Dental Supply segment   one of its major revenue components  While this can majorly dampen earnings  an expected improvement in Animal Segment operating income should drive results Notably  Patterson Companies reported adjusted earnings of 51 cents per share in second quarter fiscal 2018  missing the Zacks Consensus Estimate of 54 cents  Net sales fell 2 3  from the year ago quarter to  1 39 billion and lagged the Zacks Consensus Estimate of  1 42 billion Let us take a look at how things are shaping up before the release Dental Supply Segment to Decline in Q3The Zacks Consensus Estimate for the Dental Supply segment is  592 million for third quarter fiscal 2018  This reflects a decline of almost 5 4  year over year The loss of exclusive distribution rights with Dentsply Sirona   NASDAQ XRAY   forced the company to shift to a new enterprise resource planning system to efficiently manage inventory  However  the system is creating short term challenges  Undoubtedly  the termination of the contract presents new opportunities for Patterson Companies to expand distribution platform to a wider range of product offerings  However  the company continues to witness heavy initial impact from the loss of this deal Patterson Companies  Inc  Price and EPS Surprise     
The company s decision to end exclusive distribution will affect results through fiscal 2018  In fact  dental segment sales have been sluggish over the last couple of quarters  Management has provided a dull guidance for the coming quarters as well In the last quarter  dental sales  40  of total sales  fell 8 4  at constant currency  cc   year over year to approximately  553 6 million  The downside was caused by lower sales of CEREC and digital technology products  Management expects headwinds in the technology based equipment business to persist through fiscal 2018  adding to the company s woes Other Factors at PlayEstimates   GuidanceFor the third quarter  the Zacks Consensus Estimate for adjusted earnings is pegged at 51 cents  reflecting a decline of 12 1  year over year  Management anticipates headwinds in its technology equipment business to persist through fiscal 2018  This is primarily because of Patterson Companies  initiatives to transit its sales model to an expanded technology product portfolio Further  the Zacks Consensus Estimate for revenues is pegged at  1 38 billion  showing a decline of 1 1  year over year In the last quarter  the company estimated adjusted earnings per share for fiscal 2018 in the range of  2 00  2 10  way below the previous band of  2 25  2 40  Patterson Companies expects deal amortization expenses of  25 3 million or 27 cents per share  The company projects integration and business restructuring expenses at  5 3 million or 6 cents per share Animal Health SegmentAnimal Health is the second important contributor to revenues for Patterson Companies after the dental unit Steady growth in this unit is expected to be a long term growth driver  Management expects solid margin improvement in the segment on the back of enhanced partnerships with product manufacturers and strong sales execution  The Zacks Consensus Estimate for operating income from the Animal Health unit is pegged at  30 9 million  reflecting an improvement of 33 1  from the last quarter However  the Zacks Consensus Estimate for net sales is  786 million  reflecting a decline of 4 6  year over year Our quantitative model does not show an earnings beat for Patterson Companies this quarter  This is because a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  This is not the case here  as you will see below Zacks ESP  The Earnings ESP for Patterson Companies is  0 65   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Patterson Companies carries a Zacks Rank  2 Key PicksHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter The Cooper Companies Inc    NYSE COO    has an Earnings ESP of  0 04  and a Zacks Rank  3  You can see  DexCom  Inc    NASDAQ DXCM   has an Earnings ESP of  126 5  and a Zacks Rank  3 Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-02-25,Zacks Investment Research,https://www.investing.com/analysis/patterson-companies-pdco-q3-earnings-whats-in-store-200294208,200294208
113895,335410,DXCM,Will Admissions Drive Universal Health s  UHS  Q4 Earnings ,opinion,Universal Health Services  Inc    NYSE UHS   is set to report fourth quarter 2017 results on Feb 28 after  market close Last quarter  the company reported adjusted earnings of  1 64 per share  having missed the Zacks Consensus Estimate by 3 5   The bottom line  however  grew 2 5  year over year on higher revenues Let s see  how things are shaping up for this announcement Why a Likely Positive Surprise Our proven model shows that Universal Health has the right combination of the following two key ingredients to beat estimates this quarter Zacks ESP  Universal Health has an  of  0 39   A stock s positive ESP raises confidence about an earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our  Universal Health Services  Inc  Price and EPS Surprise    Zacks Rank  Universal Health carries a Zacks Rank  2  Buy   which increases the predictive power of ESP as stocks with a favorable Zacks Rank  1  Strong Buy   2 or 3  Hold  have significantly higher chances of an earnings beat Conversely  we caution against Sell rated stocks   4 or 5  going into an earnings announcement  especially when the company is witnessing negative estimate revisions Q4 ExpectationsBoth segments of Universal Health namely Acute Care and Behavioral Health  have been delivering strong results over the past many quarters  Notably  the segments have also been continuously witnessing a rise in admissions  licensed beds and patient days  leading to higher revenues in turn   Moreover  the fourth quarter is likely to have experienced this favorable trend The Zacks Consensus Estimate for total revenues in the to be reported quarter is pegged at  2 6 billion  reflecting year over year growth of 6    Our consensus estimate for revenues from Acute Care and Behavioral Health segments stands at  1 4 billion and  1 2 billion  up 6  and 6 7  respectively  year over year The average number of licensed beds in the Acute Care hospitals and Behavioral Health centers kept increasing since 2012  Our consensus estimate for Average Licensed Beds in Acute Care and Behavioral Health is pegged at 6 1 billion and 23 1 billion  up 0 5  and 5 7  year over year  respectively An increase in number of beds at both the facilities will likely drive up admission volumes  The Zacks Consensus Estimate for Admissions in Acute Care and Behavioral Health is pegged at 73 2 billion and 116 3 billion respectively  up 5 4  and 4 7  year over year  respectively In addition  the company s continuous focus to enhance shareholders  value through share repurchases might have boosted its bottom line by limiting share count in the fourth quarter However  rising costs related to interest payment  reserves for settlements  legal judgments and lawsuits plus impairments of long lived assets are likely to have weighed on margins Other Stocks to ConsiderHere are some other stocks also worth considering from the medical sector with the right combination of elements to come up with an earnings beat this time around Aerie Pharmaceuticals  Inc    NASDAQ AERI   is set to report fourth quarter earnings on Feb 28  The company has an Earnings ESP of  41 20  and a Zacks Rank  3  You can see  Bio Rad Laboratories  Inc    NYSE BIO    which is set to release fourth quarter earnings on Feb 27  has an Earnings ESP of  2 61  and a Zacks Rank of 2  DexCom  Inc   NASDAQ DXCM   has an Earnings ESP of  126 47  and is a Zacks  3 Ranked player  The company is set to announce fourth quarter earnings on Feb 27 Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-02-25,Zacks Investment Research,https://www.investing.com/analysis/will-admissions-drive-universal-healths-uhs-q4-earnings-200294246,200294246
113897,335412,DXCM,DexCom  DXCM  Surpasses Earnings   Revenue Estimates In Q4,opinion,DexCom  Inc    NASDAQ DXCM   reported earnings per share  EPS  of 10 cents in the fourth quarter of 2017  beating the Zacks Consensus Estimate by 233 3   Also  the figure improved from a loss of 9 cents in the year ago quarter Full year 2017 loss of 58 cents was narrower than the loss of 78 cents in the year ago quarter  The figure was also better than the Zacks Consensus Estimate of a loss of 63 cents Total revenues grew 29 1  to  221 million from  171 2 million in the year ago quarter  Revenues surpassed the Zacks Consensus Estimate of  217 8 million Full year 2017 revenues came in at  718 5 million  beating the Zacks Consensus Estimate of  715 3 million  The figure also improved from the year ago number by 25 3  Segmental detailsSensor revenues   other revenues  73  of total revenues  grew 30  on a year over year basis to  160 6 million  Transmitter revenues  19   increased 31  from the prior year quarter to  42 4 million  Receiver revenues  8   grew 21  year over year to  18 million Operational DetailsDexCom generated gross margin  as a percentage of revenues  of 69 5   an expansion of 129 basis points  bps  year over year International business displayed continued growth in the quarter  generating  33 2 million in revenues  up 58  on a year over year basis  Notably  international business represented 15  of total revenues in the fourth quarter Research and development  R D  expenses totaled  48 7 million in the quarter  up 11 4  year over year Selling  general and administrative expenses totaled  92 8 million in the reported quarter  increasing 17 3  year over year Financial UpdateFull year 2017  DexCom had  548 6 million in cash  cash equivalents and short term marketable securities versus  123 7 million at the end of 2016 GuidanceDexCom reaffirmed the full year 2018 guidance  The company expects full year 2018 revenues in the range of  830  850 million  Gross profit margin is projected in the band of 65  to 68   Reported operating expenses  excluding investments in non intensive programs  is expected to increase 10  from 2017 Our TakeDexCom exited the fourth quarter on a solid note  The year over year growth in revenues and earnings is encouraging  The expansion in gross margin buoys optimism  The company is also focusing on product and innovation through R D Peer PerformanceSome medical stocks that reported solid results this earnings season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and Becton  Dickinson and Company   NYSE BDX   PetMed reported third quarter fiscal 2018 results  Adjusted EPS of 44 cents were up 88 3  from the prior year quarter  Revenues rose 13 7  to  60 1 million PerkinElmer reported fourth quarter 2017 adjusted EPS of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter Becton  Dickinson reported first quarter 2018 adjusted EPS of  2 48  up 3 9  at constant currency  Revenues totaled  3 08 billion  up 3 7  at constant currency The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-02-28,Zacks Investment Research,https://www.investing.com/analysis/dexcom-dxcm-surpasses-earnings--revenue-estimates-in-q4-200295334,200295334
113900,335415,DXCM,Lessons From The Dexcom Breakout,opinion,"Five months ago   for bottom fishing in DexCom  NASDAQ DXCM  following the news of competitor s Abbott  NYSE ABT  product approval  The trade was looking shaky a few weeks later when the stock made a minor new closing low from that price collapse  November earnings produced the catalyst to confirm the bottom  and the stock was off to the races for a little over a month 
Soon after the stock started drifting downward  an analyst downgraded the stock to underperform  The selling was enough to create a breakdown below 50 day moving average  DMA  support  I stopped out my position to preserve my remaining profit   concerned that the market s response validated the analyst action  DXCM never traded lower even after cutting revenue guidance a few days later  After two months of additional consolidation  DXCM broke out on Monday 
DexCom  DXCM  printed a very bullish breakout above its 200DMA on a 6 6  gain  A close of the September gap down is now within sight 
While the volume did not surge on the breakout  the move still looks bullish given the context  an on going push to fill September s massive gap down and the contrary buying pressure in the wake of a bearish downgrade and a somewhat disappointing earnings report  On Tuesday  DXCM will appear at the Barclays Global Healthcare Conference  I assume that investors are anticipating very good news 
I received a reminder of a very simple lesson  the power of the confirmation or the lack thereof  In this trade  I was too eager to preserve my profits ahead of confirming a breakdown  A confirmation would have been a lower close  I should have used my profit to buffer against the emotional urge to react with the crowd  Moreover  the stock was over extended below its lower Bollinger Band  BB  and thus over stretched  the hurdle was high for the stampede to continue exiting the stock 
Note well DXCM s breakout needs its own confirmation  a higher close 
Be careful out there 
Full disclosure  no positions",2018-03-13,Dr. Duru,https://www.investing.com/analysis/lessons-from-the-dexcom-breakout-200297482,200297482
113902,335417,DXCM,DexCom  DXCM  Gets FDA Approval For G6 CGM Monitoring System,opinion,DexCom  Inc    NASDAQ DXCM   recently announced that the FDA has granted a de novo approval for the marketing of the new Dexcom G6 CGM monitoring system to check blood sugar levels in children and adults without pricking fingers for diabetes management This is the first glucose monitoring system permitted by the FDA that can be used as a standalone Continuous Glucose Monitoring  CGM  and for integration into automated insulin dosing  AID  systems What is  de novo  Per FDA  a de novo classification for a particular product platform establishes a new device type along with classification  necessary controls and product code Further  a device that has de novo approval is eligible for a 510 k  approval submission The large and expanding diabetes market  strong product portfolio and positive tidings at the regulatory front are likely to provide DexCom with a competitive edge in the U S  MedTech sector CGM   a Prominent Space in MedTechCGM provides continuous insight into glucose levels throughout the day and night Per CISION  the global CGM market is estimated to reach  4 Billion by 2024  Per the report  United States is the leader in the global CGM market DexCom is a leading player in the global CGM markets Other than G6 CGM  DexCom s FDA cleared G4 Platinum platform is significantly boosting the company s top line  The inbuilt features of the G4 Platinum make it the most innovative system in the market In 2017  DexCom announced the receipt of FDA s approval of the DexCom G5 mobile app for android devices By the end of fourth quarter of 2017  the company confirmed the development of a fully disposable real time CGM system with Verily  This is expected to be completed by the end of 2017  The company is confident about its G6 sensor Lacklustre Price Performance DexCom s price movement in the past year has been unimpressive  The company reported a negative return of 17 8   comparing unfavorably with the  s rally of 21 9  The current level is also lower than the S P 500 Index s gain of 14 3   Zacks Rank   Key PicksDexCom carries a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector are Bio Rad Laboratories   NYSE BIO    athenahealth  Inc    NASDAQ ATHN   and Edwards Lifesciences Corporation   NYSE EW   Bio Rad Laboratories sports a Zacks Rank of 1  Strong Buy   You can see The company has a long term expected earnings growth rate of 20  athenahealth is a Zacks  1 Ranked player  The company has a long term expected earnings growth rate of 21 5  Edwards Lifesciences has a long term expected earnings growth rate of 15 1   The stock carries a Zacks Rank of 2  Buy  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-03-27,Zacks Investment Research,https://www.investing.com/analysis/dexcom-dxcm-gets-fda-approval-for-g6-cgm-monitoring-system-200301437,200301437
113904,335419,DXCM,DexCom  DXCM  Up 17 7  Since Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for DexCom  Inc    NASDAQ DXCM    Shares have added about 17 7  in that time frame 
Will the recent positive trend continue leading up to its next earnings release  or is DXCM due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers 
Recent EarningsDexCom reported loss of 32 cents per share in the first quarter of 2018  in line with the Zacks Consensus Estimate  Also  the figure was narrower than the loss of 49 cents reported in the year ago quarter Total revenues grew 29 6  to  184 4 million from  142 3 million in the year ago quarter  Revenues surpassed the Zacks Consensus Estimate of  173 million Segmental DetailsSensor revenues   other revenues  72  of total revenues  grew 30  on a year over year basis to  131 9 million  Transmitter revenues  20   increased 28  from the prior year quarter s tally to  37 7 million  Receiver revenues  8   grew 26  year over year to  14 8 million Operational DetailsDexCom generated gross margin  as a percentage of revenues  of 64 5   which contracted 160 basis points  bps  year over year  Margins were under pressure due to an inventory change and shift toward OUS and Medicare International business displayed continued growth in the quarter  up 49  on a year over year basis Research and development  R D  expenses totaled  44 8 million in the quarter  down 6 9  year over year Selling  general and administrative expenses totaled  104 8 million in the reported quarter  increasing 21 3  year over year GuidanceDexCom raised the full year 2018 guidance The company expects 2018 revenues in the range of  850  860 million  up from the previous range of  830  850 million Gross profit margin is projected in the band of 65  to 68  Operating expenses  excluding investments in non intensive programs  are expected to increase 10  from 2017 
How Have Estimates Been Moving Since Then 
It turns out  fresh estimates have trended downward during the past month  There have been four revisions higher for the current quarter compared to seven lower DexCom  Inc  Price and Consensus    VGM Scores
At this time  DXCM has an average Growth Score of C  Its Momentum is doing a lot better with an A  However  the stock was allocated a grade of F on the value side  putting it in the lowest quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of D  If you aren t focused on one strategy  this score is the one you should be interested in 
Our style scores indicate that the stock is more suitable for momentum investors than growth investors 
Outlook
Estimates have been broadly trending downward for the stock and the magnitude of these revisions indicates a downward shift  Notably  DXCM has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-05-31,Zacks Investment Research,https://www.investing.com/analysis/dexcom-dxcm-up-177-since-earnings-report-can-it-continue-200321341,200321341
113917,335432,DXCM,DexCom  DXCM  In Focus  Stock Moves 6 7  Higher,opinion,DexCom  Inc    NASDAQ DXCM   was a big mover last session  as the company saw its shares rise nearly 7  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This reverses the recent trend for the company as the stock is now down 1 7  in the past one month time frame The move came after the company reported better than expected third quarter  2017 results The company has seen three negative estimate revisions in the past few months  while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few months  suggesting there may be trouble down the road  So make sure to keep an eye on this stock going forward  to see if this recent move higher can last DexCom currently has a Zacks Rank  3  Hold  while its is negative DexCom  Inc  Price and Consensus   A better ranked stock in the Medical   Instrumentsindustry is Fresenius Medical Care Corporation   NYSE FMS    which currently carries a Zacks Rank  1  Strong Buy   You can see  Is DXCM going up  Or down  Predict to see what others think  or More Stock News  Tech Opportunity Worth  386 Billion in  From driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future advantage of this exciting investment opportunity   Most importantly  it reveals 4 stocks with massive profit potential ,2017-08-03,Zacks Investment Research,https://www.investing.com/analysis/dexcom-dxcm-in-focus-stock-moves-67-higher-200205053,200205053
113918,335433,DXCM,Here Are Two Pivotal Trials To Watch During Late 2017,opinion,"The next twelve months promise to be a busy period in the biotechnology sector  A number of companies are about to kick off pivotal trials that   if successful   could bring new and updated treatment options to populations for which there currently exists a large unmet need 
Here are two companies to keep an eye on near term  with a look at the treatments in question and the catalysts that could get each moving 
VBI Vaccines Inc  NASDAQ VBIV  
VBI Vaccines is a young biotechnology company that s working to bring a host of different treatments to market  most of which are rooted in a technology it calls its envelope virus like particle  eVLP  platform  The technology allows the company to create vaccine candidates  primarily preventative  but not limited to such  that stand to offer patients an improved option over the current standard of care therapies in their respective indications  The company s lead program right now is rooted in hepatitis B and it revolves around an asset called Sci B Vac 
Sci B Vac is a prophylactic vaccine that VBI hopes can compete against GlaxoSmithKline s  NYSE GSK  Engerix B  which is the vaccine that dominates this space right now  The latter has certain limitations  it s been shown to lack efficacy in immunosuppressed patients  for example  and Sci B Vac may be able to overcome these limitations and offer patients in this population an improved rate of seroprotection 
VBI has collected a large amount of safety and efficacy data from both real world administrations  the drug is already approved in a number of regions globally  but none of the major markets  and from investigator sponsored trials and the company is about to initiate a global phase III program that will underpin regulatory applications in the US  Canada and Europe  That s the plan  at least 
The program is split into two parts  one of which is further broken down into two separate  but concurrent  primary endpoints  The first part is a lot to lot study that s set up to demonstrate consistent quality  The second is a study that s designed to prove both that Sci B Vac is non inferior to Engerix B in patients ages 18 years and older  the first co primary endpoint  and that it is superior to the latter in patients ages 45 years and older  the second co primary endpoint  
The trial is pretty small for a pivotal in a vaccine indication  with VBI seeking to enroll just 4 800 patients  This is rooted in the above mentioned legacy data  which the health authorities in the regions for which VBI is targeting approval with this study have suggested they are willing to accept as part of the submission 
The trial should kick off before the end of this year and it s a fifteen month study  so catalysts derive from initiation  an interim release  which the company hasn t confirmed  but the protocol allows for at least some safety and early efficacy data after a couple of the pre planned three doses are administered  and  of course  completion and topline  The latter should hit press during the first or second quarter of 2019 
The second pivotal trial sees us switch from hepatitis to diabetes and  specifically  to a company called Tandem  NASDAQ TNDM   This one might not be immediately recognizable to some reading but there s a reason we re highlighting this one as a trial to watch   it s heavily tied to diabetes giant  DexCom Inc  NASDAQ DXCM   The latter developed and had approved its Continuous Glucose Monitor  CGM  a couple of years ago and the product is now widely used among sufferers of both type 1 and type 2 diabetes  For those not familiar with the technology  it s an implant style asset that   as the name suggests   allows for the continuous monitoring of glucose in a patient and  when combined with certain other technologies  we ll get to one in a little more detail shortly  can provide a sort of closed loop system that helps a diabetes sufferer stay on top of their disease 
Right now  one of the companies that DexCom works with and one a company that provides the secondary component of the above discussed system is Tandem Diabetes Care Inc  Tandem s technology  what s called the t slim X 2 insulin pump  combines with DexCom s CGM to administer the insulin patients need as and when they need it  The CGM monitors blood glucose  notifies the t slim pump when insulin is required and the pump does its job 
So what s under investigation 
Tandem has developed an algorithm that it believes can combine with the DexCom CGM system and its own t slim pump to improve on the stability and   by proxy   efficacy of the system  It s called the Predictive Low Glucose Suspend  PLGS  algorithm and the way it works is pretty neat  In a nutshell  it is able to predict when blood glucose levels are about to fall and pause insulin delivery accordingly  Conversely  it can predict when blood glucose levels are about to rise and can ramp up insulin delivery in anticipation of said increase 
That s the theory  at least  Right now there s plenty of mid stage data that seems to validate the tech  but this is the US biotechnology industry and  as such  the company needs to prove efficacy and  perhaps more importantly in this instance  safety as part of a large sample phase III before the algorithm can be built into the on shelf product 
And it s this pivotal that qualifies the two companies for inclusion here  The trial is actually already underway  having kicked off mid August  and it s expected to close out at some point during early 2018  It pitches the DexCom Tandem combination against the same  but with the PLGS algorithm built in  in 90 diabetes patients ages 6 and older  The endpoint on this one is the demonstration of a reduction in the percentage of CGM values below 70mg dL for patients using the algorithm based tech  as compared to the standard already approved system 
Beyond trial readout  which we can realistically expect as early as first quarter next year  the major catalyst on this one is the submission of a registration application to the FDA  which  assuming the trial hits its endpoint  should come the mid year 2018 
As a final note  it s worth touching on why this algorithm is important and why it could be a game changer for Dexcom and Tandem in this population  Stability of these sorts of automatic systems is tough to achieve when compared to manual administration insulin  A diabetes sufferer knows when he or she is going to eat  Right now  the technology doesn t  This lack of predictive technology  and by proxy  the reactive nature of the system as opposed to the predictive nature  is one of the hurdles companies like Dexcom and Tandem have to overcome in order to convince patients and physicians this is the right route  If the company can prove its algorithm is effective to the above stated aim  there s a good chance a large portion of the undecided patient population will make the switch from manual to automatic insulin ",2017-08-18,Samuel Rae,https://www.investing.com/analysis/here-are-two-pivotal-trials-to-watch-during-late-2017-200208105,200208105
113920,335435,DXCM,DexCom Lily Partnership To Boost CGM Platform  Customer Base,opinion,DexCom  Inc    NASDAQ DXCM   recently announced the signing of a development agreement with Eli Lilly and Company   NYSE LLY    Per the agreement  DexCom s flagship continuous glucose monitoring system  CGM  will be added to Lilly s Connected Diabetes Ecosystem Through the integration of CGM with Lily s smart insulin delivery devices  DexCom aims to provide a holistic approach to diabetes management for its customers  Notably clinical trials are expected to begin by the end of 2017 DexCom s FDA cleared CGM system   the DexCom G4 Platinum   is contributing significantly to the top line  DexCom G4 Platinum is the most innovative CGM system in the market  In June  DexCom had announced the FDA approval of the DexCom G5 mobile app for Android devices Moreover  DexCom has collaborative agreements with several companies  which should not only bring in cash in the form of milestone payments and royalties but should also help expand its product use  In September 2017  DexCom announced a tie up with leading wearables brand Fitbit to develop and market products to help people better manage diabetes and get a clearer picture of their overall health  The first planned initiative is to bring DexCom CGM data to Fitbit s new smartwatch  Fitbit Ionic  The companies aim to make the smartwatch available in 2018 and will continue to explore ways to develop tools to improve diabetes management We believe the glucose monitoring market represents significant commercial opportunity for DexCom  Per a report by Mordor Intelligence  the global market for diabetes care devices is projected to reach a value of  30 25 billion by 2021  at a CAGR of 5 93   Also  the International Diabetes Federation  IDF  estimates that by 2035  the worldwide incidence of people suffering from diabetes will reach 592 million Recently  management at DexCom confirmed that the company is well poised to congregate the unmet demand in the global diabetic space  especially when it comes to CGM  DexCom s increased patient convenience  enhanced connectivity  data analytics  and lower cost platforms fortify the company s foothold in the global diabetic space However  the diabetes market is dominated by many well established players  Abbott   NYSE ABT   being the most prominent one  In this space  Abbott recently announced the receipt of FDA approval for the FreeStyle Libre Flash glucose monitoring system in the United States Share Price PerformanceDexCom has been gaining investor confidence on consistently positive results  Over the last month  the company s share price outperformed the broader   The stock has gained 23 1   as compared with the broader industry s 1   The company has also outperformed the 0 9  gain of the S P 500 market   Zacks Rank   Key PickDexCom carries a Zacks Rank  3  Hold  A better ranked medical stock is PetMed Express  Inc    NASDAQ PETS    with a Zacks Rank  1  Strong Buy   You can see PetMed has a long term expected earnings growth rate of 10   The stock has rallied roughly 80 9  in a year Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-11-21,Zacks Investment Research,https://www.investing.com/analysis/dexcomlily-partnership-to-boost-cgm-platform-customer-base-200267582,200267582
113922,335437,DXCM,Lilly Inks Deal To Include Dexcom Products In Diabetes System,opinion,"Eli Lilly and Company   NYSE LLY   announced that it has inked a development deal with DexCom  Inc    NASDAQ DXCM    to integrate the latter s continuous glucose monitoring  CGM  products and tools into Lilly s Connected Diabetes Ecosystem 
A Connected Diabetes Ecosystem connects devices and technologies to provide solutions that can cater to an individual s unique needs in managing diabetes   In fact  devices such as CGM  smart pens and insulin pumps  drugs  apps and other analytical tools can link patients and their care teams to deal with the disease in a better way  The Connected Diabetes Ecosystem will depend on Lilly s core diabetes expertise along with the devices and tools provided by Dexcom 
Per Lilly  the agreement with Dexcom will enable the company to reduce the daily burden for people with diabetes  Studies are expected to begin by the end of 2017 
So far this year  shares of Lilly have increased 13 5  compared with the  s gain of 14 8  

 
Lilly has a strong portfolio of diabetes treatments including Trulicity  GLP 1   Jardiance  SGLT 2   Trajenta  Humulin  Basaglar  Humalog  and Glyxambi  Also  it has a diabetes alliance with Boehringer Ingelheim for many of these products  The company is seeking label expansion of some of these drugs 
Zacks Rank   Stocks to Consider
Lilly carries a Zacks Rank  3  Hold   Some better ranked health care stocks in the same space are Sucampo Pharmaceuticals   NASDAQ SCMP   and Ligand Pharmaceuticals   NASDAQ LGND   carrying a Zacks Rank  2  Buy   You can see  
Sucampo s earnings per share estimates have moved up from  1 01 to  1 12 for 2017 and from  1 06 to  1 19 for 2018 over the last 30 days  The company delivered a positive earnings surprise in three of the trailing four quarters  with an average beat of 15 63  
Ligand s earnings per share estimates have climbed  3 68 to  3 70 for 2018 over the last 60 days  The company pulled off a positive earnings surprise in two of the trailing four quarters  with an average beat of 8 22   The share price of the company has increased 27 9  year to date 
Wall Street s Next Amazon  NASDAQ AMZN  
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-11-21,Zacks Investment Research,https://www.investing.com/analysis/lilly-inks-deal-to-include-dexcom-products-in-diabetes-system-200267546,200267546
113925,335440,DXCM,DexCom  DXCM  Banks On Collaborations  Competition Rife,opinion,On Dec 19  we issued an updated research report on DexCom  Inc    NASDAQ DXCM    The company has been trading above the broader  over the past month  The stock has gained 5 5   higher than the broader industry s gain of 0 8  We believe the glucose monitoring market represents significant opportunity for DexCom  The diabetes market is large and growing  In the third quarter of 2017  management at Dexcom confirmed that the company is well poised to meet the unmet demand in the global diabetic space  especially when it comes to the continuous glucose monitoring facility DexCom has collaborative agreements with several companies  which should not only bring in cash in the form of milestone payments and royalties but should also help expand its product portfolio  In this regard  DexCom announced its collaboration in September 2017 with leading wearables brand Fitbit to develop and market products for better management of diabetes and get a clearer picture of overall health with easy to use mobile tools   DexCom continues to focus on international markets  especially Germany  The company is also eyeing the sizeable markets of India  China and Japan  Given the demographic trends and lifestyle in countries outside the United States and Europe  we believe that DexCom has bountiful opportunities in the international market However  the company faces reimbursement risks owing to efforts to control healthcare expenses  Further  with an increasing demand for its offerings  DexCom might face supply constraints in the near term The market for blood glucose monitoring devices is highly competitive  subject to rapid change and significantly affected by product launches  With respect to the G4 Platinum system  DexCom competes directly with Roche Diabetes Care   a division of Roche Diagnostics  LifeScan  Inc    a division of Johnson   Johnson  NYSE JNJ   the MediSense and TheraSense divisions of Abbott Laboratories  NYSE ABT   and Bayer  DE BAYGN  Corporation Zacks Rank   Key PicksDexCom carries a Zacks Rank  3  Hold  A few better ranked medical stocks are athenahealth  Inc    NASDAQ ATHN    Align Technology  Inc    NASDAQ ALGN   and Luminex Corporation   NASDAQ LMNX    Notably  athenahealth  and Align Technology sport a Zacks Rank  1  Strong Buy  while Luminex carries a Zacks Rank  2  Buy   You can see athenahealth has a long term expected earnings growth rate of 22 3   The stock has rallied roughly 17 1  over a year Align Technology has a long term expected earnings growth rate of 28 9   The stock has gained 134 5  in a year Luminex has a long term expected earnings growth rate of 16 3   The stock has gained 4 6  in the past three months 5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2017-12-19,Zacks Investment Research,https://www.investing.com/analysis/dexcom-dxcm-banks-on-collaborations-competition-rife-200274733,200274733
113927,335442,DXCM,4 MedTech Stocks To Explode In 2018,opinion,"The medical devices industry  which was once acclaimed for its high paying jobs and research and development opportunities  has been subject to the much controversial 2 3  medical device excise tax  The MedTech fraternity is leaving no stone unturned to permanently do away with the dreadful tax   but has not been able to 
Interestingly  the year 2017 has been quite an eventful one  courtesy of a series of socio political occurrences that favored the space  The year witnessed the much talked about election wherein Donald Trump took over the nation s charge as President  Not only were the new administration s health schemes thoroughly criticized but the reforms that were brought in taxation schemes became a much talked about subject  Needless to say  these developments kept investors on their toes Standing at the threshold of 2018 it is imperative for the investors thus to find the means which can dilute the macroeconomic woes and help them gain more  But before guiding you to make prudent investments for the year let s take a look at the various developments that have taken place within the space and see what awaits the investors in the coming year Health Policy Qualms to Continue in 2018   It has already been a year since trump became the President   However  his policies continue to be the most debated issue in the space  The new administration s Obamacare  repeal   replacement  effort through Congress and the latest  Executive Order   which apparently has been designed to provide quality healthcare to the nation at affordable rate  has already posed a serious threat to the healthcare community Per critics  this order  forsaking the consideration of pre existing health conditions has been designed to push people into  junk  insurance plans  The American Hospital Association has put forward an extremely bearish view on the executive order related to promote health care choice and competition  The association apprehends that the executive order will solely allow health insurance plans that cover fewer benefits and give lesser consumer protections Tax Reform May Hit Hard in 2018  According a report by Business Insider  the Republican tax plan repeals an itemized deduction that applies to healthcare expenses  If the new bill gets implemented  families with high healthcare expenditure will be impacted as these expenses will no longer be deducted from their taxes  Hence  people will no longer be interested in expensive healthcare or MedTech procedures   A report by The Hill says that the Section 4303 of the Republican tax bill plan imposes a 20  excise tax on goods manufactured overseas by subsidiaries of U S  companies  Under the U S  tax code  Puerto Rico is considered a foreign land which implies that U S  parent companies will have to pay excise taxes if they purchase from their subsidiaries in the island  In this regard  the FDA recently found that around 30  of Puerto Rico s gross domestic product was driven by pharmaceuticals and medical devices in 2016  Undoubtedly  the latest tax plan has created an uproar among MedTech players who might witness a huge reduction in their turnover with the approval of the bill Medical Device Tax Returns in 2018  The medical community was extremely hopeful about Trump s regulatory agenda as it promised to abolish the infamous 2 3  medical device tax that was first was included in the 2010 health care reform law The dreaded tax  imposed on the selling price instead of net profit and amounting to a stupendous sum  wiped out almost a quarter of the profit of medical technology companies  Realizing this  the U S  House and Senate temporarily suspended it for two years at the beginning of 2015 Going by the available data  it is quite evident that this partial two year repeal of the medical device tax has benefited the sector s development  Per data provided by the medical device trade group  in a Ken Blackwell article published by The Daily Caller   within this period  there was roughly an 83  rise in research and development  R D  investments by MedTech players The Republicans however have tightlipped on this tax raising the probability of its return in 2018  Undoubtedly  its comeback will be an additional burden for the MedTech fraternity  largely discouraging R D activities  Per an article by Matt Murphy in wbur  sectors which are going to be hampered most by reimposition of this levy are X ray and MRI machines  surgical instruments and pacemakers Use of  PRO  Concept May Delay Regulatory Process in 2018  The Center for Devices and Radiological Health s  CDRH  strategic priorities have been recently published where it has elaborately discussed the Value and Use of Patient Reported Outcomes  PROs  in Assessing Effects of Medical Devices  According to a Medcitynews article by John Speer  CDRH  the umbrella organization at the FDA  talked about a plan that would entitle patients to have access to high quality  safe and effective medical devices  PRO basically means a patient s assessment of their own health status or quality of life This is especially impactful because the majority of medical devices in the United States are cleared by FDA via the 510 k  premarket submission where patients have no voice as such  With the new PRO concept  this is no longer going to be valid  Per the report   given the expected behavior of the FDA by industry  it might increase the time taken to get through the regulatory process and increase costs to produce Class II devices   This is because  now they will have to conduct some sort of PRO study if this becomes a requirement  Also they will need additional funding to support the study activities FDA User Fee Increase  May Pose a Threat  Per an Emergo Group report  the FDA s 2018 user fees  established by the Medical Device User Fee Amendments of 2017  MDUFA IV   will increase for all registration related categories  including a sizeable fee increase for 510 k  premarket notification submissions by larger companies  In addition  FDA Establishment Registration fees will jump 37  to  4 642 for the 2018 fiscal from  3 382 in 2017  This implementation may pose a huge burden for the digital health industry and small companies in the medical device space 4 Stocks to Brave the Threats
In such a tumultuous scenario  to save investors from the time taking process of identifying the powerful MedTech stocks who may brave the industry threats in 2018  we have taken the help of the  
Here we have highlighted four MedTech stocks with market cap of  500 million or more with a  Zacks Rank  1  Strong Buy  or 2  Buy  and positive estimate revision trend of more than 5  for fiscal 2018  Based on strong fundamentals and positive vital metrics  these stocks have ample credential to return more to shareholders amid eco political threats  Looking for the Best Stocks for 2018  Be among the first to see our  
Bio Rad Laboratories  Inc    NYSE BIO    Over the years  this  7300 billion market cap stock has successfully demonstrated solid top line growth driven by strong sales of Droplet Digital PCR instruments and consumables  cell biology and food safety products in the life science group  Additionally  the company has a strong cash balance that enables it to carry out share repurchases and provide solid returns to investors  The expansion in gross and operating margin also buoys optimism  The company is also constantly investing in R D for product innovation 
Based on this bullish sentiment  over the past four weeks the company s EPS estimate for the upcoming fiscal has improved 6 08   The stock sports a Zacks Rank  1  You can see 
Bio Rad Laboratories  Inc  Price
 
   Mazor Robotics Ltd    NASDAQ MZOR    Market is particularly upbeat about the company s CE Mark approval for its Mazor X Surgical Assurance platform  The approval will allow Mazor Robotics and its partner Medtronic  NYSE MDT  to commercialize  co promote and market the Mazor X platformin countries that recognize CE Mark  This development should get reflected in Mazor s 2018 performance  This  1384 billon stock has a Zacks Rank  2  Over the past month  estimates for the company have moved 9 57  north for the next fiscal 
Mazor Robotics Ltd  Price
 
   Tactile Systems Technology  Inc    NASDAQ TCMD    This  522 billion company develops and markets at home therapy devices that treat lymphedema and chronic venous insufficiency  The company s offering includes advanced  clinically proven pneumatic compression devices  as well as continuity of care services provided by a national network of product specialists and trainers  reimbursement experts  patient advocates and clinical staff 
Meanwhile  the figures for Tactile Systems  next year are quite promising  with one estimate moving higher in the past month  compared to none lower  The consensus estimate trend has also seen a 40 4  rise over the said frame  The stock flaunts a Zacks Rank  1 
Tactile Systems Technology  Inc  Price
 
   DexCom  Inc    NASDAQ DXCM    DexCom has collaborative agreements with several companies  which should not only bring in cash in the form of milestone payments and royalties but should also help expand its product portfolio  In this regard  DexCom announced its collaboration in September 2017 with leading wearables brand Fitbit  FIT  to develop and market products for better management of diabetes and get a clearer picture of overall health with easy to use mobile tools 
In November 2017  the company partnered with Eli Lilly and Company  NYSE LLY   Per the agreement  DexCom s flagship continuous glucose monitoring system will be added to Lilly s Connected Diabetes Ecosystem 
This Zacks Rank  2 stock with a market cap of  4 93 billion is a valuable pick for 2018   Over a month  estimates for the company have moved 9 76  north for the next fiscal 
DexCom  Inc  Price
   Where Do Zacks  Investment Ideas Come From 
You are welcome to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buy  stocks free of charge  There is no better place to start your own stock search  Plus you can access the full list of must avoid Zacks Rank  5  Strong Sells  and other private research ",2017-12-22,Zacks Investment Research,https://www.investing.com/analysis/4-medtech-stocks-to-explode-in-2018-200275503,200275503
113945,335460,DXCM,4 Stocks To Watch  LNTH  TSRO  LXFT  TXRH,opinion,"Swing trade Lantheus Holdings Inc  NASDAQ LNTH  popped a coil  and we put a swing on it  It went right up to resistance and pulled back in an orderly falling wedge  In the last three days it s been up in a lousy market  and on Wednesday  it bounced 45 cents  or 5   to 9 50  on 908 848 shares traded  If this stock gets up to 10 30  I m looking at 13 00  maybe higher as the next target  This is a great looking chart 
TESARO Inc  NASDAQ TSRO  is unbelievable  It was up another 2 21  or 2   to 123 35  on 1 million shares traded on Wednesday  reaching a new time all high at 124 32  I can see this stock making it to the 140 50 range very quickly  It has 6 4  
Stocks on the Short Side   
Luxoft Holding  NYSE LXFT  has finally broken it s multi month wedge  down on Wednesday another 1 65  or 3   to 50 35  on 220 721 shares traded  It looks like it s 4 waves down  and wave 5 would take it to the mid 30 s  taking it from the initial move at 43 45 zone  and then maybe 36 7 
Texas Roadhouse Inc  NASDAQ TXRH  dropped 97 cents  or 2 4   to 39 49  on 1 7 million shares traded  It s four waves down  formed a bear flag  and looks like it s going to keep on going  Target is 34 
Stocks on the long side included Amkor Technology Inc  NASDAQ AMKR   AveXis Inc  NASDAQ AVXS   Cameco Corp  NYSE CCJ  Criteo Sa  NASDAQ CRTO   VelocityShares 3x Inverse Natural Gas linked to S P GSCI Natural Gas Excess Return  NYSE DGAZ   Direxion Daily Gold Miners Bear 3X ETF  NYSE DUST   Direxion Daily Junior Gold Miners Bear 3X Shares  NYSE JDST   Direxion Daily Gold Miners Bull 3X Shares  NYSE NUGT   VelocityShares 3x Inverse Crude linked to S P GSCI Crude Oil Excess Return  NYSE DWTI   Direxion Daily S P Biotech Bear 3X Shares  NYSE LABD   Lantheus Holdings Inc  NASDAQ LNTH   Shopify Inc  NYSE SHOP   Skyline Medical Inc  NASDAQ SKLN   sq  TESARO Inc  NASDAQ TSRO   Direxion Daily Small Cap Bear 3X Shares  NYSE TZA   ProShares Ultra VIX Short Term Futures  NYSE UVXY   and Zillow Group Inc  NASDAQ Z  
On the short side  stocks included Alliance Data Systems Corporation  NYSE ADS   Air Methods Corporation  NASDAQ AIRM   Acuity Brands Inc  NYSE AYI   DexCom Inc  NASDAQ DXCM   Honeywell International Inc   NYSE HON   L Brands  Inc   NYSE LB   Luxoft Holding  NYSE LXFT   MercadoLibre Inc  NASDAQ MELI   Molina Healthcare Inc  NYSE MOH   Natural Health Trend  NASDAQ NHTC   Universal Display Corp   OLED   Signet Jewelers Limited  SIG   Splunk  Inc   SPLK   Atlassian Corp Plc  NASDAQ TEAM   Texas Roadhouse Inc  NASDAQ TXRH   Veeva Sys Inc  NYSE VEEV   and WebMD Health Corp  NASDAQ WBMD  ",2016-11-03,Harry Boxer,"https://www.investing.com/analysis/lnth,-tsro,-lxft,-txrh-200162412",200162412
113946,335461,DXCM,Weighing The Week Ahead  Possible Stimulus And How To Pay,opinion,"It is a short week without much new data  Even FedSpeak is on holiday  The big story will continue to be the Trump transition  I expect the punditry to be asking a dual question 
How much economic stimulus and how to pay  
Last Week
Once again  last week s economic news was nearly all good  but not the focus of discussion 
Theme Recap
In my last WTWA  I predicted that it would be  all Trump  all of the time   And so it was  Speculation about the effect of Trump policies is rampant  usually wrong  and revised daily  This is profitable for media sources and the punditry  so we can expect it to continue 
The Story in One Chart
I always start my personal review of the week by looking at this   He captures the continuing rally as well as the late week weakness  despite options expiration  

Doug has a special knack for pulling together all the relevant information  His charts save more than a thousand words  Read his entire post where he adds analysis grounded in data and several more charts providing long term perspective 
The News
Each week I break down events into good and bad  Often there is an  ugly  and on rare occasion something very positive  My working definition of  good  has two components  The news must be market friendly and better than expectations  I avoid using my personal preferences in evaluating news   and you should  too  
This week s news was quite good  If I missed something for the  bad  list  please feel free to suggest it in the comments 
The Good 
Jobless claims decreased to 235K  the lowest since 1973 despite a larger labor force  Amazingly  some are looking for any modest uptick in this series to be some sign of disaster 
Heavy truck sales slump over 
OPEC might be on track for a deal on production limits  The market is skeptical  so this would be a real plus for oil prices   See also OPEC news below under  bad  
Earnings continued to show the strength we have been reporting for several weeks  The earnings recession is over 
Small business optimism is higher  Since uncertainty and weak confidence has been cited as a drag on business investment  it will be interesting if this indicator starts to show more strength 

Housing starts beat expectations with a shift from multi family to single family   has been right on target with this trend  as well as the overall growth rate 
Retail sales were strong up 0 8  on top of upward revisions for the prior month  The reports handily beat expectations  See Doug Short s Big Four update in the Quant Corner 
The Bad 
Industrial production continues to lag with a flat report instead of the small expected increase 
Pre OPEC actions  The market still seems to appreciate higher oil prices  Iran and Iraq continue to increase production in front of the meeting   But see OPEC above  

The Ugly 
Fake News   and the reaction  The bogus news sites had  during the election campaign  This led Google  NASDAQ GOOGL  and Facebook  NASDAQ FB  to   prohibiting sites that traffic in lies to make money 
Do we need social media sites as editors  deciding what is fake and what is not  Izabella Kaminska explains the consequences 

The rot at the core of media has little to do with the propagation of fake news on the fringes  Alternative news sites and underground press with questionable journalistic practices have been a phenomenon since forever  In free societies  the public sphere tolerates single issue publishers  special interest groups or anti establishment newsletters  because we know that for every outlet which propagates nonsense there s another that might be ahead of the curve on a topic of great cultural  commercial or political significance 


Accepting the fringes   which includes fake news   is what liberty and a free press is about  It s our greatest strength  especially when positioned within the constructs of a fair and reasonable slander  libel and defamation framework  Suppressing marginal views is not the answer 

Tyler Cowen  that this is little different from misleading forwarded emails 
There is no easy answer  but we must start by asking whether it is really a problem  We expect consumers of information to discriminate 
The investment world has seen an avalanche of lies and deceptive information from the most popular sites  The lesson from losing money does not seem to have much effect  This is a bad omen for issues where there are less direct financial consequences 
The Silver Bullet 
I occasionally give the Silver Bullet award to someone who takes up an unpopular or thankless cause  doing the real work to demonstrate the facts  No award this week  Nominations are welcome 
The Week Ahead 
We would all like to know the direction of the market in advance  Good luck with that  Second best is planning what to look for and how to react  That is the purpose of considering possible themes for the week ahead  You can make your own predictions in the comments 
The Calendar 
We have a normal week for economic data  with most of the reports concentrated on two days before the holiday 
The  A  List 
New home sales  W   Important sector for improved economic growth 
Michigan sentiment  W   Strength continuing after the election 
FOMC minutes  W   Probably no surprise  Confirmation of a tilt to a hike in December 
Initial claims  Th   The best concurrent indicator for employment trends 
The  B  List 
Existing home sales  T   Not as important as new homes  but still a good read on the market 
Durable goods  W   Volatile series  Any signs of strength in a sluggish sector 
Crude inventories  W   Recently showing even more impact on oil prices  Rightly or wrongly  that spills over to stocks 
Earnings season is ending  The limited Fedspeak is early in the week 
Next Week s Theme 
This should be a very quiet week  There is little data  Most of the A Teamers will be taking some time off   Not me  A competitor used to suggest  Talk to Chuck   He must have been hard to get on the line  but you can still  Talk to Jeff    We can expect more Trump speculation from the B Team  It can t be worse than we have already seen 
Analyzing the Trump effects requires a good analytic framework and a non political approach  I hope these concepts will be familiar to regular readers  I was delighted to read a great piece from Prof  Aswath Damodaran  covering both themes  He produces this excellent diagram 

That is a lot on the plate for the punditry  It is all requiring some digestion   Sorry  I can t help it  At least I took it out of the title  
I expect the initial focus to be on taxing and spending 
How large will the stimulus be  and how will it be financed 
I am always delighted when a theme I am working on is delivered to me in Barron s on Saturday morning  Their cover story is  The argument is very good and this chart is especially helpful 

Barry Ritholtz joins in  suggesting what he calls     He offers many points supporting the desirability and probability of a major debt refinancing 
There is a lot of complexity facing investors  Right now  the stimulus plan is probably the most important  As usual  I ll have a few ideas of my own in today s  Final Thoughts  
Quant Corner 
We follow some regular great sources and the best insights from each week 
Risk Analysis 
Whether you are a trader or an investor  you need to understand risk  Think first about your risk  Only then should you consider possible rewards  I monitor many quantitative reports and highlight the best methods in this weekly update 
The Indicator Snapshot 

The increased yield on the 10 Year note has lowered the risk premium a bit  I suspect much more to come  By this I mean that the relative attractiveness of stocks and bonds will continue to narrow 
The Featured Sources  
Bob Dieli  The  C Score  which is a weekly estimate of his Enhanced Aggregate Spread  the most accurate real time recession forecasting method over the last few decades   His subscribers get  including both an economic overview of the economy and employment 
Holmes  Our cautious and clever watchdog  who sniffs out opportunity like a great detective  but emphasizes guarding assets 
Brian Gilmartin  Analysis of  for the overall market as well as coverage of many individual companies 
Georg Vrba  The   and much more   for an array of interesting methods  Georg  Bob Dieli s enhanced aggregate spread  considering when it might first give a recession signal  Georg thinks it is still a year away  It is interesting to watch this approach along with our weekly monitoring of the C Score 
RecessionAlert  Many  for both economic and market analysis  While we feature his recession analysis  Dwaine also has several interesting approaches to asset allocation  Try out his new public   His most recent research update suggests some    from labor markets 
Doug Short  The   and much more   It is time for another look at Doug s   the most important indicators for recession dating  The NBER looks for a significant drop from a peak  All but one are still rising  with industrial production the laggard 

 provides more reassurance  His long leading indicators have now filtered into the shorter term measures  especially the most recent housing results  Like our other sources  he now sees no recession for 9 12 months 
How to Use WTWA  especially important for new readers  
In this series  I share my preparation for the coming week  I write each post as if I were speaking directly to one of my clients  Most readers can just  listen in   If you are unhappy with your current investment approach  we will be happy to talk with you  I start with a specific assessment of your personal situation  There is no rush  Each client is different  so I have six different programs ranging from very conservative bond ladders to very aggressive trading programs  A key question 
Are you preserving wealth  or like most of us  do you need to create more wealth  
My objective is to help all readers  so I provide several free resources  Just write to info at newarc dot com  We will send whatever you request  We never share your email address with others  and send only what you seek   Like you  we hate spam   Free reports include the following 
Understanding Risk   what we all should know 
Income investing   better yield than the standard dividend portfolio  and less risk 
Holmes and friends   the top artificial intelligence techniques in action 
Why it is a great time to own for Value Stocks   finding cheap stocks based on long term earnings 
You can also check out my website for   and a discussion of the    I welcome questions on this subject  What scares you now  
Best Advice for the Week Ahead 
The right move often depends on your time horizon  Are you a trader or an investor 
Insight for Traders 
We consider both our models and the top sources we follow 
Felix and Holmes 
We continue with a strongly bullish market forecast  Felix is fully invested  Oscar holds several aggressive sectors  The more cautious Holmes also remains fully invested  but has done a lot of profit taking and position switching  Now joined by Athena  the group has a regular Thursday night discussion which they call the     This week s question was about how to spot a good chart  You might be surprised at the answer  You can see that discussion as well as the most recent ideas for consideration   and you can ask questions 
Top Trading Advice 
Brett Steenbarger is on the verge of retiring our award for best trading advice  Every trader should be reading him daily  as well as his books  Readers will not agree with every conclusion  but it will get them thinking about the right issues  It is a challenge to pick the best post each week  but I ll try once again 
His analysis is  for this week s issues  He notes the short term effect of the election as well as the long term concerns  As a trader  he is aware  but flexible  You could also check out posts on how to react to a  and how to  
Adam H  Grimes has a    not the normal expected losses  but the big ones  He suggests five reasons  which are worth your consideration  The one that I see most often is  3  taking trades of the wrong size 
Insight for Investors 
Investors have a longer time horizon  The best moves frequently involve taking advantage of trading volatility 
Best of the Week 
If I had to pick a single most important source for investors to read this week it would be Bill McBride s cold water splash in the face for those who have been spending too much time on the wrong sites    It is a nice  objective summary of overall conditions  His summary hits the high spots  citing the relevant data and providing his customary charts  Here is his conclusion 
Sure  there are problems  Not everyone has participated in the current expansion  Wealth and income inequality are record extremes  There is too much student debt  And climate change is posing a real threat to the economy in the future  I could offer proposals to address those issues without negatively impacting the current expansion  and we will see if those issues are addressed in the coming years 
However  the bottom line is the cupboard is full  The expansion should continue for some time  What could possibly go wrong 
Here is an example of the several helpful charts  how population will drive housing expansion 


Meanwhile  plenty of financial  cyclical  technology  and homebuilding stocks are trading at recession pricing 

Backing up this conclusion is  yet another  great entry by  Davidson  via   He emphasizes the significance of single family housing for the overall economy  Here is a key quote 

Housing Starts and financing go hand in hand  The T Bill U S  10 Year Treas spread used by banks in mtg lending decisions narrowed to 1 2  in July 2016 indicating a potential slowing in housing which this data reflects  This morning this spread has widened rapidly since the election to 1 8  and the trend looks higher  10yr rates should continue to rise faster than T Bills and this will confound many forecasters 


The election of Trump has not yet been factored into housing  I would buy Toll Brothers Inc  NYSE TOL  and Lennar Corporation  NYSE LEN  at current levels with their excellent CEOs  Single Family Housing starts should be higher by June 2017 after Trump strips away some of the impediments to mtg lending 

Stock Ideas 
Time for energy investments   with his objective  earnings driven analysis  He also cautions 

What we hear from the new Administration will matter 


There is a lot of angst over the sector now  with the choppiness of crude trading  what the new Administration does with solar credits  etc 


Give it more time 

Our trading model  Holmes  has joined our other models in a weekly market discussion  Each one has a different  personality  and I get to be the human doing fundamental analysis  We have an enjoyable discussion every week  with four or five specific ideas that we are also buying   Holmes revisits a pick from about a month ago  DexCom Inc  NASDAQ DXCM   On the last round Holmes stopped out for a small loss  avoiding a bigger decline  With a new bottom Holmes is trying again  Check out the post for my own reaction  and more information about the trading models 

While we cannot verify the suitability of specific stocks for everyone who is a reader  the ideas have worked well so far  My hope is that it will be a good starting point for your own research  Holmes may exit a position at any time  If you want more information about the exits  just sign up via holmes at newarc dot com  You will get an email update whenever we sell an announced position 

Time for biotech   for several stocks  including one of our favorites  Cara Therapeutic  NASDAQ CARA  
And an evaluation of the  bump from Trump   
Personal Finance 
Professional investors and traders have been making Abnormal Returns a daily stop for over ten years  If you are a serious investor managing your own account  you should join us in adding this to your daily reading  Every investor should make time for a weekly trip on Wednesday  Tadas always has first rate links for investors in his  There are always several great choices worth reading  My personal favorite this week is the very practical discussion of  in finding a house to rob 
Stickers do not help much  but big dogs do  Your hiding places are not helpful  They know all of them  This surprised me the most 

 NRA sticker on car bumper   Lots of guns to steal   wrote one burglar 

Seeking Alpha Editor Gil Weinreich s Financial Advisors  Daily Digest is a must read for financial professionals  The topics are frequently important for active individual investors  That is especially true this week as he highlights key questions  among others  about what advisors do and their   I especially  with analysis and links you can use to see whether you would benefit from an advisor  Here is a key quote 

A true leader educates clients on what are the key principles that should define their financial decision making  how does one invest  how one can increase his savings rate  spending restraint  etc  The best advisors do this  The worst follow the same trends as Johnny come lately investors  I still recall Wall Street Journal articles in the aftermath of the dot bomb detailing how many brokers made it big promising the moon and stars to all too eager clients 

This is very true  In my first interview with clients I try to align expectations with reality  especially in keeping risk under control  One woman had  2 million to invest and needed to turn it into  6 million in three years  I suppose she found someone who told her that he would do that 
Here is another test  If you can deal with the challenges in my latest paper  The Top Twelve Investor Pitfalls   and How to Avoid Them  you can fly solo  Readers of WTWA can get a free copy by sending an email to info at newarc dot com  We will not share your address with anyone 
Market Outlook 
Plenty of sources  mostly of the permabear variety  cited low interest rates as bad news for stocks  Now that rates are moving higher  that is also supposed to be a negative  Scott Grannis effectively explains this relationship   
I ve been arguing for years that higher interest rates won t be a problem  since they would be symptomatic of stronger growth  Higher rates won t lead to an exploding deficit  because the stronger growth that pushes interest rates higher will also work to reduce the deficit by boosting tax revenues  Interest rates have been low because the market has had a very pessimistic view of the future growth potential of the U S  economy 
I agree 
Watch out for  
 Cheap  put protection  The oft cited advice to buy puts when markets are calm is 
Mixing up your politics and your evaluation of the business cycle     
Coal stocks  The President elect may not be able to deliver on this front as along as natural gas prices are so low    
Final Thoughts 
The stimulus infrastructure theme is getting a lot of attention   of the needs  labor shortages  and implementation problems 
My conclusion is that something major on infrastructure needs will be approved  Here are three key reasons 
Congress loves to spend money and point to the effects in specific districts 
It is easy to imagine a bipartisan coalition  This week showed support from the GOP side via Barron s and the Dem side via Barry Ritholtz  The philosophies are in alignment 
It is the right thing to do  There are important needs  The exact term of new bonds is up for debate  but locking in low rates seems pretty obvious 
Time Frames encourage a wide range of conclusions  Many are predicting that Trump policies will all end badly   eventually 
Moody s Mark Zandi has  

The firm s  outlook for the U S  and global economies has been shaken up by the shocking election of Donald Trump as president of the United States   writes Zandi in the firm s latest monthly economic outlook   Based on our analysis to date  the economy under President Trump will likely perform a bit better in the near term but ultimately it will be diminished  


Zandi is projecting that GDP growth under four years of President Trump will be less than 2  per year  below the 2 2  he had been forecasting before the election   That is not a big difference in any given year  but it is meaningful over a four year period   writes Zandi 

Ed Yardeni  in a thoughtful analysis  asks     His analysis does not have an easy conclusion  but deserves some thought about each point 
 increasing inequality  paving the road to ruin  He sees skewed tax effects and a shortage of skilled tradespeople for proposed programs 
My own perspective for investors is about one year ahead  None of the key issues permit longer forecasts  The immediate stimulus effects will be positive  Investors should do a regular reassessment of progress 
Digestion  There is plenty to do  Here are the key issue areas in my planning for the Trump administration  Each requires study of political dynamics as well as overall impact  Most of the punditry is still reaching far beyond what they know  writing on deadline  driving too fast for the reach of their headlights  
I am starting with the most general and important themes  I welcome suggestions about interesting topics or themes I have omitted  In each case I am evaluating probabilities  impacts  and stocks affected 
Stimulus
Infrastructure
Tax cuts
Financing

Sectors
Health stocks   biotechs  pharma  insurance  hospitals   all different
Energy
Construction

Trade policy
Exporters
Importers   corporate and consumers

Immigration
Law and Order
Defense
And finally  Happy Thanksgiving to readers of WTWA  I hope that my work has given you a little more to be thankful and happy about ",2016-11-20,Jeff Miller,https://www.investing.com/analysis/weighing-the-week-ahead:-possible-stimulus-and-how-to-pay-200165614,200165614
113948,335463,DXCM,4 Stocks To Watch Today  CPE  SLCA  COO  MELI ,opinion,"The stock market had a very tough session on Wednesday  They had a pop at the opening  and then the S P 500 rolled over in a 5 wave decline and took the Nasdaq 100 with it  However  some of our stocks did do well  We are going to take a look at both longs and shorts here  so you ll get to see both 
Callon Petroleum Company  NYSE CPE   one of our favorites  has a long channel of waves with the fifth wave up underway  up 3 19  or 22   to 17 64  on 11 5 million shares traded on Wednesday  It could very well reach 20 21  which is our original target  With the overall structure of the big base that was broken  it may very well get into the high 20 s  or thereabout 
U S  US Silica Holdings Inc  NYSE SLCA   a swing trade of ours and an old favorite  was up 5 42  or 12   to 50 61  on 6 million shares traded on Wednesday  It made a significant move out of a wedge pattern and hit a new high at 51 31  What is beckoning to me  is something in the high 50 s 
Stocks on the Short Side   
The Cooper Companies Inc  NYSE COO  really got smacked down 5 66  or 3 33   to 164 49  on 1 36 million shares traded  The top pattern of this chart has been completed  it formed a bear flag  another bear flat  a bear wedge  and then had a breakdown on Wednesday  I think this may lead to a test of at least 158 00  but more than likely  we ll see a test of 150 00 
MercadoLibre Inc  NASDAQ MELI  looks like it may have broken its bear flag on Wednesday  It formed a top  broke down  formed a rising bear flag to resistance  and then rolled over  dropping 5 09  or 3   to 157 82  on 2 7 million shares traded  I m looking to see if it can test 145 00  and then head down toward 125 00 
Stocks on the long side included CLR  Callon Petroleum Company  CPE   California Resources Corp  NYSE CRC   E  I  du Pont de Nemours and Company  DD   Direxion Daily Energy Bull 3X ETF  ERX   Federal National Mortgage Association AN Pref  OTC FNMAN   Direxion Daily S P Oil   Gas Exp   Prod Bull 3X Shares  NYSE GUSH   Marathon Oil Corporation  NYSE MRO   MasTec Inc  NYSE MTZ   Oasis Petroleum Inc  NYSE OAS   Resolute Energy Corp  NYSE REN   U S  Silica Holdings  Inc   SLCA   and Whiting Petroleum Corporation  NYSE WLL  
On the short side  stocks included athenahealth  Inc   ATHN   The Cooper Companies  Inc   COO   DexCom Inc  NASDAQ DXCM   Flowers Foods  Inc   FLO   G III Apparel Group  Ltd   GIII   Lululemon Athletica Inc   LULU   MercadoLibre Inc  NASDAQ MELI   NetEase  Inc   NTES   Red Robin Gourmet Burgers Inc   RRGB   Teleflex Incorporated  NYSE TFX   and VCA Inc   WOOF  ",2016-12-01,Harry Boxer,"https://www.investing.com/analysis/cpe,-slca,-coo,-meli-200167570",200167570
113952,335467,DXCM,4 Stock To Watch Today  CETX  DEPO  GEO  SUPN,opinion,"The markets had an interesting day on Tuesday  gapping up and running  and then backing off midday  but coming on at the end of the day  It was definitely a good way to start the week and the year  with the Dow Jones 30 up over a hundred points  and the rest of the indices strong  particularly Nasdaq 100  We re going to take a look at mostly longs  but a few shorts 
Cemtrex Inc  NASDAQ CETX  has had a nice little move since the swing trade  It popped  pulled back  formed a wedge  exploded out of the wedge  formed a breakaway gap  and ran up  On Tuesday  it was up 67 cents  or 9   to 8 05  on 1 9 million shares traded  My target is 8 8 1 4  It s already up in my target zone  so I would look for some pullback consolidation  Ultimately  this could be a stock that reaches in the low teens  maybe 12 or 13 
Depomed Inc  NASDAQ DEPO   on rumors of a takeover  popped 2 32  or 13   to 20 34  on 6 million shares traded on Tuesday  and closed at the upper end of the range  Key resistance now lies at about 21 1 2  Watch the gap and double top  If it gets through that  look for it to be a 24 1 2 25 dollar stock  It has 9 5  
Geo Group Inc  NYSE GEO  extended its move and broke out  up 50 cents  or 1 39   to 36 43  on 648 589 shares traded on Tuesday  Its volume needs to be a little bit better  but it looks like it s making a run up towards 371 2 38 short term  and then 40 intermediate term  There s 3 28  
Supernus Pharmaceuticals Inc  NASDAQ SUPN  may be on the verge of coming out of a wedge  On Tuesday  it popped up through  up 70 cents  or 2 77   to 25 95  on 365 319 shares traded  If it can get the volume up to about 400 000  this stock could be a 32 34 dollar stock 
Stocks on the long side included Aerie Pharmaceuticals  Inc   AERI   Cymabay Therapeu  NASDAQ CBAY   Cemtrex Inc   CETX   Ceragon Networks Ltd   CRNT   Depomed  Inc   DEPO   VelocityShares 3x Inverse Natural Gas linked to S P GSCI Natural Gas Excess Return  NYSE DGAZ   The GEO Group  Inc   GEO   Direxion Daily Junior Gold Miners Bull 3X Shares  NYSE JNUG   Direxion Daily Gold Miners Bull 3X ETF  NUGT   Supernus Pharmaceuticals  Inc   SUPN   Valero Energy Corporation  NYSE VLO   and Zynerba Pharmaceuticals  Inc   ZYNE  
On the short side  stocks included Ambarella Inc  NASDAQ AMBA  and DexCom Inc  NASDAQ DXCM ",2017-01-03,Harry Boxer,"https://www.investing.com/analysis/cetx,-depo,-geo,-supn-200171359",200171359
113955,335470,DXCM,Dexcom Shares  Potential Rise In The Next 3 Years,opinion,"Recently  shares of the DexCom Inc  NASDAQ DXCM  have probably made the bottom and started a new uptrend  Dexcom is a medical device company  The company is focused on the development of continuous glucose monitoring systems  Let s look at the price movement of this stock  which is traded at  85 13 now  from the technical point of view  Here is the monthly chart 

Clear motive Elliott Wave structure
There is a pretty clear and obvious motive Elliott Wave structure here  started in 2009  The top of the wave 1 occured in April 2011  followed by the mid term downtrend presented by the wave 2  a zigzag pattern   which was ended in November 2011 
After that  the motive wave 3 took place till September 2015  And in the September 2015   December 2016 period we can see the wave 4 that seems like a  running flat  correction pattern  There is a high possibility that the new motive wave 5 is beginning right now  Everything fits into a correct trend channel  Here is a motive Elliot Wave structure with a channel shown schematically  
Wave symmetry
Wave 1 had 1 147  growth and 29 months length  Wave 3 had 1 417  growth and 46 months length  The coming wave 5 should have the same or comparable percentage of growth and the same or comparable length  So there is a high possibility of at least 1 100  growth in the next 3 years  compared to the recent bottom at  57  The calculated price target is around  600 by 2020 
Trend channel
By the trend channel rules  we can see the similar price and time targets 

The price is likely to make the next top at the upper line of the trend channel  which shows us   680 somewhere in 2020  Moreover  the trend channel can help us to recognize early if the forecast is incorrect  in the unlikely case the price fails to reach the target and falls below the lower line of the trend channel  then this wave structure will become invalid and we need to re analyse it and get out of the market 
The year 2020  Again 
Dexcom is another asset that is gonna have long term reversal in 2020  See my previous articles 
US Dollar Index Likely to Make Grand Top in 2020",2017-01-17,Anatoly Grigoryev,https://www.investing.com/analysis/dexcom-shares:-potential-8x-rise-next-3-years-200172621,200172621
113957,335472,DXCM,5 Trade Ideas For Monday  AXP  DXCM  FFIV  MCD  ROK,opinion,"American Express  NYSE AXP 
American Express  AXP  gapped up in October and after a brief digestive move  started higher  It made a top in early January and has been consolidating since  As it marks time the RSI has reset from overbought  remaining bullish  while the MACD has moved lower  Both now have room to run  Look for a move over resistance to participate to the upside   
DexCom Inc  NASDAQ DXCM 
DexCom  DXCM  gapped higher at the start of January  moving out of its Bollinger Bands   It pulled back from that move quickly  into those Bollinger Bands  and has now stabilized  The RSI has also pulled back from an overbought condition and the MACD retrenched from an extreme  Both remain in bullish territory  The move up off of support Friday is a signal to participate in the upside  
F5 Networks  NASDAQ FFIV 
F5 Networks  FFIV  went through a long consolidation before gapping higher in November  That move continued until a top in mid December  It consolidated there for a month as the Bollinger Bands  squeezed and then dropped at the end of January  It ran lower for a few days on declining volume in a pennant before catching a bid Friday and reversing higher  The RSI turned back up as well and the MACD stopped falling  Look for continuation to participate higher   
McDonald s Corporation  NYSE MCD 
McDonald s  MCD  was a Top 10 pick at the start of the year and if you are still holding from then congratulations  The move higher places the price at the December high now and a push over that is bullish  The RSI is bullish and rising while the MACD is crossing up and rising as well  Look for continuation to participate higher   
Rockwell Automation  NYSE ROK 
Rockwell Automation  ROK  moved higher out of consolidation in November  and then slowed the pace into January  It broke above resistance a couple of weeks ago and gapped higher  That took the price out of the Bollinger Bands  and it has drifted back lower since  into the Bollinger Bands  Friday it started back higher  ending the retracement  The RSI is also reversing higher with the MACD still falling  Look for continuation to participate to the upside   
Elsewhere look for Gold to continue in its short term uptrend while Crude Oil churns with more sideways price action  The US Dollar Index looks to continue to the downside  although it is at a good support area should it want to reverse  while US Treasuries are biased lower 
The Shanghai Composite looks to continue to drift around resistance but higher and Emerging Markets look to continue their recent strength  Volatility looks to remain at exceptionally low levels keeping the bias higher for the equity index ETF s SPDR S P 500  NYSE SPY   iShares Russell 2000  NYSE IWM  and PowerShares QQQ Trust Series 1  NASDAQ QQQ   Their charts all look strong on the weekly timeframe and are at the edge of breaking out of ranges on the daily timeframe  Use this information as you prepare for the coming week and trad em well 
DISCLAIMER  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2017-02-06,Gregory W. Harmon,"https://www.investing.com/analysis/5-trade-ideas-for-monday:-american-express,-dexcom,-f5,-mcdonalds,-rock-200174749",200174749
113960,335475,DXCM,Medical Product Q1 Earnings Due On May 2  BDX  DXCM   More,opinion,"The first quarter earnings season has gathered pace  with results from 288 S P 500 members or 63 8  of the index s total market capitalization already out  as of April 28  As per the latest   total earnings for these companies are up 13 7  from the same period last year on 8 2  higher revenues  with 76 4  beating EPS estimates and 68 1  beating revenue estimates  The proportion of companies beating both EPS and revenue estimates is 55 2  For the remaining 212 index members  combined with the already reported 288 index members   earnings are estimated to improve 11 2  on 6 2  higher revenues this season  Notably  this could be the third straight quarter of earnings growth after five quarters of back to back decline  The current week is set to see a plethora of earnings releases as many bigwigs are lined up to report their quarterly numbers  This week will bring in results from more than 1000 companies  including 126 from the S P 500 index Coming to the Medical universe  this is one of the major broader sectors among the 16 Zacks sectors in the S P 500 cohort that are expected to report earnings growth in the first quarter  The medical product sector shines bright at the moment owing to the prevalence of minimally invasive surgeries  liquid biopsy tests  and use of IT for ensuring quick and improved patient care among other things  Furthermore  cost effective products and techniques targeting emerging markets raise optimism Here  we take a sneak peek into four Medical stocks set to report their quarterly figures on May 2 Based in Franklin Lakes  NJ  Becton  Dickinson and Company   NYSE BDX    commonly known as BD  is a medical technology company engaged principally in the development  manufacture and sale of medical devices  instrument systems and reagents Our proven model conclusively shows that Becton  Dickinson is likely to beat on earnings in first quarter fiscal 2017  This is because the company currently has an  of  0 45  and a Zacks Rank  2  Buy   You can see  BD s innovative product line  number of regulatory approvals both in the U S  and international markets  and strategic partnerships are likely to boost its growth trajectory  read more     Becton  Dickinson and Company Price and EPS Surprise
    DexCom  Inc    NASDAQ DXCM   is scheduled to report first quarter 2017 numbers on May 2  This medical device company is focused on the design  development and commercialization of continuous glucose monitoring systems  Intensifying competition  entry of new products  reluctance on the part of physicians and patients to adopt DexCom s products  reimbursement risks  supply constraints and working capital problems are the key concerns DexCom currently has a Zacks Rank  3  Hold  and an Earnings ESP of  10 91   That is because the Most Accurate estimate stands at a loss of 61 cents while the Zacks Consensus Estimate is pegged at a loss of 55 cents  Hence  we cannot conclusively predict that DexCom is likely to beat estimates this quarter  You can uncover the best stocks to buy or sell before they re reported with our   DexCom  Inc  Price and EPS Surprise
    Owens   Minor  Inc    NYSE OMI   is set to report first quarter figures on May 2  after market close  This is a global healthcare services company that provides vital supply chain services to healthcare providers and manufacturers of healthcare products  It also provides logistics services across the spectrum of medical products from disposable medical supplies to devices and implants Our proven model does not conclusively show that Owens   Minor is likely to beat on earnings in first quarter fiscal 2017  This is because the company currently has an Earnings ESP of 0 00  and a Zacks Rank  3  This makes surprise prediction difficult  Owens   Minor  Inc  Price and EPS Surprise
    Halyard Health Inc    NYSE HYH   is expected to release first quarter fiscal 2017 financial numbers on May 2  Headquartered in Alpharetta  GA  Halyard develops  manufacture and market clinical solutions that improve medical outcomes and business performance in more than 100 countries Halyard Health is unlikely to surprise as it currently has a Zacks Rank  4  Sell  and an Earnings ESP of 0 00   Both the Most Accurate estimate and the Zacks Consensus Estimate stands at 43 cents  Also  we caution against Sell rated stocks  Zacks Rank  4 or 5  going into an earnings announcement Halyard Health  Inc  Price and EPS Surprise   Sell These Stocks  Now Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These are sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500 ",2017-04-30,Zacks Investment Research,"https://www.investing.com/analysis/medical-product-q1-earnings-due-on-may-2:-bdx,-dxcm---more-200186278",200186278
113971,335486,DXCM,5 Stocks To Watch  BRCM  CF  DXCM  FMER  JBHT,opinion,"Here are the Rest of the Top 10 
Broadcom  O BRCM 
Broadcom  BRCM  had been moving higher off of an October 2014 low until it spiked in May  That spike sold off  making a low with the market in August  Now it has hit resistance and backed off to a higher low and is rising again toward resistance  The RSI is rising and in the bullish zone along with the MACD  Watch for a push through resistance 
CF Industries  N CF 
CF Industries  CF  started lower in July in a falling wedge  These are often thought of as bullish  but it broke the wedge to the downside  It made a low at the end of September and consolidated a few days before a strong thrust higher  Now it is at resistance and making a series of higher lows  The RSI is rising and on the edge of a move into the bullish zone with the MACD rising 
DexCom  O DXCM 
DexCom  DXCM  was a pharma favorite all of 2015 until the August meltdown  The stock quickly recovered making a new high before the pharma biotech sell off of September brought it down 30   It has bounced off of that and built a small bull flag  Friday saw it push through the top of that flag  The RSI is at the mid line after a bounce off of oversold levels as the MACD is crossed up and rising 
FirstMerit  O FMER 
FirstMerit  FMER  ran higher to a peak in June  The pullback from there found a bottom with the market in August and has been consolidating since  Friday saw a push through the important 18 30 level and to the 200 day SMA  The RSI is moving into the bullish zone and the MACD is rising  both supporting continued upside 
JB Hunt Transport Services  O JBHT 
JB Hunt Transport Services  JBHT  traveled lower in a falling channel until it pulled off that road to the downside when the market sank in August  Since making a low  it has bounced in a wide range against resistance  It is back against resistance again and has support for a push through to the upside from the rising and bullish RSI and MACD 
Up Next  Bonus Idea
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Friday which  heading into the last week of October  sees the equity markets looking strong  Elsewhere  look for gold to continue lower in its longer term downtrend while crude oil heads lower in the short term  The US dollar index is breaking to the upside  while US Treasuries are marking time sideways  The Shanghai Composite and Emerging Markets are biased to the upside  with Emerging Markets at a major resistance level  Volatility looks to remain subdued  keeping the bias higher for the equity index ETFs N SPY  N IWM and O QQQ  The SPY and QQQ had major moves and look set up to continue higher into next week  with the IWM lagging and at resistance  Use this information as you prepare for the coming week and trad em well 
Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  Please see my Disclaimer page for my full disclaimer ",2015-10-26,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas-for-the-week-of-october-26,-2015:-the-rest-269198",269198
113972,335487,DXCM,5 Stocks To Watch  DBD  DXCM  ITW  LUV  OSK,opinion,"Here are the Rest of the Top 10 
Diebold  N DBD 
Diebold started a move lower after topping in June over 38 on a big one day move  After a 255 drawdown  it bounced in a  W  fashion  finally heading higher to start October  The move touched the prior high area near 38 but pulled back again  This time it was a shallow pullback though and Friday found the price back at resistance on strong volume  The RSI turned back higher at the mid line and is bullish  while the MACD is about to cross up  Both support more upside 
DexCom  O DXCM 
DexCom had a long run higher until topping over 102 in September  It pulled back hard with all healthcare related stocks in September finding a bottom after breaking through the 200 day SMA  Since then  it has moved back higher as consolidated at resistance  This price level was important as resistance in August and then support in September  Many battles here  The RSI is trying to move up off of the mid line while the MACD has turned flat after rising to zero  Look for a break higher to participate 
Illinois Tool Works  N ITW 
Illinois Tool Works went through a long channel lower from March through August before  exploding to the downside with the market at the end of August  After some consolidation  it started back higher in October and is now back at resistance  The RSI is rising and bullish and the MACD is about to cross up  The Bollinger Bands  are starting to open after a squeeze as well  A break above resistance could run to new highs 
Southwest Airlines  N LUV 
Southwest Airlines had a strong run higher from a base at  8 from the end of 2012  Bags fly free is apparently winning some business  But as the calendar turned into 2015  it started a pullback  The stock retraced 38 2  of the move up and then started back higher  Last week it had made it back to resistance again  and started a small pullback  Momentum is supportive with the RSI in the bullish zone  having reset and turning back higher  The MACD has pulled back a bit and a turn higher would also confirm the upside 
Oshkosh  N OSK 
Oshkosh pulled back from a double top at 55 in May  It made a double bottom in August and has been consolidating since against resistance  The RSI is trending higher as it consolidates along with the MACD rising  A break over the top triggers a trade opportunity  with a more conservative entry over the 200 day SMA 
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad  picture reviewed Friday which  heading into the shortened Thanksgiving Holiday week sees the equity markets have moved strongly higher maybe a bit too fast in the short run 
Elsewhere look for gold to continue lower while crude oil consolidates in its downtrend  The US dollar index is consolidating with an upward bias and US Treasuries are moving higher in the consolidation range  The Shanghai Composite looks ready to resume the move higher out of consolidation and Emerging Markets are biased to the upside short term in their downtrend  Volatility looks to remain low adding some wind to the backs of the equity index ETFs N SPY  N IWM and O QQQ 
Their charts look good in the short term  with the SPY and QQQ moving higher and the IWM biased higher in consolidation  Longer term  the SPY and QQQ look ready to attack their all time highs  while the IWM lags behind  Use this information as you prepare for the coming week and trad em well 
Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  Please see my Disclaimer page for my full disclaimer ",2015-11-23,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas-for-the-week-of-november-23,-2015:-the-rest-272163",272163
113973,335488,DXCM,Medtronic Launches MiniMed 630G  Expands In Diabetic Care,opinion,Medical device major Medtronic plc s   NYSE MDT   MiniMed 630G system with SmartGuard technology   a new insulin pump that facilitates diabetes care   recently won the U S  FDA  Food and Drug Administration  approval for its commercial launch in the U S  This system will be useful particularly on people aged sixteen years or more The MiniMed 630G basically combines SmartGuard technology which is already featured in the MiniMed 530G system with a brand new user friendly design  We note that  the SmartGuard technology acts against low blood sugar and is the only system at present to reduce the frequency of night time low episodes by one third We believe this system will receive huge market acceptance taking into consideration the fact that up to 75  of severe hypoglycemia occurs during night time while patients are asleep MiniMed 630G has a user friendly design which enables personalized diabetes management and also provides advanced clinical performance  Apart from that  this system  unlike the other members of the MiniMed family uses the Contournext Link 2 4  the blood glucose meter of Ascensia Diabetes Care which claims to provide accurate blood glucose test results MEDTRONIC Price and Consensus   We note that  with rapidly rising incidents of diabetes across the U S   healthcare organizations are now focused on innovating technologies that will effectively help the nation s 29 1 million diabetics manage their health conditions  Remarkably  diabetes has been growing at an exponential rate lately with the global diabetic population expected to reach 552 million by 2030 from 366 million in 2011  With such a scenario looming  disease management and providing optimal therapy has become a major challenge for healthcare providers Medtronic is leaving no stone unturned to consolidate its position as a leading holistic diabetes management company in the U S  In this regard  we should refer to the company s investment to buy Qualcomm  NASDAQ QCOM  Life  a wholly owned subsidiary of Qualcomm Incorporated  to jointly develop future generation continuous glucose monitoring  CGM  systems that aspire to improve health outcomes for people with diabetes Other major medical device companies that are prominent players in the diabetic space are Becton  Dickinson and Company   NYSE BDX    DexCom  Inc    NASDAQ DXCM   and Abbott Laboratories   NYSE ABT   among others ,2016-08-14,Zacks Investment Research,"https://www.investing.com/analysis/medtronic-launches-minimed-630g,-expands-in-diabetic-care-200147956",200147956
113974,335489,DXCM,New Strong Sell Stocks For October 4th,opinion,"Here are 5 stocks added to the Zacks Rank  5  Strong Sell  List today 
     DexCom  Inc    NASDAQ DXCM   is developing continuous glucose monitoring systems for people with diabetes  The Zacks Consensus Estimate for its current year earnings has been revised 3  downward over the last 30 days 
     Syntel  Inc    NASDAQ SYNT   is a worldwide provider of advanced technology services to Fortune 1000 companies  as well as to government entities  The Zacks Consensus Estimate for its current year earnings has declined 2 5  over the last 30 days 
     FTD Companies  Inc    NASDAQ FTD   provides floral  gift and related products and services to consumers  retail florists  and other retail  It has seen the Zacks Consensus Estimate for its current year earnings being revised 3 5  downward over the last 30 days 
     China Southern Airlines Co  Ltd    NYSE ZNH   is one of the leading air transportation enterprises in China  especially in passenger volume and the total amount of tax and profit for the past three years  The Zacks Consensus Estimate revision for its current year earnings was a negative of 1 8  over the last 30 days 
     Sonic Corp    NASDAQ SONC   operates and franchises one of the largest chain of drive in restaurants in the U S  The Zacks Consensus Estimate for its current year earnings has moved 6 6  lower over the last 30 days 
View the entire  ",2016-10-03,Zacks Investment Research,https://www.investing.com/analysis/new-strong-sell-stocks-for-october-4th-200157043,200157043
113978,335493,DXCM,The Week Ahead  Has The Rotation From Bonds To Stocks Begun ,opinion,"We have a normal week for economic data  and a big week for earnings reports  The last Presidential debate will grab headlines  We have been monitoring these factors for weeks  but something new is showing up in the data  Let s call it a  stealth rotation  from bonds to stocks and from bond substitutes to less favored stocks  If the punditry carefully watches the data  they will be asking 
Has a market rotation begun  
Last Week
Last week s news was pretty good  despite the negative reaction in stocks 
Theme Recap
In my last WTWA  I predicted special attention to the early earnings reports and questions about whether the earnings recession was ending  That was a reasonable guess  although most of the commentary seemed to focus on a couple of big earnings misses  There was also plenty of competition from some surprising China data  the ongoing Fed debate  and of course  the election news 
The Story in One Chart
I always start my personal review of the week by looking at this  from Doug Short  Stocks had a negative week  You can see the opening gap on Thursday after the Chinese trade data  and also Friday s failed rally 

Doug has a special knack for pulling together all of the relevant information  His charts save more than a thousand words  Read his entire post where he adds analysis grounded in data and several more charts providing long term perspective 
The News
Each week I break down events into good and bad  Often there is an  ugly  and on rare occasion something really good  My working definition of  good  has two components  The news must be market friendly and better than expectations  I avoid using my personal preferences in evaluating news   and you should  too  
The Good 
JOLTS continues to show a solid labor market  Chair Yellen uses it as a signal for a tight labor market  The healthy  quit rate  shows that many people are comfortable in voluntarily leaving jobs  Some reports focused strictly on the number of job openings  which is a poor use of the data 

Initial jobless claims also show labor market strength 

Retail sales provided the week s best economic news  rising 0 6   the best increase in three months    
Corporate earnings nicely beat expectations   has some interesting early data   76  of the reporting companies have beaten earnings expectations and 62  have beaten on sales 



The Bad 
Import container counts are again lower  Steven Hansen    smooths out the effects of the Hanjin Shipping bankruptcy and finds a troubling trend  Does it portend weak holiday spending  The chart below is the year over year change in the three month moving average 

Chinese exports and imports both declined more than expected 
Q3 GDP estimates edge lower as more data is reported   summarizes the move from various sources  Here is one example 

Michigan consumer sentiment slips to 87 9 in the October preliminary report   updates the story and the terrific Doug Short chart combining multiple elements of the story in a single look 

The Ugly 
The political sideshow  There were polls to determine the  winner  of the debate  Not so long ago debates were seen as a way for the trailing candidate to show equality of stature   same stage  same rules  etc  Many challengers have used this effectively  It is also a way to demonstrate that a  Presidential  image  If an expert from years ago  without any context  read the transcript of this  town hall forum  debate s he would not believe it  Campaigns are ever more focused on the undecided or uncommitted voters  especially in the key states  Suppose for a moment that these voters may not have been the ones sitting at the front of the class  What do we expect the campaigns to do  The sound bite negative ads are one approach  but this is reaching a whole new level   and not a high one 
The most important thing you can do as an investor is to vote your conscience while still using sound  unemotional judgement concerning your personal finances 
The Silver Bullet 
I occasionally give the Silver Bullet award to someone who takes up an unpopular or thankless cause  doing the real work to demonstrate the facts  No award this week  Nominations welcome  I also note that Dr  Ed Yardeni joined us in applauding the  on CAPE  Dr  Ed provides his own thoughts about market valuation and the advantages of forward earnings 

I am not a fan of valuation measures based on trailing earnings  especially if they trail over the past 10 years  I believe that the stock market is forward looking and discounts analysts  consensus expectations for earnings over the year ahead  More specifically  I use S P 500 12 month forward consensus expected operating earnings  which is a time weighted average of analysts  expectations for the current year and the coming one 

The Week Ahead 
We would all like to know the direction of the market in advance  Good luck with that  Second best is planning what to look for and how to react  That is the purpose of considering possible themes for the week ahead  You can make your own predictions in the comments 
The Calendar 
We have a fairly big week for economic data  as well as earnings reports  I watch everything on the calendar  so you do not need to  Check out WTWA to focus on what is really important   and ignore the noise 
The  A  List 
Housing starts and building permits  W   Important forward looking data on a crucial sector 
Industrial production  M   Volatile September data  Any sign of a rebound from last month s loss 
Fed Beige Book  W   Prepared for the next FOMC meeting  this provides color from each Fed district  going beyond the data 
Leading indicators  Th   Widely followed  despite some controversy  Rebound expected from last month s negative reading 
Initial claims  Th   The best concurrent indicator for employment trends 
The  B  List 
Existing home sales  Th   Without the impact of new homes  but still a good read on the overall housing market 
CPI  T   Inflation is still not very important  and it will not be until there are a few higher months 
Philly Fed  Th   Has earned some respect as one of the few regional indicators that can move markets  The first October data 
Crude inventories  W   Often has a significant impact on oil markets  a focal point for traders of everything 
More important than the economic data will be continuing earnings news 
Next Week s Theme 
The Presidential campaign and the final debate continue to dominate the news  The regular economic data this week include important leading indicators about housing  These will not get the attention deserved  Corporate earnings reports will also get some attention  but the emphasis seems to be on spectacular  misses   Did you even realize that the earnings season is positive so far  Unless you look at the FactSet data  you would not know 
Through this haze there have been a few glimmers of a new trend  If you are alert  you will see more attention to the question 
Has a market rotation begun  
There is some evidence 
The 10 year note has moved noticeably higher while the yield curve has steepened 
Utilities are losing ground while banks are gaining  Brian Gilmartin astutely asks  whether banks are assuming that role 
Economic skepticism remains intense   but perhaps the result of the election  Chris Matthews    notes that concern about the economy has grown even as data show improvement 

 a voter s political beliefs and the overall political environment instead drives how they feel about their economic circumstances 


There s no better way to interpret the latest results from the latest Marketplace Edison Research Poll   of Americans are very fearful they will lose their job in the next six months  up 10  from last year 


And also  

A particularly telling figure in this year s survey  While 37  of those surveyed said their personal economic situation has improved over the past year versus 21 5  who said it got worse just 30 3  said the overall economy improved  What s more  36 9  said it got worse 


If more people s financial situation improved than deteriorated  why do more people think it s the opposite for the economy in general 

As always  I ll have a few ideas of my own in the conclusion 
Quant Corner 
We follow some regular great sources and also the best insights from each week 
Risk Analysis 
Whether you are a trader or an investor  you need to understand risk  Think first about your risk  Only then should you consider possible rewards  I monitor many quantitative reports and highlight the best methods in this weekly update 
The Indicator Snapshot 

The Featured Sources  
Bob Dieli  The  C Score  which is a weekly estimate of his Enhanced Aggregate Spread  the most accurate real time recession forecasting method over the last few decades   His subscribers get  including both an economic overview of the economy and employment 
Holmes  Our cautious and clever watchdog  who sniffs out opportunity like a great detective  but emphasizes guarding assets 
Brian Gilmartin  Analysis of  for the overall market as well as coverage of many individual companies 
Doug Short  The Big Four Update  the World Markets Weekend Update  and much more  
RecessionAlert  Many  for both economic and market analysis  While we feature his recession analysis  Dwaine also has a number of interesting approaches to asset allocation 
Georg Vrba  The   and much more   for an array of interesting methods  Georg  Bob Dieli s enhanced aggregate spread  considering when it might first give a recession signal  Georg thinks it is still a year away  It is interesting to watch this approach along with our weekly monitoring of the C Score  This week  his unemployment based indicator  still not signaling a recession as you can see from the chart below 
 that the ECRI s growth index remains solid  despite a marginal fall last week  Meanwhile  the ECRI continues its prediction of  stagflation lite  and Fed criticism 
This is a good time to review the    vastly superior to anecdotes and headlines 

How to Use WTWA  important for new readers  
In this series I share my preparation for the coming week  I write each post as if I were speaking directly to one of my clients  Most readers can just  listen in   If you are unhappy with your current investment approach  we will be happy to talk with you  I start with a specific assessment of your personal situation  There is no rush  Each client is different  so I have six different programs ranging from very conservative bond ladders to very aggressive trading programs  A key question 
Are you preserving wealth  or like most of us  do you need to create more wealth  
My objective is to help all readers  so I provide a number of free resources  Just write to info at newarc dot com  We will send whatever you request  We never share your email address with others  and send only what you seek   Like you  we hate spam   Free reports include the following 
Understanding Risk   what we all should know 
Income investing   better yield than the standard dividend portfolio  and also less risk 
Holmes and friends   the top artificial intelligence techniques in action 
Why it is a great time to own for Value Stocks   finding cheap stocks based on long term earnings 
You can also check out my website for   and a discussion of the    I welcome questions on this subject  What scares you  
Best Advice for the Week Ahead 
The right move often depends on your time horizon  Are you a trader or an investor 
Insight for Traders 
We consider both our models and also the best advice from sources we follow 
Felix and Holmes 
We continue with a strongly bullish market forecast  Felix is fully invested  Oscar holds several aggressive sectors  The more cautious Holmes also remains fully invested  They now have a regular Thursday night discussion  which they call the  Stock Exchange   This is the place to get some ideas from the best technical analysis   and you can ask questions 
Top Trading Advice 
 that we should always consider what we would be doing if not trading  Is it a good choice  He also highlights an interesting   It leads both to prizes and to job opportunities  While performance is measured  the criteria do not encouraging taking wild shots  You can still apply  but do so right away if interested since the contest has started 
Do you have an edge in your trading  Do you have a tested  trusted system   describes this important first step for traders as well as what they should do next 
If you don t meet Adam s tests  you should definitely re read Dr  Brett s post 
Insight for Investors 
Investors have a longer time horizon  The best moves frequently involve taking advantage of trading volatility 
Best of the Week 
If I had to pick a single most important source for investors to read this week it would be  of a client question about real estate versus stocks  In a generic sense  it is a common question faced by nearly everyone  Neal realizes that everyone s situation differs  Using the couple s investment goals and time frame  he compares three alternative choices  From this analysis one of the choices is easily eliminated  It is an excellent demonstration of sound contextual analysis  To appreciate the result  you should read the whole post  Here is an intriguing chart 

Stock Ideas 
Chuck Carnevale s most recent idea is CVS Health Corporation  NYSE CVS   His analysis shows that the stock has moved from overvalued territory to fair value   and with plenty of upside 
Our newest trading model  Holmes  has joined our other models in a weekly market discussion  Each one has a different  personality  and I get to be the human doing fundamental analysis  We have an enjoyable discussion every week  with four or five specific ideas that we are also buying  This week Holmes likes Dexcom  DexCom Inc  NASDAQ DXCM    Check out the post for my own reaction  And his choice from last week  Air Products and Chemicals  NYSE APD   has now been endorsed by Athena  Check out the post to see the other picks  ask questions  and choose your favorite model 
While we cannot verify the suitability of specific stocks for everyone who is a reader  the ideas have worked well so far  My hope is that it will be a good starting point for your own research  Holmes may exit a position at any time  If you want more information about the exits  just sign up via holmes at newarc dot com  You will get an email update whenever we sell an announced position 
 into the numbers in his study of IBM  NYSE IBM   Read his post to see why artificial intelligence is a crucial factor 
 four dividend stocks from the defense sector  And also  with good yield 
Personal Finance 
Professional investors and traders have been making Abnormal Returns a daily stop for over ten years  The average investor should make time  even if not able to read AR every day as I do  for a weekly trip on Wednesday  Tadas always has first rate links for investors in his  There are always several great choices worth reading  My personal favorite this week is the  on a survey of young adults  It is a good read for young people and for investors wanting to understand current trends 

Gil Weinreich continues his excellent series for investment advisers  and of great interest to investors as well  He frequently features ideas about best practices for the advisor community  This week he   Neal Frankle  It is this week s  best investment advice    And thanks to Gil for mentioning me along with others in his fine group  
Market Outlook 
Mark Hulbert notes the seasonal strength typical of year s end  Could there be a    
Final Thoughts 
There is a continuing gap between perception and reality when it comes to economic progress and risks  This has translated into extremely defensive investment decisions  emphasizing anything that seems to provide yield  The incessant political accusations have made this worse 
The resulting environment encourages stories   even by unbiased journalists   seizing upon the dramatic  I am seeing the  R word  thrown around much more often  and by people without any special experience or track record 
The developing market rotation is still some weeks away from popular recognition  but there are signs it is getting closer  This  is well worth watching  Lee s market read and forecasts have been excellent for years  He has remained bullish  and for the right reasons  I am encouraged when I see him commenting on the themes that I am also seeing 
One catalyst will be absolute losses in bond mutual funds  Investors are about to learn something important and possibly painful  Bonds and bond substitutes do not come with guarantees ",2016-10-16,Jeff Miller,https://www.investing.com/analysis/weighing-the-week-ahead:-has-the-market-rotation-begun-200158988,200158988
113980,335495,DXCM,Stock Exchange  Great Chart Ideas Include WB  DDD  DXCM  and APD,opinion,"Each week Felix and Oscar host a poker game  We listen in on current trading ideas in the few minutes before the game starts  They like to call this their  Stock Exchange   I am the only human present  and the only one using fundamental analysis  Their methods are excellent  as you will learn if you join us for a few weeks  Since the time frames and risk profiles differ  so do the stock ideas 
Do the markets predict future events  Or should you use fundamentals to predict the markets  
That is an ongoing debate at the Stock Exchange 
This Week s Ideas 
Our technical experts have some very aggressive ideas this week 
Felix 
I look for long term themes  and I have a great one this week  This week I am revisiting technology  specifically Weibo Corp  NASDAQ WB   There are not too many social media platforms that are available for trading  but this is one that is  we hear  popular in China  It sounds pretty interesting and maybe  if not  already  will show up here soon 
Just look at the chart  What a strong momentum play   

Our question for this week s post is from  of SeekingAlpha  as follows 

I really appreciate your work Jeff  and group   Felix  and Jeff   I am wrestling with my current position in BMY   should I stay or should I go 

Felix responds 
BMY is on my sell list  a negative rating   There are many better choices 
 Jeff  The 20 multiple is pretty rich for the stodgy recent growth rate  3  dividend is OK  If the expected earnings growth for 2016 17 comes through  it is probably fairly valued  I agree with Felix that there are better choices 
 Felix  Please keep your questions coming  I could use the overtime pay 
Oscar 
It seems like every week that we have some crashing  dynamic stock that we can liken to a pinch hitter or an offensive lineman  My choice for this week is a change of pace  Take a look at the moving averages on 3D Systems Corporation  NYSE DDD  below  This reminds me of the long  smooth strokes you see from the US Olympic Rowing team  Sure  it may not be as exciting as the MLB Division series   but it sure is pretty  Here we ve got steady  sustainable growth from a major name in the broader sector of 3D printing  What s not to like  The chart is very encouraging  Breakout coming 

 Jeff  With a PE over 40  this might be breaking hearts rather than breaking out  This makes sense only as a speculation 
 Oscar  I am good at speculating 
Holmes 
I am the rebounding specialist  Here is a  fetching  opportunity  Dexcom  DexCom Inc  NASDAQ DXCM   hit an all time high around 97 in September of 2015  sold off to a low of 53 before rebounding back to 95  this most recent sell off gives us a nice technical entry into this name looking for a run back to 95  with a stop around the 200d MA  75 17  

 Jeff  Do you know what it means when you look for the multiple on a stock and see  NMF  
 Holmes  What s a multiple 
 Jeff  It stands for  not meaningful   You see it when a stock has no earnings  It is important for determining value 
 Holmes  I get paid nicely for stock rebounds whether there are earnings or not  The chart tells the story 
Athena 
I have a very interesting choice this week  Air Products and Chemicals  NYSE APD  
 Jeff  That has a familiar sound  Didn t we just discuss that pick 
 Holmes  Yes  It was my choice last week  She is copying  I was stopped out with a small loss 
 Jeff  I did not care for it last week  and I still don t  The price is a bit lower  but not low enough for me 
 Athena  I need not copy from humans and dogs  The Holmes rebound play did not work  APD fits my style just fine  My average holding period is about four months  We can revisit this after some time  Here is the updated chart 

Questions 
If you want an opinion about a specific stock or sector  even those we did not mention  just ask  Put questions in the comments  Address them to a specific expert if you wish  Each has a specialty  Who is your favorite   You are allowed to choose me  although my feelings will not be hurt very much if you prefer one of the models  
Cast of Characters
Felix is fussy  precise  and very cautious  He looks for what is working  but it also must have upside potential  He is an investor who thinks long term  Felix will not usually announce new picks  but he will answer questions  saying what he thinks about specific stocks  He will also comment on favorite themes and sectors 
Oscar is naturally optimistic and a bit excitable  He definitely likes to go with winners  and focuses on a one month time frame  He trades either sector ETFs  or a basket of stocks  equally weighted  that reflect a sector  Oscar will mention a favorite sector each week  and will also answer questions about sectors 
Holmes is a trader  but a cautious one  Holmes emphasizes asset protection through profit taking  stops  and trailing stops  He is careful in selecting new positions  and generally looks at an intermediate time frame  While he does not know the definition of  mean reversion  he loves rebounds  There is no set holding period  but two or three months is not unusual  Holmes will tell us one stock recommended that week  For those who sign up for his email list  no charge  privacy respected  holmes at newarc dot com  he will report exits with a one day delay 
Athena trades more frequently than the others  but still limits risk  Her inspiration helps to find good ideas  Her excellent quant skills find attractive risk reward opportunities  Her wisdom leads her to exit trades that are not working  Athena will provide a new idea each week 
Jeff usually has some comments about stock or market fundamentals  Unlike the other witty participants  he sounds like an old prof 
An Important Note to Readers   from Jeff 
All of the characters  except me   are models  carefully engineered and tested by one of the leading developers of the last thirty years  I humanize them to make it easier to understand the characteristics in their design  I always remind readers that my posts are informational  not investment advice  and that is especially true here   While we are trading based upon all four models  we are always watching and can act quickly when necessary  The models are not suitable for all investors  If you like the approach  reach out to us  info at newarc dot com  and we will provide more information 
The conversation is light hearted  but the stock analysis is serious  We own positions in each of the stocks mentioned ",2016-10-16,Jeff Miller,"https://www.investing.com/analysis/stock-exchange:-great-chart-ideas-include-wb,-ddd,-dxcm,-and-apd-200158989",200158989
113997,335512,DXCM,Stock Watch  Dexcom s Glucose Monitoring System Receives FDA Approval,opinion,"By Sarah RodenDexcom s    G4 Platinum Continuous Glucose Monitoring System received FDA approval on January 27th  DexCom Inc  NASDAQ DXCM  develops monitors that detect glucose levels to help manage diabetes The new device utilizes Bluetooth technology to connect the monitoring system to the patient s smartphone  The patient s phone sends the glucose count to up to 5 chosen  followers   who will receive notifications  allowing family of the patient to have  peace of mind and reassurance when they are apart   Since the new monitor can be used for children as young as two years old  it will be particularly beneficial for caregivers of toddlers and children who have diabetes  Dexcom anticipates the devices will be ready for shipping in early March Dexcom CEO Kevin Sayer noted 

 The Dexcom Share receiver represents a significant step forward for our company and our mobile strategy  but more importantly  it will provide a huge improvement for people managing their diabetes and for those parents and caregivers who help them each and every day  

On January 26th  analyst  of Wedbush reiterated an Outperform rating on Dexcom with a  70 price target  In light of Dexcom s new device earning FDA approval  Levy noted   We believe  the new receiver with Bluetooth technology  could drive greater adoption of CGM technology  especially among the pediatric patients where a caregiver also can receive the data   Surrounding the market  the analyst noted   We estimate the current penetration in the US CGM market at approximately 10   and with each 1  increase in penetration  it would potentially represent approximately  24 million in revenue for DXCM   He continued   We are incrementally more confident in our Street high estimates and continue to believe the company is well positioned to expand the underpenetrated CGM market  given its best in class CGM technology   has rated Dexcom 3 times since August 2013  earning a 100  success rate and a  61 6  average return per DXCM recommendation  Overall  Levy has a 71  success rate recommending stocks with a  24 1  average return per recommendation 
Separately on January 26th  analyst from Canaccord Genuity maintained a Buy rating on Dexcom with a price target of  69 William Plovanic has rated Dexcom 11 times since July 2011 with a 90  success rate recommending the stock and a  60 0  average return per DXCM recommendation  Overall  Plovanic has a 70  success rate recommending stocks with a  22 1  average return per recommendation On average  the top analyst consensus for DXCM on TipRanks is  Disclosure  All DXCM recommendations sourced from TipRanks ",2015-01-27,Sarah Roden,https://www.investing.com/analysis/stock-watch:-dexcoms-glucose-monitoring-system-receives-fda-approval-239896,239896
113998,335513,DXCM,Canaccord Genuity Remains Bullish On EnteroMedics Following Q4 Earnings,opinion,Healthcare company NASDAQ  EnteroMedics Inc  NASDAQ ETRM  reported its fourth quarter 2014 earnings result on Wednesday  February 18th after market close  coming in slightly ahead of analysts  expectations Highlights from the report include a net loss of  6 2 million  or  0 09 per share  The profit loss was due to Operating expenses for clinical trials and commercialization of VBLOC  the company s treatment for weight loss On January 14th  Enteromedics announced it was granted FDA approval for VBLOC  delivered via the Maestro  System  for patients 18 and older  This is the first treatment to cater to obesity that has been approved by the FDA in over a decade By December 31  2014  the Company raised  11 6 million through cash  cash equivalents and short term investments  So far this year  Enteromedics has raised about  6 4 million Greg S  Lea  Chief Financial Officer and Chief Operating Officer of Enteromedics said of the company s Q4 results   Execution of our commercial strategy is well underway following the FDA approval that was received earlier this year We believe that our current resources will permit us to start to build the necessary infrastructure  invest in inventory  fund product improvements and implement process changes to support our commercial strategy  As we achieve our early commercial objectives  we will continue to review actions required to strengthen our balance sheet to support the growth requirements of our strategy into 2016  Canaccord Genuity analyst  reiterated a Buy rating on Enteromedics following the company s Q4 earnings results with a  4 price target  He stated   We reiterate our BUY rating and  4 price target on EnteroMedics following the Q4 14 results  The quarterly results came in slightly better than expected but the prevailing highlight was initial commercialization efforts post FDA approval early in the Q1 15  William Plovanic has rated Enteromedics 11 times since June 2011  earning a 50  success rate recommending the stock and a  18 7  average return per recommendation  Overall  the analyst has a 71  success rate recommending stocks and a  21 1  average return per recommendation Plovanic has a lot of experience rating healthcare stocks  such as Globus Medical  NYSE GMED  and DexCom Inc  NASDAQ DXCM   The analyst has rated Globus Medical 8 times since December 2012  earning a 100  success rate recommending the company and a  25 1  average return per recommendation  Likewise  Plovanic has rated Dexcom 11 times since July 2011 when an 82  success rate recommending the stock and a  56 6  average return per recommendation However  Plovanic has not always made the best recommendations as he has rated Insulet Corporation  NASDAQ PODD  12 times since June 2012 with a 45  success rate and a  6 1  average return Do you trust  s latest recommendation based on his financial advice history ,2015-02-19,Carly Forster,https://www.investing.com/analysis/canaccord-genuity-remains-bullish-on-enteromedics-following-q4-earnings-242482,242482
